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Abstract
This thesis describes an investigation into the molecular basis of two rare autosomal 
recessive conditions: Jeune asphyxiating thoracic dystrophy (JATD) and Cenani-Lenz 
syndrome (CLS).
JATD is a skeletal dysplasia sometimes complicated by chronic nephritis, hepatic and 
pancreatic fibrosis, and retinal degeneration. Although it is a serious condition with a 
high mortality and morbidity, predominantly from respiratory insufficiency in infancy 
and chronic renal failure in childhood, its molecular basis is currently unknown. This 
project focused on twelve consanguineous and nineteen non-consanguineous affected 
families. Haplotype analysis was undertaken in the consanguineous families to exclude 
linkage to several previously proposed candidate genes and loci. A homozygosity 
mapping approach was then adopted, and a genome-wide linkage scan was carried out in 
the three most statistically powerful consanguineous families. Each family was consistent 
with linkage to a different locus, on chromosomes 3q24-q26, 8q24 and 14q24-q32. The 
remaining families were genotyped across each locus to define minimal critical intervals. A 
number of candidate genes were then selected and screened for mutations in families which 
were consistent with linkage, but no mutations were identified.
CLS is a distal limb malformation characterised by total digit syndactyly and radio­
ulnar synostosis. Limb deformity (Id) mice have a very similar phenotype. The Id 
phenotype is caused by mutations in the Formin-l gene, leading to loss of Gremlin 
expression in the limb bud mesenchyme. In this project, haplotype analysis in one 
consanguineous CLS family excluded linkage both to FORMIN-1 (FMN-1) and to 
GREMLIN, which are immediately adjacent to each other on chromosome 15ql3. 
Haplotype analysis in another consanguineous CLS family was consistent with linkage 
to this region, but no mutations were identified in either FMN-1 or GREMLIN. The 
coding sequence of GREMLIN was analysed in two further consanguineous and three 
non-consanguineous CLS families, but no mutations were identified.
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Chapter 1 Introduction: Jeune and Cenani-Lenz 
syndromes
1.1 Jeuue syndrome
1.1.1 Clinical features
Jeune syndrome or asphyxiating thoracic dystrophy (JATD; MIM 208500) is a rare 
autosomal recessive skeletal dysplasia with renal, pancreatic, hepatic and retinal 
involvement. The disorder was first described in an affected sister and brother in 1954 
and 1955 by Jeune (Jeune M, 1955; Jeune M, 1954). Over one hundred cases have been 
so far reported (Tongsong et al., 1999). JATD has an incidence of 1 in 100,000- 
130,000 live births (Oberklaid et al.f 1977).
The main skeletal features of JATD consist of a small chest, mild short stature, mild 
shortening of limbs (usually rhizomelic) and post-axial polydactyly (in about half of 
cases). No developmental delay or facial dysmorphism are described. The thoracic 
malformation with short ribs usually leads to pulmonary hypoplasia with a marked 
reduction in alveoli, resulting in respiratory problems during the neonatal period 
(Finegold et a l , 1971; Langer, 1968; Turkel et al., 1985). Up to 70% of patients die of 
respiratory failure and infections in early childhood, usually within the first year of life 
(Ozcay et al., 2001). Nevertheless, advances in respiratory neonatal intensive care have 
now improved chances of survival (Kajantie et a l , 2001). In these cases, there is 
usually progressive improvement in the relative growth of the chest. There are 
characteristic skeletal abnormalities on radiological examination, which are essential to 
confirm the diagnosis. These include small bell-shaped thorax with short horizontal ribs 
and ‘handlebar’ clavicles (Fig. 1.1 A); small iliac wings with a ‘trident’ appearance of 
the acetabular roofs (Fig. 1 .IB); flaring of metaphyses of long bones (Fig. 1.1C and D); 
and, in the hands, short broad middle phalanges, hypoplastic distal phalanges and cone-
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Figure 1.1 Radiographs showing the typical features of JATD. The thoracic 
cage is small and narrow with short ribs (A). The acetabular roofs have a 
‘trident’ configuration (B). The proximal bones of the limbs are shorter than the 
middle bones (C and D). The middle and distal phalanges of the fingers are 
abnormally small (E).
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shaped epiphyses (Fig. 1.1E).
In those patients who survive respiratory failure, chronic renal failure is the commonest 
cause of death (Langer, 1968; Turkel et al., 1985; Shah, 1980; Shokeir et al., 1971; 
Oberklaid et al., 1977). It is therefore important to monitor renal function, in order to 
intervene with dialysis or renal transplant. Clinical problems due to pancreatic 
insufficiency may be present in some cases, and may require pancreatic enzyme 
supplements (Hopper et al., 1979; Turkel et al., 1985). Histologically, cystic changes 
and fibrosis in the pancreas have been described (Georgiou-Theodoropoulos et al., 
1988). Prolonged neonatal jaundice can occur and in severe cases there may be hepatic 
fibrosis and biliary cirrhosis with portal hypertension (Hudgins L, 1990; Whitley et al., 
1987; Labrune et al., 1999). In the eyes, progressive retinal degeneration can occur, 
leading in some cases to blindness (Casteels et al., 2000; Wilson et al., 1987).
Although JATD is autosomal recessive, there are occasional reports of a possible 
heterozygous phenotype in parents and siblings of affected children consisting of short 
stature, mild chest deformity and brachydactyly (Ozcay et al., 2001; Shokeir et al., 
1971).
The name JATD is rather misleading, as asphyxia does not occur in all cases and there 
are numerous reports of patients with only mild or no respiratory problems (Giorgi et 
al., 1990; Oberklaid et al., 1977; Capilupi et al., 1996). Also, the extra-skeletal 
complications do not always occur. Therefore there is a wide variation in phenotypic 
severity. Variation between different families could be due to genetic heterogeneity or 
to different types of mutations in the same gene, but variation is also reported within 
affected families (Ozcay et al., 2001). This can most likely be explained by the 
modifying effects of other genes/environmental factors.
1.1.2 Overlap with Ellis-van Creveld syndrome
The abnormalities in the rib cage, limbs and pelvis of JATD patients are extremely 
similar to those that occur in another autosomal recessive skeletal dysplasia, Ellis-van 
Creveld syndrome (EVC; MIM 225500). There are, however, some significant
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differences between the two conditions. In EVC syndrome, 50-60% of patients have a 
congenital heart defect, which is not a feature of JATD, and many EVC patients also 
have other abnormalities not seen in JATD, including urogenital tract abnormalities 
(epispadias, hypospadias, cryptorchidism), dysplastic nails and teeth, and partially cleft 
upper lip (Brueton et a l, 1990). On the other hand, neonatal respiratory problems, 
involvement of the kidney, pancreas, liver, and retinal degeneration are features of 
JATD, but do not occur in EVC. The best distinguishing feature is the polydactyly, that 
is a constant feature in the hands but rarely affects the feet in EVC. In JATD, 
polydactyly is an inconstant feature, but when present, usually affects both the hands 
and the feet (Brueton et a l , 1990). Nevertheless, the similarities between the two 
syndromes have led some authors to suggest that they form part of the same disease 
spectrum rather than being distinct conditions (Brueton et al., 1990; Moudgil et al., 
1998).
1.1.3 Overlap with short rib-polydactyly syndromes
JATD also shows considerable clinical overlap with the short rib-polydactyly 
syndromes (SRPS), a group of recessively-inherited lethal skeletal dysplasias all 
characterised by a hypoplastic thorax, short ribs, short limbs, polydactyly and visceral 
abnormalities. These syndromes have been classified into four different types (type I - 
Saldino-Noonan, type II - Majewski, type III - Varma-Naumoff, and type IV - Beemer- 
Langer), but they have many clinical, radiological and histological similarities, and may 
well represent different variants of the same disease spectrum, with a common cause or 
at least a common pathogenic pathway (Franceschini et al., 1995). Some patients have 
in fact been reported with clinical/radiological features of all four types (Martinez-Frias 
et a l, 1993; Sarafoglou et a l, 1999). Ho and colleagues reported a case of JATD and 
SRPS type III occurring in the same consanguineous Asian family. One first-cousin 
marriage produced two brothers with typical mild JATD; another first-cousin marriage 
produced a boy with lethal SRPS type III. This suggests the two conditions may be 
different forms of the same disorder with the intrafamilial variation in severity 
reflecting the modifying influence of genetic/environmental factors (Ho et a l , 2000).
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1.1.4 Candidate genes and loci
1.1.4.1 Two candidate genes: EVC and EVC2
A possible candidate gene for JATD was thought to be the gene mutated in EVC 
syndrome because of the overlapping features between the two conditions. The EVC 
syndrome has been mapped to a critical region on chromosome 4pl6, with no evidence 
of genetic heterogeneity (Howard et al., 1997). A first underlying gene, named EVC, 
was cloned and shown to be mutated in a number of EVC patients (Ruiz-Perez et al., 
2000). It codes for a novel, widely-expressed protein of unknown function with no 
homology to known proteins. In situ hybridisation in human embryonic tissue showed 
EVC expression in developing bones, heart, kidney and lung. In bone, EVC was 
expressed in the developing vertebral bodies, ribs and both upper and lower limbs with 
higher expression in the distal limb compared to the proximal limb.
In a patient with EVC syndrome, two homozygous mutations were subsequently 
identified in a second gene named EVC2, which lies immediately 5’ of EVC (Galdzicka 
et al., 2002). Mutations in EVC and EVC2, leading to an identical phenotype were also 
reported by Ruiz-Perez and colleagues (Ruiz-Perez et al., 2003). The authors identified 
mutations in EVC2 in six consanguineous EVC pedigrees consistent with localization 
to the EVC region but with no mutations in EVC. EVC and EVC2 are non-homologous 
genes with unknown function arranged in a head-to-head configuration probably 
sharing a single promoter or elements of overlapping promoters (Ruiz-Perez et al., 
2003). EVC2 is expressed in heart, placenta, lung, liver, skeletal muscle, kidney and 
pancreas. A transcript is also found in lymphoblasts and chondrocytes (Galdzicka et al.,
2002). The bovine orthologue of EVC2 named LIMBIN (.LBN) is mutated in bovine 
chondrodysplastic dwarfism, an autosomal recessive disorder characterised by short 
limbs and joint abnormalities. The mouse orthologue is strongly expressed in the 
proliferative chondrocytes of long bone epiphysial growth plates, adult heart and 
kidney (Takeda et al., 2002).
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However, in one family with JATD and one with SRPS type III, linkage to the 
EVC/EVC2 locus has clearly been excluded (Krakow et al., 2000). Nevertheless, the 
pathogenesis of the two conditions could well be similar, and the JATD gene could 
have similar biological and/or developmental functions or even act in the same 
molecular pathway as the EVC and/or the EVC2 gene.
In addition, for all four types of SRPS, the underlying gene(s) have not yet been 
mapped or cloned; one or more of them could be allelic to JATD.
1.1.4.2 A candidate locus: 12pll-pl2
Nagai and colleagues have described a boy with a de novo deletion on the short arm of 
chromosome 12, at 12pll.21-pl2.2, who had a small rib cage, a hypoplastic pelvis, 
short stature and radiological findings similar to those in JATD and EVC syndromes 
(Nagai et al., 1995). They therefore proposed that the gene underlying JATD might be 
located on chromosome 12pl 1-12. This patient also had features not seen in JATD, 
including mild developmental delay, oligodontia, and hypoplastic hair and skin. The 
breakpoints of the deletion were later fine-mapped and the deletion was found to 
remove an approximately 15 cM region between markers D12S1682 and D12S345 
(Bahring et al., 1997).
1.1.4.3 A candidate mouse model: shorty
A possible mouse model for JATD has been identified in a screen of embryos derived 
from mice mutagenised with N-ethyl-N-nitrosourea, which generates single-nucleotide 
mutations (Herron et al., 2002). One mutant, named ‘shorty’ (srt), had an extremely 
small chest, and died soon after birth from respiratory failure. However, the skeletal 
abnormalities in this mouse are not exactly the same as in JATD patients. They include 
major vertebral anomalies, resulting in a shortened body axis and severe lordosis of the 
lower cervical/upper thoracic spine, absence of the proximal portion of the ribs and 
clefting of the secondary palate. None of these features are described in JATD.
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Furthermore, there is no report of histological changes in the kidney, liver or pancreas, 
which typically occur in JATD.
The srt phenotype is similar to that of the ‘pudgy’ mouse, which is caused by mutations 
in D113 on mouse chromosome 7 (Kusumi et a l, 1998). In humans, mutations in DLL3 
cause spondylocostostal dysostosis, a rare autosomal recessive skeletal dysplasia 
(Bulman et a l , 2000). Linkage analysis in srt excluded chromosome 7, and instead 
mapped the locus to a 7 cM interval on mouse chromosome 17. A good candidate gene 
in this region was Dill, but no mutations in it were identified, so the underlying gene is 
at present unknown. In humans, regions corresponding to srt critical interval lie on 
6p21, 6q25-q27 and 16pl3.3.
1.2 Cenani-Lenz syndrome
1.2.1 Clinical features
Cenani-Lenz syndrome (CLS; MIM 212780) is a rare recessively-inherited congenital 
limb malformation, first described by Cenani and Lenz in 1967 (Cenani and Lenz, 
1967) in two brothers with pronounced radioulnar and metacarpal synostosis. The 
upper limbs are usually much more severely affected than the lower limbs. In the 
hands, there is syndactyly between all the digits, with central digits often sharing the 
same nail; digits are short, and some may be missing (Fig. 1.2B and D). Radiographs 
show malformation, fusion and absence of most of the phalanges, metacarpals and 
carpals (Fig. 1.2A and C), often accompanied by partial or complete radio-ulnar 
synostosis, resulting in limitation of pronation and supination. In the feet there is 
usually just soft tissue syndactyly between some of the toes, and tibio-fibular synostosis 
has never been observed. Recently, four reports described abnormalities not previously 
associated with CLS, namely rib and vertebral abnormalities (Seven et a l, 2000), renal 
hypoplasia (Bacchelli et a l, 2001), facial dysmorphism (Temtamy et a l, 2003), 
congenital cataract and duplication of the big toes (Percin and Percin, 2003).
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Figure 1.2. The hands of a patient with CLS. There is severe shortening 
and syndactyly of all the digits, with malformation, fusion or absence 
of many of the phalanges, metacarpals and carpals.
27
To date, only twenty-five cases of CLS have been described (Cenani and Lenz, 1967; 
Drohm et a l, 1976; Verma et a l, 1976; Temtamy and McKusick, 1978; Dodinval, 
1979; Pfeiffer and Meisel-Stosiek, 1982; De Smet et al., 1992; Elcioglu et a l, 1997; 
Seven et al., 2000; Bacchelli et al., 2001; Nezarati and McLeod, 2002; Percin and 
Percin, 2003; Temtamy et al., 2003). Of these, two also have extreme shortening of the 
forearms, and may represent a separate condition (Drohm et al., 1976; Verma et a l, 
1976). Although most cases are sporadic, there are four reports of affected siblings bom 
to unaffected non-consanguineous parents (Cenani and Lenz, 1967; Temtamy and 
McKusick, 1978; Dodinval, 1979; Pfeiffer and Meisel-Stosiek, 1982), and six reports 
of affected children bom to unaffected consanguineous parents (Temtamy and 
McKusick, 1978; Verma et a l, 1976; Elcioglu et a l, 1997; Bacchelli et al., 2001; 
Temtamy et al., 2003), strongly suggesting autosomal recessive inheritance.
A dominantly-inherited limb malformation originally reported as CLS in an affected 
father and two affected daughters (De Smet et a l, 1996), and associated with a 
t(12;22)(pl 1.2;ql3.3) balanced translocation, was subsequently re-classified as a novel 
type of complex synpolydactyly with metacarpal, metatarsal and tarsal synostosis 
(Debeer et al., 1998a; Debeer et al., 1998b; Debeer et al., 2000; Debeer et al., 2002). 
The chromosome 22 breakpoint has been shown to disrupt the fibulin-1 gene (FBLN1), 
which is expressed in the extracellular matrix in various tissues during development, 
including the interdigital regions and the perichondrium of the digits (Debeer et al.,
2002). Quasi-dominant inheritance is reported in one CLS family (Temtamy et al.,
2003).
The molecular basis of CLS is currently unknown and at the commencement of this 
project, no attempt to locate the CLS gene had been made.
1.2.2 Mouse mutants as models for human diseases
Mice are the most widely used animal models of human disease. Because of their small 
size, short lifespan and generation time, and because they can be bred easily and 
cheaply, large-scale breeding, genetic crosses and systematic mutagenesis programs
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have been arranged and studied for decades (Wynshaw-Boris, 1996). A large number of 
mouse mutants have been generated following mutagenesis programs and phenotypes 
for many mutants have been described. Some mutants originated spontaneously, others 
have been generated artificially by a variety of different processes such as exposure to 
mutagenic chemicals, for example ethylnitrosourea (ENU), or high doses of X-rays. 
Chemically-induced and irradiation-induced mutagenesis however, has the 
disadvantage of being random. More recently, gene targeting, insertional mutagenesis 
and transgenic techniques have allowed the creation of animal disease models 
resembling corresponding specific human diseases by introducing mutations into a 
particular gene in vivo (Gordon and Ruddle, 1983). Mice can be generated with a 
particular alteration in a chosen target gene, or simply by disrupting a particular gene 
with a large insertional cassette, thereby generating null mutations (known as gene 
knockouts). Such techniques are largely used to model loss of function mutations.
Homologous mouse and human mutants often show similar phenotypes, offering 
valuable clues for identification of human disease genes. Almost all human genes have 
an easily identifiable mouse homolog because of the high level of conservation between 
human and mouse coding sequences. Because the homologous regions of mouse and 
human genomes have been well documented and become easily accessible (see recent 
Ensembl freeze at http://www.ensembl.org/ or human/mouse homology maps at 
http://www.ncbi.nlm.nih.gov/Omim/Homology) once a disease gene in one species has 
been identified, it is possible to predict the location of that gene in the other species. 
For example, the spontaneous mouse mutant Hypodactyly has similar limb 
abnormalities to those seen in the human condition hand-foot-genital syndrome 
(HFGS). When the Hypodactyly mouse was shown to be due to a mutation in Hoxal3, 
the human homologue H0XA13 immediately became a candidate gene for HFGS, and 
indeed mutations were identified (Mortlock and Innis, 1997).
However, mouse models of disease sometimes show considerably different phenotypes 
from the corresponding human disorders. Some difference in biochemical and 
developmental pathways in mice and humans are known and often transgenic or 
knockout (KO) mice show a dissimilar phenotype from the human disease. Phenotypic 
differences may be due to an altered pattern of transgene expression, an altered or
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absent developmental pathway, a redundant or altered biochemical pathway or an 
unknown mechanism of mutation (Wynshaw-Boris, 1996). Modifier genes in different 
strains of mice could sometimes be responsible for differences in phenotype between 
mouse and human mutants.
A significant number of spontaneous mutations in mice cause congenital limb 
malformations and have been proven to be crucial to our understanding of the 
molecular mechanisms regulating limb bud morphogenesis.
1.2.3 The limb deformity mouse
The limb abnormalities in CLS patients were noted to be very similar to those found in 
a recessive mouse mutant, limb deformity (Id) (Winter, 1988). Homozygous Id/ld mice 
have fully penetrant, symmetrical distal limb abnormalities, including soft tissue and 
bony syndactyly, oligodactyly, fusion of carpals and metacarpals in the paws and of 
tarsals and metatarsals in the feet together with synostosis of the long bones of the 
zeugopod (radius and ulna, tibia and fibula) (Woychik et al., 1985). In CLS, the upper 
limbs are more severely affected than the lower limbs and tibia-fibula synostosis is not 
usually a feature. In addition Id/ld mice often show partially penetrant and 
asymmetrical renal agenesis or hypoplasia (Maas et al., 1994), which are not typical 
characteristics of CLS.
1.2.3.1 Background on Formin-1 role in Id phenotype
At the commencement of this investigation, and until very recently, the gene underlying 
the Id mouse phenotype was thought to be Formin-1. Identified in 1985, after chance 
insertion of a transgene resulted in a mouse with Id phenotype (Woychik et al., 1985), 
the gene was originally called Form in, but after a closely related mouse gene, Formin- 
2, was discovered, Formin has been re-named Formin-1 (Leader and Leder, 2000). 
Over the years, a total of five Id alleles have been identified. Two Id alleles (/<iTgHd,
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ldTgBri) arose by chance insertional mutagenesis disrupting the C-terminal region of the 
Formin-1 gene (Wang et al., 1997). A third Id allele, ld nl, was due to a ~40 Mb 
inversion with breakpoints in the C-terminal region of Formin-1 (Woychik et al., 
1990a). The molecular lesions in the remaining two alleles, ld0R and ldJ, have been 
identified only very recently and are discussed in more detail in section 1.2.3.2 (Zuniga 
et al., 2004).
It had been assumed for a long time that the Id phenotype was caused by disruption of 
the C-terminal Formin-1 domain. In Id homozygous embryos, the epithelial- 
mesenchymal signaling interactions regulating limb bud development are disrupted. _ 
Ld/ld mice also have renal hypoplasia/agenesis, or hydronephrosis, resulting from 
failure or delay in the outgrowth of the ureteric bud. The model that was originally 
proposed, suggested that Formin-1 played an important role in the reciprocal inductive 
interactions between mesenchyme and ectoderm in developing limb and kidney. 
Abnormalities in the kidney could be due to failure of inductive interactions between 
the ureteric bud and metanephric mesenchyme.
In the limb, Formin-1 was thought to be essential for maintaining the feedback loop 
between the two signalling centres that co-ordinate outgrowth and patterning of the 
limb bud; namely, the apical ectodermal ridge (AER) and the zone of polarizing 
activity (ZPA) (section 1.3 and Fig. 1.3) (Zuniga and Zeller, 1999). The AER, a ridge 
of thickened ectoderm extending along the distal tip of the limb bud, promotes 
proximo-distal outgrowth of the limb by maintaining the mesenchyme immediately 
underneath it (called the progress zone) in a state of proliferation (Tickle, 2003). The 
ZPA, a specialised group of mesenchymal cells at the posterior margin of the limb, is 
important for controlling polarisation across the antero-posterior axis of the limb and 
establishing digit identity. Maintenance of both the AER and ZPA depends on a 
feedback loop between them. The signal from the ZPA is Sonic hedgehog (Shh); the 
signal from the AER comprises members of the fibroblast growth factor (Fgf) family. 
Genes encoding several different Fgfs (Fgf4, Fgf8, Fgf9, FgflO and Fgfl7) are 
expressed in complex dynamic patterns during limb development and are now thought 
to act together to help maintain Shh expression (Moon et al., 2000; Sun et al., 2000; 
Boulet et al., 2004).
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In Id/ld mice, Shh expression in the ZPA is initially normal, but is not maintained and 
propagated, due to failure of Fgf expression in the AER (Zuniga et a l , 1999); this in 
turn is due to a mesenchymal defect in transducing the Shh signal to the AER, so that
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Figure 1.3 Schematic representation of the Shh-Fgf signaling loop and 
antagonistic interactions regulating limb development. The apical ectodermal 
ridge (AER) is indicated in yellow and the zone of polarising activity (ZPA) 
in green.
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the AER fails to develop properly and is poorly organised and incompletely 
differentiated (Zeller et al., 1989). Subsequently, it was suggested that mesenchymal 
Formin-1 was required to relay the Shh signal from the ZPA to the AER. A second 
mesenchymal signal downstream of Formin-1 then relays the signal on to the AER. 
This is Gremlin, a secreted signaling molecule which is a member of the 
DAN/Cerberus family and belongs to the TGFp superfamily (Hsu et al., 1998). 
Gremlin is a bone morphogenetic protein (BMP) antagonist that antagonises 
preferentially Bmp2 and Bmp4. Several BMPs are expressed in the mesenchyme and 
AER, and are thought to repress Fgf expression in the AER (Zuniga et al., 1999). 
Gremlin could act by relieving this repression. In Id/ld limb buds, Gremlin is not 
expressed, suggesting that Gremlin expression requires activation by Formin-1. 
Grafting Oe/w/w-expressing cells into the mesenchyme of Id/ld limbs restores the 
Shh/Fgf4 feedback loop (Zuniga et al., 1999). Inactivation of specific Formin-1 
isoforms by gene targeting in the mouse, however, results in partial renal agenesis 
phenotypes, but fails to reproduce the Id limb phenotype, since limb morphogenesis is 
normal (Wynshaw-Boris et a l, 1997).
1.2.3.2 Gremlin role in limb and renal Id phenotype
Only very recently it has been demonstrated that the Id phenotype has been wrongly 
attributed to disruption of Formin-1 (Zuniga et al., 2004). Analysis of Gremlin- 
deficient mouse embryos generated by gene targeting has confirmed the essential 
functions of Gremlin during limb bud development (Khokha et al., 2003; Michos et al., 
2004). The Shh-Fgf feedback loop is disrupted in Gremlin mutant mice indicating an 
important role of Gremlin in maintaining the AER and the Shh-Fgf feedback loop 
during early limb development and patterning (Khokha et al., 2003). Interestingly, it 
was noted that homozygous Gremlin KO mice have an identical phenotype to 
homozygous Id mice which results from defects in the Formin-1 gene. The limb and 
kidney abnormalities were exactly the same as in Id mice. Furthermore, mice 
heterozygous for both the Gremlin null mutation and the Id1 mutation have the full Id
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phenotype showing that the Gremlin null mutation is actually allelic to Id1, one of the 
five previously identified Id alleles (Khokha et al., 2003).
Michos et al. (2004) showed that in Gre/w/m-deficient embryos a distinct and 
functional AER fails to form. The disruption of AER function blocks propagation of 
Shh expression by the polarizing region as was observed in Id mutant limb buds 
(Michos et al., 2004). In addition, a more general role of Gremlin in epithelial- 
mesenchymal signaling during organogenesis was described (Michos et al., 2004). 
Gremlin-deficient embryos have complete renal agenesis revealing that Gremlin is 
required for the induction of metanephric kidney organogenesis. Furthermore, 
incomplete differentiation of lung airway epithelia in the mouse mutant causes neonatal 
lethality (Michos et al., 2004).
The relationship between Gremlin and Formin-1 is interesting because in mice, as in 
humans, they lie very close together, only 40 kb apart. Zuniga and colleagues identified 
the remaining two Id alleles, lc? and lcPK, and established that they are loss-of-function 
mutations directly disrupting the Gremlin gene product (Zuniga et al., 2004). The Id? 
mutation is a point mutation which affects splicing of the Gremlin transcript and thus 
results in the truncation of the 5’ part of Gremlin exon 2, whereas the complete Gremlin 
ORF encoded by exon 2 is deleted by the lcPR mutation. Furthermore, a shared cis- 
regulatory element within Formin-1 genomic regions that is required for both Formin-1 
and Gremlin expression as well as for Gremlin activation in the posterior limb bud 
mesenchyme was also identified in this study (Zuniga et al., 2004). This region was 
demonstrated to be the region either deleted or disrupted in the hypomorphic Id alleles 
ldTgHd, lc?nl and ldTgBri.
In conclusion, taken together these latest studies establish that the Id phenotype is a 
direct consequence of loss of Gremlin expression in the limb bud mesenchyme and not 
due to disruption of Formin-1 functions as previously assumed (Zuniga et al., 2004). It 
also shows that despite early speculations (section 1.2.3.1) Gremlin and Formin-1 are 
not part of the same pathway, although these two genes are coexpressed during 
organogenesis in various embryonic tissues such as kidney (Michos et al., 2004; 
Wynshaw-Boris et al., 1997).
34
1.2.4 Formin-1
1.2.4.1 Formin-1 gene
Formin-1 is a very large and complex gene that spans over 400 kb and contains at least 
24 exons on mouse chromosome 2 (Wang et al., 1997). Some introns are as large as 50 
kb. Formin-1 has four major splice forms expressed in a variety of fetal and adult 
tissues (brain and testis, as well as limb and kidney) (Zeller et al., 1999). These 
isoforms share the same C-terminal region, but have isoform-specific N-termini. The 
promoter regions of the gene have not yet been characterised. There may be a promoter 
for isoform IV, lying within the gene upstream of exon 6 (Chan et al., 1995; Jackson- 
Grusby et al., 1992); but a promoter for isoforms I to III has not been identified in the 
650 bp upstream of exon 1 (Jackson-Grusby et al., 1992; Woychik et al., 1990b). The 
limb bud c/s-regulatory element shared by Formin-1 and Gremlin lies within the 
genomic region encompassing Formin-1 exons 19-23 (Zuniga et al., 2004).
1.2.4.2 Formin-1 protein
Formin-1 is the founding member of a multigene family that mediates cytoskeletal 
rearrangements in response to signals that induce, for example, cell polarisation 
(section 1.2.4.3) (Evangelista et al., 2003). The role of Formin-1 at a cellular/molecular 
level is not well understood. The subcellular site of Formin-1 activity is not yet clear. 
Early studies found that it localises to the nucleus (Trumpp et al., 1992); a later study 
found that Formin-1 is both cytoplasmic and nuclear and that Id mutations cause it to be 
retained in the cytoplasm (Chan and Leder, 1996). It has been proposed that nuclear 
Formin-1 acts as a transcriptional regulator (Zeller et al., 1999).
All Formin-1 isoforms have a proline-rich region, encoded by exon 9, called the FH1 
domain. This domain matches consensus sequences for Src homology 3 (SH3) ligands.
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One study used this proline-rich region to screen a mouse limb bud expression library 
for proteins that might interact with Formin-1 and found two different classes: proteins 
containing one or more SH3 domains and proteins containing a WW motif (Chan et al., 
1996). The proteins in this second class, which were all novel, were given the name 
‘formin binding proteins’ (FBPs). However, there is no evidence so far that Formin-1 
actually interacts in vivo with any particular protein containing a SH3 or WW domain 
(Leader and Leder, 2000).
Recently, Kobielak and colleagues, in an attempt to analyse alpha-catenin binding 
partners using a yeast 2-hybrid system, found direct interaction between alpha-catenin 
and Formin-1 (Kobielak et al., 2004). They found that Formin-1 localises to adherens 
junctions and nucleates unbranched actin filaments in vitro and functions in vivo in 
alpha-catenin-dependent, radial actin cable formation. Disruption of the alpha-catenin- 
Formin-1 interaction blocks assembly of radial actin cables and perturbs intercellular 
adhesion.
1.2.4.3 Formin homology proteins
An increasingly large number of proteins closely related to Formin-1 have been 
discovered (Tanaka, 2000; Wasserman, 1998; Katoh, 2004a; Katoh, 2004b; Westendorf 
and Koka, 2004). They are called the formin homology (FH) proteins or formins. Over 
twenty are now known, isolated from a wide variety of species, including plants and 
fungi, as well as flies, worms and mammals. Their main role is in organising the 
cytoskeleton as actin nucleators in the formation of new filaments and they exert their 
effects on microtubule networks during meiosis, mitosis, the maintenance of cell 
polarity, cell migration, vesicular trafficking, signaling to the nucleus and embryonic 
development (Koka et al., 2003; Wallar and Alberts, 2003). FH proteins are best 
defined by the presence of the unique, highly conserved, approximately 400 residue 
region, called the formin homology domain 2 (FH2) which has recently been found to 
nucleate actin filaments in vitro (Pring et al., 2003; Zigmond, 2004). The FH1 domain
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has been found to bind profilin, an actin monomer-binding protein which controls actin 
polymerisation and enhances nucleation.
Studies of FH proteins in yeast, have shown that these proteins are specifically required 
for the assembly of bundles of parallel actin filaments known as cables (Evangelista et 
a l , 2002; Sagot et a l , 2002; Evangelista et a l, 2003). All the defects associated with 
loss-of-function mutations in FH proteins, including defects in spindle formation, 
cytokinesis and cell polarity, could be due to failure of proper assembly of actin cables, 
which would then affect other cytoskeletal structures (Lew, 2002).
1.2.5 Gremlin
Gremlin, also known as CKTSF1B1 (cysteine knot superfamily 1, BMP antagonist 1), 
is a member of the DAN/Cerberus family of BMP antagonists, highly conserved 
through evolution and known to bind and block BMP2, BMP4 and BMP7 in vivo and 
in vitro (Hsu et a l, 1998). Gremlin contains a highly conserved cysteine rich repeat 
region called a cysteine knot. BMPs constitute a large family of secreted growth factors 
belonging to the TGFp superfamily which are known to be expressed during embryonic 
limb development. Their functions include control of mesodermal cell proliferation, 
chondrogenic differentiation, induction of apoptosis, regulation of growth and 
regression of the AER and regulation of the anteroposterior axis of the early limb bud 
by exerting a negative effect on the Shh/Fgf feedback loop (Merino et a l, 1999; Zuniga 
et a l, 1999). A number of BMP antagonists such as Noggin, DAN, Chordin and 
Follistatin, spatially and temporally regulate different specific BMPs during limb 
patterning, preventing their interaction with their receptors. In particular, Gremlin 
expression is restricted to the distal limb bud mesenchyme and concentrated 
posteriorly. Gremlin has a major role in maintaining the AER and the Shh/Fgf feedback 
loop, as outlined in sections 1.2.3.1 and 1.2.3.2 (Zuniga et a l, 1999; Zuniga et a l,
2004). A potential role of Gremlin in processes such as glomerulosclerosis, 
tubulointerstitial fibrosis and cellular hypertrophy has been described (Dolan et a l,
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2003). More recently, Gremlin expression has been demonstrated in a variety of 
embryonic structures including lung and kidney rudiments (Michos et al., 2004).
1.3 General aspects of limb development
A limb consists of four segments: a root (zonoskeleton), a proximal segment 
(stylopodium) consisting of a single bone (humerus, femur), a medial segment 
(zeugopodium) consisting of two bones (radius and ulna, tibia and fibula), and a distal 
more complex part (autopodium - hand and foot) (Fig. 1.4A). Correct formation of 
these segments requires coordination of several processes (Tickle, 2004). The limb 
develops from the embryonic limb bud through a rapid cell proliferation process and its 
development is mediated by reciprocal interaction between specific signaling regions 
within the limb bud. A long-standing model for limb development has been the 
progress zone model. The zone of undifferentiated mesenchyme that is preserved at the 
limb bud tip during outgrowth was named the progress zone and it was thought that the 
amount of time mesenchyme cells spend in this zone determined whether they form 
proximal or distal structures (Tickle, 2003). Recently this model has been challenged 
and an alternative model has been proposed according to which all the structures along 
the proximo-distal axis are already specified in the early limb bud and not progressively 
in a sequence linked to cell differentiation (Dudley et al., 2002; Sun et al., 2002).
1.3.1 Molecular basis of limb development
In both progress zone and early specification models, limb bud outgrowth is essential 
for establishing the pattern along the proximo-distal axis. A number of reciprocal 
ephithelial-mesenchymal interactions between the thickened apical ectodermal ridge 
(AER) at the distal tip of the limb bud and the underlying mesenchyme mediate limb 
bud outgrowth (Fig. 1.4B). Dorso-ventral patterning of the limb is controlled by 
signaling of the ectoderm covering the side of the bud (Fig. 1.4C), whereas the position
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Figure 1.4 Schematic representation of the main segments of the limb (A) and 
view of limb patterning in relation to the three main axes of the limb (B). The 
apical ectodermal ridge (AER), the zone of polarising activity (ZPA) and the 
associated signalling molecules are indicated. A cross-section view of the 
limb bud and the dorsal ectoderm with the associated signal is also shown 
(C).
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along the antero-posterior axis is specified by a signaling interaction between the 
polarizing region (zone of polarizing activity - ZPA) a region of mesenchyme at the 
posterior margin of the bud and the adjacent mesenchyme cells at the bud tip (Fig. 
1.4B) (Tickle, 2003).
Signaling molecules associated with each of these three sets of interactions are 
fibroblast growth factors (Fgfs) associated with the AER, Wnt7a associated with the 
dorsal ectoderm and retinoic acid, Shh and Bmp2 associated with the ZPA (Fig. 1.4B 
and C). In addition, genes encoding transcription factors are expressed in the 
developing limb, including genes from the Tbx family, the Hoxa and Hoxd complexes, 
and Lmxl (Tickle, 2003).
The AER is present throughout all the phases of limb development. Four different Fgf 
genes (.Fgf4, FgfS, Fgf9, FgflO and Fgf 11) are expressed in complex dynamic patterns 
in the AER of vertebrate limb buds during development. Experiments in mouse have 
shown that when Fgf function is deleted in the AER from very early stages of mouse 
limb bud development, there is no limb formation (Tickle, 2004).
In dorso-ventral patterning, Wnt7a acts as a dorsalising factor. It is expressed very early 
in limb bud development, suggesting a possible role in maintaining Shh expression, and 
its expression is maintained in dorsal ectoderm throughout limb outgrowth and into 
digit stage formation (Tickle, 2004).
Retinoic acid, a vitamin A derivative, was the first defined chemical discovered to have 
a polarizing activity (the ability to induce additional digits) due to induction of Shh 
expression in anterior limb mesenchyme (Tickle, 2003). Shh is expressed in the ZPA 
and its role in controlling digit number and identity is almost certain. The type of digit 
that develops in a particular position, digit identity, is related to the strength of Shh 
signaling with the highest level of signaling being required for specification of the most 
posterior digit. In absence of Shh signaling, structures distal to the elbow/knee are very 
reduced.
Shh signaling in the limb bud is mediated by the zinc finger transcription factor Gli3. In 
the limb bud there is a gradient of repressor and activator forms of Gli3. Shh prevents 
processing of Gli3 to its repressor form and diffusion of Shh from the polarizing region
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creates a concentration gradient across the bud. This results in a dose-dependent relief 
of inhibition imposed by high levels of the repressor form of Gli3 and thus allows 
expression of target genes with the downstream consequences of specification of digit 
number and specification of antero-posterior position leading to digit identity (Tickle, 
2003). Shh signal specifies digit identity acting via bone morphogenic proteins (Bmps), 
in particular Bmp2, which acts downstream of Shh. Bmp2 is expressed posteriorly in 
normal limb buds but whether it represents the polarizing morphogen or not is still 
controversial. Another main downstream target of Shh signaling is an apical ridge 
maintenance factor produced by the ZPA in order to specify digit number. This is the 
Bmp antagonist Gremlin, whose expression is inhibited by high levels of the repressor 
form of Gli3. Gremlin antagonises Bmp signaling in the AER thus allowing expression 
of Fgf4 and the AER function to be maintained (section 1.2.3.1)(Zuniga et al., 1999).
Members of the Tbx family of genes encoding transcription factors have recently been 
shown to be implicated in digit and limb identity. In chick embryos, posterior 
expression of Tbx2 and Tbx3 regulates posterior digit identity, whereas Tbx4 and Tbx5 
are expressed in regions of the embryos that will give rise to legs and wings 
respectively (Tickle, 2004).
Finally, different combinations of Hoxa and Hoxd genes are known to be responsible 
for patterning the different limb segments. Hoxdl3 and Hoxa 13 pattern the digits, 
Hoxdll and Hoxa 11 the lower arm/leg, Hoxd9 and Hoxa9 the upper arm and HoxlO 
paralogs the upper leg (Tickle, 2004). Hox gene expression changes in the developing 
limb are induced by a combination of Fgf signaling with retinoic acid, Shh, and Bmps. 
The 5’ Hoxd genes are expressed very early in lateral plate mesoderm, while the 5’ 
Hoxa genes are activated in sequence initially in lateral plate mesoderm and later into 
the limb bud. 5’ genes in both clusters are also expressed at a later stage during 
patterning of digits.
Determination of the number of digits and their identity is mediated by cell-cell 
interactions in the developing limb bud. Both Bmp and Fgf signaling in mesenchyme 
and AER are known to be implicated in these processes. Separation of individual digits 
is then mediated by cell death of the soft tissue web between the digits, which is 
regulated by Bmps (Tickle, 2004).
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1.3.2 Limb anomalies in humans
In humans, limb malformations occur in approximately one in a thousand neonates. 
Two classification schemes are currently favored by clinicians, the Temtamy and 
McKusack classification purely based on clinical descriptions (Temtamy and 
McKusick, 1978), and the Winter and Tickle classification based on embryological and 
clinical concepts that distinguish abnormalities related to defects in embryological 
patterning from those that are not (Winter and Tickle, 1993). Nowadays, the increasing 
knowledge of the genetic basis of many limb malformations enables classification to be 
made by their underlying genetic defects (reviewed in Wilkie, 2003). The list of genes 
that are known to be responsible for human limb defects continues to grow. Amongst 
the first genes to be discovered were the fibroblast growth factor receptors, mutations in 
which are responsible for achondroplasia and several other conditions with digit 
anomalies such as Apert syndrome (Wilkie, 2003). Mutations in the GLI3 gene are 
responsible for Grieg cephalopolysyndatctyly (Wild et a l , 1997). Mutations in 
HOXD 13 were found to be associated with human synpolydactyly (Muragaki et al., 
1996), whereas defects in HOXA 13 have been identified in hand-foot-genital syndrome 
(Mortlock and Innis, 1997). TBX genes have also been implicated in Holt-Oram 
syndrome (TBX5) (Basson et al., 1997; Li et a l , 1997) and ulnar-mammary syndrome 
(77LD)(Bamshad et a l , 1997). More recently, mutations in regulatory elements of SHH 
have been associated with preaxial polydactyly (PPD)(Lettice et a l , 2003).
1.4 General aspects of kidney development
The kidney develops from the intermediate mesoderm, a strip of cells along the 
posterior wall of the abdominal cavity which connects the somite (dorsal mesoderm) to 
the lateral plate mesoderm (Fig. 1.5A). The mesoderm which will form the kidney is
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Figure 1.5 Schematic of kidney development. A transverse section showing the 
pronephric (A) and mesonephric (B) tubules is represented. The development of the 
metanephros to adult kidney is also shown (C). Adapted with permission from 
http://www. uoguelph. ca/zoology/devobio/210labs/kidney2. html
43
also called the nephrogenic mesoderm or the nephrogenic cord. The kidney is 
composed of two elements: the kidney tubules, which filter the blood, and the kidney 
ducts, which collect and carry the filtrate to the cloaca. The development of the kidney 
is complex and depending on species, two or three different kidneys form in temporal 
and spatial sequence. The first and most anterior to develop is the pronephric kidney or 
the pronephros. The second kidney to form is the mesonephros. A third kidney 
develops posterior to the mesonephros in birds, reptiles and mammals and is called the 
metanephros.
The pronephros is first seen as a segmenting of the intermediate mesoderm into 
nephrotomes (Fig. 1.5A). The nephrotomes then develop into pronephric tubules, 
which empty into a pronephric duct. At the proximal end of the pronephric tubules, 
ciliated funnels called nephrostomes form and open into the coelomic cavity (Fig. 
1.5A). The glomus is a vascular ridge near the nephrostome where waste products are 
filtered from the blood. The excretory products are then released into the coelomic 
space where they are propelled by ciliary action from the coelom, through the 
nephrostome and into the pronephric tubules. The waste products then move through 
the pronephric duct and into the cloaca from where they are excreted. In embryos of 
birds, reptiles and mammals, the pronephros appears briefly as a transitory structure 
that degenerates as the mesonephros develops immediately posterior to it.
When the second embryonic kidney, the mesonephros, develops, the mesonephric 
tubules form an expanded, blind-ended region that invaginates to form a double walled 
cap called the Bowman’s capsule (Fig. 1.5B). This invagination is caused by a group of 
capillaries, called a glomerulus, pushing into and becoming surrounded by the 
Bowman’s capsule (Fig. 1.5B). The structure formed by the glomerulus surrounded by 
the Bowman’s capsule is called a renal corpuscle or Malpighian corpuscle. Meanwhile, 
the mesonephric tubules become long and coiled with their distal ends opening into the 
mesonephric duct (also called archinephric ducts or Wolffian ducts).
The third kidney, the metanephros, develops from a diverticulum, called the ureteric 
bud, of the mesonephritic duct posterior to the mesonephros (Fig. 1.5C). The ureteric 
buds elongate into the region of presumptive metanephrogenic mesenchyme and induce 
the mesenchyme to form the nephric renal tubules. Reciprocal interactions between the
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mesenchyme and the ureteric bud cause the latter to branch and form a tree-like system 
of collecting ducts (Fig. 1.5C). The initial tube portion of the ureteric bud is called the 
ureter. At the metanephric end of the ureter, an expansion called the renal pelvis forms 
and branches numerous times to form the collecting ducts. One end of the nephric 
tubules will connect to the collecting ducts, while the other end will form the 
Bowman’s capsule that surrounds the glomerulus. The nephritic tubules become long, 
S-shaped and develop specialized regions. Subsequently, the ureters separate from the 
mesonephric ducts, elongate and serve to carry urine from the kidney to the bladder.
The adult kidney is bean shaped with the indent being called the hilum where the renal 
artery and nerves enter and the ureter and renal vein exit (Fig. 1.6A). The renal pelvis is 
immediately adjacent to the hilum. The periphery of the kidney is surrounded by a 
connective tissue capsule and beneath the capsule is a region called the cortex (Fig. 
1.6B). The cortex is where the renal corpuscles (glomeruli plus Bowman’s capsules) 
and most of the nephric tubule is located. Below the cortex is the medulla composed of 
nephric tubules, collecting ducts and numerous capillaries (Fig. 1.6B). The medulla 
narrows into a pyramid-shaped structure, the renal papilla, near the renal pelvis. Urine 
is discharged from the collecting ducts, which open into the renal papilla, and moves 
through the renal papilla to the renal pelvis and out of the kidney through the ureter.
1.4.1 Molecular basis of kidney development
Although the morphogenetic steps of kidney development have been well 
characterised, the nature of many of the molecules involved in this process are still 
unknown. However, the use of genetically modified mice, zebrafish and Xenopus laevis 
has provided valuable models to elucidate the role of some of these molecules. There 
are a growing number of potential molecules that are expressed during embryonic 
kidney development including growth factors and their receptors, transcription factors, 
integrins, extracellular matrix components and proteoglycans.
45
Artery
1
B
Figure 1.6 Gross morphology of the kidney (A and B). Adapted with 
permission from http://www.auburn.edu/~deruija/renal_partl Zsld006.htm
Cortc*
'Fibrous capsule
Papilla of pyramid 
Renal column
Minor calyces
Major calyces
M oduila
Renal pelvis
Medullary rays
Ureter
46
It has been proposed that development of the definitive metanephric kidney depends on 
a series of sequential and reciprocal molecular interactions between the ureteric bud 
epithelium and the metanephric mesenchyme. The development of the kidney initiates 
by formation and growth of the ureteric bud. As the ureteric bud invades the 
metanephric mesenchyme, it induces condensation and nephrogenesis through 
reciprocal interactions.
One of the earliest markers of the metanephrogenic mesenchyme is the Wilms tumor 
suppressor gene Wtl, which is initially expressed in the intermediate mesoderm and 
then restricted to the metanephrogenic mesenchyme and gonads, amongst other tissues, 
but absent from ureteric bud tissue (Armstrong et a l , 1993). In Wtl null mice the 
metanephric mesenchyme can be identified, but at day 11 of gestation the cells undergo 
apoptosis (Kreidberg et a l , 1993).
Genetic analysis in mice shows that Pax2, Pax8, Eyal, Sixl and Six2 transcription 
factors are expressed during early stages of kidney development. In Pax2-deficient 
embryos, initial formation of the pro- and mesonephros occurs normally, but the 
metanephros as well as the genital tract never develop (Torres et a l , 1995). In Pax8 
mutant embryos kidney development is normal. However, in Pax2, Pax8 double-mutant 
embryos, the intermediate mesoderm is lost by apoptosis, suggesting that Pax2 and 
Pax8 transcription factors can at least in part substitute for each other in development 
and together specify the nephric lineage (Bouchard et a l , 2002).
The first signal from the metanephric mesenchyme in the form of a diffusible signaling 
molecule causing the initial budding of the nephric ducts and elongation of the buds 
towards the mesenchyme is Gdnf (glial-cell-line-derived neurotrophic factor). The Gdnf 
gene is expressed in the metanephric mesenchyme before ureteric bud induction and 
mice with inactivated Gdnf alleles die soon after birth due to renal agenesis (Sanchez et 
a l , 1996). Gdnf promotes the formation of primary ureteric buds acting as a ligand for 
the c-Ret receptor tyrosine kinase that is located at the tip of the ureteric bud (Trapp et 
a l , 1996). Gdnf expression is regulated by a variety of different factors, which have 
been recently identified through gene knockout experiments. Genetic ablation of the 
Drosophila sine oculis homolog Sixl, for example, leads to a variety of kidney 
phenotypes including agenesis (Li et a l , 2003). The ureteric bud forms but does not
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invade the metanephric mesenchyme completely. There is no induction of nephron 
tubules and the metanephric mesenchyme undergoes apoptosis (Li et al., 2003). In Sixl 
mutant metanephric mesenchyme, Gdnf expression is reduced. SIX1 protein binds the 
Gdnf promoter in a complex with EYA1 protein tyrosine phosphatase, suggesting a 
direct role for Sixl in transcriptional regulation of Gdnf (Li et al., 2003). Eyal 
knockout mice show loss of Gdnf expression as well as loss of Sixl and Six2 
expression.
The Sal-like 1 (Salll) deficient mouse also shows defects in full invasion of the ureteric 
bud into the metanephric mesenchyme (Nishinakamura et al., 2001). In Sixl mutants, 
Salll expression is lost, suggesting that Sixl may act upstream of Salll.
The transforming growth factor family member 11 (G dfll) is expressed in both the 
Wolffian duct and the metanephric mesenchyme. G dfll null mutant kidneys exhibit 
bilateral agenesis, unilateral agenesis or hypoplasia (Esquela and Lee, 2003). Gdnf 
expression is not detected in the mutant mesenchyme, suggesting that Gdfll may 
regulate Gdnf expression and therefore ureteric bud outgrowth. Alternatively, loss of 
Gdnf expression could result secondarily from failure of ureteric bud invasion.
A role in restricting the Gdnf expression domain is played by the secreted Slit2 protein 
and its Robo2 receptor. In both Slit2 and Robo2 mutants, multiple ureteric buds form 
anterior to where normal ureteric bud outgrowth occur, and multilobar kidneys are 
observed (Grieshammer et al., 2004). The anterior boundary of the Gdnf expression 
domain in Slit2 and Robo2 mutants is expanded and reducing Gdnf expression rescues 
the mutant phenotype. Eyal and Pax2 expression are unchanged in mutants, suggesting 
that Slit2/Robo2 does not regulate Gdnf expression through these molecules.
Recently, a number of ureteric bud-expressed genes have been identified and described 
to be important in branching of the ureteric bud and rescuing the metanephric 
mesenchyme from apoptosis after the outgrowth of the ureteric bud. The FRAS1 gene, 
for example, the gene responsible for Fraser syndrome (a congenital disorder affecting 
several systems including the kidney) has been recently mapped (McGregor et al.,
2003). Studies in the mouse mutant model for Fraser syndrome, blebbed, in which the 
homolog of FRAS1 was found to be truncated by mutation, and in Frasl mutants
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suggest that Frasl may play a role in local interactions that regulate the survival and the 
induction of the metanephric mesenchyme (Vrontou et a l, 2003). In both blebbed and 
Frasl mutants, in fact, the ureteric bud forms and invades the metanephric 
mesenchyme, but induction does not occur resulting in apoptosis of the mesenchyme 
and termination of ureteric bud growth. In another mouse model of Fraser syndrome, 
eyeblebs, the Gripl gene is disrupted (Takamiya et al., 2004). Gene targeting of Grip1 
showed complete renal agenesis. The ureteric bud forms and invades the metanephric 
mesenchyme, but induction of the mesenchyme fails to occur as shown by a lack of 
Wtl upregulation and an increase in apoptosis. Gripl and Frasl colocalize to the basal 
surface of epithelial cells and they can physically interact.
As outlined in section 1.2.3.2, it has been recently demonstrated that the BMP 
antagonist Gremlin is required to initiate ureter growth and branching that in turn 
induces metanephric nephrogenesis (Michos et al., 2004). Gremlin is initially expressed 
in the intermediate mesenchyme and subsequently in the posterior Wolffian duct and 
metanephric mesenchyme. During branching, Gremlin is expressed locally in the 
mesenchyme surrounding the invading ureter. In Gremlin mutants, the ureteric bud 
forms, but fails to invade the metanephric mesenchyme. In the mutant metanephric 
mesenchyme, Gdnf expression is reduced at embryonic day 11.25 and lost by 
embryonic day 11.5 resulting in failure of branching. Pax2 expression is also lost by 
embryonic day 12.5 suggesting a possible failure to induce condensation of the 
metanephric mesenchyme.
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1.5 Strategies for gene identification
To identify a disease gene four main strategies are employed: functional cloning, 
positional cloning, the candidate gene approach or a combination of the latter, the 
positional candidate approach (Collins, 1995). Many varied pathways have been used 
to identify disease genes, but ultimately all methods aim to identify one or more 
plausible candidate genes, which are then examined further for evidence that they 
associate with the disease.
1.5.1 Functional cloning
A gene can be identified by a position-independent strategy with no prior knowledge of 
its chromosomal position (Ballabio, 1993; Collins, 1992). This approach requires 
information about the function of the unidentified gene and isolation of the protein 
product of the gene. The amino acid sequence can be determined if adequate amounts 
of protein are available. Partially degenerate oligonucleotides coding for the protein can 
be synthesized and used to screen a cDNA library. The cDNA clone(s) is then used to 
screen a genomic library to enable characterisation of the gene from a genomic clone. 
An alternative approach is to raise antibodies to the protein of interest and use these to 
screen an expression cDNA library.
The main limitation of this approach is that biological information about the function of 
most gene products is simply not available. This method has been successful only in a 
few cases, for example in enzyme deficiencies such as phenylketonuria, known to be 
due to deficiency of the enzyme phenylalanine hydroxylase or Haemophilia A, due to 
deficiency of Factor VIII (DiLella et a l , 1986; Gitschier et al., 1984) .
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1.5.2 The candidate gene approach
The pure candidate gene approach relies on some knowledge of the type of gene 
anticipated to be involved in a particular disorder, but no prior information regarding its 
chromosomal position. The major limitation of this approach is that predictions of the 
biochemical functions of an unknown gene are often inaccurate in view of the 
complexity of the disease. In addition, screening for mutations in multiple candidate 
genes is very time-consuming. However there are several ways in which ‘educated 
guesses’ for good candidates can be made.
A candidate gene for a human disorder may be proposed on the basis of similarity of 
the phenotype to the phenotype of another human disorder for which the gene is 
known. The expression pattern or function of a gene may support the hypothesis that it 
is a candidate for a particular disorder. Animal models, as already outlined in section 
1.2.2, whether spontaneous or artificially generated, can also suggest candidate genes 
for human disorders, since if the animal model has a similar phenotype to the human 
condition, it might result from mutations in the animal orthologue of the human disease 
gene. Although this approach can prove extremely valuable, there are limitations to the 
use of animal models as the phenotype in humans and mice may differ considerably 
despite mutations in orthologous genes.
1.5.3 Positional cloning
In this method, a disease gene is cloned from an initial approximate knowledge of its 
subchromosomal localization, with no prior knowledge of its sequence or biochemical 
function to suggest a likely candidate (Collins, 1995). The initial localization of the 
disease gene could be a chromosomal location of 10 Mb or more, which may have been 
identified by linkage analysis (section 1.6) or the presence of a visible cytogenetic 
abnormality such as a translocation, a duplication or a deletion associated with the 
disease in some patients.
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The first step is to refine the candidate region as precisely as possible. An initial 
genome-wide screen for linkage is normally carried out using markers spaced at 
relatively wide intervals (often 10-15 cM) and will therefore define a large candidate 
region. More closely spaced polymorphic markers need to be analysed once a candidate 
region has been identified. Disease haplotypes are identified in individual pedigrees by 
haplotype analysis and recombinants are identified in order to define proximal and 
distal flanking markers. This defines a candidate region, which cannot be narrowed 
further except by finding new recombinants in other affected families. Linkage 
disequilibrium (section 1.6.6) when present, can help to narrow the candidate region 
further.
The next step is to construct an ordered contig of clones, often YACs (yeast artificial 
chromosomes), across the critical region. Nowadays, with the progress of the Human 
Genome Mapping Project, an ordered contig is likely to be available for most regions 
of the genome. If not, it is possible to identify the YACs by screening publicly 
available libraries. As YACs contain large inserts (often up to 1 Mb) they can be often 
unstable and prone to rearrangements, so other vectors such as PACs (PI artificial 
chromosomes) or BACs (bacterial artificial chromosomes) with smaller insert sizes 
(100-300 kb) may be used to form the contig. BAC clone data can be accessed in many 
different ways, either directly from sequencing centers or from publicly available 
databases. Once a physical map of the interval with overlapping DNA clones has been 
built, these can be used as a substrate to identified novel candidate genes.
Several methods are then used to identify expressed sequences within these genomic 
clones. These methods include cDNA selection, cDNA library screening using genomic 
clones from the candidate region as probes, “zoo blotting” to search for evolutionarily 
conserved sequenced, identification of CpG islands which are often situated close to 
genes, exon trapping to identify genomic sequences flanked by functional splice sites 
and sequence analysis. A transcript map of all expressed sequences within the region is 
then generated, and the most likely candidate genes can then be screened for evidence 
that they are associated with the disease.
An example of the use of the positional cloning approach is the identification of FRA SI 
gene for Fraser syndrome (McGregor et al., 2003). Homozygosity mapping narrowed
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the candidate region to a 1.5 cM interval on 4q21 and then a positional cloning 
approach was used to identify suitable candidate genes. The human cDNA sequence of 
FRASl in the region was determined from the cDNA sequence used in a targeted gene 
knockout causing an identical phenotype to the blebbed mouse, which had been 
previously postulated to be a model for Fraser syndrome (McGregor et al., 2003; 
Vrontou et al., 2003).
The positional cloning approach is laborious, although in recent years as the human 
genome sequence progresses, practical approaches to the characterisation of genomic 
loci have changed and become more efficient and rapid using web-based resources. The 
wide availability of transcript maps and the gradual increase in the number of annotated 
genes allowed the positional cloning to be superseded by the positional candidate 
approach which nowadays represents the most widely used method of gene 
identification (Collins, 1995).
1.5.4 The positional candidate approach
The majority of genes have been identified using the positional candidate approach 
which combines both the pure positional cloning and the positional independent 
candidate approaches, since the most robust candidate genes are those that map to the 
same chromosomal region as the disease. This approach has been facilitated by the 
increased information and resources made available by the Human Genome Project. 
Therefore, once a candidate region is identified (usually by linkage analysis), attractive 
candidate genes mapping to this region can be selected from public databases, which 
contain rapidly increasing numbers of mapped genes often identified only as cDNA or 
ESTs. However, a candidate region often contains a considerable number of genes and 
it is essential to select appropriate candidate genes and prioritise them for further 
investigation. This demands careful consideration of information on their spatial and 
temporal pattern of expression (from Northern blotting, RT-PCR or in situ 
hybridisation of mRNA in tissue sections), likely function or functional domains, and
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homology to other genes implicated in similar human phenotypes, model organisms or 
relevant natural mutants.
The identification of the gene for recessive Robinow syndrome represents an example 
of how the positional candidate approach was successfully adopted. The condition was 
mapped to 9q22 by homozygosity mapping in consanguineous families (Afzal et al., 
2000a). This region overlapped with the locus for autosomal dominant brachydactyly 
B. The identification of ROR2 as the gene mutated in brachydactyly B and the 
observation that homozygous knockout mice (Ror2 -/-) show mesomelic dwarfing 
made this a candidate for Robinow syndrome. Afzal and colleagues subsequently 
showed that ROR2 mutations are associated with recessive Robinow syndrome (Afzal 
and Jeffery, 2003; Afzal et al., 2000b).
1.6 Linkage analysis
1.6.1 Recombination and linkage
The positional cloning and positional candidate approaches outlined above in sections
1.5.3 and 1.5.4 both rely on the identification of the chromosomal region of interest as a 
starting point. When there are no cytogenetic ‘clues’, such as a translocation, a 
duplication or a deletion, the method most commonly used to achieve the initial 
localisation is linkage analysis. The principle behind linkage analysis is that two loci 
that lie close to each other on the same chromosome (i.e. are syntenic) tend to segregate 
together during meiosis and thus tend to be inherited together as a ‘linked unit’, 
whereas the further apart two syntenic loci lie on a chromosome, the more likely it is 
that they will be separated by a recombination event during meiosis. If alleles at two 
loci cosegregate together in significantly more than 50% of all the observed meioses, 
then the two loci are said to show genetic linkage.
The recombination fraction (0) is the measurement of genetic linkage. This decribes the 
chance of recombination occurring between two loci and is the probability that a parent
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will produce a recombinant offspring. The recombination fraction (0) is an indirect 
measure of the genetic distance between genetic loci and ranges from zero, for tightly 
linked loci, to 0.5 for loci that are unlinked or on different chromosomes (Terwilliger, 
1994). The smaller the recombination fraction, the smaller the genetic distance between 
two loci. A recombination fraction of 0.01 (only one in every 100 offspring inherits the 
recombinant haplotype) corresponds to a genetic distance of one centimorgan (1 cM). 
A genetic distance of 1 cM approximates to a physical distance of 1 Mb, although this 
is variable as recombination is more likely to occur in some chromosomal regions than 
others, for example the telomeres, and is greater in females compared to males.
1.6.2 Lod scores
The lod score is defined as the logarithm to base 10 of the odds of linkage, and is a 
measurement of the likelihood of genetic linkage between two loci. It is a statistical 
score in which the likelihood of alleles at two genetic loci being inherited together 
because they are situated close together on the same chromosome (i.e. linked) is 
compared to the probability that this happened by chance (i.e. not linked). The lod 
score is therefore equal to the logarithm to base 10 of the ratio of the probability that 
two alleles are linked with a given recombination value 0 divided by the probability 
that they are unlinked. The likelihood of observing a particular pattern of inheritance of 
a disease and a marker locus is calculated assuming varying degrees of linkage over a 
range of recombination fractions (0 = 0 to 0.5) and compared to the likelihood of 
observing the same inheritance pattern assuming no linkage (0 = 0.5).
The lod score is calculated according to the following formula:
Lod score (Z) = logio L (0 = x) / L (0 = 0.5)
where L is the likelihood of the observed inheritance pattern and x is a particular value 
of 0, usually between zero and 0.5. When the lod score reaches its maximum, the most 
likely recombination fraction is located. If there are no recombinants, the lod score will 
be maximal at 0 = 0, but if there are recombinants, the lod score will be highest at the
55
most likely recombination fraction. This is a two-point lod score as it refers to linkage 
between two loci, i.e. the disease locus and the marker locus. There is usually enough 
evidence for linkage between two loci if the lod score is greater than 3 for a 0 value. A 
lod value of 3, in fact, means that the chances are greater than 1000:1 that the two loci 
are linked than the odds that they are not. If the lod score is below -2, this is accepted 
as evidence excluding linkage to the region. Values in between -2  and +3 are 
inconclusive (Terwilliger, 1994).
A limitation in using linkage mapping in humans is that families are often too small to 
generate statistically significant linkage information. However, since lod scores are 
logarithms, it is possible to add together lod scores from separate small families. 
Human linkage analysis relies on computer programs such as LIPED or MLINK, which 
is part of the LINKAGE package (Terwilliger, 1994) to compute the lod scores.
Multipoint linkage analysis is an extension of the two-point linkage analysis. Instead of 
finding the recombination fraction between a single marker and a disease locus, 
multipoint analysis aims to map a disease locus against several markers at the same 
time and establishes between which two markers the gene is most likely to be located. 
The MLINK and LINKMAP programs from the LINKAGE package can both be used 
for multipoint analysis (Terwilliger, 1994).
1.6.3 Polymorphic markers
Multiple highly informative DNA polymorphic markers are used in a genome wide 
screen for genetic linkage, to see whether a marker at a particular locus segregates with 
the disease in a family. The earliest polymorphisms used in linkage analysis were 
enzyme polymorphisms and blood group markers.
Restriction fragment length polymorphisms (RFLPs) were the first type of DNA 
marker used in linkage analysis, but a whole genome scan using this method was 
extremely time consuming as it involved typing the RFLPs using radiolabelled probes 
hybridised to Southern blots of restriction digests. Moreover they had limited 
informativeness, as restriction enzyme sites are either present or absent and therefore
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they give rise to two alleles. Minisatellite markers (or variable number tandem repeats, 
VNTRs) represented the next generation of markers. They had greater informativeness, 
but the technology available at the time still required the use of Southern blotting and 
hybridisation with radiolabelled probes.
The informativeness of a marker is measured by the polymorphism information content 
(PIC), which is a mathematical formula showing the probability of identifying the 
parental chromosome contribution in any given offspring. The PIC is calculated 
according to the following formula:
PIC = 1 - (p2 + q2 + r2) -  (2p2q2 r2) where p, q and r are allele frequencies.
It was only with the advent of PCR and the identification of multiple polymorphic 
microsatellite markers (mainly short (CA)n repeats) that mapping had been greatly 
facilitated allowing large-scale rapid genome-wide linkage analysis to be developed. 
Tri- and tetranucleotide repeats are increasingly being used for their advantage to be 
less prone to ‘stutter’ bands when amplified by PCR, which makes the allele size hard 
to interpret. Panels of fluorescent-labelled primers to amplify markers spaced at 10-20 
cM density across the genome, which can be multiplexed, are available for high 
throughput genotyping. Detailed genetic linkage maps of microsatellites throughout the 
genome have been generated and are available on public databases (Dib et al., 1996).
Nowadays with the advent of DNA microarray technology, single nucleotide 
polymorphisms (SNPs) represent a powerful high throughput tool for linkage analysis. 
Although SNPs are less informative than the currently used genetic markers, having 
only two alleles, they are much more abundant and widespread throughout the genome. 
More than 10,000 SNPs can be genotyped simultaneously per single DNA sample 
enabling a genome-wide screen to be performed rapidly. Efforts have been made to 
integrate information from existing genetic and physical maps to provide a high 
resolution map which includes SNP positions and is now publicly available (dbSNP at 
the NCBI website).
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1.6.4 Homozygosity mapping
Recessive disorders are usually rare in the general population, but common in 
consanguineous families. Rare recessive diseases arise relatively more in 
consanguineous families usually because the affected children have inherited the same 
disease allele from each of their parents. Each of the parents has in turn received this 
disease allele from a recent common ancestor.
Homozygosity mapping is a method of mapping the genes underlying rare recessive 
disorders using consanguineous families. This strategy was first proposed by Lander 
and Botstein in 1987 (Lander and Botstein, 1987). The basic principle is that affected 
offspring of consanguineous parents are homozygous not just for the same disease 
allele, but they are also likely to be homozygous for a whole segment of the 
chromosomal region around the disease locus (Fig. 1.7). In each child of first-cousin 
parents, whether affected or not, on average 1/16 of the genome is expected to be 
identical-by-descent (IBD) (This is 1/64 for a child of second cousin parents; and 1/256 
for a child of third cousin parents). Such regions can be detected by genotyping with 
polymorphic markers. If several closely-linked polymorphic markers are all 
homozygous, then the region is IBD. If just one isolated marker in a region is 
homozygous, and the flanking markers are heterozygous, then the isolated marker must 
just be identical-by-state (IBS), and the region as a whole is not IBD. If several 
different affected individuals from the same consanguineous family, and/or several 
affected individuals from different consanguineous families are analysed, it is very 
unlikely that they will all share the same region of IBD unless this region contains the 
disease gene. In homozygosity mapping, therefore, affected individuals from 
consanguineous families are genotyped with a set of polymorphic markers spanning the 
whole genome, in order to define a region where the affected individuals are all 
homozygous. This region is then highly likely to contain the disease locus.
This approach has several advantages over standard methods for carrying out linkage 
analysis in non-consanguineous families. Firstly, families consisting just of the parents
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Figure 1.7 Schematic representation of the principle of homozygosity mapping. A 
simple three-generation first cousin pedigree for an autosomal recessive condition 
is illustrated. The disease locus is indicated in black and the preserved ancestral 
area surrounding the locus is shown in orange. Recombination events occurring in 
generations II and III have narrowed down the region homozygous by descent in 
the patient. The identification of common regions homozygous by descent between 
unrelated affected individuals is the basis of homozygosity mapping. The solid 
symbol represents the affected individual in generation IV. Dotted symbols 
represent carriers.
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and a single affected child are informative for linkage. This is a major advantage when 
trying to map rare recessive conditions, as families with more than one affected child 
are often hard to find. Secondly, the approach has high statistical power. A 
consanguineous family consisting of a single affected child bom to first-cousin parents 
can provide the same support for linkage as a non-consanguineous nuclear family with 
three affected sibs (Lander and Botstein, 1987). Homozygosity mapping therefore 
allows the use of smaller and fewer families to obtain linkage. Finally, much less 
genotyping work is required. Instead of typing the whole family across the entire 
genome, only the affected individuals are used in the initial genome-wide screen. Once 
the candidate regions have been identified, where the affected individuals are IBD, then 
other family members can be typed across these regions, to see whether the IBD 
haplotype segregates with the disease.
There are, however, potential problems associated with homozygosity mapping, one of 
which is locus heterogeneity (section 1.6.6). If the disease is caused by mutations at 
more than one locus, it will be misleading to pool results from different families. The 
best solution is to find large multiply-affected consanguineous families and analyse 
them separately or use statistical methods for detecting locus heterogeneity in large 
numbers of small families (Sheffield et a l , 1995). Allelic heterogeneity, when two 
different disease causing mutations within a gene segregate in the family, may also 
represent a problem in homozygosity mapping and cause a locus to be missed by loss 
of homozygosity in flanking markers (Miano et al.9 2000). In addition, the 
identification of a homozygous IBD region unrelated to the disease locus may occur 
merely by chance (Miano et al., 2000). Finally, the potential for inflation of LOD 
scores as a result of underestimation of the extent of inbreeding may also be quite 
common (Miano et al., 2000).
The availability of suitable markers is an important issue. The approach depends on 
having a good genetic map of the human genome and suitable highly-polymorphic 
closely-spaced markers covering all parts of the genome evenly.
The choice of marker spacing in the initial genome-wide scan is another critical issue. 
If markers are too far apart, the locus of interest can be missed, as affected individuals 
may not be homozygous at the nearest marker to the locus that is tested. But if the
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markers are too close together, it will involve testing an excessive number of markers 
(Geninet al., 1998).
Finally, the degree of consanguinity should be taken into account. The more remote the 
consanguinity between the parents, the smaller the region of homozygosity around the 
disease locus in the affected child, so more densely-spaced markers to detect it will be 
necessary. However, in such cases the interval containing the disease locus can be more 
precisely mapped.
Over the last 10 years, many genes underlying rare recessive disorders have been 
mapped using homozygosity mapping. Some of the earliest were genes for alkaptonuria 
(Poliak et al., 1993), Friedreich ataxia with selective Vitamin E deficiency (Ben 
Hamida et al., 1993) and Bardet-Biedl (Kwitek-Black et al., 1993a). More recent 
examples include many genes for autosomal recessive non-syndromic deafness 
(Kalatzis and Petit, 1998; Willems, 2000); Robinow syndrome (Afzal et a l , 2000b; van 
Bokhoven et al., 2000); recessive hypercholesterolemia (Eden et al., 2001); and Fraser 
syndrome (McGregor et al., 2003).
1.6.5 Haplotype analysis
The refinement of a candidate region identified by linkage analysis is often achieved by 
the ascertainment of additional family members and construction of haplotypes using 
additional markers in the region. The presence of recombinants, especially if they occur 
in an affected individual, can help to narrow down the region of interest. Recruitment 
of additional families may also help to refine the candidate region by identifying 
overlapping regions of homozygosity.
1.6.6 Linkage disequilibrium
Linkage disequilibrium (LDE), or allelic association, can provide a powerful tool to 
refine the candidate region once the general location of the gene has been established
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by conventional linkage analysis. LDE is the association of a particular allele of a 
polymorphic marker with the disease at a population level. It occurs when apparently 
unrelated affected individuals all derive their disease chromosome from a common 
ancestor, and tends to occur in diseases with low mutation rates. This phenomenon is 
usually only seen with markers closely linked to the disease locus. LDE was 
successfully employed in the identification of the disease gene for cystic fibrosis 
(Kerem et al., 1989).
1.6.7 Genetic heterogeneity
Mutations in several genes may produce the same disease phenotype. This is known as 
locus heterogeneity. Allelic heterogeneity describes the case when different mutations 
within the same gene cause the same clinical phenotype. The situation in which 
mutations in the same gene cause different diseases is known as clinical heterogeneity.
Locus heterogeneity represents a complicating factor when the homozygosity mapping 
approach is adopted as a tool for locating disease genes in a small number of 
consanguineous families. This problem can be solved by using larger numbers of small 
consanguineous families and statistical methods which detect heterogeneity or by the 
use of isolated populations to identify extended inbred kindreds(Sheffield et al., 1995).
For example, three extended Bedouin kindreds were used to map three Bardet-Biedl 
syndrome loci to chromosome 16q21 (BBS2), 3ql2-ql2 (.BBS3) and 15q22.3-q23 
(BBS4) (Kwitek-Black et al., 1993b; Sheffield et al., 1994; Carmi et al., 1995). An 
extended Bedouin family was also used to map a novel type of autosomal recessive 
infantile nephronophthisis on chromosome 9q22-31 by homozygosity mapping (Haider 
et al., 1998). Statistical analysis for linkage heterogeneity can be carried out using the 
HOMOG program package (Terwilliger, 1994).
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1.7 Confirmation of a candidate gene
Once a candidate gene has been identified, by whatever approach, it must be analysed 
to find evidence for association with the disease. The gene is screened for mutations in 
a panel of DNAs from unrelated affected individuals and controls. If the selected gene 
turns out to be the disease causing gene, the unrelated patients will show a number of 
different mutations predicted to have a deleterious effect on gene function, which 
segregate with the disease and which are not present in controls. Pairs of specific 
primers are designed to amplify the coding DNA, either from a genomic DNA sample 
if the intron/exon boundaries are known, or from cDNA produced by RT-PCR from 
patient mRNA.
Large-scale deletions, duplications and translocations can be detected by cytogenetic 
techniques such as fluorescence in situ hybridisation (FISH) or array-comparative 
genome hybridization (CGH). Southern blotting may also be useful to detect large 
insertions or deletions. Methods employed to screen for small-scale (single base) 
mutations include heteroduplex analysis, single strand conformational polymorphism, 
denaturing gradient gel electrophoresis and the protein truncation test. Any sequence 
variations identified with these methods must be checked by direct DNA sequencing to 
define the precise nucleotide change(s) involved.
The early chemical methods for DNA sequencing of Maxam and Gilbert required that 
the DNA fragment to be sequenced was labeled at one end usually by adding either a 
radioactive phosphate to the 5’- or 3’-end or a nucleotide to the 3’-end. This method 
has largely been superseded by the enzymatic method of Sanger (dideoxy sequencing 
method), which uses four specific dideoxynucleotides (ddNTPs) to terminate 
enzymically synthesized copies of a template. A sequencing primer is annealed to a 
single strand DNA template molecule and a DNA polymerase extends the primers 
using dNTPs. The extension reaction is split into four and each quarter is terminated 
separately with one of the four specific ddNTPs, which act as chain terminators as they 
lack the 3’-OH group on the deoxyribose necessary to extend the growing chain by the 
polymerase. Instead of ddNTPs, automated DNA sequencing uses four different
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fluorescent dye-labeled chain terminators. All four reactions can be performed in one 
tube and loaded in one gel lane of the electrophoresis gel. A laser at the bottom of the 
gel reads the sequence of the four different colours causing the dyes to fluoresce at 
different wavelengths. The sequence data is given as a series of base specific intensity 
profiles which can be read either by specific computer programs or manually.
1.8 Aims of the project and overview of thesis
The aim of this project was to identify the disease gene or genes causing JATD and 
CLS. A number of suggestions about possible candidate genes and loci for JATD had 
been made before the commencement of this project as described in section 1.1.4. It 
was decided to look in more detail at the EVC/EVC2 region, the 12p 11 -p 12 region and 
the three regions potentially syntenic to the interval to which srt maps in the JATD 
families from whom DNA had been obtained by that time. If these three regions were 
excluded as showing no evidence of linkage to the JATD locus, a full genome-wide 
screen was to be undertaken adopting the technique of homozygosity mapping. Suitable 
candidate genes would then be chosen and screened for disease causing mutations. 
JATD patients analysed in this study and their families are described in Chapter 2. The 
results of this investigation are described in Chapter 4 and discussed in Chapter 5. 
Future directions for this work are also presented in Chapter 5.
This project also describes an investigation into the molecular basis of CLS, aiming to 
identify the disease gene by adopting a position-independent strategy through an animal 
model, the Id mutant mouse, which shows a similar phenotype to CLS patients. Human 
FORMIN-1 (FMN-1) and GREMLIN were identified as candidate genes for the disease 
and were screened for mutations in a panel of CLS patients. Patients are described in 
Chapter 2 and results are described and discussed in Chapter 3.
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Chapter 2 Patients, Materials and Methods
2.1 Patients
2.1.1 JATD patient samples
The JATD patients and their families studied in this project were ascertained with the 
approval of the Institute of Child Health Ethics Committee in several ways. Family 1 
was recruited through clinicians working in the Clinical and Molecular Genetics Unit at 
Great Ormond Street Hospital. Other patients were ascertained following calls for 
patients or direct discussion with clinical geneticists working both in the UK and 
abroad at the British Society of Human Genetics Conferences in autumn 2001 and 
2002; the Dysmorphology Club Meeting of spring 2001; the Manchester Birth Defects 
Conference in autumn 2002; and the European Society of Human Genetics Conferences 
(held in spring 2001 and 2003). Further notices explaining the project and calls for 
patients were also published in the British Society o f Human Genetics Newsletter and 
the American Journal o f Human Genetics. The corresponding authors of previously 
published papers on JATD families were contacted and asked whether they and the 
families were interested in participating in the project. The Jeune Syndrome 
Information and Support Group in Italy was also contacted.
Patients were diagnosed with JATD by the referring clinician through clinical and 
radiological examinations according to the diagnostic criteria described in section 1.1.1. 
Where possible, clinical photographs and radiographs were obtained from the referring 
clinician and reviewed by Prof. Christine Hall to confirm the diagnosis.
For most of the patients and their families, DNA samples or stored blood were already 
available for laboratory analysis. When this was not the case, the referring clinicians 
were asked to obtain samples of venous blood from consenting individuals, and 
forward these for DNA extraction. In the case of one deceased child (Family 7, patient
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II.3), paraffin embedded tissue samples were sent for DNA extraction. Additional 
venous blood samples were obtained from patients IV. 1 and IV.3 in Family 1 and from 
patients VI.3 and VI.5 in Family 2 in order to establish lymphoblastoid cell lines.
For the work described in this thesis, DNA samples, venous blood or tissue samples 
were obtained from a total of 35 affected individuals from 12 consanguineous and 19 
non-consanguineous families. The 12 consanguineous families comprised 9 first cousin 
parent matings, 1 third cousin mating, 1 multiply consanguineous mating and 1 family 
in which the parents were distantly related. All pedigrees were consistent with 
autosomal recessive inheritance.
A collaboration with Dr Colin Johnson, Dr Louise Brueton and Prof. Eammon Maher at 
the University of Birmingham Medical School was set up in autumn 2001. They had 
identified five affected consanguineous families, three of which originated in Pakistan 
but were resident in the UK; the other two originated in Italy and France. They had also 
obtained DNA samples from six affected non-consanguineous families. At the 
beginning of 2003, a collaboration with Dr Valerie Cormier-Daire at the Hopital 
Necker in Paris was set up. Her group had identified seventeen affected families, ten of 
which were consanguineous.
For the study described in this thesis, all DNA samples were ascertained by our group 
except for DNA samples from Families 8, 9 and 16 provided by collaborator Dr Colin 
Johnson and DNA samples from Family 10 sent by collaborator Dr Valerie Cormier- 
Daire.
66
2.1.1.1 Clinical details o f  consanguineous families
(i) Family 1
This multiply-consanguineous Pakistani family (Fig. 2.1) was clinically assessed by Dr 
Louise Wilson, Consultant Clinical Geneticist at Great Ormond Street Hospital, and I 
myself was able to meet them when they were reviewed in the Genetics Clinic. There 
were two affected boys (IV. 1 and IV.3), each the child of a different first-cousin 
marriage (they are double first cousins). Both had a very mild form of JATD.
Patient IV.3 (Fig. 2.2 and 2.3) was noted on antenatal ultrasound (US) to have short 
femora. He had no respiratory problems in the neonatal period. He was referred to the 
Genetics Clinic at GOSH from Thorpe Coombe Children’s Centre because of short 
limbs and a relatively large head. He was first seen at Great Ormond Street Hospital at 
the age of 14 months. His clinical features were consistent with a diagnosis of JATD. 
His height was between the 9th and the 25th centiles, while his weight was on the 50th 
centile. He had mild rhizomelic limb shortening, a small narrow chest, a protuberant 
abdomen, short broad hands and fingers and small feet. A small number of oral 
mucosal frenulae were observed. He had a bossed forehead, sparse and patchy scalp 
hair and sparse eyebrows with normal eyelashes. His developmental progress was 
normal. A full skeletal survey was performed and reviewed by Prof. Christine Hall, 
who confirmed the diagnosis of JATD (Fig. 2.3). Chromosome studies, renal 
assessment and eye examination were normal. At the age of 4 V2 years, his height 
remained between the 9th and 25th centiles. To date he has not developed any extra- 
skeletal problems, but he continues to be followed up in the renal and eye clinic.
Both his parents (III.2 and III.3) and his older sister (IV.2) were unaffected, with 
normal stature. His mother (III.3) had serial US scans during her next pregnancy, but 
no limb abnormalities were detected. When the baby (IV.4) was bom, he too was found 
to be unaffected. His full skeletal survey was normal.
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Figure 2.1 Pedigree drawing of Family 1, a multiply-consanguineous family with 
Jeune syndrome. Solid symbols represent affected individuals.
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Figure 2.2 Clinical photographs of patient IV.3 from Family 1. He has mild rhizomelic 
limb shortening and a narrow chest (A), with a bossed forehead, sparse scalp hair (B) 
and small broad hands with short fingers (C).
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Figure 2.3 Radiographs of patient IV.3 from Family 1. 
The upper thorax (A) is slightly narrow. In the pelvis 
(B), the acetabulae have a trident appearance with 
medial and laterals spurs. In the hand (C), the middle 
phalanges are rather small. In the leg (D), there is mild 
bowing of the femur, and the metaphyses are mildly 
irregular.
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Patient IV. 1 (Fig. 2.4) was also noted to have short femora on antenatal US. He too had 
no respiratory problems in the neonatal period. He was referred to the Genetics Clinic 
at Great Ormond Street Hospital from Whipps Cross Hospital because of short limbs 
and was seen at Great Ormond Street Hospital at the age of 12 months. His main 
clinical features, again consistent with JATD, were mild rhizomelic limb shortening, a 
small narrow chest, a protuberant abdomen, broad hands and 5th finger clinodactyly. 
His height was on the 50th centile, while his weight was between the 75th and 91st 
centiles. He also had a few lower jaw gum frenulae and he was bom with a right 
inguinal hernia and hypospadias (neither of which are particular features of JATD). 
His development was normal, and there were no renal or eye problems. A skeletal 
survey, reviewed by Prof. Christine Hall, supported the diagnosis of JATD (Fig. 2.4). 
At the age of 33/4 years, his height was between the 9th and the 25th centiles. He is also 
being followed up in the renal and eye clinics. Both parents (III. 1 and III.4) were 
unaffected, and he has no siblings.
DNA samples were obtained from affected individuals (IV.3 and IV. 1), both sets of 
parents (III.2 and III.3; III. 1 and III.4), unaffected sib (IV.2) and maternal grandmother 
(II.3).
(ii) Family 2
This consanguineous Dutch family (Fig. 2.5) was clinically assessed by Dr Joep 
Tuerlings, Clinical Geneticist at the University Hospital Nijmegen. There were two 
affected sisters (VI.3 and VI.5), the children of a third-cousin marriage, and three 
unaffected sibs (VI. 1, VI.2 and VI.4). Both patients had a mild form of JATD.
Patient VI.3 (Fig. 2.6A) was delivered at home, but had to be transferred to hospital due 
to asphyxia. She was intubated and ventilated for about six weeks and was re-admitted 
to hospital twice in her first year with respiratory problems. She has a small chest, 
slight short stature and mild shortening of the limbs. Her chest and pelvic radiographs 
are said to be typical of JATD. Her renal function and eyesight are being monitored and
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Figure 2.4 Clinical photographs and radiographs of patient IV. 1 from 
Family 1. There is mild rhizomelic limb shortening (A) and the hands 
are broad (B) with 5th finger clinodactyly (C). The upper thorax is 
rather narrow (D).
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Figure 2.5 Pedigree drawing of Family 2, a consanguineous family with Jeune 
syndrome. Solid symbols represent affected individuals.
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Figure 2.6 Clinical photographs of patients VI.3 (A) and V1.5 (B) from Family 2. Both 
patients have a narrow chest and mild rhizomelic limb shortening.
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so far no abnormalities have arisen. She has also feeding difficulties and speech 
problems, and, at the age of 17 years, now attends a special school.
Patient VI.5 (Fig. 2.6B and 2.7) also suffered from asphyxia at birth. She was intubated 
and ventilated for about two weeks, re-admitted three times in her first year with 
respiratory problems and required home oxygen for a period. Like her sister, she has a 
small chest and only slight shortening of the limbs. She had changes typical of JATD 
on her chest, pelvic and limb radiographs, which have been reviewed by Prof. Christine 
Hall. She had no problems with renal function and eyesight. Now, aged 10 years, she is 
making good progress, although she has developed asthma.
DNA samples were obtained from affected individuals (VI.3 and VI.5), both parents 
(V.5 and V.6) and two unaffected sibs (VI.2 and VI.4).
(iii) Family 3
This consanguineous Pakistani family (Fig. 2.8) was clinically assessed by Dr Jenny 
Morton, Consultant Clinical Geneticist at Birmingham Women’s Hospital and has 
recently been reported in the literature (described as proband A)(Morgan et al., 2003).
There was only one affected individual (II. 1), the child of unaffected first cousin 
parents. She was 39 months of age at the time of the study and had relatively mild 
JATD with short stature, short upper and lower limbs and a very narrow chest. She had 
respiratory problems in the neonatal period and was found to have rod/cone dystrophy 
at 9 months, but had normal renal and hepatic function by 39 months.
A full skeletal survey was performed and reviewed by Prof. Christine Hall, who 
confirmed the diagnosis of JATD. Her thorax was narrow and small with short 
horizontal ribs. She had handle-bar shaped clavicles, shortening and bowing of the 
radius and ulna with subluxation of the radial head, small iliac bones and large rounded 
capital femoral epiphyses.
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Figure 2.7 Radiographs of patient VI.5 from Family 2. There is significant shortening 
of the ribs (A), a trident appearance of the acetabulae (B), mild shortening of the 
humerus (C) and mild shortening and bowing of the femora with few metaphyseal 
spurs (D).
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Figure 2.8 Pedigree drawing of Families 3, 4 and 5, three consanguineous families 
with JATD. Solid symbols represent affected individuals.
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DNA samples from the proband (II. 1) and her parents (1.1 and 1.2) were sent to our 
laboratory by Prof. Judith Goodship, Consultant Clinical Geneticist in Newcastle. Our 
collaborators in Birmingham had also independently obtained DNA from this family.
(iv) Family 4
This consanguineous Arab family (Fig. 2.8) was clinically assessed by Dr Lihadh Al- 
Gazali, Consultant Clinical Geneticist at the Faculty of Medicine and Health, A1 Ain, 
United Arab Emirates. The proband (II.6) was the sixth child of first cousin parents. 
There were six unaffected sibs, five older sisters (II.1-II.5) and one younger brother 
(11*7).
The patient (Fig. 2.9 and 2.10) had short stature, short limbs, a narrow chest and 
postaxial polydactyly of the right foot. He had an operation to remove the extra-digit 
and the fifth and the sixth toes were found to share the same metatarsal. He had normal 
fingernails but dysplastic toenails, which is not a feature of JATD but of EVC. He had 
no neonatal respiratory problems but had recurrent mild chest infections from age 1 XA 
years to the present, a chronic cough and airway hyper-reactivity. He had a systolic 
heart murmur, but his echocardiogram was normal. Renal US soon after birth showed 
possible mild dilatation of the left renal pelvis, but repeat US at VA years of age was 
normal. He had no dysmorphic features (apart from a depressed nasal bridge which is 
familial) and his development was normal. Now, aged 5 lA years, he has no retinal, 
renal or hepatic problems. Radiographs were reviewed by Prof. Christine Hall who 
confirmed the diagnosis of JATD (Fig. 2.10).
Very recently another affected baby (II.8) was bom in this family. She is said to have a 
very small chest, bilateral postaxial polydactyly in the hands and no nail dysplasia. 
Radiographs are said to be typical of JATD.
Initially DNA samples from the proband (II.6) and his parents (1.1 and 1.2) were 
obtained from Dr Judith Goodship. DNA samples were subsequently obtained from the
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Figure 2.9 Clinical photographs and pre-operative radiograph of the feet of patient II.6 
from Family 4. He has short stature, a narrow chest (A) and dysplastic toenails (B). The 
right 5th and 6th toes share the same metatarsals (C).
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Figure 2.10 Radiographs of patient II.6 from Family 4. The upper thorax is narrow 
with short ribs (A). In the pelvis, the acetabulae have a trident appearance with medial 
and lateral spurs (B).There is shortening of the long bones, bowing of the femora, 
disproportionate shortening of the fibulae and advanced ossification of the capital 
femoral epiphyses (C). In the hand, there are coned shaped epiphyses of the middle 
phalanges (D).
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six unaffected sibs and very recently from the affected baby (II.8) directly from Dr 
Lihadh Al-Gazali.
(v) Family 5
This consanguineous Pakistani family (Fig. 2.8) was clinically assessed by Dr Richard 
Gibbons and Dr Ed Blair, Consultant Clinical Geneticists at Oxford. The proband (II. 1) 
was the only child of first cousin parents. He had short stature and signs of mild spastic 
diplegia.
A full skeletal survey reviewed by Dr T R Goodman, Consultant Radiologist in Oxford, 
showed that he had an unusual non-specific skeletal dysplasia that is similar to but not 
typical of either JATD or EVC. He had a bell-shaped thorax with short anterior ribs, 
some bowing of the left femur and mild lumbar scoliosis. He had normal iliac bones, no 
trident deformity of the acetabulae, no shortening/thickening of the long bones and 
normal vertebrae. Radiographs were shown at a Skeletal Dysplasia Society meeting in 
2002 and no definite diagnosis could be made. An MRI scan showed a slightly narrow 
spinal canal with an area of abnormality in the upper cervical cord thought to be a long­
standing lesion which was not investigated further.
DNA samples from the proband (II. 1) and his father (1.1) were obtained from Dr Judith 
Goodship.
(vi) Family 6
This consanguineous Turkish family (Fig. 2.11) was clinically assessed by Dr Beyhan 
Tuysuz, Consultant Clinical Geneticist at the University of Istanbul, Turkey. The 
proband (II.2) was the second child of first cousin parents. She had short stature, a 
small chest and postaxial polydactyly in the feet. She had no respiratory, renal or retinal 
complications. Radiographs were reviewed by Prof. Christine Hall who confirmed the
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Figure 2.11 Pedigree drawing of Families 6, 7, 8 and 9, four consanguineous families 
with JATD. Solid symbols represent affected individuals.
82
diagnosis of JATD (Fig 2.12). DNA samples were obtained from all members of the 
family (1.1,1.2, II. 1 and II.2).
(vii) Family 7
This consanguineous Turkish family (Fig. 2.11) was also clinically assessed by Dr 
Beyhan Tuysuz. There was one deceased affected child (II.3), one unaffected sister 
(II. 1), one unaffected brother (II.4) and one deceased unaffected sister (II.2), all 
children of first cousin parents. The proband (II.3) had short stature and a very small 
chest and died at VA months because of respiratory insufficiency. Diagnosis of JATD 
was confirmed by Prof. Christine Hall who reviewed his radiographs (Fig. 2.13A). He 
had a narrow thorax, trident appearance of the acetabulae and advanced ossification of 
the upper femoral epiphyses.
DNA samples were obtained from the unaffected sister (II. 1) and brother (II.4) and 
both parents (1.1 and 1.2) as well as paraffin embedded tissues from the proband (II.3).
(viii) Family 8
This consanguineous Pakistani family (Fig. 2.11) was clinically assessed by Dr Jill 
Clayton-Smith, Consultant Clinical Geneticist at St Mary’s Hospital, Manchester and 
DNA samples were sent to our collaborator Dr Colin Johnson in Birmingham. The case 
has recently been reported in the literature (described as proband C)(Morgan et al., 
2003). The parents were first cousins and they had dizygotic twin fetuses, one severely 
affected (II. 1) and one unaffected (II.2).
Fetus II. 1 (Fig. 2.13B) was stillborn at 30 weeks and had a narrow chest. There were no 
detectable abnormalities in the liver, kidney or heart on post-mortem examination. Prof. 
Christine Hall reviewed the fetal radiographs and confirmed the diagnosis. He had the 
typical skeletal abnormalities of JATD in the thorax and pelvis.
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Figure 2.12 Clinical photograph and radiographs of patient II.2 from Family 6. She 
has a narrow chest (A) with short ribs (B). The acetabulae have a trident appearance 
and the iliac bones are rather short (C). There is advanced ossification of the upper 
femoral epiphyses and metaphyseal irregularities (C).
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Figure 2.13 Radiographs of patients II.3 from Family 7 (A), II. 1 from Family 8 (B) 
and II. 1 from Family 9 (C). Patients have a small thorax with short ribs. Proband II. 1 
from Family 8 (B) has medial and lateral spurs on the acetabular roofs and additional 
lateral spurs on the iliac wings. Mesomelic shortening of the lower limbs with some 
cupping of the metaphyses is also present. Femurs are mildly curved. In the hands, 
there is shortening of the middle phalanges and metacarpals, but no polydactyly.
Proband II. 1 from Family 9 (C) has mild narrowing of the thorax and horizontal acetabular 
roofs with spur-like projections. There is rather severe mesomelic limb shortening and 
significant irregularity of the distal ends of the femora with flared metaphyses.
85
DNA samples from the affected fetus (II. 1) and his parents (1.1 and 1.2) were provided 
by Dr Colin Johnson.
(ix) Family 9
This consanguineous Italian family (Fig. 2.11) was clinically assessed by Dr 
Margherita Silengo, Consultant Clinical Geneticist at the University of Turin, Turin, 
Italy and DNA samples were sent to Dr Colin Johnson in Birmingham. The case has 
also been reported in the literature (described as proband D)(Morgan et al., 2003).
The patient II. 1 (Fig. 2.13C) was the only child of first cousin parents and was mildly 
affected. Antenatal US at 24 weeks gestation revealed shortening of the limbs. He was 
30 months of age at the time of the study and had relatively mild JATD with short 
upper and lower limbs and a mildly narrow chest (chest circumference below 3rd 
percentile). He had normal renal and hepatic function and normal eyesight. Prof. 
Christine Hall reviewed the radiographs and confirmed the diagnosis. However, 
because of the extremely mild radiological findings, she described the child as not a 
classic JATD case. He had mild narrowing of the thorax and some minor changes of the 
acetabular roofs (see Fig. 2.13C).
DNA samples from the proband (II. 1) and both parents (1.1 and 1.2) were provided by 
Dr Colin Johnson.
(x) Family 10
This consanguineous Moroccan family (Fig. 2.14) was clinically assessed by Dr A. 
Toutain, Consultant Clinical Geneticist at Tours, France. The proband (11.10) was the 
10th child of first cousin parents. There were six affected deceased sibs and three 
unaffected sibs. The proband (Fig. 2.15A), now 8 years old, had the typical features of 
JATD such as short stature, short limbs, a narrow chest and postaxial polydactyly. She
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Figure 2.14 Pedigree drawing of Families 10, 11 and 12, three consanguineous 
families with JATD. Solid symbols represent affected individuals.
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Figure 2.15 Radiographs of patients 11.10 (A), 11.1 (B and C) and fetus 11.9 (D) 
from Family 10 showing the typical skeletal abnormalities of JATD. They have 
narrow thoraces with short ribs and the acetabulae have a trident appearance.
also had severe mental retardation, never previously associated with JATD, and Dandy- 
Walker malformation which has been reported in one other JATD case (Silengo et al., 
2000).
From the six affected deceased sibs, II. 1 died at age 3 days from respiratory failure 
(Fig. 2.15B and C), II.3 died at age 2 months also from respiratory failure, II.6 died at 
age 3 days and had cleft palate, II.8 died at age 24 days from respiratory failure and II.9 
was a termination of pregnancy for cerebellar anomaly (Fig. 2.15D). Radiographs of 
affected individuals II. 1, II.3, II.9 and proband 11.10 were reviewed by Prof. Christine 
Hall who confirmed the diagnosis of JATD in all cases.
DNA samples from the proband (11.10) and both parents (1.1 and 1.2) were collected by 
Dr Valerie Cormier-Daire in Paris and aliquots were subsequently sent to our lab.
(xi) Family 11
This consanguineous Turkish family (Fig. 2.14) was clinically assessed by Dr Beyhan 
Tuysuz. There were two affected siblings (II. 1 and II.2). The parents (1.1 and 1.2) were 
first cousins once removed. Both affected children had short stature, a narrow thorax 
and postaxial polydactyly. No major respiratory problems occurred in the neonatal 
period. Now aged of 14 years old (II. 1) and 4 years old (II.2), no other complications 
have been reported.
Initially the two affected children were clinically and radiologically diagnosed as 
having JATD and were included in our study. DNA samples were obtained from the 
two affected sibs (II. 1 and II.2) and both parents (1.1 and 1.2). When copies of the 
radiographs were obtained, however, it became clear that the diagnosis was not 
straightforward. Radiographs were reviewed by Prof. Christine Hall, our collaborator 
Dr Valerie Cormier-Daire and Prof. Geert Mortier and they all agreed that the diagnosis 
was not typical JATD. Prof. Hall suggested acromesomelic dysplasia, Maroteaux type, 
while Dr Cormier-Daire suggested an atypical form of EVC.
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(xii) Family 12
This distantly consanguineous English family (Fig. 2.14) was clinically assessed by Dr 
Peter Turnpenny, Consultant Clinical Geneticist at the Royal Devon and Exeter 
Hospital, Exeter. The parents (1.1 and 1.2) were said to be almost certainly 
consanguineous because both the father’s parents and the mother’s grandparents 
originated from the same area at the tip of Cornwall and the same surname occurs on 
both sides of the family. There was one affected fetus (II.2) terminated at 19 weeks for 
probable JATD and two unaffected sibs (II. 1 and II.3). Post-mortem findings were 
compatible both with JATD and with EVC. The fetus had short ribs and polydactyly. 
There was no evidence of congenital heart disease. Kidneys appeared normal and there 
were no gross abnormalities of the liver.
DNA samples were obtained from the fetus (II.2), the two unaffected children (II. 1 and 
II.3) and both parents (1.1 and 1.2).
2.1.1.2 Clinical details o f non-consanguineous families
(xiii) Family 13
This Italian family (Fig. 2.16) was clinically assessed by Prof. Romano Tenconi, 
Consultant Clinical Geneticist at Padua Hospital, Italy. The proband (III. 1) is the only 
child of unrelated parents. The two families have been living in the same area near 
Vicenza for over a century and the surname of the maternal grandmother, although a 
very common surname in the region, is the same as that of the father, so the two 
families may be distantly related.
Patient III. 1 (Fig. 2.17A) was severely affected and had short stature, shortening of the 
upper and lower limbs and a very narrow chest. She was admitted to hospital several 
times in her first year of life due to dyspnea and feeding difficulties. Congenital hepatic 
fibrosis was diagnosed at 5 months of age and since then she has been treated with
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Figure 2.16 Pedigree drawing of Families 13, 14, 15 and 16, four non- 
consanguineous families with JATD. Solid symbols represent affected individuals.
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Figure 2.17 Clinical photographs of patients III.l from Family 13 (A), II.3 (B) 
and II.4 (C) from Family 14 showing typical clinical findings of JATD. Limb 
shortening and a very narrow chest are present in all three cases.
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Ursodesoxycholic acid. Abdominal US at 10 months of age revealed an enlargement of 
the spleen. Exocrine pancreatic insufficiency had appeared since the age of 14 months. 
Now aged 2XA years, she is <0.4th centile in height and 0.4th centile in weight and she is 
suffering from recurrent chest infections (bronchiolitis) and episodes of respiratory 
distress. The skeletal radiographs taken at birth supported the diagnosis of JATD. She 
had a narrow thorax with short thin ribs, rhizomelic limb shortening with no significant 
alterations in the metaphyses and a hypoplastic iliac crest.
DNA samples were obtained from the unaffected child (III.l), both parents (II. 1 and
II.2) and both sets of grandparents (1.1,1.2,1.3 and 1.4).
(xiv) Family 14
This non-consanguineous Pakistani family (Fig. 2.16) was clinically assessed by Dr 
Helen Firth, Consultant in Medical Genetics at Addenbrooke’s Hospital, Cambridge. 
There were two mildly affected sibs (II.3 and II.4) and one unaffected sister (II. 1). A 
pregnancy (II.2) was terminated at 7-8 weeks of gestation.
Patient II.3 (Fig. 2.17B) had short stature (2nd centile for height at the age of 3 years), 
mild rhizomelic limb shortening and a narrow upper chest with a prominent sternum, 
but no polydactyly. She had no particular respiratory problems in the neonatal period 
and had not developed any extra-skeletal complications by the age of 9 years.
Patient II.4 (Fig. 2.17C and 2.18) was more severely affected with short stature, 
proximal limb shortening and a long narrow chest. His hands and feet were normal with 
no polydactyly or nail dysplasia. He had problems with respiratory insufficiency and 
died at the age of 3 months from respiratory infection (bronchiolitis). Prof. Christine 
Hall reviewed the radiographs of both affected children and confirmed the diagnosis of 
JATD.
DNA samples were first obtained from the two affected children (II.3 and II.4) and both 
parents (1.1 and 1.2) and subsequently from the unaffected sib (II. 1).
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Figure 2.18 Radiographs of patient II.4 from Family 14 showing flaring of the ribs (A), 
trident appearance of the acetabulae (B) and rhizomelic limb shortening of the upper 
and lower limbs with flaring of the metaphyses (B and C).
(xv) Family 15
This non-consanguineous English family (Fig. 2.16) was clinically assessed by Dr 
Sarah Smithson, Consultant Clinical Geneticist at St Michael Hospital, Bristol. There 
were 3 affected fetuses (II.2, II.3 and II.4) and two unaffected sibs (II. 1 and II.5). The 
three fetuses had post-mortem examinations and fetal radiographs were consistent with 
a diagnosis of JATD. Radiographs were reviewed by Prof. Christine Hall who 
confirmed the diagnosis.
DNA samples were obtained from the three fetuses (II.2, II.3 and II.4), the unaffected 
sibs (II. 1 and II.5) and both parents (1.1 and 1.2).
(xvi) Family 16
This non-consanguineous Lithuanian family (Fig. 2.16) was clinically assessed by Dr 
Augustina Jankauskiene, Consultant Clinical Geneticist at the Vilnius University 
Children’s Hospital, Vilnius, Lithuania and has been reported in the literature 
(Jankauskiene and Bematoniene, 2000). There was one severely affected child (II.3), 
one unaffected sib (II.2) and a termination of pregnancy (II. 1). The proband (II.3) had 
disproportionate short stature, short limbs, a short neck and a narrow chest. At 4 
months and at 2 years of age she had episodes of respiratory failure. She also suffered 
from ear-nose-throat infections and experienced severe pneumonia and infectious 
mononucleosis. By 7 months, she developed renal insufficiency. Her liver was 
enlarged, but liver function tests were normal. Eye examination was normal. Skeletal 
radiographs showed a long, narrow thorax with short horizontal ribs, short limbs and 
distal phalanges and trident appearance of the acetabulae in the pelvis.
DNA samples were collected by Dr Colin Johnson in Birmingham and aliquots from all 
four members of the family were subsequently sent to our lab.
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(xvii) Family 17
This non-consanguineous Lebanese family (Fig. 2.19) was clinically assessed by Dr 
Imad Kaddoura, Chief Plastic Surgeon at the American University of Beirut Medical 
Center, Beirut, Lebanon. The proband (II. 1) has been reported in the literature 
(Kaddoura et al., 2001). He was the third child of unaffected parents (1.1 and 1.2). 
There were two unaffected sisters (II.2 and II.3). The proband was severely affected 
with a small chest and short long bones in the lower limbs and died at 18 months of age 
despite thoracoplasty. There was no renal or hepatic involvement.
Radiographs were reviewed by Prof. Christine Hall who confirmed the diagnosis of 
JATD. He had a very narrow thorax with short ribs. In the pelvis, the acetabular roofs 
showed a trident configuration with medial and lateral spurs. The long bones in the 
lower limbs were short with irregular metaphyses and premature ossification of the 
capital femoral epiphyses.
DNA samples were obtained from the two unaffected sibs (II.2 and II.3) and both 
parents (1.1 and 1.2).
(xviii) Family 18
This non-consanguineous Scottish family (Fig. 2.19) was clinically assessed by Dr John 
Dean, Consultant Clinical Geneticist at the Grampian University Hospital, Aberdeen, 
Scotland. There was one unaffected child (II.2) and two affected children (II. 1 and
II.3). The first (II. 1) was a severely affected girl who died aged 6 hours (II. 1). She was 
small and had a bell shaped chest and pulmonary hypoplasia. The second (II.3) was a 
less severely affected girl. She had mild skeletal involvement with short stature, 
rhizomelic limb shortening and a long narrow bell-shaped chest. She had no neonatal 
respiratory problems and no renal or hepatic involvement. Radiographs of the affected 
child (II.3) were reviewed at the London Dysmorphology Club and the diagnosis of 
JATD was confirmed. She had slightly bowed femurs and short humeri.
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Figure 2.19. Pedigree drawing of Families 17-22, six non-consanguineous families 
with JATD. Solid symbols represent affected individuals.
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DNA samples were obtained from the parents (1.1 and 1.2) and one affected child (II.3).
(xix) Family 19
This non-consanguineous Belgian family (Fig. 2.19) was clinically assessed by Dr 
Jean-Pierre Fryns, Consultant Clinical Geneticist at the Center for Human Genetics, 
Leuven, Belgium. There was one affected female fetus (II. 1). Post-mortem examination 
was compatible with JATD. She had a narrow thorax and short limbs, but no 
polydactyly or dysmorphic features. Radiographs showed a narrow thorax with short 
ribs, shortening of the long bones of the limbs and irregular metaphyses with spikes, 
but no bowing of the femora.
DNA samples were obtained from both parents (1.1 and 1.2) and from the fetus (II. 1).
(xx) Family 20
This non-consanguineous Portuguese family (Fig. 2.19) was clinically assessed by Dr 
Ana Medeira, Consultant Clinical Geneticist at the Santa Maria Hospital, Lisbon, 
Portugal. The proband (II.2) was the second child of healthy parents (1.1 and 1.2). Short 
limbs were noted on antenatal US. He had short stature, mild rhizomelic limb 
shortening and a narrow chest. He had episodes of respiratory distress (asthma) in the 
first two years of life. There was no renal or hepatic involvement. Radiological 
examination showed short ribs with anterior flaring, small ilia with square wings, 
trident acetabulae and irregular metaphyses of the long bones. The films were reviewed 
by Prof. Christine Hall who confirmed the diagnosis of JATD.
DNA samples were obtained from the proband (II.2), the unaffected sib (II. 1) and both 
parents (1.1 and 1.2).
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(xxi) Family 21
This non-consanguineous Australian family (Fig. 2.19) was clinically assessed by Dr 
Ravi Savarirayan, Consultant Clinical Geneticist at the Royal Children’s Hospital 
Genetics Clinic, Victoria, Australia. The proband (II.2), the second child of healthy 
unrelated parents (1.1 and 1.2), was mildly affected. He had short stature, a narrow chest 
and soft tissue syndactyly of the fingers and toes. He had no respiratory problems and 
normal renal function, but had abnormal liver function tests and cholestasis and was 
treated with bile acids.
DNA samples were obtained from the proband (II.2), the unaffected sib (II. 1) and both 
parents (1.1 and 1.2).
(xxii) Family 22
This non-consanguineous Italian family (Fig. 2.19) was clinically assessed by Dr Carlo 
Poggiani, Consultant Clinical Geneticist at Cremona Hospital, Italy and has been 
reported in the literature (Poggiani et al., 2000). The proband (II.2) had severe skeletal 
involvement and died 24 hours after birth of respiratory failure. She was small and had 
short limbs and a very narrow chest. Cranial and renal US were normal. Post-mortem 
examination and fetal radiographs confirmed the diagnosis of JATD. She had a narrow 
thorax with short ribs and a trident appearance of the acetabular roofs in the pelvis.
DNA samples were obtained from the unaffected sib (II. 1) and both parents (1.1 and 
1.2).
(xxiii) Family 23
This non-consanguineous English family (Fig. 2.20) was clinically assessed by Dr 
Tessa Homfray, Consultant Clinical Geneticist at St George's Hospital, London. There 
was one affected fetus (II. 1) terminated at 22 weeks of gestation. Diagnosis of JATD
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Figure 2.20 Pedigree drawing of Families 23-31, nine non-consanguineous 
families with JATD. Solid symbols represent affected individuals.
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was confirmed at post-mortem examination and on fetal radiographs reviewed by Prof. 
Christine Hall. DNA samples were obtained from the parents (1.1 and 1.2).
(xxiv) Family 24
This non-consanguineous family from Kosovo (Fig. 2.20) was clinically assessed by Dr 
Radovan Bogdanovic, Consultant Clinical Geneticist at the Institute of Mother and 
Child Health, Belgrade, Serbia. There was only one affected child (II. 1) with skeletal, 
renal and hepatic involvement. DNA samples were obtained from the proband and his 
parents (1.1 and 1.2).
(xxv) Family 25
This non-consanguineous family from Serbia (Fig. 2.20) was also clinically assessed by 
Dr Radovan Bogdanovic. There was only one affected child (II. 1) with skeletal, renal, 
retinal and hepatic involvement. DNA samples were obtained from the proband and his 
parents (1.1 and 1.2).
(xxvi) Family 26
This non-consanguineous family from Serbia (Fig. 2.20) was also clinically assessed by 
Dr Radovan Bogdanovic, Belgrade, Serbia. There was only one affected child (II. 1). 
No clinical information about the proband has been obtained yet. DNA samples were 
obtained from the proband and his parents (1.1 and 1.2).
(xxvii) Family 27
This non-consanguineous family from Serbia (Fig. 2.20) was also clinically assessed by 
Dr Radovan Bogdanovic, Belgrade, Serbia. There was only one affected child (II. 1). 
No clinical information about the proband has been obtained yet. DNA samples were 
obtained from the proband and his parents (1.1 and 1.2).
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(xxviii) Family 28
This non-consanguineous Dutch family (Fig. 2.20) was clinically assessed by Dr Ben 
Hamel and Prof. Han Brunner, Consultant Clinical Geneticists at the Department of 
Human Genetics, Nijmegen, Netherlands. There were two affected children (II.4 and 
II.5) and three unaffected sibs (II. 1, II.2 and II.3). Patient II.5 died 38 days after birth. 
DNA samples were obtained from patient II.4, the three unaffected children and their 
parents (1.1 and 1.2).
(xxix) Family 29
This non-consanguineous Dutch family (Fig. 2.20) was also clinically assessed by Dr 
Ben Hamel and Prof. Han Brunner. There was one affected child (II. 1) and one
unaffected sib (II.2). DNA samples were obtained from the proband (II. 1), the
unaffected sib (II.2) and both parents (1.1 and 1.2).
(xxx) Family 30
This non-consanguineous Dutch family (Fig. 2.20) was also clinically assessed by Dr 
Ben Hamel and Prof. Han Brunner. There was one affected child (II.3) and three 
unaffected sibs (II. 1, II.2 and II.4). DNA samples were obtained from the proband 
(II.3), the three unaffected children and their parents (1.1 and 1.2).
(xxxi) Family 31
This non-consanguineous Dutch family (Fig. 2.20) was also clinically assessed by Dr 
Ben Hamel and Prof. Han Brunner. There was one affected child (II. 1) and one
unaffected sib (II.2). DNA samples were obtained from the proband (II. 1), the
unaffected sib (II.2) and both parents (1.1 and 1.2).
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2.1.2 CLS patient samples
The project started when an affected child from a consanguineous family (Family A) 
was seen by clinicians working in the Clinical and Molecular Genetics Unit at Great 
Ormond Street Hospital. DNA samples were later obtained from three further 
consanguineous families (B, C, D) and three non-consanguineous families (E, F, G). 
DNA samples from whole Family B were obtained through Dr Nursel Elcioglu, 
Consultant Clinical Geneticist at Marmara University Hospital, Istanbul, Turkey. DNA 
samples from Family C and Family D were obtained through Prof. Sarnia A. Temtamy, 
Professor of Human Genetics at the National Research Centre of Cairo, Egypt.
A DNA sample from an affected child from a non-consanguineous family (Family E) 
was obtained through Prof. Jean-Pierre Fryns, Consultant Clinical Geneticist at the 
University of Leuven, Belgium. Samples from two further non-consanguineous 
families (Family F and Family G) were obtained later through Dr Nursel Elcioglu.
2.1.2.1 Clinical details o f CLS families
(a) Family A
This consanguineous Asian family (Fig. 2.21) was clinically assessed by Prof. Robin 
Winter, Consultant Clinical Geneticist at Great Ormond Street Hospital. The proband 
(II.2) was the second child of first-cousin parents. Her parents (1.1 and 1.2) and older 
sister (II. 1) were unaffected. She had severe symmetrical involvement of both hands, 
with total soft tissue syndactyly and shortening of all fingers (Fig. 2.22A and B), as 
well as bilateral radio-ulnar synostosis, preventing pronation and supination of the 
forearms. Radiographs of her upper limb (Fig. 2.22C and D) were reviewed by Prof. 
Christine Hall, Consultant Radiologist in the Department of Radiology at Great 
Ormond Street Hospital and were consistent with a diagnosis of CLS. In the feet, the 
only abnormality was partial soft tissue syndactyly between the second and third toes.
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Figure 2.21 Pedigree drawing of Families A and B, two consanguineous families 
with Cenani-Lenz syndrome. Solid symbols represent affected individuals.
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Figure 2.22 Clinical photographs and radiographs of the hands and arms of patient II.2 
from Family A. The rudimentary thumbs, index and little fingers have separate nails, 
but the middle and ring fingers shared a single fused nail (A, B). The phalanges and 
metacarpals of both hands are malformed and fused, and there is bilateral fusion of the 
entire shafts of the radius and ulna, with some dislocation of the elbow joints (C, D).
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Interestingly an abdominal US showed bilateral renal hypoplasia, more severe on the 
left then on the right. A short report describing this child has already been published 
(Bacchelli et a l , 2001), and a copy is included at the back of this thesis. She is now 
under the care of the Plastic Surgery team at Great Ormond Street Hospital, and is 
undergoing a series of operations on her hands. DNA samples were obtained from both 
parents (1.1 and 1.2) and the affected child (II.2).
(b) Family B
This consanguineous Turkish family (Fig. 2.21) was clinically assessed by Dr Nursel 
Elcioglu, Consultant in Clinical Genetics at Marmara University Hospital, Istanbul, 
Turkey, and has already been reported in the literature (Elcioglu et al., 1997). The 
proband (II.4) was the fourth child of healthy first-cousin parents (1.1 and 1.2). His three 
older sibs (II. 1, II.2 and II.3) were unaffected. He had bilateral symmetrical 
abnormalities of the hands with four short, partly syndactylous fingers with nails (Fig. 
2.23A and B). The radii and ulnae were slightly short, but there was no radio-ulnar 
synostosis. The only abnormality in the feet was bilateral syndactyly between the 
second and third toes (Fig. 2.23A). No other malformations apart from the limbs were 
detected and his developmental progress was normal. DNA samples were obtained 
from both parents (1.1 and 1.2), the affected child (II.4) and the three unaffected sibs 
(11.1,11.2 and II.3).
(c) Family C
This consanguineous Egyptian family (Fig. 2.24) was clinically assessed by Prof. 
Sarnia A. Temtamy, Professor of Human Genetics at the National Research Centre of 
Cairo, Egypt, and has also been reported in the literature (Temtamy et a l , 2003). The 
proband (III.4) was the fourth child of double first cousin parents. She had bilateral 
symmetrical malformations of both upper limbs and feet and facial dysmorphism. She 
had short forearms, disorganised fingers with two malformed central digits, restricted 
supination and pronation at the elbows and restricted flexion and extension at the wrist.
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Figure 2.23 Clinical photograph and radiograph of the limbs of patient 11.4 from 
Family B. In the hands, there is bilateral soft tissue syndactyly of all the digits, 
with shortening, fusion or absence of many of the phalanges and metacarpals (A 
and B). In the feet, there is bilateral syndactyly between the second and third toes. ^ 7
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Figure 2.24 Pedigree drawing of Families C, D, E and F, two consanguineous 
and two non-consanguineous families with Cenani-Lenz syndrome. Solid 
symbols represent affected individuals.
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Radiological examination revealed fusion of the radius and ulna, fusion of the carpals 
and of the first and second metacarpals and of the phalanges. On each foot only four 
toes were visible with a wide gap between the first and second toes. X-rays showed 
bilateral asymmetrical malformations with fusion of some metatarsals and proximal 
phalanges, absence of middle phalanges and biphalangeal second to fifth toes. Facial 
dysmorphism consisted of a broad, prominent forehead, hypertelorism, downslanting 
palpebral fissures, a depressed nasal bridge, a short nose, prominent central incisors and 
a bow shaped upper lip. Tooth abnormalities like enamel hypoplasia and premature loss 
of permanent teeth were described. She also had a high arched palate and partial 
inferior ankyloglossia. Both kidneys were of normal size on abdominal US.
The father (II. 1) had died and was said to have upper and lower limb malformations 
and facial dysmorphism similar to the proband’s. His parents were unaffected first 
cousins suggesting a quasi-dominant inheritance in this family. The proband had two 
unaffected sibs (III. 1 and III.3) and a brother (III.2) who was also said to be similarly 
affected and died at the age of 5 months from measles. DNA samples were obtained 
from the proband (III.4) and the proband’s mother (II.2).
(d) Family D
This consanguineous Egyptian family (Fig. 2.24) was clinically assessed by Prof. 
Sarnia A. Temtamy and has been reported in the literature together with Family C 
(Temtamy et al., 2003). The proband (II.2) was the second child of first cousin 
unaffected parents. He had bilateral symmetrical malformations of upper limbs, feet 
and facial dysmorphism. Both upper limbs were severely affected with bilateral 
symmetrical shortening of the forearms, limited extension, pronation and supination at 
the elbows and disorganised fingers. Radiological examination showed partial radio­
ulnar synostosis and fusion of proximal phalanges into two cone shaped structures. 
Only four metacarpals were identified. The feet were small with only four vestigial toes 
bilaterally, syndactyly of the first to third toes, a gap between the third and last toe, and 
hypoplastic nails. X-rays showed absence of one metatarsal and some phalanges. He
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had facial features similar to those of proband III.4 from Family C including 
hypertelorism and orodental abnormalities such as partial tongue-tie, high arched 
palate, and delayed eruption of teeth. Both kidneys were normal on abdominal US.
The sibling (II.3) was unaffected but a baby (II. 1) who was said to have severe limb 
abnormalities, cleft lip and palate and ambiguous genitalia, died a few hours after birth. 
DNA samples were obtained from four members of the family (1.1,1.2, II.2, II.3).
Family C and D had atypical features such as facial dysmorphism, dental abnormalities 
and partial tongue-tie, which have never been described before in CLS patients.
(e) Family E
This non-consanguineous Belgian family (Fig. 2.24) was clinically assessed by Prof. 
Jean-Pierre Fryns, Consultant Clinical Geneticist at the University of Leuven, Belgium 
and has also been reported (De Smet et a l , 1992). The proband (II. 1) was the only child 
of unaffected unrelated parents. His hands were hypoplastic with complete syndactyly 
between all fingers, fusion of some of the nails, and shortening, fusion or absence of 
many of the phalanges and metacarpals (Fig. 2.25A, B and C). A series of surgical 
operations were performed to release the syndactyly. The forearms were normal, except 
for a dislocation of the radial head of the right elbow, and the feet were normal too. He 
had no other abnormalities apart from the hand malformations. A DNA sample was 
obtained from the proband (II. 1).
(f) Family F
This non-consanguineous Turkish family (Fig. 2.24) was clinically assessed by Dr 
Nursel Elcioglu and has been reported in the literature (Seven et a l , 2000). The 
proband (II. 1) was the first child of healthy parents. She had upper and lower limb 
abnormalities typical of CLS. She had mesomelic shortening of both arms, symmetrical 
complete syndactyly of all the fingers and of the second to fifth toes on the right foot 
and of the second and third toes on the left foot. Radiological examination showed
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Figure 2.25 Clinical photographs and radiograph of the hands of patient II. 1 from 
Family E. There is soft tissue syndactyly of the fingers and fusion of some of the 
nails, more severe on the right (B) than on the left (A). Many of the phalanges and 
metacarpals are malformed, fused or missing, especially on the right, where the 
phalanges form a disorganized mass of bone.
I l l
bilateral radio-ulnar synostosis, disorganisation of metacarpals and phalanges and 
synostosis between the fourth and the fifth metatarsals. She also had extra features not 
previously reported in CLS patients such as vertebral abnormalities (scoliosis of the
ththoracic spine and hemivertebrae in T10, T11 and T12); rib anomalies (fork-like 5 rib, 
wide separation between the 6th and 7th rib and thickened 8th rib) and mixed hearing 
loss. DNA samples were obtained from the proband (II. 1) and from both parents (1.1 
and 1.2).
(g) Family G
This Turkish family (Fig. 2.26) was also clinically assessed by Dr Nursel Elcioglu and 
has been reported in the literature (Percin and Percin, 2003). The proband (IV. 11) was 
the tenth child of unaffected, unrelated parents. There were eleven unaffected siblings. 
She had severe typical CLS features in her upper limbs including syndactyly between 
all digits and fusion of the entire shaft of the right radius and ulna preventing pronation 
and supination. Interestingly, in the feet, which are commonly less severely affected 
than the hands in CLS, she had an unusual form of duplication of the phalanges of both 
first toes and of the right second toe, a feature which has not previously been reported 
in CLS. She had hypoplasia of the middle and distal phalanges of the second to fifth 
toes and the same feature was present in her mother (III.2). The proband also had 
congenital cataract in the right eye, again a feature not previously associated with CLS. 
A half-cousin of the proband (V.2) whose parents were related, had an unusual form of 
mesoaxial syndactyly characterised by bilateral synostosis of the phalanges of the third 
and fourth fingers and partial soft tissue syndactyly between the right second and third 
toes, which does not fit any recognised type of syndactyly. This is very similar to a 
sporadic case, the child of unrelated parents, reported by Temtamy and McKusick, who 
classed it as either a severe form of syndactyly type 1 (SD1) or a ‘new’ type of 
syndactyly (Temtamy and McKusick, 1978). Percin et al. (1998) have described a 
similar severe mesoaxial syndactyly in three patients from a large inbred pedigree with 
SD1, the children of affected first cousin parents. Their severe phenotype was thought 
to represent a homozygous form of SD1 (Percin et al., 1998).
112
O -rO Family G
1 Dt U i-rD
III
IV 0  if ir i* i  i  6 i  i  * 4ja 6 o
1 I 2 3 4 5 I 6 7 8 9 10 11 12 13 14
6 ®  i
1 2 3
0 D O
4 5 6
Figure 2.26 Pedigree drawing of Family G, a non-consanguineous family with Cenani-Lenz syndrome. 
Solid symbol represents affected individual. Striped symbol represents an unusual type of syndactyly.
DNA was obtained from the proband (IV. 11), her parents (III. 1, III.2), an unaffected 
sibling (IV.7) and the half-cousin (V.2).
2.2 Materials
2.2.1 Reagents
All reagents were of AnalaR grade, or the best grade obtainable, and were obtained 
from British Drug Houses (BDH) Laboratory Supplies or Sigma Aldrich, unless 
indicated otherwise. Glassware, solutions and media were autoclaved at 105kPa 
(15psi), 121 °C for 20 minutes where necessary. Water was purified using a Milli-Ro 15 
Water Purification System (Millipore SA), further purified where necessary using a 
Milli-Q Reagent Grade Water Ultrafiltration System (Millipore), and sterilised by 
autoclaving.
NuSieve GTG low melting point agarose was from FMC Bioproducts. Electrophoresis 
grade agarose and TEMED (N,N,N’,N’-tetramethylethylenediamine) were obtained 
from Gibco-BRL Life technologies. Acrylamide stock solution (40% w/v, 29:1 
acrylamide:N,N’-methylene bisacrylamide) and urea were from Bio-Rad Laboratories. 
Alconox detergent was from Alconox, Inc. Absolute ethanol and isopropanol were 
from Hayman Ltd. Bacto-agar, bacto-tryptone and yeast extract were from Difco 
Laboratories. Deionised formamide was from Eastman Kodak Co. RPMI 1640 
medium, penicillin and streptomycin were from Gibco-BRL Life Technologies. Fetal 
bovine serum (FBS) and L-glutamine were from Imperial Laboratories Ltd. Amberlite 
resin and blue dextran/EDTA (50mg/ml and 25mM respectively) were from Perkin 
Elmer Applied Biosystems Division. Ultrapure dNTPs were supplied by Amersham 
Biosciences. Proteinase K was obtained from QIAGEN Ltd. NaOH pellets were from 
Fisons Scientific Equipment. Pellet Paint® NF Co-Precipitant was supplied by 
Novagen. lOx MegaBACE™ LPA Buffer was from Amersham Biosciences.
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2.2.2 Non-standard materials
In addition to standard laboratory materials, use was made of the following special 
items. Falcon 15ml tubes, 50ml tubes, 2059 polypropylene tubes and tissue culture 
flasks were from Becton Dickinson Labware. Culture plates were from Bibby Sterilin 
Ltd. ART aerosol resistant barrier tips were from CLP. Sterile loops, cryotubes and 
filter sterilisation units were from Nalge Nunc International. 0.2ml individual PCR 
tubes and 0.2ml strip tubes were from ABgene. Polycarbonate 96 well microplates 
OMNIPLATE 96 ThermoHybaid were from Hybaid Ltd or ABgene (Thermofast ® 96 
skirted plates). Plate seals HB-TD-TAPE Micro sealing sheets were from Hybaid Ltd. 
PCR Miniflex 0.2mm flat tips were from Sorenson BioScience, Inc. Glassware was 
obtained from Pyrex ® and Schott Duran. Plasticware was from Becton Dickson Lab 
ware or Bibby Sterilin Ltd. Micropore 0.2pm acrodisc ® syringe filters were supplied 
by Paul Gelman Labs. Plastic and paper sharks tooth combs were supplied by Perkin 
Elmer Applied Biosystems Division.
DNA electrophoresed on agarose gels was visualised by ethidium bromide fluorescence 
when the gels were illuminated at 300nm on a Chromato-Vue transilluminator (UVP, 
Inc.). Gels were photographed on a videocamera using Polaroid film (Polaroid 
Corporation) printing onto thermal paper (Mitsubishi Electric Corporation). PCR 
amplification was carried out using a T3 Thermocycler, a Personal Cycler™ (both from 
Biometra) or an Eppendorf Mastercycler gradient thermocycler (Eppendorf). DNA 
sequence analysis and microsatellite repeat analysis were performed on an ABI 
PRISM™ 377 DNA Sequencer (Perkin Elmer Applied Biosystems Division) or a 
MegaBACE 1000 DNA Sequencer (Amersham Biosciences).
2.2.2.1 Nucleotide size markers
The 50bp and lkb DNA ladders were from Gibco-BRL Life Technologies. The 
GENESCAN-500™ TAMRA internal lane standard was from Perkin Elmer Applied
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Biosystems Division. The MegaBACE™ ET400-R and MegaBACE™ ET550-R size 
standard were from Amersham Biosciences.
2.2.2.2 Oligonucleotides
Oligonucleotide primers were synthesized to order by MWG-Biotech, Genosys 
Biotechnologies Inc or QIAGEN Ltd. Fluorescent dye labelled oligonucleotides used in 
the genome-wide screen were from the Single Chromosome Scan linkage set (Research 
Genetics, Inc.), the Genome-wide Human Screening Set Version 8a (Research 
Genetics, Inc.) and the ABI PRISM™ Linkage Mapping Set (Perkin Elmer Applied 
Biosystems Division), available in the laboratory.
2.2.2.3 Enzymes
Hpall restriction endonuclease was from Promega Corporation. Restriction enzyme 
Acil and E.coli exonuclease III were from New England Biolabs Inc. AmpliTaq Gold™ 
was obtained from Perkin Elmer Applied Biosystems Division. HotStarTaq DNA 
Polymerase was from QIAGEN Ltd. Cloned Pfu DNA polymerase and Herculase™ 
Hotstart DNA polymerase were from Stratagene. Biopro™ Taq polymerase was from 
Bioline. All enzymes were used with the appropriate lOx buffers supplied by the 
manufacturers. ExoSAP-IT™ was from USB Corporation.
2.2.2.4 Commercial kits
ABI PRISM Big Dye™ Terminator v2.0 Cycle Sequencing Ready Reaction kits were 
from Perkin Elmer Applied Biosystems Division. QIAamp Blood Kits, QIAamp Blood 
Maxi Kits, DNeasy Tissue Kit, QIAquick PCR Purification Kits, QIAquick Gel 
Extraction Kits and QIAprep Spin Miniprep Kits were from QIAGEN Ltd. PCR- 
Script™ Amp Cloning Kit was from Stratagene. GenomiPhi™ DNA Amplification Kit 
was from Amersham Biosciences.
116
2.2.3 Stock Solutions, Buffers and Media
2.2.2.1 General solutions and buffers
TE lOmM Tris, ImM EDTA (pH 8.0)
TBE buffer 89mM Tris borate, 2.5mM EDTA (pH 8.3)
Where appropriate, solutions and buffers were autoclaved at 105kPa for 20 minutes 
before use.
2.2.3.2 Gel loading buffers
Orange G
Blue dextran
Genotyping loading 
mix (ABI 377)
Genotyping loading mix 
(MegaBACE)
0.25% w/v orange G, 20% w/v Ficoll 400, lOOmM 
EDTA
Blue dextran/EDTA and deionised formamide in a 1:5 
ratio
3:1:1 ratio of deionised formamide: GS-500 TAMRA 
internal lane standard: blue dextran (50mg/ml)/EDTA 
(50mM)
7.5pl distilled H2O, 0.5pl MegaBACE™ ET size 
standard
2.2.3.3 Bacterial culture media
LB broth lOg bactotryptone, 5g yeast extract, lOg NaCl (pH 7.0) per litre
LB agar As above, but with 17g bacto-agar added prior to autoclaving
NZY broth lOg of NZ amine, 5g yeast extract, 5g NaCl (pH 7.5) per litre
NZY+ broth 9.6ml NZY broth, with lOOpl 1M MgCl2, lOOpl 1M MgS04 and
200pl filter-sterilised 20% w/v glucose solution added 
immediately prior to use
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LB broth, LB agar broth and NZY4" broth were sterilised by autoclaving. Ampicillin 
(50pg per ml of medium) was used for host cells carrying the pPCR-Script Amp 
cloning vector and was added to aliquots of LB broth immediately prior to use, and to 
LB agar once it had cooled after autoclaving, immediately prior to pouring it into sterile 
petri dishes. LB agar plates were stored at 4°C, wrapped in Clingfilm, for 1 month or 
less.
2.2.3.4 Lymphblastoid cell culture media
Cell lines were cultured in RPMI 1640 medium, supplemented with 10% v/v FBS, 
2mM L-glutamine, 100 IU/ml penicillin and 100 pg/ml streptomycin. For long term 
storage at -70°C, the medium was further supplemented with 10% v/v DMSO and 
additional FBS, to give a final concentration of 20% v/v.
2.3 Methods
2.3.1 Preparation of DNA
2.3.1.1 Extraction o f DNA from human venous blood
For routine isolation and purification of genomic DNA from whole venous blood, 
QIAamp Blood kits (QIAGEN Ltd.) were used in accordance with the manufacturer’s 
instructions. These kits were chosen because they are suitable for DNA preparation 
from fresh and frozen blood, and yield pure DNA, free from contaminants and PCR 
inhibitors, which can be used directly as templates for PCR amplification. QIAamp 
DNA Blood Maxi kit was used for extracting DNA from 10ml blood. QIAamp Blood 
Mini kit permits DNA extraction from as little as 200pl, which is convenient if it is 
only possible to take a small blood sample, especially from a young child. In this 
system, white blood cells are lysed in the presence of proteinase K and the DNA is then 
adsorbed onto a silica membrane by brief centrifugation in a ‘spin column’. The salt
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and pH conditions ensure that protein and other contaminants are not retained on the 
membrane. The DNA is washed and then eluted from the column membrane.
2.3.1.2 Extraction o f DNA from EBV immortalised lymphoblastoid cell line
Immortalised lymphoblastoid cell lines were established for the two affected girls (VI.3 
and VI.5) from Family 2 and the two affected boys (IV. 1 and IV.3) from Family 1. 
Establishing a cell line is convenient because it allows the preparation of as much DNA 
as needed without having to take repeat blood samples from affected children. Cell 
lines were cultured in RPMI 1640 medium with glutamax, supplemented with 10% v/v 
FBS, 100 IU/ml streptomycin at 37°C in a humid atmosphere containing 5% CO2. 
Cultures were expanded by 2-3 volumes every 2-3 days until they reached a volume of 
50ml. Cells from each culture were harvested, pelleted by centrifugation at 1,000 rpm 
for 5 minutes and resuspended at 5xl06 cells/ml in freeze mix which consists of 
medium supplemented with 10% v/v DMSO (dimethyl sulfoxide) and additional FBS, 
to give a final concentration of 20% v/v. 1ml aliquots were then placed in cryotubes, 
allowed to freeze slowly at -70°C overnight and transferred to liquid nitrogen for long 
term storage. The remaining cells were pelleted by centrifugation at 1,000 rpm for 5 
minutes and resuspended in 10 ml of PBS to wash them, pelleted again at 1,000 rpm for 
5 minutes and resuspended in 5 ml of PBS. DNA was extracted with QIAamp Blood 
Maxi kit, in accordance with the manufacturer’s instructions.
2.3.1.3 Extraction o f DNA from paraffin embedded tissue
DNA extraction from a post mortem paraffin embedded specimen was required, and for 
this purpose the QIAamp tissue kit (QIAGEN Ltd.) was used. This kit allows rapid 
isolation of genomic DNA from fixed tissue using a very similar principle to that 
described above for DNA extraction from blood. The paraffin was removed from the 
sample by extraction with xylene and the manufacturer’s protocol was followed.
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2.3.1.4 GenomiPhi DNA amplification
To amplify small amounts of DNA, the GenomiPhi™ DNA Amplification Kit 
(Amersham Biosciences) was used in accordance with the manufacturer’s instructions. 
This kit was chosen because it allows DNA amplification from nanogram amounts of 
starting material. It utilizes bacteriophage Phi29 DNA polymerase to exponentially 
amplify single- or double-stranded linear DNA templates during an isothermal (30°C) 
strand displacement reaction, lpl of template DNA (minimum of lng in lpl) was added 
to 9pl of sample buffer containing random hexamers that non-specifically prime 
polymerisation catalysed by Phi29 DNA polymerase. The sample was heated to 95 °C 
for 3 minutes to denature the template DNA. After cooling at 4°C, the sample was 
mixed with 9pl of reaction buffer containing salts and deoxynucleotides and lpl of 
enzyme mix and incubated at 30°C for 16-18 hours. After amplification, the sample 
was incubated at 65°C for 10 minutes to heat-inactivate the enzyme. Phi29 DNA 
polymerase starts replication at multiple sites on the linear single-stranded DNA and 
while polymerisation proceeds, strand displacement of downstream replicated DNA 
generates new single-stranded DNA. Subsequent priming and strand displacement 
produce large quantities of double-stranded DNA that can be used directly in other 
applications without purification.
2.3.1.5 Preparation o f plasm id DNA
Preparation of plasmid DNA was carried out using QIAprep Spin Miniprep kits 
(QIAGEN Ltd.), in accordance with the manufacturer’s instructions. In this system, 
bacterial cells are lysed under alkaline conditions and selective adsorption of plasmid 
DNA is ensured by the use of silica-gel membrane. The DNA is then washed to remove 
salts and eluted. This method is fast, simple and yields pure, concentrated DNA that 
can be used directly in subsequent applications with no need for phenol/chloroform 
extraction or ethanol precipitation.
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2.3.1.6 Quantification o f DNA
DNA was quantified by diluting a lOjxl aliquot of DNA in 1ml TE buffer and the 
absorbance of the solution was read at 260 nm using a spectrophotometer (JENWAY 
6505 UV/Visual spectrophotometer). The DNA concentration was then determined 
using the A260 value (an A260 of 1 corresponds to approximately 50pg/ml for double­
stranded DNA).
2.3.2 PCR Amplification of DNA
2.3.2.1 Microsatellite marker sets for genotyping
For the first-pass genome-wide screen in patients IV. 1 and IV.3 from Family 1, patients 
VI.3 and VI.5 from Family 2 and patient II.6 from Family 4, the Single Chromosome 
Scan linkage marker set (Research Genetics, Inc.), which has an average resolution of 7 
cM, was used. This set consists of 516 fluorescent dye-labelled (6-FAM, HEX, and 
TET) primers for trinucleotide and tetranucleotide microsatellite markers that can be 
pooled and loaded into a single gel lane. Markers are grouped by chromosome in panels 
and can be multiplexed by colour and allele size within each panel(Levitt et al., 1998). 
Gaps larger then 10 cM obtained in the results from the first-pass genome-wide screen 
were filled in, where possible, using two other linkage marker sets available in the 
Molecular Medicine Unit: the ABI PRISM™ Linkage Mapping Set (Perkin Elmer 
Applied Biosystems Division) and the Genome-wide Human Screening Set Version 8a 
(Research Genetics, Inc.) which both have an average resolution of 10 cM. The ABI 
PRISM™ set consists of primers to amplify dinucleotide microsatellite repeats while 
the Research Genetics set consists of primers for trinucleotide and tetranucleotide 
microsatellite markers.
2.3.2.2 Primer design for genotyping
Where none of the three available sets contained primers to a suitably located marker, 
new fluorescent primers were designed. The primer sequence was often taken directly
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from public databases (uniSTS at http://www.ncbi.nlm.nih.gov/genome/sts (Dib et al., 
1996) and UCSC Human Genome Browser database). In some cases, for example when 
published primers seemed very short or had a low annealing temperature, primers were 
re-designed to be at least 20-22  bp long and with higher annealing temperatures with 
the aid of PRIMER3-Design primers pair and probes program at 
http://workbench.sdsc.edu. The program was used to select primers from the genomic 
sequence available around the microsatellite repeat. 6-FAM and TET 5’ labelling (blue 
and green respectively) was preferred as HEX-labelled products (yellow) are usually 
faint and difficult to read.
For haplotype analysis in CLS Families A, B, C and D, fluorescent primers for two 
markers on chromosome 15ql3 were taken from the above linkage sets available in the 
laboratory, while the others were designed as described above. Details of the markers 
used are shown in Table 2.1. Details of the primer sequences and optimally determined 
PCR conditions for the markers used for haplotype analysis in JATD families on 
chromosomes 4pl6, 12p, 6 , 16, 3q, 8q24, 12q and 15q are listed in Tables 2.2, 2.3, 2.4, 
2.5, 2.6,2.7 and 2.8. Dye-label, heterozygosities and allele sizes are also given.
2.3.2.3 Primer design for direct sequencing
For sequencing of exons, oligonucleotides primers were designed from genomic 
sequence with the aid of the program PRIMER3-Design primers pairs and probes as 
described in section 2.3.2.2. Since these primers were used for direct sequencing of the 
PCR product after the initial PCR amplification, they were designed to be far enough 5’ 
and 3 ’ from the region of interest so that good quality sequence of the entire exon and 
splice site could be obtained. Details of the primer sequences and their optimally 
determined PCR conditions for direct sequencing are shown in Tables 2.9-2.15.
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M arkers
Allele size 
range (bp)
Het.
Index
Prim er sequences forward  
and reverse (5' to 3 ’)
Labelling
dye
Repeats
A nnealing
tem perature
(°C)
D15S165 180-208 0.79
Marker from ABI PRISM Linkage 
Mapping Set HEX di 55
D15S976 142-154 0.63 CCATGAGCCACTATGCC
GCCTATGACCCAGCAATTC
FAM di 53
D15S1031 299-321 0.74
CAATCATGTGAGCCAATTCC
ACCCTGCATCATCCTCGTT TET tetra 53
D15S1010 211-237 0.8
TAGGGGCAAATTCAATCTC
TTCACACAGCGTGGAAG TET di 53
D15S144 156-170 0.67 AGAGACATCAATACATGATTGGG
GAGGTGAAGATTGCCGTGAG
FAM di 53
D15S1007 165-189 0.87 GGGGAACCT AC ACTTCCG 
CCAGGAATCTCAAATGGCTT
TET di 53
D15S1040 197-211 0.77 TGGGAGGCTGAGTCAC 
AAAGCC AAAT GT AGAGGAAT
FAM di 53
ACTC 68-92 0.87
Marker from Research Genetics linkage 
marker set FAM tetra 55
D15S118 218-230 0.75 TCAAAGACCCATATCAACCA
GTGCTGAAAAGCGACACTTA
TET di 53
Table 2.1 Microsatellite repeat markers on chromosome 15q used for haplotype analysis 
in CLS families.
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Markers
Allele size 
range (bp)
H et
Index
Primer sequences forward 
and reverse (S' to 3')
Labelling
dye
Repeats
Annealing
temperature
(°C)
D4S3360 166-182 /
CTAGCTTTGATTCTATTGACC
GGTCTAAATCAATGACCTAAGC FAM di 55
D4S412 159-171 0.76 Marker from ABI PRISM Linkage Mapping Set HEX di 55
D4S2375 -288 /
GTTGTTTCTCCTTTCATTAGTGC
ACCCCCTAACTGTCTCACCT TET tetra 55
500H20P5 -235 /
TGCAACCAAAACTAAGAG
CATTCCCCAAGATCAACCAGA FAM di 59
500H20P3 -165 / TTTGCTCTACTTTCCTTGTTGTTT 
GAT AGTACCCAGCCTTCA
TET di 55
D4S23S4 -218 / TCTGCCTTTCTCCCTAACAGAG
TTAGGCTAAGTGAGCGTTCCTC
FAM di 60
EVC  - 
Exon 18
-225 / AGCCTGCCTGTGGGGACTG
GCTGGTGCACTGGGAACTG FAM tetra 67
D4S827 -216 / CAGGGGAAGGAGAGGACTTCACGGCGTCTTGTAGTTGACAGTTTAC TET di 55
D4S2366 120-144 0.77 Marker from Research Genetics linkage marker set TET tetra 55
D4S2983 -200 0.87 CCAGTTGGCAGGGATAAAATAGCACAAGTTCAAAGAGGCATCAG TET di 60
Table 2.2 Microsatellite repeat markers on chromosome 4pl6 used for haplotype analysis 
across the EVC/EVC2 locus in JATD families.
124
Markers
Allele size 
range(bp)
Het.
Index
Primer sequences forward 
and reverse (5' to 3')
Labelling
dye
Repeats
Annealing
temperature
(°C)
D12S373 208-224 0.76
Marker from Research Genetics linkage 
marker set TET tetra 55
D12S1066 208-224 0.81 Marker from Research Genetics linkage marker set FAM tetra 55
D12S1042 118-136 0.81
Marker from Research Genetics linkage 
marker set TET tetra 55
D12S345 208-242 0.87
Marker from ABI PRISM Linkage 
Mapping Set TET di 55
Table 2.3 Microsatellite repeat markers on chromosome 12pll-pl2 used for haplotype analysis 
in JATD families.
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Markers
Allele size 
range (bp)
H et
Index
Primer sequences forward 
and reverse (5' to 3')
Labelling
dye
Repeats
Annealing
temperature
(°C)
D6S276 197-229 0.83
Marker from ABI PRISM Linkage 
Mapping Set FAM di 55
D6S2427 198-223 0.77
Marker from Research Genetics linkage 
marker set FAM tetra 55
D6S1017 150-174 0.68
Marker from Research Genetics linkage 
marker set TET tetra 55
D6S2410 236-252 0.72
TTGCCTTGTTAACATGTACAGG
AGTGCTAGACTGGGAGCAGA FAM tetra 55
D6S2436 121-149 0.75
CAGGATTTTTCAGAAAGGCA
CTGTCACAGACTTTTTCAGCC FAM tetra 60
D6S1581 -238 0.72
TTAATGTCTTCCAGGCTCATCC
GAATACCTGCATTCCCACATTT TET di 60
D6S1273 188-205 0.8 Marker from Research Genetics linkage marker set HEX tetra 55
D6S1719 -180 0.75 ATGGAACTACTCCCATTCCAACGAGATACAAGCAGGAGGTAGCA TET di 58
D6S1027 177-139 0.77 Marker from Research Genetics linkage marker set TET tri 55
D16S521 -234 0.71 AGCTGGCAGTGAGCCAAGATAAATGTCGTATTCACCATGTGC FAM di 60
D16S2622 71-87 0.88 Marker from Research Genetics linkage marker set FAM tetra 55
D16S423 133-157 0.73 Marker from ABI PRISM Linkage Mapping Set HEX di 55
Table 2.4 Microsatellite repeat markers on chromosomes 6p21, 6q25-q27 and 16pl3.3 
used for haplotype analysis.
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Markers
Allele size 
range (bp)
H et
Index
Primer sequences forward 
and reverse (S' to 3')
Labelling
dye
Repeats
Annealing
temperature
(°C)
D3S1764 217-261 0.79
Marker from Research Genetics linkage 
marker set FAM tetra 55.5
D3S1309 -171 0.74 CTTTGGGGAATCATTAGTCTGT
CTTGCATCCCTGAGATAAATCC
TET di 60
D3S3694 -299 0.84 TCCATCAACATGGGAATGAATA
CCCAACTCCTCACTACTCCAAC
FAM di 60
D3S1569 147-169 0.8 Marker from ABI PRISM Linkage Mapping Set FAM di 55.5
D3S1593 -210 0.78 GGAACAGTATTCTTGGTTGAAAG
G
TET di 60
D3S1744 131-173 0.77 Marker from Research Genetics linkage marker set TET tetra 55.5
D3S1306 -166 0.72 TTTTTGTGTTGCACAGTGAAAAT
TGGATTTAGTCTGCTGGTAGGAA
FAM di 57
D3S1555 -163 0.8 TTCCCAGTCACAAACACACTTCATATGCCATTCTTGGATTTCA FAM di 60
D3S1308 -196 0.69 ATGCCTAGTCAGTCCAAGGAAC
TTTTATTGCTTTTGCCACCTCT
FAM di 60
D3S3705 -228 0.67 GGCAATTTTGAAATCTCTTCCATGCGTAGTCAAGATTGTATGGC TET di 60
D3S1299 -201 0.62 GGGGG AAAAATTG AAAG AC AAT 
TGCACGCTACCAAACTACTGTT
TET di 60
D3S1279 264-282 0.85 Marker from ABI PRISM Linkage Mapping Set FAM du 55.5
D3S4531 257-273 0.69
Marker from Research Genetics linkage 
marker set TET tetra 55.5
D3S1746 248-284 0.85
CCCCTGCAAACAAATTTTTT
GTGTCTTAAAATAATCCAGGCG TET tetra 60
D3S1280 -222 0.75 CTGCTGGAGGCTGTTTTACAGT
CACCAGAGGACTACAACCCACT
FAM di 60
D3S1237 -297 0.79
CAGGAAGAGTGATGTGCCTACA
GTTAATGCGGCAAAGAGTAACC FAM di 60
D3S3710 -243 0.74 TATTCCACCTGACTCTATTGCCCTGCTTTTATGCAAGATGAAGTGG FAM di 62
D3S3531 210-256 0.73 AAG AGCCTAAATTAGG AAAATAA 
AA AAACAAAGCAAGACTCCATC
TET di 60
D3S1607 -235 0.8
TTTGTAATAAACAGCAGCCTGTC
TGCACGTAACGAAAATGAAGAG TET di 60
D3S3692 -242 0.62 TTTTGCAAGAGCCTGTCACTAACATCTTGGGAATGGACTACACA FAM di 60
D3S3575 -192 0.79 GGGAACAGACAATTCCACAGAT 
TC AGGGGTTGCTT AAGAGACTT
FAM di 60
D3S3S80 -242 0.66 GGCCATTGCAGAGAAGTTTGATTTGGGGCTACAGTTACAAGGGT FAM di 62
AC026118 -183 TATAAGCGAGGGTGACTGCTTGAAGCTCATTGCCTTTCAAAC FAM di 59
AC024221 -237 AACAAAATGGAATCACAGTTGCGCAAATAGCAAAATGGTTCTGA TET di 59
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AC069224 -223 ACTCTGGCCCTTAAATGGATAAAGGTCTATTTTTCAACAGGGGA FAM di 59
D3S3579 -183 0.79 TATGGGAAATTTTGAGCAACCTTGGGGATTTGACAGTATTAGGG TET di 60
D3S1268 -209 0.86
GCTTAGTGAAAAGGTGCAGTGGT
CTTGGCCAATTCCACAACTTTAG TET di 62
D3S3668 -225 0.83
TGGGAATTAAAAACTTCAGGAGA
TGAGCTCACTGGCTAATCTCAA TET di 60
D3S1763 260-280 0.8
Marker from Research Genetics linkage 
marker set FAM tetra 55.5
D3S1614 100-122 0.83 Marker from ABI PRISM Linkage Mapping Set TET di 55.5
D3S1282 -167 0.78
GCTGTGATTTGTTTCTTCTGAGAT
TTCCACTGTATCACAGGTTTTCA FAM di 57
D3S3523 -193 0.68
TGAAAACAAAATCAGCAGACTTA 
CA CCAACCTTGCCACTATCATGT TET di 60
D3S3723 -166 0.63
TAAGTGAATTTGTCAGGCACCA
TGGACCATGACAGAGTGGTAAG FAM di 60
R1
AC026316
-276 /
AAGTAGGGTGGCC AAT GTTGTT 
TTCCTCTCAGCATGGTCTTCCT FAM di 62
R2
AC061708
-199 / CCTCCCAACTCAGGATTTCAACTGCTGGAAGAAGCATATCAGGA TET di 62
R3
AC092919
-286 / CAGGTGGTTGAGAGACCATCAGGTGGATGCCAAATGAAGAATTG FAM di 62
D3S1574 -129 0.79 GTTAACTCCCCTACCCCAGTGTTCTTCACAATTTCCATTCCCTTA FAM di 60
D3S3053 226-238 0.73
Marker from Research Genetics linkage 
marker set TET tetra 55.5
D3S3725 -204 0.84 CTTAAGGTTAGAGGTGCCATGCTCACAGTGCCCTGACTTTACTG FAM di 60
D3S1565 175-189 0.63
Marker from ABI PRISM Linkage 
Mapping Set FAM di 55.5
D3S2427 216-260 0.85
Marker from Research Genetics linkage 
marker set HEX tetra 55.5
D3S3730 -287 0.83
TT GTAATGGC AAGTTGGTT CTG 
TGAAGATGAGTCCTGAGCATGT TET di 60
D3S1262 107-129 0.8 Marker from ABI PRISM Linkage Mapping Set FAM di 55.5
D3S2436 164-180 0.67
Marker from Research Genetics linkage 
marker set TET tetra 55.5
D3S1580 212-232 0.84 Marker from ABI PRISM Linkage Mapping Set FAM di 55.5
D3S2398 266-298 0.77 Marker from Research Genetics linkage marker set TET tetra 53
Table 2.5 Microsatellite repeat markers on chromosome 3q24-q26 used for haplotype analysis
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Markers
Allele size 
range (bp)
Het.
Index
Primer sequences forward and 
reverse (5' to 3’)
Labelling
dye
Repeats
Annealing
temperature
(°C)
D8S1128 240-268 0.76
Marker from Research Genetics linkage 
marker set HEX tetra 55.5
D8S1720 -153 0.82 CTGAAAGAAAATGCCCACCCTA
GTTTTTGTCTGCCTTTGCTTCT
FAM di 60
D8S1732 -2 0 6 0.78 ATGGGGATACCCCCATGTTTC
ATCTGCAAGGGCTCTATTTCCA
FAM di 62
D8S1701 -275 0.7
TACTTGGTCTTGGCTTTCCAAT
AGTGAAACCCCATCTCTACCAA FAM di 60
AC131568 i 00 00 / GAATTTCTGACCAGTTGGCTTCGAGACTGCAGTGAGCTGTGATT TET di 60
AC103725 -226 /
ACTGTTAAGTGCTGGAATGGGT
ATGAAGACCTGTGTCCCTCCTA FAM di 60
AC009682 -232 / CCATCCCACTACTCTAACCCAAC
GGTGACAGAGTAAGATCCCGTCT
TET di 61
D8S284 268-300 0.83 Marker from ABI PRISM Linkage Mapping Set HEX di 55.5
D8S1712 -231 0.72 ACTGACTGGAGACGTGAAATGGT
GGATCTCCTCTCTCCTGGAACTC
FAM di 62
D8S557 -214 0.76 CAGACATGAAATTGCTGAGACA
CCTGGGGTCCTAGAGATTTAGA
TET di 58
D8S558 -164 0 .8 6 TTTTTAAGCCCCTAGTGTGGAA
CTGAGAAGTCTCTGGGGCTTTA
TET di 60
D8S529 -247 0.81 GTAATTAGCATGCTGGCATTGACATAATCCCTCCCAATCAAAGA TET di 60
D8S256 -221 0.83 GGCACTTTGCTTTTCTTCCTGTATGGAGTGAAGGCTCTCCTCTG FAM di 61
D8S1708 -154 0 .6 8 TCACCAAACTTCTAAATGAAGGC
GTGAACTGCTGTGTTTATGTGGT
FAM di 59
D8S1796 -221 0 .6 6 GAGAGCACCTAAGCCAGTGTTTGAGAGCACCTAAGCCAGTGTTT FAM di 59
D8S1746 -203 0.7 GGGTTCCTC ATC ATC AGCTT AG 
AGATCCAGTGAACATCAACCCT
TET di 59
D8S1462 151-170 0.75 Marker from Research Genetics linkage marker set FAM tetra 55.5
D8S1710 -260 0.78 TATACAGACCTCCATTCATGCGTCAAATGGGCTTTGTTTTTCTT TET di 58
D8S537 -182 0.89 TCTATGAATTTTGGACTTGCCA
TTTGGTCTCGTATATGCCTCTG
FAM di 58
D8S1108 -258 / AATGCCTACAAAAACCAGTGCTGCTTGCCTGGTCTCTTACACTT TET tetra 60
D8S534 -177 0.81 CTTGCAGCACGACTCACAATAACCCATGTTGTCAAAAATGGCAGTA FAM di 61
D8S1100 183-192 0.65 CTGTGATTATTGCAAACCCCCCAGAGTACCTGGCATATGG TET tri 55.5
D8S1783 -172 0.78 TTATCAGAAAAGATGATGAAGGCAATAATATCCAGAAAATCAAGGCCA FAM di 60
D8S1761 -287 0.71
TATCCAATGTTGATGGCACCTC
TGTTATCTCTGGCCTGTTGGA FAM di 60
129
D8S274 -117 0.77
ATAATCCACTAAGCCCAGCAGA
TTCTAAGTTCCCCAATTTGGAC TET di 60
D8S272 -239 0.8
CAAAATGCTATTGAGTTCTTCCCT
GCAACCTGGATCTTATTTGCTTAT TET di 61
D8S1837 -230 0.81 CT AATGAAAGGCTGACCTCCTG TTATGCTCTGCTCTCTGCTTTG TET di 60
AFM316xbl -192 / GATTTCCAAGAGAAATTGGCACTCCTTCTTTGGAAGGATGTGAT TET di 60
AC087711 -198 /
ACTGGAATGATACCACCTGCACT
GTTCTCCAGAGAAACAGGACCAA TET di 62
AC087711-2 -244 /
TGAGCTGGGCTATGACTTTACA
AATGACCCTTGAAAGGAGATGA TET di 60
AC068467 -212 / TATCCCAAGCATGGAGCTAGTGTTTAGTAAGGCCTTGGAGGAAAGC FAM di 62
AC105130-R1 -257 / ACTCACCCCTGGTGATTCTGATATTTCATATTTGGGTGATGGGC FAM di 60
AC053480-R1 -286 / CAGAGAATAGGATGGTGGCTTCCATCACCTCCAAAATTTCCTGT FAM di 61
D8S1743 -245 0.83
TGGTT AATAAAGGGC AGGG AAA 
AGTTTCCTCCCACTCCCCTTAC TET di 60
D8S373 -271 0.78 CTTGGTCTCCTCTGATGGGTAGCAACAAGTAAGTGCTGGCTGTC TET di 60
D8S2334 -155 / CTGAAGCCTAATGCATCCAATGTTCCAGCATAGCACTTCTGGTC FAM di 61
D8S1926 -253 / TGAACTTGAAAAAT ATTTGGGCTT TGATCATGTGGGACAGATAAACTT FAM di 60
Table 2.6 Microsatellite repeat markers on chromosome 8q24 used for haplotype analysis.
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Markers
Allele size 
range(bp)
Het.
Index
Primer sequences forward 
and reverse (5' to 3')
Labelling
dye
Repeats
Annealing
temperature
(°C)
D12S346 184-208 0.84
Marker from ABI PRISM Linkage 
Mapping Set TET di 55
PAH 229-257 0.8
Marker from Research Genetics linkage 
marker set HEX tetra 53
D12S78 171-201 0.91 / FAM di 55
D12S317 250-280 0.71 / HEX di 55
D12S1342 266-288 0.83 / FAM di 55
D12S353 89-105 0.77 / HEX di 55
D12S1605 195-205 0.78 / FAM di 55
D12S84 199-219 0.84 / HEX di 55
D12S1583 219-247 0.87 / FAM di 55
D12S1645 212-248 0.77 / HEX di 55
D12S1339 266-278 0.71 / FAM di 55
D12S1646 247-259 0.72 / FAM di 55
D12S1341 203-221 0.79 / FAM di 55
D12S79 155-181 0.87 Marker from ABI PRISM Linkage Mapping Set TET di 55
D12S2070 86-104 0.79 Marker from Research Genetics linkage marker set TET tetra 53
D12S395 181-217 0.85 Marker from Research Genetics linkage marker set HEX tetra 53
D12S324 230-252 0.69 Marker from ABI PRISM Linkage Mapping Set TET di 55
Table 2.7 Microsatellite repeat markers on chromosome 12q23-q24 used for haplotype analysis. 
/ means primer sequence is unknown.
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M arkers
Allele size 
range (bp)
Het.
Index
Prim er sequences forward and  
reverse (5' to 3')
Labelling
dye
Repeats
A nnealing
tem perature
(°C)
D15S817 140-164 0.79
Marker from Research Genetics linkage 
marker set HEX tetra 55
D15S1021 -221 0.79
CTACAGCCTGGATGACAGAGT
GGCATCTCTTGCCATTTTCTTA TET di 60
D15S128 193-211 0.78
Marker from ABI PRISM Linkage 
Mapping Set TET di 55
D15S822 242-306 0.86 / FAM tetra 55
D15S1002 -1 3 6 0.79
GTATCCCAAGGCCATACCCTG
GTCTTGCTAGGTTCCCCTTTTT TET di 62
D15S219 203-227 /
GAGTCTGTCTGTGGGAGGGAG
AATGCTTTCTAAGCCAGCCAA FAM di 62
D15S156 -251 0.51
GAC AC AAAAGCC AGGT ATGAC A 
TGTGGATTTATTTCTGGGCTCT TET di 60
D15S217 211-250 /
Marker from Research Genetics linkage 
marker set FAM tetra 55
AC079090 -2 3 7 /
GTGTGCCTCTCTGTACACCTGG
TTCATCGGTCACCAAGTCCAT TET di 62
AC024474 205-215 / CACATAAAACTTCAAAGGCCCTG
GATATGCTGCCTTGAAAGTGTCC FAM di 62
D15S1019 -2 2 2 0.63
ATTCTGGACCACGCATACTAGG
TTTTTCCCACTCAATATCAGGC FAM di 60
AC090763 -2 6 7 /
ATTTGGCTCCTGCTTCATCTTC
GCTCAACTAGCACCCTGGTTTT TET di 62
D15S1048 203-233 0.84 / TET di 55
AC022613 -2 7 4 /
AGGTTGCAGTGAGCCAAGACTG
TTCCTTCAGTCCCATAGCATCA FAM di 62
D15S1043 -231 0.52 AAGAACTATGAGGCAAGGAACGTAGGGGGTTCAGTGTGCTTATT TET di 59
D15S165 180-208 0.79
Marker from ABI PRISM Linkage 
Mapping Set HEX di 55
D15S976 142-154 0.63 CC ATGAGCC ACT ATGCC 
GCCTATGACCCAGCAATTC
FAM di 53
D15S1013 169-179 0.53 / TET di 55
D15S1031 299-321 0.74
CAATCATGTGAGCCAATTCC
ACCCTGCATCATCCTCGTT TET tetra 53
D15S1010 211-237 0.8
TAGGGGCAAATTCAATCTC
TTCACACAGCGTGGAAG TET di 53
D15S231 102-114 0.5
Marker from Research Genetics linkage 
marker set FAM tri 55
ACO19278 -1 9 6 /
ATCCTGATGATGCCACTAAGCA
ATGTGTTTCCCGCTCTCAATTT TET di 62
D15S995 -2 4 2 0.67
C AAAGC AAAGAAGGC AT AGTT G 
CTGGCTCTAAGCTCATCTCTCA FAM di 59
D15S1007 165-189 0.87 GGGGAACCTACACTTCCG
CCAGGAATCTCAAATGGCTT
TET di 53
AC087638 -2 9 5 /
TGTTCGCACTCTAGCTTTCCT
GAAGAGGTGGTTGGTGATGATG FAM di 62
D15S1232 -3 0 9 / TGTCCATGCTCTTAACCATTCTT
ATGATGTTGCTCCACTCTTTTCT
TET di 60
132
ACTC 68-92 0.87
Marker from Research Genetics linkage 
marker set FAM tetra 53
D15S971 -2 9 8 0.82
CCACCACAGCTTGCTACTTAACC
AACAGAGCGAGACTCTATCTCGAA TET di 62
D15S1042 -2 7 8 0.82
GGCTAATGCCATGATAAGCAGA
GCCAAGTTTTCCTCATCCATCT
FAM di 62
GATA50C03 274-290 0.72
Marker from Research Genetics linkage 
marker set FAM tetra 53
D15S994 -1 8 3 0.72
CATCCAGGAAGTAGTGCAGGTG
AGTGCATCTCCTAAGGGCAAAG FAM di 62
D15S659 174-210 0.84 / TET tetra 55
Table 2.8 Microsatellite repeat markers on chromosome 15ql3 used for haplotype analysis. 
/ means primer sequence is unknown.
133
Prim er pair
Prim er sequences forward and 
reverse (5' to 3 ’)
Annealing
tem perature
(°C)
Product size 
(bp)
FMN IF  
FM N1R
ATCAGTTTACTGCTCACCTCGG
CTCATTCCAAGAACCCTGAAAG 60 294
FMN 2AF  
FMN 2AR
ATCTGGCTGTTGTCTGATTCCT
GAAAAATATGTCGCCTGGATGT 60 498
FMN 2 BF  
FMN 2 BR
AGGAGTCAGACATCATCAGCCT
CCAAAGGTTAGGCCTTGTTCTA 60 473
FM N 2C F
FM N2CR
GAAGAGGACCAAAAGAAAAGGG
CTTTGGAGACAGGTTTCTGCTT 60 494
FMN 2 DF  
FMN 2 DR
AGAGGCAGAAAAGGATGAGATG
TCCTCTTGTTTCTCGTTTCTGG 60 458
FMN 2 EF  
FMN 2 ER
CACACGAGTGTCCCTCACAC
GCAGACTGATAGTTCCCCAATC 60 600
FMN ex2FF  
FMN ex2FR
AGCCTCCATTTCTAGTGTGTCG
TTAAGAGCAGCTTCCCTCTCAC 60 447
FMN 3 F  
FMN 3 R
GCTATAAAGTGGCGAAACCTGT
CAATGAACACCCTTCTCTCTCC 60 365
FM N4F
FM N4R
TTTGCATTCTGTCTGCTTCTGT
CAGCTGACCACGGTTAATACAA
60 194
FM N 5F  
FMN 5 R
GAGTTCCCC AAAT ATGGCTTT A  
CACAGCACAATCACCAAGATTT 60 283
FMN 6AF  
FMN 6AR
GAAGTTTCAGAAGAGCAGCCTC 
CT ATGGAATGCTTTC AGO AC AG
60 483
FM N6BF
FM N6BR
AATCCAGAAGAGGAAGATGCTG
ATCCTTTGAGGATCTTCTGCAC 60 482
FM N 6C F
FM N6CR
GGAAAATACTGTCACTGGGGAA
GTCAATGTTGAGCAGCAGAGAG 60 493
FM N 6D F  
FMN 6DR
GAAGAAAGCAACTGATCCGAAG 
T AGGATTC ACTTTGGGAGGAAA 60 472
FM N7F
FM N7R
C ATTTTTC AGGAATT AATCGGC 
AACCCCAAATTCTGAGAGTCAA 60 273
FMN 8F  
FMN 8R
TGATGTCAAATTGTGGCATTTAT
TTCAGCATAGGAGAAAACCAAG
59 242
FMN 9AF  
FMN 9AR
ATGCTACAGTGGCACCATGA
GGAGACAAAGATCCAAGTCCTG 60 545
FMN 9BF  
FMN 9BR
CAAATGACCACAAAGACATCCA
AATATCACTTGGGCCAAATCC 60 519
FMN 10F  
FMN 10SR
CATTCCTTCCTGTTTTGGTTCT
CAGCTTTGCCATAATCACTCAG 59 228
FMN 1 OF 
FMN 10LR
CATTCCTTCCTGTTTTGGTTCT
TCATGAACTATTGGCTCCCTTT 59 489
FMN 1 IF  
FMN U R
AAAGACTGCATGGTCATTTGAG
TGAGTTGATGGTTCTGTAGCTGA 60 285
FMN 12F 
FMN 12R
GGAAGCTGGATGT GG AGTAAAC 
GCCACGTCAAAACCCTTACTAC 60 246
F M N 13F  
FMN 13R
TGCTGCT AGTCT AGGAACC AC A  
TTT AGCTGGCTGC AC ATTT AGA 60 308
FMN 14F 
FMN 14R
CCCTGGGAATCCCTTGAGTCTA
GCATTAAAGTGGTCTCTCCCAC 60 361
FMN 15F  
FM N15R
GTTACTGAATGAACATGGGTGC 
AAT AAT GGC AG ATC ATGGGAAC 60 254
F M N 16F  
FMN 16R
AGATTTCACCTCTCAACCGTGT
ATTCTATGTTGGGCTTGCAGTT 60 243
FMN 18F 
FMN 18R
TCAACTGAAAGTGACAATTGGG
TCCCACTCTATGAACCAGACCT 60 272
FMN 19F 
FMN 19R
CACAATTGATAGCCAAGTGCA 
AT GG AAT G AAGGATGTTTC AGG 60 246
F M N 21F  
FMN 2 1R
TTACGCAAAGGAGACAACAGAA
TGGGGAAGTAAAAATGTTTTGG 60 227
F M N 22F  
FMN 22 R
TGGCAATTTCTCACCTCTACCT
CTTCCCCTATGACCACTTCATC 60 329
F M N 23F
FM N23R
TTGGGTTTATGTTTAACCTGCC
CATGACAATCGTTAGATTATGTTGAA 60 224
F M N 24F
FM N24R
ATTCCGGAAACTC AGC ATTCT A  
GGCTTCCACAAGAAACAGTCAT 60 337
Table 2.9 Oligonucleotide primer pairs used for PCR amplification and direct
sequencing of FMN-1 exons.
Prim er pair
Prim er sequences forward and 
reverse (5* to 3')
Annealing
tem perature
(°C)
Product size 
(bp)
GRE1F
GRE1R
ATTTAAACGGGAGACGGCG
GCGATGGTTCTTCACAATTCAC 62 341
GRE2AF
GRE2AR
TGCGTTTAAATGCTAGGTGCTA
GTAACAGAAGCGGTTGATGATG 60 448
GRE2BF
GRE2BR
GGGAGGAGGTGCTGGAGTC
GGGTTCTTCTGGCCTCTAGGTT 62 455
Table 2.10 Oligonucleotide primer pairs used for PCR amplification and direct 
sequencing of GREMLIN exons.
Primer pair
Primer sequences forward and 
reverse (S’ to 3')
Annealing
temperature
(°C)
Product size 
(*>p)
SHOX2 1AF 
SHOX2 1 BR
TCTGCTGGCAGAGGTTGAGC
CCCCACCCTTCCACTATCACT 62 571
SHOX2 2F 
SHOX2 2R
ACAGGATTTGCTGTGCTGTTTT
CCAGACACTAGAAGCACCACCT 62 408
SHOX2 3F 
SHOX2 3R
TGCTTGCTGTATCTCCCAATTC
GGACTCCATTAACAGCCTTTGA 62 326
SHOX2 4F 
SHOX2 4R
ACCCTTTGGAACCCTGAAAAAT
CAGAAGGGACTAGGCATTCAGG 62 356
SHOX2 5F 
SHOX25R
CCCAAACACAACCCAACTCTCT
TCTCAAAGGGGTAACGGAGAAG 62 462
Table 2.11 Oligonucleotide primer pairs used for PCR amplification and direct
sequencing of SHOX2 exons.
Primer pair
Primer sequences forward and 
reverse (5' to 3’)
Annealing
temperature
(°C)
Product size 
(bp)
WISP I IF 
WISP11R
GAAAATGCAGGGTTTGTCCTTC
GCTCTGTCCTTGCCCTGTAAGT 62 394
W1SP1 2F 
WISP1 2R
GAAC AGC AT GAGGAC AGGAAT G 
TGTATCTCCTGCTGAACGGAAG 62 499
WISP1 3F 
WISP1 3R
CTTTGTGCCTCTGTTCCTCCTC
AGGTAGTGGACTGGGGAATGAG 62 506
WISP1 4F 
WISP I 4R
CCTGGGTACCTTTGCTGGTTAG
TTCCCACTTTACAAATGCTCCC 62 466
WJSP1 5F 
WISP1 5R
AGGTGGAATGCTCCCACATAGT 
AGAGACAGAAATGGAGGCCAAG 62 540
Table 2.12 Oligonucleotide primer pairs used for PCR amplification and direct
sequencing of WISP1 exons.
Primer pair
Primer sequences forward and 
reverse (S' to 3')
Annealing
temperature
(°C)
Product size 
(bp)
GLYLUBF
GLYLUBR
GATT GGTTTCCT GTT GT AAAAGCC 
ACTTGGCAAGAAAACACAATGAAA 60 327
GLYLUB2F
GLYLUB2R
ATGAAGCTTGCCTGTGTAGCTG
TTTGCGCTGTTAATTGGACACT 62 418
GLYLUCF
GLYLUCR
CTGATTTCCTATGGCTTTCAGGAT
CAACATTCACCACAGATTGACTGA 60 302
GLYLU IF  
GLYLU1R
TCCGCCCTATATTCTGTGACCT
CTCATGATGACCCAGAGTCCAC 62 399
GLYLU 2F 
GLYLU 2 R
TTTT AAGCTTT GG AAATT GG AAGG 
AGCC AT GAT AGGG AAC AGCT ACTT
60 320
GLYLU 3F 
GLYLU3R
CAT GC AT GG AAATT CT GCTTT C 
TTCAAGGCTATGAGGCTATCCC 60 304
GLYLU 4F 
GLYLU 4R
TGGAGAGGCTTAATACAGACATGC
AAACCTGCAGCCTTAGAGAAACTC 60 383
GLYLU 5 F  
GLYLU 5 R
AT GACTT ATCCC AAAT GCTTC AC A 
GAGGAAGGGT C AAATT AGC AAAAA 60 361
GLYLU 6F  
GLYLU 6R
TGAACCTCCAAACATTTTGTGAAT 
ACC AGGGTT ATTCCT GT G AC ATTT 60 379
GLYLU 7F 
GLYLU 7R
GT CCTC AGC AAT GT GTTT GT CT CT 
TTTTTACAGCAAGCAAGCAACTG 61 260
GLYLU 8F  
GLYLU 8R
ACTCTAAACCTTCACTGGGGGTC 
C ACACTCTGTATGGGAGGAT GT G 61 363
GLYLU 9F 
GLYLU 9R
AAAGACTTCAGGAAGAAGACTGCTC
GTAGAGACACGAAAGCACGAAGAT 60 355
GLYLU 10F 
GLYLU 1 OR
ATTCAGAACCTTCAGGTCAGGG
ATGCAGACAGAAAGTGCAGAGG 62 348
GLYLU 1 IF  
GLYLU U R
AAAAGGATGATGGGCAGACAAT
TTTGGTCTCACTTTTGCTGGAA 62 387
GLYLU 12AF 
GLYLU 12AR
ATCTTCGAACCGAGTCCACATAG 
CCT GCTTT GTTTT G AAATT C ACC 60 392
GLYLU 12BF 
GLYLU 12BR
CATCCCAAATGGATTCTGATGA
GGTGGCTTCCACCTACTACCAC 61 405
GLYLU 12CF 
GLYLU 12CR
TAT CCAGTGGCAGATGTGGATACT 
CTCCTGCTCTTCTGTGTGAGAGTC 62 418
GLYLU 12DF 
GLYLU 12DR
TAAGCTTGAAACTCACCCCCTC
TTGGCTCTTGCTGTGCATATCT 61 527
GLYLU 13AF  
GLYLU B A R
CT GT AT CT GCT CCCCACATCAG 
TCCTGGGGTTTTCAAGTGCTAT 61 369
GLYLU 13BF 
GLYLU 13BR
AAAGGG AAGC AGTTT GAT GCTC 
CCTGCTTTATGTTTAGCCTCCG 61 398
GLYLU 13CF 
GLYLU B C R
GCATTATGGATGACACAGCATTTA
TTTGAAACAGTATGCATGAAATGG 61 486
GLYLU 14F 
G LYLU BR
GAAGTACACAGCTTGGCTTGTGAT
TGTCATTCCACAGTTGCTAATTGA 61 332
G LYLU B F
G LYLU B R
AAAACCCAGTAGAAATGGGGAAA
CCAGCATCTCTTTTCAAGGTCTC 61 325
GLYLU 16F 
GLYLU 16R
GTAGGCGCCACAGTGTTTAGTG
CATGGCAAGAAACAAGATTCCA 62 508
GLYLU 17F 
GLYLU 17R
CTTTGCCAGTTCCCCTACATTC
GGGTTCCAAGTGGAAGTACCTG 62 367
GLYLU 18F 
GLYLU 18R
CGTTCATCTCACCAAAATTCCA
TGACTAGGCCCTTCTGTGAGTG 61 305
GLYLU 19F 
GLYLU 19R
CAAATTTCCAGAGGGTGTTGAAG
TGTTCCCAATAGGCAGTCAATTC 61 268
GLYLU 20F 
GLYLU 20R
CTGCTGTATAACAGGTCTGCCC
GCTTCATTCTGAAATGGTGAGG 61 417
Table 2.13 Oligonucleotide primer pairs used for PCR amplification and direct 
sequencing of GLYLU exons.
Primer pair
Primer sequences forward and 
reverse (5* to 3 ’)
Annealing
temperature
(°C)
Product size 
(bp)
ZNF406 IF  
ZNF406 1R
ATCCGT G AAGT GGG AT AAAAAGC A 
GCACTGCTTCCCGACTCGAC 61 438
ZNF4062F  
ZNF406 2R
GCTGTGGCTGTATTGGAGAGAA
AGTTGCTATAGGCGACCAGGAG 61 306
ZNF406 3F 
ZNF406 3R
CACAATCTGGTAGAGGCTGGTG
TTTCTAGGCTTCTGCTATGCCC 61 387
ZNF406 4F 
ZNF406 4R
AC ACTT GGAGGGT GATT GT GAA 
ACTTTTTCC AG AT GGGT G AGAGC 61 459
ZNF406 5F 
ZNF406 5R
CT AC AGT G ATTCCGT GGTCT GC 
GC ACC AGCTCTGT GTT CT G ACT 61 429
ZNF406 6F 
ZNF406 6R
TCTTGCGTGGGTATCAGACAGT
AACAAGCATGCTGATCCTTCCT 61 358
ZNF406 7AF 
ZNF406 7AR
GCGTCTGTCCAGTTTTGTTCAC
ACCTTCTTGTCCTGTGGGTCAT 61 484
ZNF406 7BF 
ZNF406 7BR
CGTCAAGAACCTCATCAAGCAC
AGCTCTGGTTGATGGAACTGGT 61 398
ZNF406 7CF 
ZNF406 7CR
AAGAAGTT CGT C AGCT CC ATC AG 
GAAACCACCTCTTGAGAATGCAG 61 389
ZNF406 7DF 
ZNF4067DR
GCT AC AGCT GGT GG AAG AGG AG 
AGCTGGGTTT G ACCT GAG AC AC 61 493
ZNF406 7EF 
ZNF406 7ER
ATCACACTACTGCTGTCCAAGGC
GGAGGATGGCTCACTTAGAAGGT 61 471
ZNF4068F
ZNF4068R
CAAGCGCAAGAGGGAGATAGAT
CCTGCAGCAGAGACACCTACAT 60 319
ZNF4069F  
ZNF406 9R
GAT GACT GTT GAT AGCGT G AGGT 
GATGCATCTGAAGACCAGATAA 55 426
ZNF406 10F 
ZNF406 10R
GGTGCTGCTTAGC AAT G AGGTT 
CTCCCAAAAT GAAGGAT GGAAG 60 300
ZNF4061IF  
ZNF406 11R
CTGCTGTGTTCAAAACGGATGT
TTCCAGAAGCTCCTTCTAACGG 60 442
ZNF406 12F 
ZNF406 12R
ACCTTTGT GT ACCT GGCT CC AT 
CC AAAGCG AAGGT AAAACC AAC 61 294
ZNF406 13F 
ZNF406 13R
CTTTCAGGGTGTCAGATGCTCA 
AGC AG AACT G AACT GC AGG AT G 61 331
ZNF406 14F 
ZNF406 14R
TT GAAGC ATTT GAAC AGGAGGA 
AACGTTTCAGAAGTTCCCCAAA 60 339
ZNF406 15F 
ZNF406 15R
T GCC AGGT AAAT GAG AT GTTGC 
ATCT GC AAACGC ATT C ATT C AG 60 334
ZNF406 16F 
ZNF406 16R
AAACTGAGCGATTACGGAGAGC 
CAGGGAGAAGGAGAGAACCT G A 60 335
ZNF40617AF  
ZNF40617AR
GCACTGGTGCCTCCTAAACTGT
GGAGAGTCCTATCAGGCTGCTG 60 477
ZNF40617BF  
ZNF406 17BR
TCTCCTAGTCCAACTTGGGGTG 
CTT AAT ACTCGGGGA AGT GGG AC 60 402
Table 2.14 Oligonucleotide primer pairs used for PCR amplification and direct 
sequencing of ZNF406 exons.
Primer pair
Primer sequences forward and 
reverse (5* to 3')
Annealing
temperature
(°C)
Product size 
(bp)
TTC7B 1AF 
TTC7B 1AR
CTGTCTCCCGCCCTAGCCCC
GTACCGTTGGCGATGAGCTTGG 68 413
TTC7B 1BF 
TTC7B 1BR
GAT GGCGACCAAGAAGGC AGG 
GAC ACCCC AGACT CCGCAGAAG 68 393
TTC7B 2F  
TTC7B 2R
GGTGCCCACTTAGACCCTATGA
TAAGAAGACAAGCCCTGGCAGT 62 437
TTC7B 3F  
TTC7B 3R
TTTGGGTTGTTTCCACTGTTTG
GTCAAATAGGCAGCTCCGAAGA 62 417
TTC7B 4F 
TTC7B 4R
AAGC AT CC AG ATT GA AAAGGAGG 
GCTTT GC ACAC AGAGAC AGAC AA 62 395
TTC7B 5F  
TTC7B 5R
CCTCTGCACTGATATTTGCCTG 
GGAAAGCAAGAGAGCCAGGT AG 62 438
TTC7B 6F 
TTC7B 6R
ATGGCTAGGCATGTGCAGAGTA 
CCTAT GAGAC AAGT GCCCT GCT 62 274
TTC7B 7AF 
TTC7B 7AR
TATGAGCCTTGCAGTAGTGCTT
TGACACTTGTTCATTTGATTTTCTT 59 417
TTC7B8F
TTC7B8R
CCCTTCTGCCTACCACTAAAA
TCCCATCCAGGTATACCCTCT 59 405
TTC7B 9F 
TTC7B 9R
ACAGGCCTCTGCTCATTCCTAC
AAGATCACATGGCTGCCACTAA 62 393
TTC7B 10F 
TTC7B 10R
CAAGGGAAGCAGATTTTATGGG
CACTGAGAACGGACCACGATAG 62 344
TTC7B 1 IF  
TTC7B 11R
AGC ATTCCT GCT GGCTTTT AAC 
AATCACCCTCGCTTTCTCTCTG 62 418
TTC7B 12F 
TTC7B 12R
GTGGGATT GGGAG ATTT GAGAG 
T C AGACC AAGC AAAGAGG AC AG 62 422
TTC7B 13F 
TTC7B 13R
GCACGTAGGCACTCAGACATTG
TCAGGACGAAAGACTCTCAGGG 63 309
TTC7B 14F 
TTC7B 14R
TGCAAATGTGGAGAAGACTTGC 
GAGCCT GGAACTCCT GT GT CTT 62 365
TTC7B 15F 
TTC7B 15R
TGTGAATGAGGCACAATGTGAA
ATTATTGACTGCCAGGGTGTCC 62 423
TTC7B 16F 
TTC7B 16R
TGAGTACAGCTGCTTCTGGGTC
TCCACTGCTATCATCTGCCACT 62 366
TTC7B17F 
TTC7B 17R
CATTGGCCTTCAGGAGTCAGTA
TCCCCACTGTGAAGAAACACTT 61 372
TTC7B 18F 
TTC7B 18R
GTGCCACTCTTGAATGGAAAT
TTCTCAGCACTCAACAACCAC 59 297
TTC7B 19F 
TTC7B 19R
TTAGAAACATCATGGGGGAAGG
CCGTGAAGCTTTGATCTCTCCT 62 398
TTC7B 20F  
TTC7B20R
AGGGAACACGAACATCAGAGTG
AGGGAACACGAACATCAGAGTG 62 390
TTC7B21F 
TTC7B 21R
GAACT GACT GGAAACTCGAGGA 
GTTGGTTTGGTTGGTTCACTGT 60 459
Table 2.15 Oligonucleotide primer pairs used for PCR amplification and direct 
sequencing of TTC7B exons.
2.3.2.4 PCR amplification o f DNA for microsatellite analysis
PCR amplification of microsatellite repeats was carried out in accordance with standard 
protocols. AmpliTaq Gold (Perkin Elmer Applied Biosystems) was used. This hot start 
enzyme has the advantage of improving amplification by lowering non-specific 
background and non-specific primer annealing, as the enzyme is inactive at room 
temperature. Amplification reactions contained lx Gene Amp PCR Buffer II, 2.5mM 
MgCb, 0.25mM of each dNTP, lpM of each primer, 0.3U AmpliTaq Gold and 
approximately lOOng template DNA in a final volume of 10pl. (lOx Gene Amp PCR 
buffer II contains lOOmM Tris-HCl (pH 8.3) and 500mM KC1). Initial incubation (to 
activate the enzyme) and denaturation was at 95°C for 12 minutes, followed by 10 
cycles of denaturation at 94°C for 15 seconds, annealing at 53-55.5°C for 15 seconds 
and extension at 72°C for 30 seconds, and a further 20 cycles of denaturation at 89°C 
for 15 seconds, annealing at 53-55.5°C for 15 seconds and extension at 72°C for 30 
seconds. For the genome-wide screen, individual PCR reactions were done in 
polycarbonate 96 well microplates or strip tubes and placed in an Eppendorf 
Mastercycler gradient thermocycler (Eppendorf). For each patient, the PCR products 
generated by each panel of markers were then pooled. In this way, the products were 
diluted approximately 1:12 (6-FAM and TET) and 1:6 (HEX).
When filling gaps with single markers, PCR reactions were performed in single 0.2ml 
Micro-tubes with a domed cap (ABgene) using a T3 Biometra Thermocycler. To assess 
the success with which the repeats had been amplified, a 5 pi aliquot of each completed 
PCR reaction was first electrophoresed on a 2% NuSieve GTG agarose gel. Depending 
on the quantity of the product obtained, the remaining sample was diluted 1 in 5 or 1 in 
10 in sterile purified water.
2.3.2.5 PCR amplification o f DNA for sequencing
PCR amplification of FMN-1 and GREMLIN was carried out in accordance with 
standard protocols. Biopro™ Taq DNA polymerase (Bioline) was used except for
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FMN-1 exon 1 and GREMLIN exon 1. Amplification reactions contained lx NH4 PCR 
buffer, 1.5mM MgCh, 0.25mM of each dNTP, lpM of each primer, 1U Taq 
polymerase and approximately 100 ng template DNA in a final volume of 12.5pl. (lOx 
Biopro™ buffer contains 160mM (NLL^SCU and 670mM Tris-HCl (pH 8 .8)). Initial 
denaturation was at 94°C for 2 minutes, followed by 30 cycles of denaturation at 94°C 
for 30 seconds, annealing at 60°C for 30 seconds and extension at 72°C for 30 seconds. 
Amplification of FMN-1 exon 1 and GREMLIN exon 1 were particularly difficult 
therefore Herculase™ Hotstart DNA Polymerase (Stratagene) was preferred. This 
enzyme consists of Pfu DNA polymerase combined with Taq polymerase and it 
provides amplification of particularly difficult GC rich DNA, avoiding the 
inconvenience of non-specific primer annealing. The amplification reaction contained 
lx Herculase polymerase reaction buffer, 0.25mM of each dNTP, lpM of each primer, 
2% DMSO, 1.25U Herculase™ hotstart polymerase and approximately lOOng template 
DNA in a total volume of 12.5pl. Initial denaturation was at 98°C for 3 minutes, 
followed by 10 cycles of denaturation at 98°C for 40 seconds, annealing at 58°C for 30 
seconds and extension at 72°C for 45 seconds, and a further 25 cycles of denaturation 
at 98°C for 40 seconds, annealing at 58°C for 30 seconds, extension at 72°C for 55 
seconds.
PCR amplification of SHOX2, Glylu, ZFTF, WISP1 were carried out using HotStarTaq 
DNA Polymerase (QIAGEN Ltd.), except for SHOX2 exon 1 amplified with 
Herculase™ Hotstart DNA Polymerase (Stratagene) as described above (annealing 
temperature 62°C). HotStarTaq DNA Polymerase is a form of QIAGEN Taq DNA 
Polymerase modified to provide high specificity in hot-start PCR minimizing non­
specific amplification products, primer-dimers and background. Amplification 
reactions contained lx PCR buffer, 0.25mM of each dNTP, lpM of each primer, 2.5U 
HotStarTaq DNA Polymerase and approximately lOOng template DNA in a total 
volume of 12.5pl. (lOx PCR buffer contains 15mM MgCk). The initial heat activation 
step at 95°C for 15 minutes was followed by 35 cycles of denaturation at 94°C for 30 
seconds, annealing at 60-62°C for 30 seconds, extension at 72°C for 30 seconds and a
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final step at 72°C for 10 minutes. All PCR reactions were performed in single 0.2ml 
micro-tubes or 0.2ml strip tubes using a T3 Biometra Thermocycler.
2.3.2.6 DNA amplification using exonuclease III
For amplification of damaged templates like tissue extracted DNA from old paraffin 
sections, E.coli exonuclease III (New England Biolabs) was used according to the 
manufacturer’s instructions. This bacterial exonuclease improves long PCR 
amplification with DNA samples that are mildly or moderately damaged prior to 
extraction or during storage. 5, 25 or 50U of exonuclease III was added directly to the 
PCR mixture along with the DNA polymerases (Fromenty et al., 2000).
2.3.2.7 PCR optimisation and contamination
In order to determine the optimal PCR conditions for new primer pairs, PCR reactions 
were set up using control DNA. When no PCR product or only a weak PCR product 
was obtained, or there were non-specific products, the annealing temperature was 
varied to get optimal amplification. When preparing PCR reactions, standard 
precautions were taken to avoid contamination of samples. Aerosol resistant ART 
pipette tips were used and a work area for preparing PCR reagents was set and kept 
constantly clean. A negative control containing sterile distilled water in place of DNA 
template was included in most experiments to check for contamination. To assess the 
success of each PCR, an aliquot of each completed PCR reaction was electrophoresed 
on a 2% agarose gel.
2.3.3 Agarose gel electrophoresis
PCR products were routinely separated on a 2% NuSieve GTG agarose gel (2g agarose, 
100ml lx TBE buffer, 4pl lOmg/ml ethidium bromide) using a 50 bp DNA ladder as a 
size standard. Before loading, 2jnl orange G loading buffer and 5 pi TE buffer were 
added to 5pi PCR product. Gels were run in lx TBE buffer containing 4pl lOmg/ml
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ethidium bromide per 100ml, at 50-100V for 30-60 minutes depending on the size of 
fragment and degree of resolution required. DNA fragments were visualised by 
ethidium bromide fluorescence under UV illumination and photographed. In order to 
optimise resolution of fragments, higher percentage gels containing 4% NuSieve GTG 
agarose (4g agarose, 100ml lx TBE buffer, 4pl lOmg/ml ethidium bromide) were used 
to separate digested PCR products.
2.3.4 Restriction digestion
Restriction enzyme digestion of two PCR products (ZNF406 exon 3 and exon 4) was 
necessary to establish if single nucleotide changes found in the sequence were 
pathogenic mutations by looking at how they segregated in the family, as explained in 
Chapter 4 (section 4.4.2.9). Hpall and Acil restriction digestions were therefore carried 
out according to the manufacturer’s recommendations, at the recommended 
temperature in the minimum volume permitted by the concentration of the DNA using 
the appropriate dilution of the reaction buffer. Both digestions of PCR products were 
carried out for two hours. After incubation, DNA fragments were separated on a 4% 
agarose gel.
2.3.5 Purification of PCR products
2.3.5.1 ExoSAP-IT
For purification of sequencing samples, 5pi of PCR product were purified directly with 
2pl of ExoSAP-IT (USB Corporation), in accordance with the manufacturer’s 
instructions. ExoSAP-IT utilizes two hydrolytic enzymes, Exonuclease I and Shrimp 
Alkaline Phosphatase to remove unwanted dNTPs and primers. The Exonuclease I 
degrades residual single-stranded primers and any extraneous single-stranded DNA 
produced by PCR. The Shrimp Alkaline Phosphatase hydrolyses remaining dNTPs 
from the PCR mixture, which would interfere with the sequencing reaction. ExoSAP-IT
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is added directly to the PCR product, incubated at 37°C for 15 minutes for treatment 
and then at 80°C for further 15 minutes to inactivate the enzymes.
2.3.6 Preparation of gel for linkage and sequence analysis
For electrophoresis on the ABI PRISM™ 377 DNA Sequencer, 4.5% acrylamide gels 
were prepared. A pair of glass plates (36 cm well-to-read distance) were cleaned with 
Alconox detergent, washed in distilled water and allowed to air dry upright before 
being clamped into position in the gel cassette, separated by 0.2mm thick spacers on 
either side. The gel mix was prepared by adding 18g urea and 0.3g amberlite deionising 
resin to 27.2ml purified water and 5.6ml 40% acrylamide/bisacrylamide. After mixing 
by stirring for 10-15 minutes, the resin was removed by vacuum filtration. 5ml filtered 
lOx TBE buffer was then added to yield 50ml gel mix. To catalyse the polymerisation 
reaction, 250pl freshly prepared 10% w/v ammonium persulfate and 3 5pi TEMED 
were added to the gel mix, prior to pouring the gel between the assembled plates using 
a 50ml syringe. The flat edge of a plastic casting comb was inserted at the upper end of 
the gel and clamped into place. The gel was then left to polymerise for at least an hour. 
After this period, the casting comb was carefully removed and any remaining spots of 
acrylamide were cleaned from the plates with purified distilled water and lx TBE 
buffer. 24, 36 and 48 well disposable shark-tooth combs were used and inserted with 
the teeth just penetrating the top of the gel. To prevent leakage of samples from one 
well to another, paper combs were preferred to plastic ones as they swell when in 
contact with water and fill the gap between wells. The gel cassette was then clamped 
into the electrophoresis chamber of the automated sequencer, and the upper and lower 
buffer chambers were filled with lx TBE buffer.
2.3.7 Linkage analysis
Microsatellite repeat analysis was performed using either the ABI PRISM™ 377 DNA 
Sequencer or the MegaBACE 1000 DNA Sequencer. Preparation of sample protocols 
and analysis differ.
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2.3.7.1 Genotyping using the ABIPRISM™ 377 DNA Sequencer
Fluorescent microsatellite repeats amplified as described in section 2.3.2.4, were 
electrophoresed and analysed on the ABI PRISM™ 377 DNA Sequencer in accordance 
with the manufacturer’s instructions, using ABI PRISM™ GeneScan® 3.1.2 Analysis 
software (Perkin Elmer Applied Biosystems Division). 1.5pl diluted PCR product(s) 
was added to 3.5pl of a loading mix containing GENESCAN-500™ TAMRA, a dye- 
labelled internal lane standard (displayed as red) which allows extremely accurate 
sizing of DNA fragments in the 35-500 bp range. The 5 pi samples were then denatured 
at 95°C for 4 minutes and held on ice before loading (1.8pl/well) onto an acrylamide 
gel pre-heated to 48°C by running for 1 hour at 1,000V. They were electrophoresed for 
2-2.5 hours at 3,000V and a gel temperature of 48°C. Results were then analysed using 
ABI PRISM™ Genescan® 3.1.2 and Genotyper® 2.5 software (Perkin Elmer Applied 
Biosystems Division) run on an Apple Power Macintosh computer.
2.3.7.2 Genotyping using MegaBA CE™ 1000 DNA Sequencer
In the last stage of the project analysis of fluorescent microsatellite repeats was 
performed on the MegaBACE™ 1000 DNA Sequencer (Amersham Biosciences), a 
high-throughput fluorescence-based DNA analysis system utilizing capillary 
electrophoresis with 96 capillaries operating simultaneously. PCR products were 
adequately diluted and 2 pi of the diluted product was added to the loading mix 
containing 0.5pl MegaBACE™ ET400-R (or MegaBACE™ ET550-R depending on 
size of products) size standard and 7.5pi sterile purified water into a polycarbonate 96 
well sample plate. MegaBACE™ ET size standards consists of 20 (ET400-R) and 22 
(ET550-R) double stranded DNA fragments in which one strand is end-labelled with an 
energy transfer (ET) dye. They allow precision sizing of DNA fragments up to 400 or 
550 bp respectively. The lOpl samples were then denatured at 95°C for 2 minutes and 
injected into the MegaBACE sequencer following the manufacturer’s instructions. 3 
matrix tubes were taken out from storage (4°C) at least an hour before use and
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centrifuged at 4000rpm for 4 minutes. A 96 well buffer plate was prepared by adding 
200pl lx linear polyacrylamide (LPA) buffer (Amersham Biosciences) to each well. 
Prior to prerunning, capillaries were first rinsed with sterile purified water and then 
filled with matrix buffer. After rinsing the capillaries again with sterile water, the 96- 
sample plate containing the genotyping products was loaded into the cassette and the 
samples were injected at 3000V for 45 seconds. The sample plate was then replaced 
with the buffer plate and the run was started at 10 000V for 75 minutes. Results were 
analysed with the aid of MegaBACE™ Genetic Profiler software (Amersham 
Biosciences) which allows automated analysis of di- and tetranucleotide repeats in a 
Windows™ NT format.
2.3.7.3 Lod score calculations
Two-point lod scores were calculated using the FASTLINK and MLINK programs of 
the LINKAGE package available at the HGMP website (http://www.hgmp.mrc.ac.uk/). The 
disease parameters used in the data files were: fully penetrant autosomal recessive with 
a gene frequency of 0.001. Equal frequencies for each allele identified were used, 
because population allele frequencies were not available.
2.3.8 Sequencing analysis
2.3.8.1 Dye terminator cycle sequencing reaction
Sequencing reactions were performed using the ABI PRISM Big Dye™ Terminator 
v2.0 Cycle Sequencing Ready Reaction kit (Perkin Elmer Applied Biosystems 
Division). In this system instead of radiolabelled ddNTPs, four different, fluorescent 
dye-labelled chain terminators, recognized as different colours by the automated 
fluorescence DNA sequencer, are used to terminate DNA synthesis catalysed by 
AmpliTaq® DNA polymerase. The advantages of this method are that no radioactivity 
is involved and all four reactions can be performed in one tube and loaded in one gel 
lane. Sequencing reactions contained 4pl sequencing reagent pre-mix, 5pM sequencing
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primer, approximately 50ng PCR product and lpl of Pellet Paint™ NF Co-Precipitant 
(Novagen) made up to lOpl with sterile purified water. The primers originally used to 
amplify the product were employed as forward and reverse sequencing primers. The 
Pellet Paint™ NF Co-Precipitant is a visible, non-fluorescent, dye-labelled carrier for 
use in ethanol precipitation of nucleic acids to improve the efficiency and reliability of 
the precipitation. An initial denaturation step at 96°C for 1 minute was followed by 30 
cycles of denaturation at 96°C for 30 seconds, annealing at 50°C for 15 seconds and 
extension at 60°C for 4 minutes.
2.3.8.2 Ethanol precipitation
Unincorporated ddNTPs were removed from the completed sequencing reactions by 
ethanol precipitation. 40pl 75% ethanol was first added to each sample. After 
vortexing, samples were centrifuged at 14,000 rpm for 3 minutes. As much supernatant 
as possible was aspirated, 125pl 75% ethanol was added to wash the DNA pellet, and 
the samples were centrifuged at 14,000 rpm for 3 minutes. As much supernatant as 
possible was aspirated and the samples were left to dry at 37°C for 20 minutes.
2.3.8.3 Sequencing
rT\ASamples were electrophoresed and analysed on the ABI PRISM 377 DNA Sequencer 
in accordance with the manufacturer’s instructions, using DNA ABI PRISM™ 
Sequencing Data Collection and Analysis software, run on an Apple Power Macintosh 
computer. The gel was prepared as described in section 2.3.6 and pre-heated to 51°C by 
running at 1,000V for an hour. Samples were resuspended in 2pi blue dextran loading 
buffer, vortexed, spun, denatured at 90°C for 2 minutes and held on ice before loading 
(1.8pl/well). They were then electrophoresed for 7 hours at 1,680V, using lx TBE 
buffer and a gel temperature of 51°C.
The sequence obtained was analysed using the Sequencher™ 4.1 program 
(GeneCodes). Sequencing files in ABD format along with the known published
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sequence were imported into a Sequencher file. The program aligns similar sequences 
and highlight discrepancies of bases facilitating the finding of mutations and SNPs.
2.3.9 Cloning of PCR products
PCR products were cloned using the PCR-Script™ Amp Cloning kit (Stratagene). This 
kit was chosen because it permits the efficient cloning of blunt-ended PCR products 
with a high yield and a low false positive rate. The pPCR-Script Amp SK(+) cloning 
vector is derived from the pBluescript II SK(+) phagemid. It includes an ampicillin- 
resistance gene for antibiotic selection of the vector, as well as an Srfi restriction- 
endonuclease target sequence flanked by sites for the M l3 (-20) and M l3 reverse 
sequencing primers. The vector is supplied pre-digested with Srfi. It also provides a 
blue-white colour selection of recombinant plasmids since the pPCR-Script cloning 
vector has an E. coli lacZ gene fragment situated in the multiple cloning site, which is 
disrupted by the presence of an insert. XL 10-Gold Kan ultracompetent cells are a lac 
strain with a lacZAM15 gene, which is complemented by the lacZ gene fragment in the 
pPCR-Script vector. The lacZ gene encodes the enzyme p-galactosidase, which cleaves 
the substrate X-gal (5-bromo-4-chloro-3-indoyl-p-D-galactopyranoside) when its 
expression is induced by IPTG (isopropyl-1-thio-P-D-galactopyranoside), resulting in a 
blue colour. Thus colonies containing a vector without an insert are blue, whereas those 
with an insert remain white.
The production of high-fidelity, blunt-ended PCR products is ensured by the use of Pfu 
DNA polymerase. HotStarTaq DNA Polymerase was used instead to generate the 
inserts. To create the blunt ends needed to improve cloning efficiency, purified PCR 
products were subsequently polished, as recommended by the manufacturer, adding 1 pi 
lOmM dNTP mix (2.5mM each), 1.3pi polishing buffer, lpl cloned Pfu DNA 
polymerase to lOpl purified PCR product in a screw-topped microcentrifuge tube. After 
mixing, the polishing reaction was incubated for 30 minutes at 72°C.
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For the ligation reaction, lpl pPCR-Script vector (lOng/pl), lpl pPCR-Script lOx 
reaction buffer, 0.5pl lOmM rATP, an appropriate quantity of polished PCR product in 
5.5pi elution buffer or water, lpl Srfi (5U/pl) and lpl T4 DNA ligase (4U/pl) were 
added in that order to a screw-topped microcentrifuge tube, giving a total volume of 
lOpl. (Srfi is included in the ligation reaction to digest any vector ligated without an 
insert, maintaining a high concentration of digested vector and thus increasing ligation 
efficiency.) The quantity of PCR product was calculated to give an insert:vector molar 
ratio of 40:1 to 100:1, as recommended by the manufacturer, and was 50-150ng, 
depending on the length of the PCR product. After mixing, the ligation reaction was 
incubated for 1 hour at room temperature, heated for 10 minutes at 65°C to inactivate 
the Srfi and T4 ligase, and held on ice.
For the transformation, one 200pl vial of XL 10-Gold Kan ultracompetent cells 
(supplied with the kit and stored at -70°C) were thawed on ice, mixed gently, and 
placed in 40pl aliquots in pre-chilled 15ml Falcon 2059 polypropylene tubes. 1.6pl 
XL 10-Gold p -mercaptoethanol was added to each tube, and the cell aliquots were 
incubated on ice for 10 minutes, swirling every 2 minutes. 2pi ligation reaction was 
then added to each tube, and the cells were swirled gently, incubated on ice for 30 
minutes, heat-shocked in a 42°C water bath for 30 seconds, and incubated on ice for a 
further 2 minutes. Following the addition of 450pl of preheated NZY* medium, the 
cells were incubated for 1 hour at 37°C with shaking at 225 rpm.
About 15 minutes prior to plating the transformations, LB-ampicillin agar plates were 
spread evenly with 40pl X-gal (25 mg/ml in dimethyl formamide) and 40pl IPTG (25 
mg/ml, filter sterilised). Between 50pl and 200pl of the appropriate transformation was 
then spread on each plate, and the plates were incubated at 37°C overnight. After 1 
hour incubation at 4°C next morning to enhance the blue colour, pure white colonies, 
expected to contain only vector with insert, were selected.
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2.3.10 Colony PCR
Colony PCR was used as a method for screening colonies to identify those containing 
the desired recombinant plasmid. Individual white colonies were picked with a sterile 
loop and suspended in 30 pi of LB-ampicillin broth. 5 pi of this suspension was 
removed, incubated at 100 °C for 5 minutes to lyse the cells then diluted in a lOx 
volume of sterile purified water, This was used as the template for a PCR amplification 
using a primer pair specific for the insert. For colonies shown to contain the insert, the 
remaining 25 pi of suspension was inoculated into a 10ml aliquot of LB-ampicillin 
broth for overnight culture at 37°C at 225 rpm.
For long term storage, a portion of the culture was frozen in the presence of glycerol, to 
protect cells from ice crystal formation. Glycerol stocks were made by adding 500pl 
overnight culture to 500pl sterile 50% v/v glycerol in a cryotube, which was then kept 
at -70°C.
2.3.11 Bioinformatics
For a complete list of URLs used see section 2.3.11.6.
2.3.11.1 Locating microsatellite markers within a region
Polymorphic markers used to establish a dense cover in the genome and markers 
located in candidate regions were mainly identified using the NCBI MapView at 
http://www.ncbi.nlm.nih.gov/mapview and the UCSC Human Genome Browser at 
http://www.genome.ucsc.edu. Both sites provide information on regions of the human 
genome including genes, clones, ESTs, contigs, genomic markers, STS markers, PCR 
conditions. They also supply physical, genetic, cytogenetic and radiation maps for map 
analysis and data integration and sequence variations within the human genome 
including mutations, polymorphisms, allele frequency and heterozygosity. In the initial
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stages of the project linkage map data from The Marshfield Centre for Medical 
Genetics was primarily used to locate markers, their primer sequences and 
heterozygosities. Later, the deCode Icelandic map available on the NCBI and UCSC 
websites was preferred to choose markers. The improved resolution of the deCode map 
guarantees more accuracy in the genetic distances of markers and provides more highly 
polymorphic markers, important for the statistical power of linkage analysis. Details of 
primer sequence, alternative names, heterozygosity, product size and sequence were all 
available on the NCBI database uniSTS at http://www.ncbi.nlm.nih.gov/genome/sts/.
2.3.11.2 Locating genes within a region
Genes within or near the linked regions were identified using a number of websites 
including the NCBI MapViewer and the UCSC Genome Browser. They both provide 
list of known genes lying in a particular region, their DNA and mRNA sequence, B AC 
clones from which the sequence was derived, protein sequence and function, if known. 
The UCSC site also gives a list of predicted genes, including Acembly genes, Ensembl 
genes, RefSeq genes, and also provides links to the NCBI Entrez documents for each 
clone. Link to OMIM, PubMed and Mouse Genome Informatics are also available. The 
Ensembl Genome Browser http://www.ensembl.org/ provides more information about 
gene structure, genomic sequence and intron/exon boundaries, protein sequence and 
SNPs. More recently easy access to sequence data from other species including mouse, 
fugu, zebrafish, rats, chimp, mosquito, fruitfly have also been made available.
2.3.11.3 Database homology searches
In order to identify the genomic sequence of a particular gene when only the mRNA 
sequence was known, BLAST (Basic Local Alignment Search Tool) searches located 
either at http://www.ncbi.nlm.nih.gov/BLAST/ or at http://www.ensembl.org/ and 
BLAT searches available on the UCSC website were performed against the human 
genomic sequence using the FASTA formatted mRNA sequence obtained from Entrez. 
BLAST searches were also used to identify homologous genes to candidate genes in the 
genome.
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2.3.11.4 SNPs database
The Database of Single Nucleotide Polymorphisms (dbSNP) located at 
http://www.ncbi.nlm.nih.gov/SNP was used to verify if changes in the genomic 
sequence identified during sequencing of candidate genes were known SNPs or not.
2.3.11.5 Protein prediction program
In order to determine the structure of a protein from a given nucleotide sequence, the 
sequence was translated using the SIXFRAME translator program available at 
http://workbench.sdsc.edu and the structure of the protein determined using the 
PROSITE (http://www.expasy.org/prosite/) and PSORT (http://psort.nibb.ac.jp/) 
protein prediction programs.
2.3.11.6 URLs
PRIMER3-Design primers pairs and probes 
http://workbench.sdsc.edu
Databases homology searches
http://www.ncbi.nlm.nih.gov/BLAST
NCBI
http://www.ncbi.nlm.nih.gov/
University of California, Santa Cruz, Genome Browser Gateway 
http://genome.cse.ucsc.edu/
Ensembl human genome server 
http://www.ensembl.org/
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OMIM
http://www.ncbi.nlm.nih.gov/Omim/
Entrez-PubMed
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
Entrez nucleotide search
http://www.ncbi.nlm.nih.gov/entrez/nucleotide.html
UK HGMP-RC
http://www.hgmp.mrc.ac.uk/
The Genome Database (GBD) 
http ://gdbwww. gdb.org/
Whitehead Institute
http://www-genome.wi.mit.edu
Unigene
http://www.ncbi.nlm.nih.gov/UniGene/index.html
Human/mouse homology
http://www.ncbi.nlm.nih.gov/Omim/Homology
SDSC Biology Workbench
http://workbench.sdsc.edu
Restriction sites
http://workbench.sdsc.edu
UniSTS
http://www.ncbi.nlm.nih.gov/genome/sts/
Map View
http ://www.ncbi .nlm .nih.gov/mapview
PROSITE
http://www.expasy.org/prosite/
PSORT
http://psort.nibb.ac.jp/
Chapter 3 Cenani-Lenz syndrome
The limb abnormalities in CLS patients were first noted to be very similar to those 
found in the recessive Id mouse mutant by Professor Robin Winter (Winter, 1988). 
From what was known about Id mutants at the commencement of this project (see 
section 1.2.3.1), human FORMIN-1 (FMN-1) made a promising candidate gene for 
CLS. Following recent findings showing that the Id phenotype is caused by disruption 
of regulatory elements controlling Gremlin transcription in the limb bud mesenchyme 
or by direct disruption of the Gremlin transcription unit (section 1.2.3.2), human 
GREMLIN became a second excellent candidate gene for CLS.
3.1 Results
3.1.1 Haplotype analysis
FMN-1 lies in a 1.9 cM interval on chromosome 15ql3.2 between markers D15S1010 
and D15S144 (between 30.89-30.97 Mb)(Richard et al., 1992). Interestingly human 
GREMLIN lies in the same chromosomal region (15ql3-ql5), extremely close to 
FMN-1 at 30.72-30.74 Mb (Topol et a l , 2000). In order to confirm whether the region 
containing FMN-1 and GREMLIN was linked to the CLS locus, haplotype analysis 
was performed in consanguineous Families A, B, C and D. Nine polymorphic markers 
were chosen to cover about 12 cM in the region of interest. Two were taken from the 
linkage sets available in the laboratory (D15S165 from the ABI set and ACTC from 
the Research Genetics set) (see section 2.3.2.1), while primers to a further seven 
markers were chosen from the NCBI UniSTS database (see section 2.3.11.1) and 
designed as explained in section 2.3.2.2. Markers were chosen based on map position 
and degree of heterozygosity. These were D15S976, D15S1031, D15S1010, 
D15S144, D15S1007, D15S1040 and D15S118. Details of these markers are shown in
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Table 2.1 and their positions in Figure 3.1. The centimorgan distances quoted for the 
Marshfield genetics maps were used as they were available for all markers. The 
physical distances shown in Figure 3.1 correspond to the more recent NCBI genome 
assembly build 34.
PCR to amplify microsatellite repeats was carried out as described in section 2.3.2.4 
and genotyping analysis as described in section 2.3.7.1.
3.1.1.1 Family A
Family A was the first family from whom DNA was obtained. Initial haplotype 
analysis across the chromosome 15q region where FMN-1 and GREMLIN lie, showed 
that patient II.2 was heterozygous for all nine markers, thereby excluding a 
recessively-acting inherited-by-descent (IBD) mutation in either FMN-1 or GREMLIN 
as the cause of her limb and renal abnormalities (Fig. 3.2). The results were reported 
in (Bacchelli et al., 2001).
3.1.1.2 Family B
DNA from Family B was obtained in a second instance. Marker D15S976 was found 
to be located on chromosome 3 and not on chromosome 15 following revision of the 
human genomic sequence and therefore it was not included in the haplotype analysis 
of Families B, C and D. Results in Family B showed homozygosity across the region 
in all eight markers tested (Fig. 3.3). The affected child II.4 was homozygous across 
the region while his parents (1.1 and 1.2) and three siblings (II. 1, II.2 and II.3) were 
heterozygous, suggesting that the affected child might carry an IBD mutation in either 
FMN-1 or GREMLIN.
3.1.1.3 Family C and Family D
Haplotype analysis in Families C and D was performed using four polymorphic 
markers in the chromosome 15q region (Fig. 3.4). Both probands were heterozygous
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Telomere
Figure 3.1 Schematic representation of the region on chromosome 15ql3-ql5 
where FMN-1 and GREMLIN lie. Genetic and physical positions of polymorphic 
markers used for haplotype analysis in consanguineous Families A, B, C and D are 
given.
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Family A
D15S165
D15S976
D15S1031
D15S1010
D15S144
D15S1007
D15S1040
ACTC
D15S118
r
1 2
1 1 21
32 1 1
1 2 31
22 1 2
31 22
31 22
1 3 21
12 32
43 1 2
1 2
D15S165 1 2
D15S976 3 1
D15S1031 1 3
D15S1010 2 1
D15S144 3 2
D15S1007 3 2
D15S1040 1 2
ACTC 1 3
D15S118 4 1
Figure 3.2 Results of haplotype analysis in Family A using 9 polymorphic 
markers on chromosome 15ql3-ql5. Father (1.1) was informative and 
heterozygous for all the markers except D15S165 and D15S1010; the mother 
(1.2) was informative for all the markers except D15S976, D15S144 and 
D15S1007.
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Family B
D15S165 199 207 197 207
D15S1031 302 302 302 302
D15S1010 212 230 228 230
D15S144 162 166 162 166
D15S1007 177 173 175 173
D15S1040 199 207 213 207
ACTC 84 82 70 82
D15S118 220 220 226 220
o
1
D15S165 207 197 199 197 199 197
D15S1031 302 302 302 302 302 302
D15S1010 230 228 212 228 212 228
D15S144 166 162 162 162 162 166
D15S1007 173 175 177 175 177 173
D15S1040 207 213 199 213 199 207
ACTC 82 70 84 70 84 82
D15S118 220 226 220 226 220 220
207 207
302 302
230 230
166 166
173 173
207 207
82 82
220 220
Figure 3.3 Results of haplotype analysis in the 15ql3-ql5 region in Family B. Note 
homozygous region in patient II.4 between D15S165 and D15S118. Both parents 
and the three unaffected siblings were heterozygous across the region, except for 
marker D15S1031 which was non-informative.
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Figure 3.4 Results of haplotype analysis in the 15q region in Families C and D. Both probands (III.4 in Family C and II.2 in Family 
D) were heterozygous across the region.
across the region, thus excluding a recessively-acting IBD mutation in either FMN-1 
or GREMLIN in these two families.
3.1.2 Sequence analysis: FMN-1
The proband from Family B was found to be homozygous across the 15q region. In 
order to identify whether mutations in FMN-1 caused CLS, FMN-1 was sequenced in 
the three families from whom DNA was available at the time (consanguineous 
Families A and B and non-consanguineous Family E). DNA from Families C, D, F 
and G was obtained later and kept in storage.
3.1.2.1 Identification o f exons in human FMN-1
The mRNA sequence of mouse Formin-1 was available in the databases (GenBank 
Accession No X53599) and the intron/exon boundaries had already been identified 
(Wang et al., 1997), but the human FMN-1 sequence was not available. Therefore, 
exons of the human FMN-1 gene were identified by taking each individual mouse 
exon and doing a BLAST search against the human genomic sequence 
(http://www.ncbi.nlm.nih.gov/BLAST/). Most of the relevant regions on human 
chromosome 15ql3 were available, at least in draft form. Human exons 
corresponding to all but two of the mouse exons were identified. Exons corresponding 
to mouse exon 17 and exon 20 could not be found. It is possible that exons 17 and 20 
lie in one of the gaps in the available human sequence or they may not have human 
homologs. Exon 17 is in fact an alternatively spliced exon containing repetitive 
sequence; exon 20 is only expressed in the testis and has stop codons in all 3 reading 
frames (Wang et al., 1997).
Primers for each exon of FMN-1 were designed and synthethised as described in 
section 2.3.2.3. Primer details and PCR conditions are shown in Table 2.9. Primers 
were spaced so that splice sites as well as exons could be seen. Overlapping primers 
were designed to cover large exons. The last coding exon, exon 24, was examined up
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to and just beyond the STOP codon. Most of the 3’UTR, which is approximately 5 kb, 
was not sequenced.
3.1.2.2 PCR amplification o f FMN-1
PCR amplification of FMN-1 was carried out as described in section 2.3.2.5. Each 
exon was successfully amplified by PCR in both the carrier father (1.1) and affected 
child (II.4) from Family B as well as in patients II.2 from Family A and II. 1 from 
Family E. A single product of the expected size was obtained for each individual. 
Therefore, no evidence of a small insertion or deletion within any of the exons was 
detected on PCR in any of the patients and no single exon was homozygously deleted 
in child II.4 from Family B.
3.1.2.3 FMN-1 sequencing results
All twenty-two exons were mutation screened by direct sequencing using protocols 
detailed in section 2.3.8 and analysed using Sequencher 4.1 (see section 2.3.8.3).
(i) Family B
FMN-1 was first sequenced in Family B in the carrier father (1.1), as it is easier to see 
any sequence alteration in a heterozygote than in a homozygote. On sequence 
analysis, he was found to be heterozygous at twelve different positions scattered 
throughout the gene (Fig. 3.5) confirming that two alleles were present across most of 
the gene. Two of these were poly-T repeats, one upstream of exon 11 and one 
upstream of exon 13. A further ten positions at which he was heterozygous were 
identified. Four of these were in non-coding regions. Six were in coding regions. 
Three of these do not change an amino acid but three do.
Sequencing of the exons where a change in 1.1 had been identified was then 
performed in the affected child (II.4). The results are shown in Figure 3.5. II.4 was
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C/T Ala -► Val
11.4 homo for T (Val)
-HH— H-
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T/C (both Phe) 
II.4 homo for T
Figure 3.5 Sequence changes in FMN-1 in 1.1 and II.4 from Family B. Changes in non-coding regions are shown in blue and green boxes 
above the exons. Changes in coding regions are shown in purple boxes below the exons. Inside each box, the result for 1.1 is given above the 
results for II.4. Not all the regions sequenced in 1.1 were sequenced in II.4.
found to be homozygous for three amino acid changes, proline to alanine and alanine 
to valine in exon 2 and leucine to proline in exon 7.
(ii) Family A
FMN-1 was sequenced in the affected child (II.2). The results are shown in Figure 3.6.
II.2 was found to be heterozygous at eight positions, five in the non-coding region and 
three in the coding region, thus confirming that two alleles were present across most 
of the gene. She was homozygous for three amino acid changes, proline to alanine in 
exon 2, glycine to valine in exon 6 and leucine to proline in exon 7.
(in) Family E
FMN-1 was also sequenced in patient II. 1 and the results are shown in Figure 3.7. He 
was found to be heterozygous at six positions, four in the non-coding region and two 
in the coding region, excluding a deletion of all or most of one copy of the gene.
3.1.3 Sequence analysis: GREMLIN
Mutation screening in GREMLIN was carried out in the six probands from Families 
A, C, D, E, F, G and in the father (1.1) from Family B.
3.1.3.1 Identification o f exons in human GREMLIN
The mRNA sequence for human GREMLIN was available in the databases (GenBank 
Accession No NM_013372). Therefore, exons of the human GREMLIN gene were 
identified by taking the human mRNA sequence and doing a BLAST search against 
the human genomic sequence (http://www.ncbi.nlm.nih.gov/BLAST/). Two exons 
were identified. GREMLIN encodes a 184 amino acid protein which shows high 
homology with the mouse protein.
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Figure 3.6 Sequence changes in FMN-1 in II.2 from Family A. Changes in non-coding regions are shown in blue and green boxes above the 
exons. Changes in coding regions are shown in purple boxes below the exons.
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Figure 3.7 Sequence changes in FMN-1 in II. 1 from Family E. Changes in non-coding regions are shown in blue and green boxes above the 
exons. Changes in coding regions are shown in purple boxes below the exons.
Primers for the two exons were designed and synthesised as described in section 
2.3.2.3. Primer details and PCR conditions are shown in Table 2.10. The primers were 
spaced so that splice sites as well as exons could be screened. Two overlapping 
primers were designed to cover exon 2.
3.1.3.2 PCR amplification o f GREMLIN
PCR amplification of human GREMLIN was carried out as described in section 
2.3.2.5. GREMLIN was successfully amplified in three separate PCR reactions in both
1.1 and II.4 from Family B, excluding a homozygous deletion of part or all of the gene 
in patient II.4. GREMLIN was also successfully amplified in probands: II.2 (Family 
A), II.2 (Family D), II. 1 (Family E), II. 1 (Family F) and IV. 11 (Family G). Exon 1 
could not be amplified in patient III.4 (Family C). Therefore, exon 1 was sequenced in 
the patient’s mother (II.2) instead.
3.1.3.3 GREMLIN sequencing results
The two exons were mutation screened by direct sequencing using protocols detailed 
in section 2.3.8 and analysed using Sequencher 4.1 (see section 2.3.8.3).
The coding region of the gene was sequenced in individuals: 1.1 (Family B), II.2 
(Family A), III.4 (Family C), II.2 (Family D), II. 1 (Family E), II. 1 (Family F) and 
IV. 11 (Family G). No sequence changes were identified except for a heterozygous G 
to C change in proband IV. 11 from family G. This changes a glutamine to a histidine 
at amino acid position 175 (Glul75His).
3.2 Discussion
At the beginning of the project, no attempt to locate the CLS gene had been reported in 
the literature. This study aimed to identify the disease gene causing CLS by adopting a 
position-independent strategy. Two candidate genes were identified based on
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similarities in the phenotype between CLS patients and a mouse model, the Id mouse 
mutant (section 1.2.3). Ld mouse phenotypes were until very recently thought to arise 
from mutations in the formin-1 gene, suggesting that human FMN-1 on chromosome 
15ql3.2 was a good candidate gene for CLS. FMN-1 was screened for causative 
mutations by direct sequencing of coding regions in three CLS patients. The BMP- 
antagonist Gremlin lies very near to formin-1 in both mouse and human genomes. 
Human GREMLIN was also identified as an excellent candidate gene for CLS 
following recent findings demonstrating that the disruption of Gremlin leads to the Id 
phenotype (section 1.2.3.2). GREMLIN was therefore screened for causative mutations 
by direct sequencing of coding regions in seven CLS patients.
3.2.1 Haplotype analysis
Haplotype analysis in Family A showed that the affected child has inherited different 
alleles from her first-cousin parents across a 12 cM region containing both FMN-1 and 
GREMLIN. These results excluded the presence of a recessively-acting IBD mutation in 
either FMN-1 or GREMLIN in this child. At a later stage of the project, affected 
children from consanguineous Families C and D were also found to be heterozygous 
across the GREMLIN /  FMN-1 region.
However, in Family B, the affected child was found to be homozygous by descent 
across the same 12 cM region containing FMN-1 and GREMLIN, while the three 
unaffected siblings and the parents were all heterozygous across this region, suggesting 
that the affected child might carry an IBD mutation in either FMN-1 or GREMLIN.
The lack of homozygosity in the affected children in Families A, C and D could then be 
explained by locus heterogeneity. Alternatively, they might still carry mutations in both 
copies of FMN-1 (or GREMLIN), but instead of being two copies of the same mutation, 
inherited from a common ancestor, these could be two different mutations, one 
inherited from the father’s side, and one inherited from the mother’s side (compound 
heterozygotes). However, this is unlikely to occur in three out of four families.
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3.2.2 Mutation screening of FMN-1
3.2.2.1 Family B
FMN-1 was therefore amplified by PCR in both the carrier father and the affected child 
from Family B and the entire coding region of the gene was sequenced in the carrier 
father. Selected regions of FMN-1 were then sequenced in the affected child. The PCR 
results excluded the possibility that the child has a homozygous deletion that removes 
all of FMN-1. On sequence analysis, the father was also heterozygous at twelve 
different positions in the gene (four in exon 2, one in exon 7, one upstream of exon 8, 
one in exon 9, one upstream of exon 11, two in the intron between exons 12 and 13, 
one upstream of exon 14, and one on exon 22). This excluded the possibility that the 
child has a homozygous deletion that removes any of the following individual exons: 2, 
7, 8, 9, 11, 12, 13, 14 and 22. As expected, the child was homozygous at all the 
positions where the father was heterozygous. Four of these positions lie in non-coding 
regions, but they are not near enough to intron/exon boundaries to affect a splice site 
directly. Six of these positions lie in coding regions, but only three of them change an 
amino acid:
(i) Pro to Ala in exon 2. This could potentially be significant, as it is not a conservative 
change, and mouse formin-1 has Pro at this position too.
(ii) Ala to Val in exon 2. This is not likely to be significant, as it is a conservative 
change. Also, mouse formin-1 has Thr at this position, and the surrounding region of 
exon 2 is not strongly conserved between human and mouse.
(iii) Leu to Pro in exon 7. This is also not likely to be significant, even though it is not a 
conservative change, as mouse formin-1 has Pro at this position.
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3.2.2.2 Families A and E
FMN-1 was then amplified and sequenced in two further CLS patients, the affected 
children in Families A and E. In both cases, all exons were amplified successfully, so at 
least one copy of each exon is not deleted. In Family A, the affected child was 
heterozygous at eight positions (one in exon 2, one in exon 6, one in exon 9, one 
upstream of exon 11, two in the intron between exons 12 and 13, one downstream of 
exon 16 and one upstream of exon 24). This excluded the possibility of a deletion 
affecting any of the following exons: 2, 6, 9, 11, 12, 13, 16 and 24. In Family E, the 
affected child was heterozygous at six positions (one in exon 6, one in exon 9, one 
upstream of exon 11, two in the intron between exons 12 and 13 and one downstream 
of exon 16). This excluded the possibility of a deletion affecting any of the following 
exons: 6, 9, 11, 12, 13 and 16. Both children had several base changes that affect the 
amino acid sequence:
(i) Pro to Ala in exon 2. The affected child in Family A is homozygous for Ala, like the 
child in Family B. The affected child in Family E is homozygous for Pro.
(ii) Ala to Val in exon 2. The affected child in Family A is heterozygous. The affected 
the child in Family E is homozygous for Ala.
(iii) Leu to Pro in exon 7. The affected child in Family A is homozygous for Pro, like 
child in Family B. The affected child in Family E is homozygous for Leu.
Also, the affected children in families A and B both are heterozygous for a Gly to Glu 
change in exon 6, a non-conservative change. Mouse formin-1 has Gly at this position, 
but the surrounding region of exon 6 is not strongly conserved between human and 
mouse. The affected child in family A is also homozygous for a Gly to Val change in 
exon 6, a conservative change. Mouse formin-1 has Val at this position. Therefore, the 
change is probably not significant.
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3.2.23 Conclusion
The entire coding region of FMN-1 has been sequenced in three unrelated CLS patients, 
and there is no obvious mutation, such as a premature stop, an insertion, a deletion, or a 
splice-site mutation, in any of them. However, one or more of the base changes 
identified could in principle represent a mutation. One or more of the amino acid 
changes might be significant, but they all seem more likely to be just polymorphisms. 
This could be confirmed by investigating how often they occur in a panel of normal 
controls (by direct sequencing and/or by using a restriction digest). Other possibilities 
are that one or more of the base changes might create a cryptic splice site or one of the 
exonic base changes (including the ones that do not change an amino acid) could affect 
an exonic splicing enhancer or an exonic splicing silencer site, leading to erroneous 
inclusion or skipping of an exon (Liu et al., 2001). This could be investigated by 
looking for a splice-site abnormality by RT-PCR, but would require obtaining cell lines 
from the affected children, and these are not currently available. It is also possible that 
a mutation is present, but could not be found. In fact, not all of the introns, the 3’UTR 
or the 5’UTR were sequenced. The promoter regions were not sequenced either, mainly 
because they were poorly characterised. Finally, chromosomal rearrangement in/near 
the gene using FISH and/or Southern blots were not looked for, but this would again 
require obtaining cell lines from the affected children.
The fact that out of four consanguineous families, only the affected child of Family B is 
homozygous across the GREMLIN /  FMN-1 region, could suggest either locus 
heterogeneity or that the haplotype result in this family happened by chance. False 
positive results like this are a known pitfall in homozygosity mapping (Miano et al., 
2000).
3.2.3 Gremlin role in limb patterning
The probable role of mouse formin-1 and other formin homology proteins in organizing 
the cytoskeleton makes it difficult to explain why disruption of the cytoskeleton would
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lead to loss of Gremlin expression and interruption of Shh signalling from the ZPA to 
the AER. During the course of the project, an important paper on Gremlin was 
published in Nature Genetics (Khokha et al., 2003). It was already known that BMP 
antagonists such as Noggin, Gremlin, DAN, Chordin and Follistatin had a number of 
different roles during limb development (Merino et al., 1999; Zuniga et al., 1999). 
Khokha et al. (2003) were the first to make a Gremlin KO mouse. The Shh-Fgf 
feedback loop was disrupted in Gremlin mutant mice indicating an important role of 
Gremlin in maintaining the AER and the Shh-Fgf feedback loop during early limb 
development and patterning. Interestingly, homozygous Gremlin KO mice have an 
identical phenotype to homozygous Id mice which results from mutations within the 
formin-1 gene (see section 1.2.3). The limb and kidney abnormalities were exactly the 
same as in Id mice. Furthermore, mice heterozygous for both the Gremlin null mutation 
and the Id deformity mutation have the full Id phenotype showing that the Gremlin null 
mutation is actually allelic to Id.
The relationship between Gremlin and formin-1 is interesting because in mice, as in 
humans, they lie very close together, only 40 kb apart. Khokha et al. (2003) favoured 
the idea that the mutations previously identified in Id mice act not by disrupting formin- 
1, and therefore indirectly affecting Gremlin expression as previously thought, but by 
disrupting cis-regulatory elements for Gremlin that lie within the formin-1 gene, 
thereby affecting Gremlin expression directly. This hypothesis was later confirmed by 
Zuniga and colleagues (Zuniga et al., 2004). As explained in section 1.2.3.2, the 
authors identified a shared cis-regulatory element within Formin-1 genomic regions 
that is required for both Formin-1 and Gremlin expression as well as for Gremlin 
activation in the posterior limb bud mesenchyme (Zuniga et a l, 2004)
3.2.4 Mutation screening of GREMLIN
After the paper by Khokha et al. (2003) was published, GREMLIN was thought to be a 
more plausible candidate gene for CLS than FMN-1. DNA samples from
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consanguineous Families C and D as well as from non-consanguineous Families F and 
G was obtained in the meantime.
It was then decided to mutation screen GREMLIN in all the probands from the new 
families as well as in the two probands from Families A and E and the father (1.1) from 
Family B. At the same time, haplotype analysis in consanguineous Families C and D 
was carried out using four polymorphic markers in the region and linkage to the 
GREMLIN /  FMN-1 locus was excluded in both families.
The two coding exons of Gremlin were successfully amplified in all patients, thus 
excluding the possibility of a deletion in the gene. The only exception was patient III.4 
(Family C). Exon 1 could not be amplified by PCR in this patient, suggesting the 
possible deletion of this exon. No mutations were found in 1.1 (Family B) and in any of 
the affected patients, except for a heterozygous G to C change in proband IV. 11 from 
Family G which changes a glutamine to a histidine at amino acid position 175. The 
SNP Database does not report this as a known SNP, and the residue in question is 
glutamine in both mouse and fugu. However, comparison of the protein sequence of 
other BMP antagonists, in the Conserved Domain Database at NCBI, showed that two 
DAN-domain proteins closely related to Gremlin have a histidine instead of glutamine 
at this position. Firstly, Prdc (protein related to DAN and Cerberus, gi 3252785) and 
secondly, the DAN zinc finger protein Nbll (gi 2498287) mouse neuroblastoma 
suppressor of tumorigenicity 1 precursor (Fig 3.8). Five other DAN-domain proteins 
have glutamic acid at that position. So, the change identified in proband IV. 11 from 
Family G is probably just a non-reported SNP. Patient III.4 (Family C) needs to be 
investigated further for a possible deletion of exon 1, for example by Southern blot 
hybridization.
Even though no mutations were identified in the coding region of GREMLIN in seven 
CLS patients, an intronic mutation or a regulatory mutation affecting GREMLIN, like 
those identified in the Id mice, cannot be excluded (Zuniga et al., 2004). An example is 
given by chromosome 7q36 preaxial polydactyly (PPD), a commonly observed human 
congenital hand malformation (Lettice et a l , 2003). Point mutations leading to the PPD 
phenotype were identified in a Shh regulatory element located within intron 5 of the
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Human GREMLIN 172 RVKQCRCI S IDLD 184
Mouse Gremlin 172 RVKQCRC ISI DLD 184
Fugu Gremlin 160 RVKQCRC ISI DLD 173
Mouse Prdc 151 KVKHCRCMSVNLS 163
Mouse Nbll 113 KIVHCSCQACGKE 12 5
Figure 3.8 Gremlin amino acids sequence around the Glul75His change found in 
patient IV. 11 (Family G) in human, mouse and fugu. Two mouse DAN-domain 
proteins, Prdc and Nbll, have histidine instead of glutamine.
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Lmbrl gene, 1 Mb upstream of Shh itself, in both human and a corresponding mouse 
mutant hemimelic extra toes (Hx).
3.2.5 CLS phenotype and locus heterogeneity
3.2.5.1 Families C and D
The two Egyptian consanguineous Families C and D described by Temtamy et al. 
(2003) do not show the typical CLS phenotype (see section 2.1.2.1). In both families, 
the very severe limb abnormalities are associated with facial dysmorphism, dental 
abnormalities and partial tongue-tie, which have not previously been reported in CLS. 
The feet are very severely affected in patients from both families, while feet are usually 
less affected than hands or show no abnormalities at all in typical CLS. This may 
reflect locus heterogeneity and could be the reason why the two consanguineous 
families are not linked to the GREMLIN / FMN-1 locus. Alternatively, these two 
families could have been mis-diagnosed and could represent a separate condition.
3.2.5.2 Family G
In Family G, the proband (IV. 11) also has very severe feet abnormalities and congenital 
cataract not previously associated with CLS (see section 2.1.2.1)(Percin and Percin, 
2003). The proband’s mother has hypoplasia of the middle and distal phalanges of the 
second to fifth toes like the proband, which could suggest a manifestation of 
hererozygosity for a mutation in the CLS gene.
In the same family, a half-cousin (V.2) of the proband has an unusual form of 
mesoaxial syndactyly similar to syndactyly type 1 (SD1). Her parents are 
consanguineous, so it is possible that she has a homozygous form of SD1. However, 
neither of her parents have any limb abnormalities, although SD1 is known to exhibit 
incomplete penetrance. The locus for SD1 has been mapped to a 9.4 cM interval on
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chromosome 2q34-q36 (Bosse et al., 2000), so it would be useful to carry out linkage 
analysis with markers from this region in patient V.2, her parents and sibs and look for 
homozygosity-by-descent in V.2.
Although the authors mention the possibility of intrafamilial variable expressivity, it is 
more likely that individuals IV. 11 and V.2 represent two separate conditions occurring 
in the same family, as they are phenotypically quite dissimilar. Furthermore, no 
instances of severe SD1 have previously been reported amongst multiply affected CLS 
sibships.
3.2.5.3 Families A and F
In Family A, the affected child (II.2) has been described with renal abnormalities very 
similar to those described in Id mice. However, such defects have never previously 
been reported in CLS (see section 2.1.2.1)(Bacchelli et al., 2001).
The proband (II. 1) from Family F also has atypical features not previously described in 
CLS, such as rib and vertebral abnormalities as well as mixed hearing loss (see section
2.1.2.1 )(Seven et al., 2000).
The atypical features in Families A, C, D, F and G widen the CLS phenotypic 
spectrum. Phenotypic variability is commonly described in human disorders and could 
reflect differences in the genetic background, or be due to environmental factors. The 
variability could also be of some significance in CLS, indicating locus heterogeneity 
and the possibility that mutations in more than one gene lead to the CLS phenotype.
3.2.6 Conclusion
In conclusion, out of four consanguineous CLS families, only one was consistent with 
linkage to the GREMLIN / FMN-1 region, but no convincing mutations have been
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found in the coding region of the two genes in this family. However, it is possible that 
one or more of the changes identified in FMN-1 in this family represent a real mutation, 
but it is also possible that the haplotype result in this family happened by chance. FMN- 
1 has not been mutation screened in all the CLS patients and not all the introns, the 
3’UTR or the 5’UTR and the promoter regions were sequenced. Therefore, it is still 
possible that mutations in FMN-1 have been missed.
The recent findings on Gremlin by Khokha and colleagues (Khokha et a l , 2003) and 
Zuniga and colleagues (Zuniga et al., 2004), made GREMLIN a stronger candidate gene 
for CLS. However, no mutations have been identified in the coding region of human 
GREMLIN in six CLS cases. Patient III.4 (Family C) needs to be investigated further 
for a possible deletion of exon 1.
Despite the fact that mutations in GREMLIN and FMN-1 coding regions have not been 
identified in our panel of patients, mutations in the homologous c/s-regulatory elements 
identified by Zuniga and colleagues may be the cause of CLS malformation.
3.2.7 Future work
More CLS families need to be ascertained. The best way to find out if GREMLIN really 
does have a role in CLS would be to sequence GREMLIN in further CLS patients to see 
if a convincing causative mutation could be found. Investigation of the homologous cis- 
regulatory elements in FMN-1 also needs to be carried out.
However, other candidate genes for CLS have to be considered. The phenotypic 
similarities between CLS patients and Id mice remain striking, suggesting that CLS 
could well be caused by mutations in a gene whose product interacts with Gremlin or 
lies in the same pathway as Gremlin. It is possible that mutations in more than one gene 
are causing CLS and that once these genes are identified, they are found to be part of 
the same pathway and/or interact with each other in multi-component complexes.
The work on Gremlin being carried out in other laboratories, especially the studies of 
its function and the molecular pathway in which it acts, may help to suggest other
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candidate genes to investigate in our panel of CLS patients. Moreover, a genome-wide 
screen in the probands from the four consanguineous families has to be considered in 
order to identify the CLS locus or loci.
Finally, clinicians should establish diagnostic criteria for CLS, taking into 
consideration the features described above, including renal malformation as well as 
facial dysmorphisms and rib and vertebral abnormalities.
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Chapter 4 JATD results
4.1 Exclusion of candidate regions
4.1.1 EVC/EVC2 region
In order to exclude the EVC/EVC2 region as a possible candidate for JATD, a 
haplotype analysis was initially performed in patients IV. 1 and IV.3 from Family 1, 
VI.3 and VI.5 from Family 2, II. 1 from Family 3 and II.6 from Family 4. In a 
subsequent study, four further JATD families not consistent with linkage to any of the 
putative JATD loci subsequently identified were typed across the EVC/EVC2 region. 
These were consanguineous Families 11 and 12, as well as non-consanguineous 
Families 13 and 15. It was thought that the parents in Family 13 were possibly distantly 
related. If this was the case therefore, and there was linkage to this locus, a 
homozygous region was expected to be found in patient III. 1. In Family 15 there were 
three affected fetuses, therefore if there was linkage to this locus, a shared pair of 
haplotypes in all three patients was expected to be found in the region.
EVC and EVC2 lie on the short arm of chromosome 4 (4p 16) in a head-to-head 
configuration about 2 Kb apart (Fig 4.1) (Galdzicka et al., 2002; Ruiz-Perez et al., 
2003). A total of 10 polymorphic markers were chosen to cover about 17 cM in the 
region of interest, but not all of them were run in each family. Dye-labelled primers for 
two markers (D4S412 and D4S2366) were taken from the linkage sets available in the 
laboratory (see section 2.3.2.1), while primers to a further four markers were chosen 
from the NCBI UniSTS database (see section 2.3.11.1) and designed as explained in 
section 2.3.2.2. Markers were chosen based on map position and degree of 
heterozygosity. Primers for marker D4S3360 were provided by collaborator Dr Colin 
Johnson. Primer sequences for markers 500H20P5, 500H20P3 (telomeric to EVC2) and 
£FC-exon 18 (CCCT repeat before EVC exon 18), were kindly provided by Prof. 
Judith Goodship to screen fetus II.2 in Family 12 (Ruiz-Perez et a l, 2003).
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Figure 4.1 Schematic representation of the region on chromosome 4pl6 where 
EVC and EVC2 lie. Physical positions of polymorphic markers used for haplotype 
analysis are given for all markers.
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Details of the markers are shown in Table 2.2 and their positions in Figure 4.1. The 
centimorgan distances quoted in Figure 4.1 were taken from the Marshfield genetic 
maps and were available only for four markers. The physical distances shown 
correspond to the UCSC genome assembly build 33 (April 2003 freeze). PCRs to 
amplify microsatellite repeats were carried out as described in section 2.3.2.4 and 
genotyping analysis as described in section 2.3.7.1.
Results of haplotype analysis in affected individuals from consanguineous Families 1 
and 2 are shown in Figure 4.2 and Families 3 and 4 in Figure 4.3. Results of haplotype 
analysis in Families 11,13 and 15 are shown in Figure 4.4 and results in Family 12 are 
shown in Figure 4.5.
EVC and EVC2 genes were excluded as possible candidate genes in patients from 
families 1, 2, 3, 4, 11 and 13, as they were all heterozygous across the region, thus 
excluding a recessively-acting inherited-by-descent mutation in EVC or EVC2. EVC 
and EVC2 genes were also excluded in non-consanguineous Family 15 as the three 
affected fetuses did not share the same haplotypes across the region. Patient II. 1 from 
Family 5 was previously found not to be linked to the EVC/EVC2 locus by Prof. Judith 
Goodship’s lab. Patients II. 1 from Family 8 and II. 1 from Family 9 were also found not 
to be linked to the EVC/EVC2 locus by Dr Colin Johnson.
Nevertheless, fetus II.2 from consanguineous Family 12 was found to be homozygous 
across the EVC/EVC2 locus. DNA samples from this family were sent to Prof. Judith 
Goodship to investigate further the presence of a mutation in EVC or EVC2 as the 
possible cause of the phenotype in this family. Investigation of this family is at present 
ongoing.
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Figure 4.2 Results of haplotype analysis in affected individuals from Families 1 and 2 using 6 polymorphic markers on chromosome 
4pl6. Homozygous markers are highlighted in colour. None of the four affected individuals are homozygous across the EVC/EVC2 
locus. Only D4S412, about 2.1 Mb telomeric to the EVC2 gene, is homozygous in both affected sibs from Family 2.
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Figure 4.3 Results of haplotype analysis in affected individuals from Families 3 and 4 using 2 polymorphic markers on 
chromosome 4pl6. D4S2375 is located approximately 0.6 Mb telomeric to EVC2, while D4S827 is located 0.2 Mb centromeric 
to EVC. Homozygous result for D4S827 in patient II. 1 (Family 3) is highlighted in red. Further investigation of this region in 
Family 3 was carried out by Dr Colin Johnson and linkage to the EVC/EVC2 locus was excluded in this family.
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Figure 4.4 Results of haplotype analysis on chromosome 4pl6 in Families 11, 13 
and 15 showing no evidence of linkage to the EVC/EVC2 locus. In Family 15, note 
the different paternal haplotype in fetus II.2 compared to fetuses II.3 and II.4 
excluding linkage to the locus in this family.
187
Family 12
1 2
D4S412 164 164 166 164
D4S2375 290 294 274 290
500H20P5 241 239 241 241
500H20P3 143 151 163 143
D4S2354 215 221 227 215
EVC-ex on 18 258 222 222 258
D4S827 214 204 204 214
D4S2366 118 130 130 118
1 2 3
D4S412 164 166 164 166 164 166
D4S2375 290 274 290 290 294 274
500H20P5 241 241 241 241 239 241
500H20P3 143 163 143 143 -
D4S2354 215 227 215 215 221 227
EVC-ex on 18 258 222 258 258 222 222
D4S827 214 204 214214 204 204
D4S2366 118 130 118 118 130 130
Figure 4.5 Haplotype analysis on chromosome 4pl6 in Family 12 using 8 
polymorphic markers in the region. Fetus II.2 demonstrates homozygosity from 
D4S2375 to D4S2366 (as shown by boxed haplotype) while the parents (1.1 and 
1.2) and two unaffected siblings (II. 1 and II.3) are heterozygous across the 
region. Marker 500H20P3 could not be typed accurately in individual II.3 
therefore the result is marked with a dash.
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4.1.2 12pll-pl2 region
A haplotype analysis was also performed in individuals III.l, III.2, III.3, III.4, IV. 1 and 
IV.3 from Family 1 and in patients VI.3 and VI.5 from Family 2 to exclude 12pl 1.21- 
pl2.2 as a possible candidate locus. Four fluorescent polymorphic markers in the 
region were chosen from the three linkage sets available in the laboratory to cover 
about 20 cM: D12S373, 12S1066, D12S1042 and D12S345. Details of the markers are 
shown in Table 2.3 and their positions in Figure 4.6. PCRs to amplified microsatellite 
repeats were carried out as described in section 2.3.2.4 and genotyping analysis as 
described in section 2.3.7.1.
The results are shown in Figure 4.7. Linkage to the 12pl 1.21-pl2.2 locus was excluded 
in VI.3 and VI.5 from Family 2 because they were both heterozygous across this 
region. Patient IV. 1 from Family 1 was homozygous for markers D12S373 and 
D12S1042. His cousin (IV.3) was also homozygous for markers D12S1042 but for 
different alleles. Therefore the 12pl 1.21-pl2.2 locus was excluded in Family 1 as well.
The region was also excluded in affected individuals II. 1 from Family 3, II. 1 from 
Family 8 and II. 1 from Family 9 by Dr Colin Johnson.
4.1.3 Shorty syntenic regions
The three human chromosomal regions syntenic to the srt locus were identified using 
the Human-Mouse Homology Map at http://www.ncbi.nlm.nih.gov/Omim/Homology 
(Herron et al., 2002). The 7 cM critical interval on mouse chromosome 17 between 
markers D17Mitl34 and D17Mit51 corresponds to regions on human chromosomes 
6p21, 6q25-q27 and 16pl3.3. In order to exclude these loci as possible candidate 
regions for JATD, a haplotype analysis was performed in patients IV. 1 and IV.3 from 
Family 1, VI.3 and VI.5 from Family 2. Four, five and three fluorescent polymorphic 
markers were chosen to cover the regions on 6p21, 6q25-q27 and 16pl3.3 respectively. 
Six of them were available from the linkage sets in the laboratory (see section 2.3.2.1),
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Figure 4.6 Schematic representation of the region on chromosome 12pll-pl2. 
Genetic and physical positions of polymorphic markers used for haplotype analysis 
are given. The genetic distances quoted were taken from the high resolution 
deCode genetic map. The physical distances shown correspond to the NCBI 
genome assembly build 30.
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Figure 4.7 Results of haplotype analysis in Families 1 and 2 using 4 polymorphic markers on chromosome 12pl 1 -pi 2. Homozygous 
results are highlighted in colour. None of the four affected individuals are homozygous across the region.
while primers to a further six markers were chosen from the NCBI UniSTS database 
(see section 2.3.11.1) and designed as explained in section 2.3.2.2. Markers were 
chosen based on map position and degree of heterozygosity. Details of the markers are 
shown in Table 2.4 and their positions in Figure 4.8. PCRs to amplified microsatellite 
repeats were carried out as described in section 2.3.2.4 and genotyping analysis as 
described in section 2.3.7.1.
Results of haplotype analysis in affected individuals from Families 1 and 2 across all 
three regions are shown in Figures 4.9, 4.10 and 4.11. Linkage to all three loci was 
excluded in Families 1 and 2, as a region of homozygosity was not detected in the 
affected individuals. The three regions were also excluded in affected individuals II. 1 
from Family 3, II. 1 from Family 8 and II. 1 from Family 9 by Dr Colin Johnson.
Once linkage to the proposed candidate regions was excluded, it was decided to 
undertake a full genome-wide screen in the affected children of the two families with 
greater statistical power, Families 1 and 2.
4.2 Linkage screen and candidate regions
The homozygosity mapping approach was adopted to identify candidate regions. 
Initially, a genome-wide screen in the four affected children from Families 1 and 2 was 
performed. The Single Chromosome Scan linkage marker set from Research Genetics, 
which has an average marker spacing of 7 cM, was used as described in section 2.3.2.1. 
PCRs to amplify microsatellite repeats were carried out as described in section 2.3.2.4 
and genotyping analysis as described in section 2.3.7.1.
As there was no positive evidence that JATD was genetically heterogeneous at the 
commencement of this project, the aim of the genome-wide screen was to find markers 
at which all four affected children were homozygously IBD. It was also thought that the 
region of homozygosity around the disease locus was likely to be larger in Family 1, 
where the affected children’s parents were first cousins, than in Family 2, where the 
affected children’s parents were third cousins.
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6q25-q27. Homozygous markers are highlighted in colour. Note that patient VI.5 in Family 2 is homozygous for two consecutive 
markers (D6S1273 and D6S1719), but her affected sib VI.3 is heterozygous across the region. Linkage to this locus is excluded in both 
families.
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Figure 4.11 Results of haplotype analysis in affected individuals from Families 1 and 2 using 3 polymorphic markers on chromosome 
16pl3.3. Homozygous markers are highlighted in colour. Note that patient IV. 1 in Family 1 is homozygous for two consecutive markers 
(D16S2622 and D16S423), but his affected cousin IV.3 is heterozygous. Linkage to this locus is excluded in both families.
A second genome-wide screen was performed separately in affected child II.6 from 
Family 4. Complete spreadsheet tables with the results of the full genome-wide screen 
obtained in the five affected children from Family 1, 2 and 4 are shown in Appendix 1. 
A key to the colours and symbols is provided to interpret the results (see first page of 
Appendix 1). Allele sizes in individual II.6 from Family 4 might be different from the 
other four affected individuals as PCRs were run in different gels and analysed 
separately.
4.2.1 First-pass screen in Families 1 and 2
4.2.1.1 Homozygous regions in the four patients
In the first-pass screen, four regions of possible homozygosity in all four patients (IV. 1 
and IV.3 from Family 1, VI.3 and VI.5 from Family 2) were identified. A key to the 
colours and symbols to interpret the results is provided in Figure 4.12.
On chromosome 4, two regions of possible interest were identified. The first was on 4q 
between markers D4S2432 and D4S2433 (Table 4.1). D4S3249 was homozygous in all 
four patients. Moreover, individuals VI.3 and VI.5 from Family 2 were also 
homozygous for two adjacent markers D4S3243 and D4S2361. The second region was 
on 4q between markers D4S2623 and D4S1625 (Table 4.1). D4S2394 was found to be 
homozygous in all four affected children and an adjacent marker D4S1644 was also 
homozygous in patients IV. 1 and IV.3 from Family 1. To investigate the two regions 
further, more markers were typed in the four affected children. When possible, markers 
from the other two linkage sets available in the laboratory were used. Alternatively, 
new primers to amplify polymorphic markers were designed as explained in section 
2.3.2.2. Both regions on chromosome 4 were subsequently excluded, with no evidence 
of linkage when more flanking markers were tested and found to be heterozygous in the 
patients (Table 4.2). On chromosome 8q, a potentially interesting region of about 30 
cM was identified between markers D8S1113 and GAAT1A4 (Table 4.3).
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M arkers
Black (e.g. D8S1119) = 7 cM Single Chromosome Scan linkage marker set (Research 
Genetics, Inc.) -  tri- and tetra-nucleotide repeats
Bold red (e.g. D2S206) = 10 cM ABI PRISM™ Linkage Mapping Set (Perkin Elmer 
Applied Biosystems Division) -  di-nucleotide repeats
Bold purple (e.g. D15S822)= new markers chosen to fill in gaps -  di-nucleotide 
repeats
Heterozygosity and distances
Het column gives heterozygosity of the marker available on the NCBI database 
uniSTS, Marshfield genetic map
Mb column gives distances in Mb from the top (tip of short arm) of the chromosome 
according to the UCSC Human Genome Assembly (April 2003 freeze) NCBI build 33
cM (Marshfield) column gives distances in cM from the top of the chromosome 
according to the Marshfield genetic map
cM (deCode) column gives distances in cM from the top of the chromosome according 
to the deCode genetic map
[light blue fill indicates low heterozygosity 
/ indicates heterozygosity or position unknown
Results
|light green fill indicates individual is homozygous for that marker 
dark green fill indicates all four patients are homozygous for that marker
|green fill] indicates two individuals from the same family are homozygous for 2 
different alleles
■ ■  indicates candidate regions 
|ight orange fill| indicates result not clear 
/ indicates no result could be obtained for that marker 
Empty box indicates marker not tested
Figure 4.12 Key to genome-wide screen results tables.
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M arkers 
Chromosom e 4
Het Mb 
Build 33
cM
Marshfield
cM
deCode
D4S2366 0.77 6.47 12.93 12.46
D4S2639 0.88 18.53 / /
GATA158G03 0.78 21.55 35.03 37.29
D4S2397 0.78 26.94 42.74
D4S3244 0.86 28.73 / /
D4S2632 0.81 35.53 / 54.21
D4S1627 0.81 44.02 60.16 64.7
D4S2379 0.79 56.04 / /
D4S1645 0.78 61.92 72.52 /
D4S2432 0.76 66.5 75.2 78.49
D4S2367 0.74 68.22 78.43 /
D4S3249 0.71 76.76 / /
D4S3243 0.66 81.32 / 88.45
D4S2361 0.7 85.39 93.48 92.3
D4S2433 0.69 95.72 100.06 /
D4S1647 0.77 99.82 104.94 103.77
D4S2623 0.75 111.28 114.04 113.7
D4S2394 0.81 130.69 / 128.08
D4S1644 0.72 142.21 143.31 137.88
D4S1625 0.74 143.96 145.98 140.08
D4S1629 0.76 158.8 157.99 152.23
D4S2368 0.77 169.3 167.55 162.47
D4S2431 0.82 175.4 176.19 168.27
D4S2374 0.85 179.64 / /
D4S2417 0.67 180.75 181.93 17631
D4S3335 0.54 185.84 195.06 /
D4S2390 0.76 190.33 208.07 204.18
Family 1 
IV .l IV.3
Family 2 
VI.3 VI.5
123-127 119-119 123-135 123-123
175-183 163-175 159-183 159-175
299-303 299-307 303-311 299-311
127-141 141-141 137-141 137-141
“ 7 281-285 285-285 285-285
142-158 146-154 134-150 134-150
184-188 188-200 180-184 180-192
/ / / /
241-245 241-241 241-241 241-245
264-268 244-264 244-264 260-264
129-129 129-129 137-137 141-141
367-367 367-367 363-363 363-363
160-164 160-172 160-160 160-160
152-155 155-158 158-158 158-158
246-246 246-250 246-250 246-250
/ / / /
204-224 220-224 204-220 204-220
209-209 209-209 209-209 209-209
196-196 196-196 196-200 200-200
197-201 197-197 197-205 197-205
/ / / /
319-319 319-319 315-319 311-323
246-254 246-258 236-254 240-244
220-228 220-228 228-232 224-228
263-263 263-263 263-267 259-267
/ / /
/ 107-107 / /
Table 4.1 Genotyping results on chromosome 4 obtained after the first pass genome-wide screen in patient IV. 1, IV.3 from Family 
1 and VI.3, VI.5 from Family 2 using microsatellite markers from the Single Chromosome Scan linkage marker set from Research 
Genetics. Heterozygosity, physical and genetic distances (both from the Marshfield and deCode genetic maps) of each marker are 
given. Arrows indicate the 2 markers at which all four patients were homozygous.
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Markers 
Chromosome 4
Het Mb 
Build 33
cM
Marshfield
D4S3360 / 0.1 0
D4S412 0.76 3.41 4.74
D4S431 0.83 6.4 12.35
D4S2366 0.77 6.47 12.93
D4S2983 0.87 7.73 17.49
D4S403 0.76 13.43 25.9
D4S2639 0.88 18.53 /
GATA158G03 0.78 21.55 35.03
D4S2397 0.78 26.94 42.74
D4S391 0.85 27 3 43.59
D4S3244 0.86 28.73 /
D4S2632 0.81 35.53 /
D4S405 0.85 40.2 56.95
D4S1627 0.81 44.02 60.16
D4S428 0.77 55.48 64.24
D4S2379 0.79 56.04 /
D4S1645 0.78 61.92 72.52
D4S2432 0.76 66.5 75.2
D4S2367 0.74 68.22 78.43
D4S392 0.83 70.77 78.97
D4S3249 0.71 76.76 /
D4S3042 0.84 77.29 83.29
D4S2964 0.77 81.16 88.35
D4S3243 0 .66 8 132 /
D4S2361 0.7 85.39 93.48
D4S2433 0.69 95.72 100.06
D4S414 0.89 92.83 100.75
D4S1647 0.77 99.82 104.94
cM
deCode
0
4.42
12.46
12.46
/
26.71
/
37.29
47.33
/
54.21
60.23
64.7
69.01
/
/
78.49
/
80.38
/
85.42
88.45
88.45  
92.3
/
100.16
103.77
Family 1
IV.l IV.3
172-182 178-184
162-164 156-166
154-158 158-162
123-127 119-119
194-198 194-200
179-179 169-179
175-183 163-175
299-303 299-307
127-141 141-141
213-226 213-221
/ 281-285
142-158 146-154
284-292 278-292
184-188 188-200
186-192 186-186
/ /
241-245 241-241
264-268 244-264
129-129 129-129
101-103 101-101
367-367 367-367
196-214 196-218
237-237 237-245
160-164 160-172
152-155 155-158
246-246 246-250
227-233 233-233
/ /
Family 2
V U VI.5
172-174 172-178
162-162 162-162
123-135 123-123
190-194 190-194
159-183 159-175
303-311 299-311
137-141 137-141
285-285 285-285
134-150 134-150
180-184 180-192
/ /
241-241 241-245
244-264 260-264
137-137 141-141
99-105 99-103
363-363 363-363
225-237 225-237
160-160 160-160
158-158 158-158
246-250 246-250
/ /
D4S1572 0.84 104.16 107.95 107.52 200-202 200-202 198-198 198-202
D4S2623 0.75 111.28 114.04 113.7 204-224 220-224 204-220 204-220
D4S402 0.9 120.54 124.45 122.1 129-135 131-135 107-127 107-109
D4S2938 0.78 129.71 129.38 / 183-183 179-179 177-177 187-187
D4S2394 0.81 130.69 / 128.08 209-209 209-209 209-209 209-209
D4S1575 0.5 135.18 132.05 131.59 290-290 290-290 288-290 290-290
D4S3039 0.76 136.35 132.72 / 166-172 168-172
D4S1644 0.72 142.21 143.31 137.88 196-196 196-196 196-200 200-200
D4S424 0.83 142.66 144.56 138.87 194-198 198-204
D4S1625 0.74 143.96 145.98 140.08 197-201 197-197 197-205 197-205
D4S1629 0.76 158.8 157.99 152.23 / / / /
D4S413 0.86 158.81 157.99 / 282-282 282-294 285-318 293-316
D4S2368 0.77 1693 167.55 162.47 319-319 319-319 315-319 311-323
D4S1597 0.74 170.42 169.42 163.65 274-290 /
D4S2431 0.82 175.4 176.19 168.27 246-254 246-258 236-254 240-244
D4S2374 0.85 179.64 / / 220-228 220-228 228-232 224-228
D4S2417 0.67 180.75 181.93 176.31 263-263 263-263 263-267 259-267
D4S1535 0.75 185.82 195.06 189.38 247-253 251-259 253-259 251-253
D4S3335 185.84 195.06 / / /
D4S426 0.78 189.69 206.98 202.69 160-160 156-156 158-158 150-170
D4S2390 0.76 190.33 208.07 204.18 / 107-107 / /
I
Table 4.2 Genotyping results on chromosome 4 obtained in patient IV. 1, IV.3 from Family 1 and VI.3, VI.5 from Family 2 after 
testing more microsatellite markers. Note that regions between markers D4S2432 and D4S2433 and between D4S2623 and 
D4S1625 (indicated by brackets) no longer represent blocks of homozygosity in the four patients.
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M arkers  
C hrom osom e 8
H et M b  
Build 33
cM
M arshfield
cM
deC ode
D8S1469 0.67 8.96 16.19 /
D8S1130 0.8 11.7 22.41 18.18
D8S1106 0.73 12.61 26.43 23.58
D8S1989 0.61 24.46 50.05 /
D8S1477 0.86 31.92 60.34 /
D8S1104 0.68 40.38 64.6 59.17
D8S1110 0.77 52.9 67.27 65.47
D8S1113 0.81 59.43 77.89 70.74
D8S1136 0.74 65.79 82.26 /
D8S2323 0.84 69.79 87.54 /
GATA14E09 0.75 73.97 94.08 /
D8S1119 0.8 86.84 101.01 /
D8S1988 0.63 93.15 104.33 97.63
GAAT1A4 0.66 98.85 110.2 104.28
D8S1459 0.68 105.08 117.62 /
D8S1470 0.81 111.89 122.96 115.83
D8S1471 0.73 113.37 123.54 116.22
D8S1142 0.69 114.42 / /
D8S592 0.67 118.12 125.27 118.41
D8S586 0.85 120.85 128.16 1 2 1 3 7
D8S1179 0.81 125.57 135.08 129.33
D8S568 0.82 126.4 / /
D8S1128 0.76 128.26 139.53 135.57
D8S1462 0.75 135.06 / /
D8S1100 0.65 136.77 154.02 148.81
Fam ily 1
IV .l IV .3
/ 213-213
/ 134-138
137-141 141-141
/ /
162-162 162-166
132-136 136-140
280-280 260-280
232-236 232-236
/ 253-253
302-302 302-302
204-204 204-204
173-173 173-173
/ /
148-156 156-156
125-131 125-131
354-358 354-362
289-289 285-297
354-358 350-354
165-165 161-173
/ /
173-185 181-185
254-254 254-270
/ /
156-160 156-156
185-188 188-188
Fam ily 2
V I.3 V I.5
193-209 205-209
134-142 142-146
137-141 /
211-215 193-211
138-162 138-138
128-132 128-140
272-276 276-276
220-236 216-236
245-257 249-257
298-302 302-302
204-212 204-212
181-181 181-181
/ /
152-156 152-156
131-134 131-134
354-362 354-362
293-293 293-293
354-354 354-354
161-173 161-173
/ /
169-181 169-181
258-266 258-266
/ 238-242
160-160 160-160
182-182 182-182
N
►
Table 4.3 Genotyping results on chromosome 8 obtained after the first pass genome-wide screen in patient IV. 1, IV.3 from Family 
1 and VI.3, VI.5 from Family 2 using microsatellite markers from the Single Chromosome Scan linkage marker set from Research 
Genetics. Marker D8S1119 is homozygous in all four patients and a potential shared region of homozygosity in patients IV. 1 and 
IV.3 from Family 1 between markers D8S1113 and GAAT1A4 (indicated by bracket) could extend up to 30 cM.
This region of homozygosity was subsequently excluded when more markers known to 
lie in the region were tested and were found to be heterozygous (Table 4.4). In addition 
marker D8S1119 was run on separate gel lanes for the four patients and was found to 
be heterozygous in individuals IV. 1 and IV.3 from Family 1. Marker GATA14E09 was 
also found to be heterozygous in individual IV.3 from Family 1 when the sample was 
run on a separate gel lane (Table 4.4).
After the first-pass screen, all four patients were homozygous for marker D17S1298 
located at 10.72 cM from the 17pter (See Appendix 1). When a very close marker 
D17S1876 was typed in all four affected children, individual IV. 1 from Family 1, VI.3 
and VI.5 from Family 2 were found to be heterozygous, thereby excluding the region.
4.2.1.2 Difficulties o f the genome-wide screen
In general, the results from the first-pass screen were unsatisfactory. They gave 
inadequate coverage of the genome. There were several reasons for this. First of all the 
Research Genetics linkage set contains a certain number of gaps between markers; 
three gaps greater than 20 cM, fourteen gaps greater than 15 cM, and seventy greater 
than 10 cM were counted. Therefore, even if all markers had worked perfectly, 
complete coverage of the genome could not have been achieved. Furthermore, other 
gaps were generated where the PCR failed to amplify the markers. Out of 516 pairs of 
primers, 55 (10.6%) did not work at all the first time and 70 (13.5%) worked poorly 
with at least one reaction out of four that did not work. For markers that did not work 
the first time, the PCR conditions were modified. Lowering the annealing temperature 
to 53°C resolved the problem in some cases; loading more PCR product gave good 
results, especially for the faint, HEX-labelled products.
For markers with good PCR product, results were often hard to interpret. Sometimes 
the presence of extra peaks due to non-specific bands in the PCR or superimposed 
peaks from other colours made the results confusing. In order to avoid these problems, 
PCR was repeated and PCR products checked on a 2% agarose gel to ensure that only a 
single specific band was amplified. PCR conditions were changed (increasing the
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M arkers 
Chrom osom e 8
Het M b  
Build 33
cM
M arshfield
cM
deCode
D 8S504 0.72 1.16 0 0
D8S1469 0.67 8.96 16.19 /
D8S1130 0.8 11.7 22.41 18.18
D8S1106 0.73 12.61 26.43 23.58
D8S258 0.7 20.17 41.55 34.88
D8S1989 0 .0 1 24.46 50.05 /
D8S1477 0.86 31.92 60.34 /
D8S1104 0.68 40.38 64.6 59.17
D8S1110 0.77 52.9 67.27 65.47
D8S1113 0.81 59.43 77.89 70.74
D8S260 0.82 61.54 79.36 73.6
D8S1136 0.74 65.79 82.26 /
D 8S1797 0.83 66.97 82.84 77.01
D8S2323 0.84 69.79 87.54 /
D8S279 0.88 72.71 91.46 84.3
GATA14E09 0.75 73.97 94.08 /
D 8S1760 0.81 80.27 96.21 /
D8S1119 0.8 86.84 101.01 /
D8S1988 0.63 93.15 1 0 4 3 3 97.63
GAAT1A4 0.66 98.85 110.2 104.28
D8S1459 0.68 105.08 117.62 /
D8S1470 0.81 111.89 122.96 115.83
D8S1471 0.73 1 1 3 3 7 123.54 116.22
D8S1142 0.69 114.42 / /
D8S592 0.67 118.12 125.27 118.41
D8S586 0.85 120.85 128.16 121.37
D8S514 0.76 123.41 130 124.62
D8S1179 0.81 125.57 135.08 129.33
D8S568 0.82 126.4 / /
Fam ily 1 
1V.1 IV.3
Fam ily 2 
VI.3 VI.5
139-147 139-139 131-137 137-141
/ 213-213 193-209 205-209
/ 134-138 134-142 142-146
137-141 141-141 137-141 /
150-152 146-150 146-150 146-150
/ / 211-215 193-211
162-162 162-166 138-162 138-138
132-136 136-140 128-132 128-140
280-280 260-280 272-276 276-276
232-236 232-236 220-236 216-236
204-204 198-208 204-204 204-204
/ 253-253 245-257 249-257
145-145 133-143
302-302 302-302 298-302 302-302
238-244 238-244 230-246 230-246
204-204 204-216 204-212 204-212
140-152 152-154 154-156 154-156
172-187 172-181 181-181 181-181
291-291 287-295 287-291 287-291
148-156 156-156 152-156 152-156
125-131 125-131 131-134 131-134
354-358 354-362 354-362 354-362
289-289 285-297 293-293 293-293
354-358 350-354 354-354 354-354
165-165 161-173 161-173 161-173
245-245 245-249 245-249
216-218 218-222 222-222 214-222
173-185 181-185 169-181 169-181
254-254 254-270 258-266 258-266
D8S1128 0.76 128.26 139.53 135.57 / / / 238-242
D8S284 0.83 131.18 143.82 139.79 278-296 270-296 296-296 296-296
D8S1462 0.75 135.06 / / 156-160 156-156 160-160 160-160
D8S1100 0.65 136.77 154.02 148.81 185-188 188-188 182-182 182-182
D8S272 0.8 137.41 154.02 / 253-253 253-253
Table 4.4 Genotyping results on chromosome 8 after testing more polymorphic markers. The region between markers D8S1113 and 
GAAT1A4 (indicated by bracket) is no longer homozygous in all four patients. Note different results for markers GATA14E09 and 
D8S1119 after repeating the PCRs and running the samples separately in single gel lanes.
temperature) in the case of non-specific bands. Samples were then run in separate lanes 
on the ABI gel to avoid peaks coming through from other colours. Another problem 
that was encountered was that the range of allele sizes in a panel was sometimes too 
close, resulting in overlapping peaks within the same Genotyper window, again 
confusing the results. Finally, the range of allele sizes was often different from the one 
stated by the manufacturers. Genotyper calls peaks only in the interval of allele size 
that is given. If that interval is not accurate, one risks missing peaks and calling patients 
homozygous, when they are actually heterozygous.
4.2.2 Second-pass screen
In order to resolve some of the problems discussed above, a new strategy was adopted. 
In order to get an adequate coverage of the genome (with no gaps larger than 10 cM), 
markers from the other two linkage sets available in the laboratory were used and/or 
new primers were designed. The problem with using the two other linkage sets was that 
they were both quite old and thus some primers were missing from their boxes, while 
others were not working properly. In the latter case, it was necessary to vary the PCR 
conditions to amplify the products. In addition, it was difficult to define exactly the 
physical and genetic positions of the markers, especially for the Research Genetics 
markers. Some markers were not listed at all in the uniSTS database and some gave 
only the position in cM. For some of these, the position in Mb was obtained by doing a 
BLAST search (http://www.ncbi.nlm.nih.gov/BLAST/) using the sequence surrounding 
the marker against the human genome sequence.
Therefore, new microsatellite markers were ascertained from both Map View at NCBI 
(http://www.ncbi.nlm.nih.gov/mapview) and the UCSC Human Genome Browser at 
http://www.genome.ucsc.edu. Both databases were used to integrate genetic and 
physical map data. In the initial stages of the project, linkage map data from the 
Marshfield Centre for Medical Genetics was primarily used to locate markers, their 
primer sequences and heterozygosities. Later, both the deCode Icelandic map (available 
on the NCBI database, uniSTS) and the UCSC database, were preferred to choose
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markers. A second strategy was to search for novel polymorphic markers by BLAST 
searching each BAC in a particular region with a nucleotide repeat sequence, such as 
ca(n) or tg(n). Although not all the repeats identified with this strategy were found to be 
polymorphic, a few were successfully used for linkage because of their high 
heterozygosity.
The aim of the second-pass screen was to fill in any gaps greater than 7-10 cM between 
the markers tested. After this second-pass screen, a number of regions in which all four 
patients were homozygous for one or more markers were identified (Appendix 1). To 
check whether the four children were really IBD at these markers, or just IBS, 
genotyping with flanking markers, and when necessary genotyping of their parents and 
siblings, was carried out.
A possibly interesting region, for example, was located on chromosome 17q25 between 
marker D17S968 and D17S928 (Table 4.5A). All four patients were homozygous for 
D17S801 and patients IV. 1 and IV.3 from Family 1 were also homozygous for the 
three adjacent markers D17S802, D17S1847 and D17S784 (Table 4.5A). After more 
markers in the region were typed, the region was excluded in both families (Table 
4.5B). Furthermore, haplotype analysis of the parents and the children in the region was 
performed and they were all found to be homozygous for D17S801 (Fig. 4.13 and 
4.14).
4.2.3 Identification of candidate regions
After the second-pass screen, no region that was IBD in all four patients was identified. 
A possible explanation for this is locus heterogeneity, namely that the disease loci in 
Families 1 and 2 were different. A number of homozygous regions were found in each 
family individually and each of them was investigated further. Because the region of 
homozygosity around the disease locus was likely to be larger in Family 1 than in 
Family 2, initially it was decided to focus on defining and fine-mapping regions that 
were IBD in the two affected children from Family 1.
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A) Markers 
Chromosome 17
ATA43A10
D17S968
D17S801
D17S802
D17S1847
D17S784
D17S928
Het Mb 
Build 33
cM
Marshfield
cM
deCode
0.79 67.01 89.32 9 9 3 4
/ 73.07 / /
0.85 74.97 103.53 /
0.81 76.7 106.8 120.84
0.66 77.48 111.22 123.75
0.77 7 8 3 6 116.86 129.62
0.77 80.78 126.46 135.67
Family 1
IV .l IV.3
146-150 137-150
162-170 162-170
269-269 269-269
185-185 185-185
268-268 268-268
231-231 231-231
81-87 81-87
Family 2
VI3 VI.5
154-162 154-162
166-170 170-170
269-269 269-269
181-183 181-183
266-268 266-268
235-235 235-235
84-87 84-87
B) Family 2
VI.3 VI.5
154-162 154-162
166-170 170-170
226-228 228-234
269-269 269-269
181-183 181-183
266-268 266-268
201-205 201-205
253-253 253-253
244-250 244-250
235-235 235-235
84-87 84-87
M arkers 
Chromosome 17
Het Mb 
Build 33
cM
Marshfield
cM
deCode
ATA43A10 0.79 67.01 89.32 99.34
D17S968 / 73.07 / /
D17S1603 0.73 74.53 102.99 115.06
D17S785 0.83 74.89 103.53 11534
D17S801 0.85 74.97 103.53 /
D17S802 0.81 76.7 106.8 120.84
D17S1847 0.66 77.48 111.22 123.75
D17S836 0.63 77.76 112.92 125.04
D17S1806 0.72 77.9 114.41 /
D17S1822 0.7 78.34 116.86 129.24
D17S784 0.77 78.36 116.86 129.62
D17S928 0.77 80.78 126.46 135.67
Family 1
IV .l IV.3
146-150 137-150
162-170 162-170
227-241 227-241
191-205 191-205
269-269 269-269
185-185 185-185
268-268 268-268
201-205 201-205
247-259 247-259
250-252 250-252
231-231 231-231
81-87 81-87
Table 4.5 Genotyping results on chromosome 17q25 in patient IV. 1, IV.3 from Family 1 and VI.3, VI.5 from Family 2 before (A) 
and after (B) the second-pass screen showing how a potentially interesting region was excluded by running more polymorphic 
markers. D17S785, very close to D17S801, is heterozygous in IV. 1 and IV.3 from Family 1. D17S836, very close to D17S1847, 
is heterozygous in all four patients.
Family 1
ii
h i
D17S801
D17S802
D17S1847
D17S836
D17S1806
D17S1822
D17S784
269 269 
185 187 
268 270 
201 205 
247 253 
250 250 
231 233
IV
269 269 
185 187 
268 268 
201 205 
247 253 
250 250 
231 233
£
269 269 
185 187 
268 268 
205 205 
259 253 
252 252 
231 237
l 2 3
D17S801 269 26*9 269 269
D17S802 185 185 185 185
D17S1847 268 268 268 268
D17S836 201 205 201 205
D17S1806 247 259 247 259
D17S1822 250 252 250 252
D17S784 231 231 231 231
269 269 
185 187 
268 268 
205 205 
259 247 
252 250 
231 233
Figure 4.13 Results of haplotype analysis in Family 1 using seven polymorphic 
markers on chromosome 17q25. Homozygous results are highlighted in colour. Note 
that marker D17S801 is homozygous in the two affected children, but also in their 
parents. D17S1847 is semi-informative. D17S784 is homozygous in patients IV.l 
and IV.3, but a very close marker, D17S1822, is not.
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Family 2
ii
h i
IV
□ —|— O1 2
o □ D
□
O
□
O - t— □ Q
U T T ^
2 3
D17S801 _  _ 269 269
D17S802 - -
D17S1847 - -
D17S836 201 205 205 205
D17S1806 253 255 253 245
D17S1822 250 252 244 244
D17S784 235 229 235 229
O
VI
1 2 3 4 5
D17S801 269 269 269 269 269 269
D17S802 - 181 183 181 183
D17S1847 - 266 268 266 268
D17S836 205 205 201 205 201 205
D17S1806 255 253 253 253 253 253
D17S1822 252 244 250 244 250 244
D17S784 229 235 235 235 235 235
Figure 4.14 Results of haplotype analysis in Family 2 using seven polymorphic 
markers on chromosome 17q25. Homozygous results are highlighted in colour. Note 
that marker D17S801 is homozygous in the two affected children, but also in their 
parents and their unaffected brother. D17S784 is homozygous in patients VI.3 and 
VI.5, but a very close marker, D17S1822, is not. Markers which were not typed for a 
particular individual are marked with a dash.
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4.2.3.1 Family 1
Fine-mapping with the aim of not leaving gaps larger than 10 cM was carried out in 
individual IV.l and IV.3 from Family 1 (see Appendix 1). One region on chromosome 
3 was found to be particularly interesting, 3q24-q26 between markers D3S1764 and 
D3S3053 (Table 4.6). This region was the only large region in the genome in which the 
two affected children were both homozygous for the same alleles. This interval of about 
17 cM/23 Mb was homozygous in both affected children, showing a larger region of 
homozygosity in individual IV.l. This locus was investigated further. More closely 
spaced markers, approximately 1-3 cM apart, were used to genotype the two affected 
children. Markers were chosen based on map position and degree of heterozygosity. 
Primers to amplify polymorphic markers were designed as described in section 2.3.2.2. 
Details of markers are shown in Table 2.5 and their positions in Table 4.7. Markers Rl, 
R2 and R3 were found by searching for repeats in three BAC clones between markers 
D3S3723 and D3S1574 in order to better refine the minimal critical interval.
The two affected children continued to show homozygosity over the whole region 
(Table 4.7). Haplotype analysis was then performed in both sets of parents as well as in 
unaffected sib IV.2 (Table 4.8). Different colours for allele sizes represent different 
haplotypes to show how they segregate in the family. Some markers were 
uninformative or semi-informative. In this case, the allele sizes were left in black for 
the children. Both sets of parents and unaffected sib IV.2 were heterozygous for most 
of the markers supporting the hypothesis of linkage to this locus. The minimal critical 
interval was defined between markers D3S1555 and D3S1308 at the centromeric end 
due to a cross-over in individuals III.2 and between markers R3 and D3S1574 at the 
telomeric end due to a paternal cross-over in patient IV.3 (Table 4.8).
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M arkers 
Chromosome 3
Het M b 
Build 33
cM
M arshfield
cM
deCode
Fam ily 1 
IV .l IV.3
D3S2406 0.88 73.06 102.64 / 315-327 327-339
D3S4529 0.72 85.65 112.42 / 158-158 154-158
D3S1271 0.74 102.01 117.76 112.28 93-93 85-93
D3S2459 0.84 103.45 119.09 113.38 189-189 185-201
D3S3045 0.82 108.27 124.16 117.29 179-179 175-179
D3S4018 0.78 112.93 127.89 120.11 292-292 292-300
D3S2460 0.76 118.68 134.64 / 149-149 161-161
ATA34G06 0.71 / 138 126.98 230-230 230-242
D3S1267 0.88 124.32 139.12 / 93-93 93-95
D3S4527 0.7 128.17 / / 239-239 227-235
D3S1292 0.84 132.91 146.6 138.82 130-130 116-128
D3S1764 0.79 140.46 152.62 145.53 241-241 241-245
D3S1569 0.8 144.65 158.38 150.58 152-152 152-152
D3S1744 0.77 148.37 161.04 15336 150-150 150-150
D3S1279 0.85 1 5 2 3 169.6 160.19 266-266 266-266
D3S4531 0.69 152.53 169.6 160.46 263-263 263-263
D3S1763 0.8 168.64 176.54 168.52 277-277 277-277
D3S1614 0.83 169.61 177.75 169.98 110-110 110-110
D3S3053 0.73 173.15 181.87 / 232-232 236-232
D3S1565 0.63 174.88 186.04 177.94 182-182 182-182
D3S2427 0.85 177.18 188.29 / 230-230 236-230
D3S1262 0.8 187.62 201.14 194.33 114-114 114-114
D3S2436 0.67 188.23 203.28 / 171-171 171-171
D3S1580 0.84 189.94 207.73 202 224-218 218-218
D3S2398 0.77 190.82 209.41 203.31 274-294 294-294
D3S2418 0.71 193.72 215.84 / 106-109 106-109
Table 4.6 Chromosome 3q24-q26 results obtained in patients IV.l and IV.3 from Family 1 
after the second-pass screen showing a region of shared homozygosity in the two affected 
individuals between markers D3S1764 and D3S3053.
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M arkers 
Chromosome 3
Het M b  
Build 33
cM
Marshfield
cM
deCode
Fam ily 1 
IV .l IV.3
D3S2406 0.88 73.06 102.64 / 315-327 327-339
D3S4529 0.72 85.65 112.42 / 158-158 154-158
D3S1271 0.74 102.01 117.76 112.28 93-93 85-93
D3S1764 0.79 140.46 152.62 145.53 241-241 241-245
D3S1309 0.74 142 153.74 146.63 167-167 171-165
D3S3694 0.84 143.47 153.74 148.82 302-302 294-300
D3S1569 0.8 144.65 158.38 150.58 152-152 152-152
D3S1593 0.78 146.6 161.04 15231 226-226 212-226
D3S1744 0.77 148.37 161.04 153.36 150-150 150-150
D3S1306 0.72 149.08 164.25 154.18 158-158 164-158
D3S1555 0.8 150.08 165.32 156.59 211-211 203-211
D3S1308 0.69 15031 165.85 157.07 190-190 190-190
D3S1299 0.62 151.46 166.93 158.56 196-196 196-196
D3S1279 0.85 1 523 169.6 160.19 266-266 266-266
D3S4531 0.69 152.53 169.6 160.46 263-263 263-263
D3S1746 0.85 153.01 169.6 / 271-271 271-271
D3S1280 0.75 1 5 3 3 8 170.14 161.6 210-210 210-210
D3S3531 0.73 155.49 170.14 162.79 218-218 218-218
D3S1607 0.8 158.24 172.27 164.61 235-235 235-235
D3S3575 0.79 160.63 173.34 165.61 188-188 188-188
D3S3579 0.79 161.86 173.87 166.45 186-186 186-186
D3S1268 0.86 165.29 174.94 / 204-204 204-204
D3S3668 0.83 165.72 175.47 167.47 228-228 228-228
D3S1763 0.8 168.64 176.54 168.52 277-277 277-277
D3S1614 0.83 169.61 177.75 169.98 110-110 110-110
D3S1282 0.78 170.29 180.8 170.46 168-168 168-168
D3S3523 0.68 170.93 181.87 171.02 188-188 188-188
D3S3723 0.63 171.65 180.08 171.45 161-161 161-161
R1 / 171.8 / / 271-271 271-271
R2 / 172 / / 201-201 201-201
R3 / 172.6 / / 160-160 160-160
D3S1574 0.79 173.08 181.87 174.03 144-144 126-144
D3S3053 0.73 173.15 181.87 / 232-232 236-232
D3S3725 0.84 173.21 181.87 174.44 200-200 198-200
D3S1565 0.63 174.88 186.04 177.94 182-182 182-182
D3S2427 0.85 177.18 188.29 / 230-230 236-230
D3S3730 0.83 179.94 191.79 184.15 274-274 274-274
D3S1262 0.8 187.62 201.14 194.33 114-114 114-114
D3S2436 0.67 188.23 203.28 / 171-171 171-171
D3S1580 0.84 189.94 207.73 202 224-218 218-218
D3S2398 0.77 190.82 209.41 203.31 274-294 294-294
D3S2418 0.71 193.72 215.84 / 106-109 106-109
Table 4.7 Chromosome 3q24-q26 results obtained in patients IV.l and IV.3 from 
Family 1 after fine mapping with closely spaced markers. A region of about 17 cM/23 
Mb is homozygous in both patients between markers D3S1555 and D3S1574. Note that 
IV.l is homozygous for a larger region of about 100 cM (homozygous markers between 
D3S1271 and D3S1764 have not been included in this table). Blue lines define the 
minimal critical interval.
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Markers Family 1 Family 1
Chromosome 3 III.l III.4 IV.l III.2 II 1.3 IV.2 IV.3
father mother proband father mother unaff. proband
D3S1764 :;  ; 241-245 241- 241-229 241-245 241-145 241-245
D3S1309 167-171 167-165 167-167 i  “ 1-171 167-165 171-165 171-165
D3S3694 302-294 302-300 302-302 294-292 302-300 294-300 294-300
D3S1569 - 152-152 152-160 - 152-152 _ -152
D3S1593 226-212 226-212 226-226 212-210 226-212 212-212 212-226
D3S1744 150-146 150-146 150-150 150-146 150-146 150-146 i50-150
D3S1306 158-164 158-166 158-152 -1M 158-166 164-166 164-158
D3S1555 211-211 211-209 211- 203-207 211-209 203-209 203-211
D3S1308 190-190 190-188 190-13 190-194 190-188 190-188 -19U
D3S1299 196-200 196-200 196-136 196-202 196-200 196-200 - -T
D3S1279 266-268 266-276 266-266 266-272 266-276 266-276 -266
D3S4531 263-251 263-255 263-263 2( >5-263 263-255 263-255 263-263
D3S1746 271-275 271-259 271-271 271-259 271-259 271-259 7.7 ■'•-271
D3S1280 210-212 210-208 210-210 210-216 210-208 210-208 -210
D3S3531 : ! s-: i x 218-218 218-218 218-220 218-218 2 IN-218 -218
D3S1607 235-251 235-235 235-235 - 235-235 235-235 235-235
D3S3575 188-192 188-196 188-128 188-194 188-196 188-196 . '-188
D3S3579 186-172 186-180 186-186 186-184 186-180 186-180 -186
D3S1268 204-206 204-208 204-204 204-206 204-208 204-208 _204-
D3S3668 228-220 228-222 228-228 - 228-222 228-222 228-228
D3S1763 277-273 277-269 O'Tt.o'7*? 277-273 277-269 277-269 -277
D3S1614 110-108 110-106 110-110 110-108 110-106 110-106 -110
D3S1282 168-168 168-166 168-162 108-168 168-166 168-166 168-168
D3S3523 188-188 188-184 188-158 188-188 188-184 188-184 188-188
D3S3723 161-161 161-161 161-161 161-161 - 161-161 161-161
R1 271-273 271-275 27 1-2 / i 271-271 271-275 271-275 271-271
R2 201-201 201-209 201- 201-201 201-209 201-209 201-201
R3 158-160 160-160 160-160 60-160 160-160 160-160 160-160
D3S1574 144-120 144-136 144-144 144-126 144-136 144-136 126-144
D3S3053 232-232 236-232
D3S3725 200-208 200-210 200-200 200-198 200-210 200-210 198-200
D3S1565 182-182 182-178 182-122 / 182-180 182-180 182-182
D3S2427 230-236 - 230-230 236-230
D3S3730 274-284 274-284 274-274 274-274 274-280 274-280 274-274
D3S1262 114-114 114-122 114-114 114-114 114-122 114-122 114-114
D3S2436 171-171 171-175 171- 183-171 171-175 171-175 171-171
D3S1580 224-228 218-224 224-21 ' ' 1 -2 18 218-224 218-224 218-218
D3S2398 274-286 294-282 274-294 282-294 294-282 294-294
Table 4.8 Haplotype analysis results across the 3q24-q26 region in Family 1 supporting 
linkage to this locus. Homozygous results are highlighted in green. Unaffected sib IV.2 
shares the same paternal haplotype as affected individual IV.3, but the opposite 
maternal haplotype. Note that individuals III.4 and III.3 who are sisters, and also the 
mothers of the two patients IV.l and IV.3 respectively,have the same haplotype across 
the region. The region in patient IV.3 is smaller than in IV.l because of a cross-over 
occuring in individual III.2 defining the centromeric boundary and a paternal cross-over 
occuring in patient IV.3 himself which defines the telomeric boundary. Blue lines define 
the minimal critical interval. Unaff. means individual is unaffected.
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4.2.3.2 Family 2
Haplotype analysis across the 3q24-q26 region was performed in Family 2 and was not 
consistent with linkage, suggesting possible locus heterogeneity (Table 4.9). Fine- 
mapping was then performed in the two affected individuals from Family 2 (VI.3 and 
VI.5) filling in gaps in the genome-wide screen with more closely spaced markers 
(Appendix 1). Four regions were identified in which the two patients were homozygous 
for the same alleles. Each region was investigated further by genotyping with more 
markers and testing the parents and unaffected sib to identify a region IBD in this 
family.
Three consecutive markers were found to be homozygous in both patients on 
chromosome 2q31-q32 between markers D2S326 and D2S117 (Table 4.10A). The 
region of shared homozygosity was potentially about 17 cM/22 Mb in size. However, 
this region was excluded after three more polymorphic markers were chosen and typed 
in the two affected sibs, their parents and the unaffected sib VI.2 (Table 4.1 OB).
Three consecutive markers were found to be homozygous in both patients on 
chromosome 12q21-q22 between markers D12S1052 and D12S95 (Table 4.11A). The 
region of homozygosity was potentially about 14 cM/17 Mb in size. However, this 
region was excluded after four more polymorphic markers were chosen and tested in 
the two affected sibs, and three of them also in the parents and the unaffected sib VI.2 
(Table 4.1 IB).
A third homozygous region in the two affected children was identified on chromosome 
18pl 1 between markers D18S976 and D18S1153 (Table 4.12A). The region was 
potentially about 22 cM/5 Mb in size. However, this region was excluded after four 
more polymorphic markers were chosen and tested in the two affected sibs, and three of 
them also in the parents and the unaffected sib (Table 4.12B). Markers AP001032, 
AP001793 and AP000864 were found by searching for repeats in these three BAC 
clones.
The fourth region of interest was located on chromosome 8q24 between markers 
D8S1128 and D8S373, potentially spanning about 30 cM/15 Mb (Table 4.13). The
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Markers 
Chromosome 3 V.5
father
V.6
mother
Family 2 
VI.2 
unaff.
VI.3
proband
VI.5
proband
D3S1764 233-237 233-237
D3S1569 164-170 164-164
D3S1744 142-158 142-146
D3S1555 207-209 207-207 207-207 207-207 207-207
D3S1279 264-276 264-268
D3S4531 259-259 255-259
D3S1280 212-216 210-212 210-212 212-212 210-212
D3S3531 214-220 214-216 214-214 214-216 214-214
D3S1607 232-232 232-232
D3S3575 192-192 180-188 180-192 180-192 188-192
D3S3668 224-226 210-228 224-228 224-228 210-224
D3S1763 269-273 269-277
D3S1614 110-110 106-110
D3S1282 166-166 166-168 166-168 166-168 166-166
D3S3523 186-188 186-188 186-188 186-188 188-188
R1 / 272-276
D3S1574 126-128 126-128 126-128 128-128 128-128
D3S3053 224-232 224-232
D3S1565 176-178 178-178
D3S2427 234-238 234-238
D3S2436 167-171 167-171
D3S2398 292-292 288-292
Table 4.9 Haplotype analysis results across the 3q24-q26 region in Family 2. 
Linkage to this locus was excluded, since a region of homozygosity could not 
be demonstrated in affected individuals VI.3 and VI.5. Homozygous results 
are highlightedin green. Not all the markers were typed in the parents and the 
unaffected sib VI.2. Blue lines indicate the boundaries of the homozygous 
region in individual IV.3 from Family 1. Unaff. means individual is 
unaffected.
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A)
Markers 
Chromosome 2
Het Mb 
Build 33
cM
Marshfield
cM
deCode
Family 2 
VI.3 VI.5
D2S326
GATA194A05
D2S364
D2S1391
D2S117
0.86
0.56
0.80
0.79
0.82
173.06
176.13
182.99
184.95
195.58
177.53
180.79
186.21
186.21
194.45
/
182.23
187.67
189.15
194.63
97-99
235-235
248-248
127-127
200-204
97-99
235-235
248-248
127-127
200-204
B)
Markers 
Chromosome 2
Het Mb cM cM
Build 33 Marshfield deCode
Family 2
V.5 V.6 VI.2 VI.3 VI.5 
father mother unaff. proband proband
D2S326
GATA194A05
HOXD10
D2S384
D2S364
D2S1391
D2S152
D2S117
0.86
0.56
/
0.72
0.80
0.79
0.80
0.82
173.06
176.13
176.94 
181.46 
182.99
184.95 
188.19 
195.58
177.53
180.79
/
185.13
186.21
186.21
188.11
194.45
/
182.23
/
/
187.67
189.15
189.76
194.63
113-117
257-257
228-224
103-101
255-259
230-239
113-101
/
228-230
97-99
235-235
113-103
/
248-248
127-127
228-230
200-204
97-99
235-235
113-103
257-255
248-248
127-127
228-230
200-204
Table 4.10 Genotyping results on chromosome 2q31-q32 in patient VI.3, VI.5 from Family 2 (A) showing a potentially interesting 
region with three consecutive homozygous markers. The region was excluded by running more polymorphic markers and by testing 
the parents, who do not share a haplotype in common across this region (B). The two affected sibs are heterozygous for the new 
markers. Unaff. means idividual is unaffected.
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A)
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
Family 2 
VI.3 VI.5
D12S1052 0.72 75.32 83.19 87.74 152-156 152-156
D12S326 0.8 77.9 86.4 91.2 216-216 216-216
D12S1708 0.72 83.33 91.46 95.7 166-166 166-166
D12S1064 0.82 90.75 95.03 / 188-188 188-188
D12S95 0.78 92.86 96.09 102.37 172-182 172-182
D12S1044 / 94.1 / 103.94 296-299 296-299
B)
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
D12S1052 0.72 75.32 83.19 87.74
D12S1684 0.9 77.19 86.4 89.85
D12S326 0.8 77.9 86.4 91.2
D12S64 / 79.41 89.42 /
D12S1708 0.72 83.33 91.46 95.7
D12S1667 0.76 83.66 92.89 97.2
D12S1719 0.74 87.09 94.49 98.07
D12S1064 0.82 90.75 95.03 /
D12S95 0.78 92.86 96.09 102.37
D12S1044 / 94.1 / 103.94
V.5
father
V.6
mother
Family 2 
VI.2 
unaff.
VI.3
proband
VI.5
proband
257-255 259-243 255-243
152-156
257-259
152-156
257-259
216-216 216-216
253-253 251-249 253-249 253-251 253-251
166-166 166-166
268-278 278-278 278-278 268-278
i
268-278
242-252
! 88-1 88 188-188
172-182
296-299
172-182
296-299
Table 4.11 Region on chromosome 12q21-q22 results in patient VI.3, VI.5 from Family 2 (A) showing a potentially interesting 
region with three consecutive homozygous markers. The region was excluded by running more polymorphic markers and testing 
the parents and the unaffected sib across this region (B). The two patients are heterozygous for all four new markers. Unaff. 
means individual is unaffected.
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A)
Markers 
Chromosome 18
Het Mb 
Build 33
cM
Marshfield
cM
deCode
Family 2 
VI.3 VI.5
D18S976 0.86 5.23 12.81 16.6 185-188 180-185
D18S973 / 5.77 / / 215-215 215-215
D18S452 0.84 5.81 18.7 17.62 125-125 125-125
D18S843 0.78 8.6 28.1 28.11 187-187 187-187
D18S1153 0.78 10.12 35.46 / 138-150 138-150
B)
Markers 
Chromosome 18
Het Mb 
Build 33
cM
Marshfield
cM
deCode V.5
father
V.6
mother
Family 2 
VI.2 
unaff.
VI.3
proband
VI.5
proband
D18S976 0.86 5.23 12.81 16.6 185-188 180-185
AP001032 / 5.61 / / 278-280 278-282 2 7 8 - 27 8 280-282 278-278
D18S973 / 5.77 / / 215-215 215-215
D18S452 0.84 5.81 18.7 17.62 125-125 125-125
D18S471 0.66 5.97 18.7 18.37 217-231 217-217
AP001793 / 8.48 / / 305-295 299-299 305-299 305-299 305-299
D18S843 0.78 8.6 28.1 28.11 187- 187 187-187
AP000864 / 8.73 / / 319-331 317-315 319-315 319-317 319-317
D18S1153 0.78 10.12 35.46 / 138-150 138-150
Table 4.12 Region on chromosome 18pl 1 results in patient VI.3, VI.5 from Family 2 (A) showing a potentially interesting 
region with three consecutive homozygous markers. The region was excluded by running more polymorphic markers and 
testing the parents and the unaffected sib across this region (B). Note that individual VI.2 is homozygous for AP001032 as 
is his affected brother VI.5. Unaff. means individual is unaffected.
Markers 
Chromosome 8
D8S1128
D8S284
D8S1462
D8S1100
D8S272
D8S373
Het Mb 
Build 33
cM
Marshfield
cM
deCode
0.76 128.26 139.53 135.57
0.83 131.18 143.82 139.79
0.75 135.06 / /
0.65 136.77 154.02 148.81
0.8 137.41 154.02 /
0.78 144.00 167.9 166.08
Family 2 
VI.3 VI.5
/ 238-242
296-296
160-160
182-182
253-253
264-264
296-296
160-160
182-182
253-253
264-276
Table 4.13 Genotyping results on chromosome 8q24 obtained in patients VI.3 and VI.5 
from Family 2 after the second-pass screen, showing a region of shared homozygosity in 
the two affected individuals between markers D8S1128 and D8S373.
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region was investigated further and more closely spaced markers, approximately 1-3 
cM apart, were used to genotype the two affected children, their parents and two 
unaffected sibs (VI.2 and VI.4). Details of markers are shown in Table 2.6 and their 
positions in Table 4.14. In Table 4.14, different colours represent different haplotypes 
to show how they segregate in the family. Some markers were uninformative or semi- 
informative. In this case, the allele sizes were left in black for the children. DNA from 
unaffected sib VI.4 was obtained later in the study, therefore not all the markers were 
typed. Haplotype analysis across the region in the parents and the two unaffected sibs 
was consistent with linkage to this locus (Table 4.14). Both affected sibs continued to 
show homozygosity over the whole region. The parents shared a haplotype in common 
which was inherited by the two affected children. Both unaffected sibs were 
heterozygous for all the markers typed, except for the uninformative or semi- 
informative markers. The shared homozygous region of 13 cM/ 8 Mb was defined 
between markers AC 103725 and AC009682 at the centromeric end and between 
AC087711 and AC087711-2 at the telomeric end. A recombination event that occurred 
in patient VI.5 between AC087711 and AC087711-2 defines the telomeric boundary of 
the region (Table 4.14).
Haplotype analysis across the 8q24 region was performed in affected children IV. 1 and 
IV.3 from Family 1 using five polymorphic markers and was not consistent with 
linkage (Table 4.15).
4.2.3.3 Family 4
An independent genome-wide screen was performed in affected individual II.6 from 
consanguineous Family 4. The haplotype of this patient was not consistent with linkage 
to any of the putative candidate JATD loci identified or to the EVC/EVC2 locus. 
Furthermore, in this family there were six unaffected sibs who were thought to be 
useful to support the hypothesis for linkage to any homozygous region eventually 
identified in the affected child.
221
222
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode V.5
father
V.6
mother
Family 2 
VI.2 
unaff.
VI.4
unaff.
VI.3
proband
VI.5
proband
D8S1128 0.76 128.26 139.53 135.57 238-242
D8S1720 0.82 128.62 140.61 137.06 156-152 158-158 156-158 156-158 156-158
D8S1732 0.78 130.04 143.29 139.58 212-214 212-214
D8S1701 0.7 130.56 142.22 / 275-279 / 279-279 275-279 275-279
AC131568 / 130.65 / / 182-188 176-192 182-192 182-176 182-176
AC 103725 / 130.758 / / 219-225 223-233 219-233 219-223 219-223
AC009682 / 130.952 / / 239-237 239-235 239-235 239-739 239-239
D8S284 0.83 131.18 143.82 139.79 296-296 296-296
D8S1712 0.72 131.323 144.36 / 225-225 225-223 225-223 225-225 225-225
D8S557 0.76 132.761 145.97 142.18 202-212 202-216 202-216 212-216 202-202 202-202
D8S558 0.86 133.163 145.97 143.14 171-157 171-181 171-181 157-181 171-171 171 -J 71
D8S529 0.81 133.770 148.12 144.75 235-235 235-235
D8S256 0.83 134.115 148.12 145.26 : . < 2 - 232-226 232-226 232-232 232-732
D8S1462 0.75 135.06 / / 160-164 160-164 160-164 - 160-160 160-160
D8S1710 0.78 135.32 150.8 146.68 255-259 255-255 255-255 255-255 -255
D8S537 0.89 135.51 150.8 147.41 180-180 180-182 180-182 180-180 180-180
D8S1100 11.65 136.77 154.02 148.81 182-188 182-188 182-188 182-182 182-187
D8S1761 0.71 137.25 154.02 150.07 290- 290-290 290-290 290-290 290-290
D8S272 0.8 137.41 154.02 / 253-249 253-257 253-257 249-257 253-253 253-253
D8S1837 0.81 138.91 156.59 152.44 233-231 233-247 233-247 231-247 233-233 233-733
AFM316xb1 / 138.933 / / 193-191 193-191 193-191 191-191 193-193 193-193
AC087711 / 138.939 1 / 204-200 204-198 204-198 200-198 204-204 204-204
AC087711-2 / 138.955 / / 248-250 248-250 248-250 248-248 248-250
AC068467 / 139.150 1 / 209-211 209-211 209-211 209-209 209-211
AC105130-R1 / 139.350 / / 257-245 257-245 257-245 257-257 257-245
AC053480-R1 / 140.000 I / 285-287 285-287 285-287 285-285 285-287
D8S1743 0.83 140.33 162.94 / 220-226 220-246 220-246 226-246 220-220 220-246
D8S373 / 145.74 167.9 166.08 264-264 264-276
D8S1926 / 145.74 167.9 166.08 246-246 246-248
Table 4.14 Haplotype analysis results across the 8q24 region in Family 2 consistent with linkage to this locus. The two affected 
children share a homozygous region between markers AC 103725 and AC87711-2. Pink lines define the minimal critical interval.
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
Family 1 
IV .l IV.3
D8S284 0.83 131.18 143.82 139.79 278-296 270-296
D8S558 0.86 133.163 145.97 143.14 163-169 159-169
D8S1462 0.75 135.06 / / 156-160 156-156
D8S1100 0.65 136.77 154.02 148.81 185-188 188-188
D8S1837 0.81 138.91 156.59 152.44 243-243 241-243
Table 4.15 Genotyping results across the 8q24 region obtained in patients IV. 1 and IV.3 
from Family 1, showing no evidence of linkage to this locus.
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Following the linkage screen in affected individual II.6, four regions were identified in 
which he was homozygous for consecutive markers. Each region was investigated 
further by genotyping with more closely spaced markers and testing the parents and the 
six unaffected sibs to identify a region IBD in the affected child.
Three consecutive markers were found to be homozygous on chromosome Iq24-q26 
between markers D1S2851 and D1S1660 (see Appendix 1). The region of 
homozygosity was potentially about 22 cM/28 Mb in size. However, this region was 
excluded after seven further polymorphic markers were chosen and typed in the 
affected individual, and five of them also in the parents (1.1 and 1.2) and six unaffected 
sibs (Table 4.16).
A second homozygous region in the affected child was identified on chromosome 
3q28-q29 from marker D3S2398 to D3S1311 at the telomeric end (see Appendix 1). 
The region was potentially about 18 cM/8 Mb in size. However, this region was 
excluded after five more polymorphic markers were chosen and typed in the affected 
child, his parents and the six unaffected (Table 4.17). The patient II.6 showed 
homozygosity across the region, but so did two of his unaffected sibs (II.2 and II.7).
Three consecutive markers on chromosome 14q21 were also homozygous in patient
11.6 from D14S587 to D14S592 (Table 4.18). Further typing was carried out in the 
whole family and almost all the markers were uninformative. DNA from a second 
affected baby girl (II.8) was later obtained and she was found to be heterozygous for 
two markers. However results were inconclusive and more typing needs to be done to 
completely exclude this region. The interval between the two markers heterozygous in 
II.8 is in fact quite large (about 7 cM).
A fourth homozygous region was identified on chromosome 14q24-q32. Four 
consecutive markers were homozygous in proband II.6 between D14S74 and D14S81 
spanning about 19 cM/14 Mb (Table 4.19). Further polymorphic markers were typed in 
the whole family and a few of them also in the affected girl II.8. Both affected children
11.6 and II.8 showed homozygosity throughout the region, although most of the markers 
were uninformative in the father. Therefore, unaffected individuals II.2 and II.3 were 
also homozygous across the interval. Unaffected children II.2 and II.3 could have
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Fam ily 4
Markers 
Chrom. 1
Het Mb 
Build 33
cM
Marsh.
cM
deCode
1.1
father
1.2
mother
11.1
unaff.
11.2
unaff.
11.3
unaff.
11.4
unaff.
11.5
unaff.
11.7
unaff.
11.6
proband
D1S2851 0.83 167.01 188.32 172.9 270-274
D1S1589 0.77 170.84 192.05 176.25 205-205
D1S2786 0.72 173.87 193.76 178.47 124-116 116-126 124-126 116-116 124-126 124-126 / 124-116 124-116
D1S2751 0.71 176.53 194.89 180.36 286-284 286-292 286-292 284-286 286-292 286-292 286-292 286-286 286-286
D1S466 0.77 178.82 198.3 183.53 230-230
D1S191 0.73 182.34 200.96 186.76 247-245 243-245 247-245 245-243 247-245 247-245 247-245 247-243 247-243
D1S518 0.84 184.07 202.19 188.02 206-214 206-198 206-198 214-206 206-198 206-198 206-198 206-206 206-206
D1S238 0.86 184.67 202.73 188.55 190-192 / 190-194 192-190 190-194 190-194 / / /
D1S3468 0.81 188.01 205.40 / 187-187
D1S533 0.81 190.52 209.15 193.04 249-237 245-245 249-245
Table 4.16 Haplotype analysis results on chromosome lq in consanguineous Family 4 are not consistent with linkage to this locus. 
Heterozygosity, physical and genetic distances of each marker are indicated. Homozygous results in affected child II.6 obtained following 
the genome-wide screen are shown in bold black. The homozygous region was interrupted by heterozygous markers D1S2786 and 
D15S191. Moreover, D1S2751 and D1S518 were also homozygous in unaffected sib II.7. Markers which could not be typed for a 
particular individual are marked with a bar. Unaff. means individual is unaffected.
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Fam ily 4
Markers 
Chrom. 3
Het Mb 
Build 33
cM
Marsh.
cM
deCode
1.1
father
1.2
mother
11.1
unaff.
11.2
unaff.
11.3
unaff.
11.4
unaff.
11.5
unaff.
11.7
unaff.
11.6
proband
D3S1580 0.84 189.95 207.73 202 224-228
D3S3530 0.80 190.56 209.41 / 143-137 143-147 143-143 / 143-143
D3S2398 0.77 190.82 209.41 203.31 290-274 290-298 290-298 290-290 / 274-298 274-298 290-290 290-290
D3S2747 0.75 191.68 212.61 204.73 283-289 283-287 283-287 283-283 289-283 289-287 289-287 283-283 283-283
D3S3054 0.69 191.95 214.45 / 391-383 391-383 391-391 391-391 391-391
D3S1601 0.86 193.08 214.45 208.14 216-210 216-206 216-206 216-216 210-216 210-206 210-206 216-216 216-216
D3S2418 0.71 193.72 215.84 / 94-94 94-103 94-103 94-94 94-94 94-103 94-103 94-94 94-94
D3S2748 0.73 195.13 217.24 / 260-272 260-260 260-260 260-260 272-260 272-260 272-260 260-260 260-260
D3S1311 0.82 198.42 224.88 220.19 133-145 133-147 133-147 133-133 145-133 145-147 145-147 133-133 133-133
Table 4.17 Haplotype analysis results on chromosome 3q in consanguineous Family 4 are not consistent with linkage to this locus. 
Heterozygosity, physical and genetic distances of each marker are indicated. Unaffected children II.2 and II.7 are also homozygous across 
the same region as proband II.6. Almost all markers are informative. Markers which could not be typed for a particular individual are 
marked with a bar. Unaff. means individual is unaffected.
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Fam ily 4
Markers 
Chrom. 14
Het Mb 
Build 33
cM
Marsh.
cM
deCode
1.1
father
1.2
mother
11.1
unaff.
11.2
unaff.
11.3
unaff.
11.4
unaff.
11.5
unaff.
11.7
unaff.
11.6
proband
11.8
proband
D14S583 42.21 / / 308-312
D14S978 0.84 49.90 53.19 / 256-270 256-276 256-276 256-256 270-256 256-256 256-256 256-256 256-256
D14S587 0.83 52.36 55.82 / 246-262 246-250 246-250 246-246 262-246 246-246 246-246 246-246 246-246 262-250
D14S276 0.75 53.67 56.36 / 198-196 198-198 198-198 198-198 196-198 198-198 198-198 198-198 198-198
D14S285 0.82 54.96 59.43 56.52 251-251 251-253 251-253 251-251 251-251 251-251 251-251 251-251 251-251
D14S980 0.86 55.14 60.43 56.77 206-206 206-210 206-210 206-206 206-206 206-206 206-206 206-206 206-206
D14S607 / 55.61 / / 266-266 266-268 266-268 266-266 266-266 266-266 266-266 266-266 266-266
D14S274 0.72 55.65 63.25 58.15 264-264 264-270 264-270 264-264 264-264 264-264 264-264 264-264 264-264 264-270
D14S1038 0.79 57.61 66.81 60.06 212-212 212-212 212-212 212-212 212-212 212-212 212-212 212-212 212-212
D14S592 0.68 59.39 66.81 60.5 253-253 253-253 253-253 253-253 253-253 253-253 253-253 253-253 253-253
D14S63 0.77 62.64 69.18 63.50 174-186
Table 4.18 Haplotype analysis results on chromosome 14q in consanguineous Family 4. Heterozygosity, physical and genetic distances of 
each marker are indicated. Almost all markers are semi- or uninformative. Therefore, the unaffected sibs are also homozygous across the 
region as well as affected child II.6. However, proband II.8 is heterozygous for two markers in the region. Unaff. means individual is 
unaffected.
228
Family 4
Markers 
Chrom. 14
Het Mb 
Build 33
cM
Marsh.
cM
deCode
1.1
father
1.2
mother
U.l
unaff.
II.2
unaff.
11.3
unaff.
II.4
unaff.
II.5
unaff.
11.7
unaff.
11.6
proband
11.8
proband
D14S74 0.79 76.65 87.36 78.19 301-303
D14S739 0.83 80.26 91.62 81.73 192-176 192-168 192-168 176-192 176-192 192-168 192-168 192-168 192-195 192-193
D14S616 0.7 83.18 92.69 83.38 219-231 219-219 219-219 231-219 231-219 219-219 219-219 219-219 219-219
D14S1052 0.74 84.40 93.76 84.31 214-214 214-214 214-214 214-214 214-214 214-214 214-214 214-214 214-214
D14S67 0.86 86.38 95.89 / 264-264 264-260 264-260 264-264 264-264 264-260 264-260 264-260 264- f
D14S68 0.91 86.62 95.89 / 137-137 137-129 137-129 137-137 137-137 137-129 137-129 137-129 137-137 137-
D14S256 0.71 87.20 96.42 87.01 141-141 141-129 141-129 141-141 141-141 141-129 141-129 141-129 141-141.
D14S1005 0.71 87.37 96.42 87.25 259-259 259-257 259-257 259-259 259-259 259-257 259-257 259-257 259- :
D14S1044 0.67 88.06 99.88 90.62 199-199 199-203 199-203 199-199 199-199 199-203 199-203 199-203 199-199 199-
D14S995 0.82 89.57 105 / 241-241 241-241 241-241 241-241 241-241 241-241 241-241 241-241 241-241
D14S280 0.68 90.17 105 94.42 256-256 256-264 256-264 256-256 256-256 256-264 256-264 256-264 256-256
D14S617 0.78 90.19 105.53 94.47 146-146 146-142 146-142 146-146 146-146 146-142 146-142 146-142 146-1 4 146-
D14S977 0.82 91.16 107.13 / 224-220 220-218 224-218 220-220 220-220 224-218 224-218 220-218 224-220
D14S81 0.82 91.77 108.22 96.87 282-286
Table 4.19 Haplotype analysis results on chromosome 14q24-q32 in consanguineous Family 4. Heterozygosity, physical and genetic distances 
of each marker are indicated. Almost all markers are semi- or uninformative. Therefore, unaffected sibs II.2 and II.3 are also homozygous 
across the region as well as affected children II.6 and II.8. However, II.2 and II.3 might have inherited a different paternal haplotype. Unaff. 
means individual is unaffected.
inherited a different paternal haplotype compared to their affected sibs and more typing 
needs to be carried out in this family to corroborate these results. Nevertheless, 
following the genome-wide screen, this locus was thought to represent the most 
interesting region.
4.2.4 Summary
A genome-wide screen was carried out in five affected children from Families 1, 2 and 
4. A region which was IBD in all 5 patients was not identified, not even after a second- 
pass screen with more closely spaced markers was performed. Regions found to be 
homozygous in patients from each individual family were then studied further.
A region IBD of 17 cM/23 Mb was identified in Family 1 on chromosome 3q24-q26. 
The region extends as centromeric to D3S1555 and as telomeric to D3SI574 as these 
were two heterozygous markers in affected individual IV.3. Linkage to this locus was 
supported by the haplotype results in the whole family. Family 2 did not show evidence 
for linkage to this locus implying the existence of a second disease locus in Family 2 
and therefore locus heterogeneity.
In Family 2, an IBD region of 13 cM/8 Mb was subsequently identified on 
chromosome 8q24 between markers AC 103725 and AC087711-2, which defined the 
centromeric and telomeric boundaries respectively. Evidence for linkage to this locus 
was supported by the haplotype results in the whole family. Linkage to this locus could 
not be demonstrated in Family 1.
In order to confirm whether or not the two identified loci were linked to the JATD 
locus, a genotyping screen was performed in all the other JATD consanguineous 
families looking for homozygosity in the two regions as well as genotyping four non- 
consanguineous families to see if markers across the regions segregate in a way that 
was consistent with linkage. In the final stages of the project, a homozygous region of 
19 cM/14 Mb on chromosome 14q24-q32 was identified in Family 4 and genotyping 
across this locus was performed only in non-consanguineous Family 15.
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4.2.5 Linkage screens carried out by collaborators
Two independent genome-wide screens were carried out by our collaborators Dr Colin 
Johnson in Birmingham and Dr Valerie Cormier-Daire in Paris, using the 
homozygosity mapping approach in affected children from their own collection of 
consanguineous families. Results were shared between the three groups and it became 
clear that JATD was genetically heterogeneous.
A locus on chromosome 12q23-q24 between markers D12S1342 and D12S1339 was 
mapped by the Paris group supported by data from two consanguineous families.
The Birmingham group identified a locus on chromosome 15ql3 supported by data 
from five consanguineous families with a maximum two-point lod score of Z = 3.77 at 
0 = 0 obtained at D15S1031. The minimal critical interval was 1.2 cM (-1.5 Mb) in 
size, and contained 16 known or predicted genes. Interestingly, FORMIN-1 and 
GREMLIN lie in this interval and initially appeared to be good candidates for JATD but 
none of the linked families were found to harbour mutations in the coding sequence of 
either gene (Morgan et al., 2003). These results were published and a copy of the paper 
is included at the back of this thesis.
As part of the collaboration, it was decided that each group should type their own
polymorphic markers were shared between the three groups. In case one or more 
families were found to be linked to a locus discovered by another group, it was agreed 
that DNA samples should then be shared and each group continue to work on their own 
region.
4.3 Genotyping analysis of JATD families
Once the two candidate regions on chromosome 3q24-q26 and 8q24 were identified in 
Families 1 and 2, respectively, a genotyping screen was performed in 10 other JATD 
consanguineous families looking for homozygosity in the affected individuals across 
the two loci, as well as in four non-consanguineous families to see if markers across the
CvN?
collection of families across purpose, closely spaced
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regions segregate in a way that was consistent with linkage. The aim of the screen was 
to investigate whether these two regions were linked to the JATD disease locus by 
looking for evidence of linkage in other families, as well as to narrow down the 
candidate regions. In this study, the same families were also genotyped across the 
12q23-q24 and the 15ql3 regions identified by our collaborators in Birmingham and 
Paris. DNA samples from Families 8, 9 and 16 were provided by Dr Colin Johnson and 
DNA samples from Family 10 were sent by Dr Valerie Cormier-Daire for further 
genotyping. Genotyping results shown in this chapter in the above four families were 
obtained by myself. Extra markers were ascertained in an attempt to further narrow 
down the candidate regions prior to searching for candidate genes.
4.3.1 Chromosome 3q24-q26 locus
Consanguineous Families 3-12 and non-consanguineous Families 13-16 were 
genotyped across the 3q24-q26 locus with a selection of evenly spaced markers across 
the region homozygous in individual IV.3 from Family 1 (see Table 4.7). Not all the 
markers used for typing Family 1 were used in the other families. Details of all the 
markers are shown in Table 2.5. Pedigrees of the families are shown in Chapter 2.
4.3.1.1 Genotyping in JATD families consistent with linkage to 3q24-q26
Consanguineous Families 5, 6 and 8 supported the hypothesis for linkage to 3q24-q26 
with affected children demonstrating regions of homozygosity. Non-consanguineous 
Family 14 was also thought to show evidence of linkage to this locus as the two 
affected children shared the same pair of haplotypes across the region, which was 
different in the unaffected sib.
In Family 5, patient II. 1 demonstrated a region of homozygosity between markers 
D3S1306 and D3S1574, which, assuming linkage, did not help to narrow down the 
interval defined in patient IV.3 from Family 1 (Table 4.20). DNA from the mother was
231
Fam ily 5
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
II.l
proband
D3S1306 0.72 149.08 164.25 154.18 163-163 163-163
D3S1308 0.69 150.31 165.85 157.07 193-189 193-193
D3S1279 0.85 152.3 169.6 160.19 264-268 264-264
D3S4531 0.69 152.53 169.6 160.46 261-265 261-261
D3S1746 0.85 153.01 169.6 / 275-259 275-275
D3S1280 0.75 153.38 170.14 161.6 212-210 212-212
D3S3531 0.73 155.49 170.14 162.79 254-254 254-254
D3S1607 0.80 158.24 172.27 164.61 235-235 /
D3S3575 0.79 160.63 173.34 165.61 196-190 196-196
D3S3668 0.83 165.72 175.47 167.47 228-224 228-228
D3S1614 0.83 169.61 177.75 169.98 116-106 116-116
D3S1282 0.78 170.29 180.8 170.46 168-172 168-168
D3S3523 0.68 170.93 181.87 171.02 188-186 188-188
D3S1574 0.79 173.08 181.87 174.03 137-137 137-137
Table 4.20 Haplotype analysis results of chromosome 3q24-q26 region in 
consanguineous Family 5. Patient II. 1 displays homozygosity across the region 
homozygous in patient IV.3 from Family 1 (defined by blue lines). DNA from 
the mother was not available for genotyping.
not available for typing. DNA stock from affected child II. 1 was of limited quantity and 
of poor quality, therefore very few markers were used for genotyping. Attempts to 
amplify the patient DNA using GenomiPhi™ DNA Amplification Kit (Amersham 
Biosciences) failed. This kit was chosen because it allows DNA amplification of small 
quantities of starting material as detailed in section 2.3.1.4. Although this technique 
allows amplification of good quality DNA, poor quality DNA, as in the case of this 
patient, does not amplify well.
In Family 6, affected individual II.2 demonstrated homozygosity across the candidate 
locus, from D3S1744 to D3S3725 (Table 4.21). Linkage was supported by the 
haplotype in the family. Unaffected individual II. 1 was heterozygous for most of the 
markers typed as he had inherited different haplotypes from both parents compared to 
his affected sister II.2. Assuming linkage to this locus, the homozygous region in the 
patient did not help to narrow down the region of homozygosity identified in patient 
IV.3 from Family 1.
In Family 8, a region of homozygosity was demonstrated between markers D3S1593 
and D3S3523 in patient II. 1 (Table 4.22). The region of about 19 cM/25 Mb did not 
extend as telomeric to D3S1574 as in affected individual IV.3 from Family 1 and
assuming linkage, the candidate region was slightly narrowed down at the telomeric
end (Table 4.22). Markers D3S3705, D3S1237, D3S3710 and D3S3692 were 
ascertained and typed only in this family to demonstrate a convincing block of 
homozygosity in patient II.l.
Non-consanguineous Family 14 was genotyped, as there were two affected children 
(II.3 and II.4) and one unaffected sib (II.l). DNA sample from the latter (II.l) was
obtained later in the course of the project. A shared pair of haplotypes was
demonstrated in the two affected individuals across the entire region and was consistent 
with linkage to the 3q24-q26 locus (Table 4.23). Genotyping was then performed in the 
unaffected sib II.l and she was found to share the same pair of haplotypes as her 
affected sibs up to marker D3S3580, then a maternal cross-over occurred and she 
inherited the different maternal haplotype compared to her affected sibs. Therefore, 
assuming linkage in this family, the candidate region was narrowed down at the 
centromeric end between markers D3S3575 and D3S3580 due to the recombination
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F a m ily  6
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
unaff.
H.2
proband
D3S1744 0.77 148.37 161.04 153.36 150-142 150-150 142-150 150-150
D3S1306 0.72 149.08 164.25 154.18 157-163 157-163 163-163 157-157
D3S1308 0.69 150.31 165.85 157.07 193-193 193-191 193-191 193-193
D3S1279 0.85 152.3 169.6 160.19 269-271 269-267 271-267 269-269
D3S1746 0.85 153.01 169.6 / 267-267 267-267 267-267 267-267
D3S1607 0.8 158.24 172.27 164.61 246-236 246-246 236-246 246-246
D3S3575 0.79 160.63 173.34 165.61 196-192 196-192 192-192 196-196
D3S3579 0.79 161.86 173.87 166.45 180-184 180-186 184-186 180-180
D3S1268 0.86 165.29 174.94 / 194-206 194-206 206-206 194-194
D3S3668 0.83 165.72 175.47 167.47 222-228 222-224 228-224 222-222
D3S1763 0.8 168.64 176.54 168.52 276-276 276-272 276-272 276-276
D3S1614 0.83 169.61 177.75 169.98 110-110 110-110 110-110 110-110
D3S1282 0.78 170.29 180.8 170.46 166-176 166-166 176-166 166-166
D3S3523 0.68 170.93 181.87 171.02 191-189 191-187 189-187 191-191
D3S1574 0.79 173.08 181.87 174.03 126-136 126-130 136-130 126-126
D3S3725 0.84 173.21 181.87 174.44 197-197 197-203 197-203 197-197
Table 4.21 Haplotype analysis results of chromosome 3q24-q26 region in consanguineous 
Family 6. Patient II.2 displays homozygosity across the region homozygous in patient IV.3 
from Family 1 (defined by blue lines). Unaffected sib II.l has inherited different haplotypes 
from both parents compared to his affected sister II.2. Unaff. means individual is 
unaffected.
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Markers Het Mb cM cM 1.1 1.2 II.l m
Chromosome 3 Build 33 Marshfield deCode father mother proband
D3S1764
D3S3694
0.79
0.84
140.46
143.47
152.62
153.74
145.53
148.82
232-248
306-300
240-252
302-300
232-240
306-302
D3S1593 0.78 146.6 161.04 152.31 212-226 226-226 212-226
D3S1744 0.77 148.37 161.04 153.36 161-153 161-137 161-161
D3S1306 1 0.72 149.08 164.25 154.18 -
164-164 164-164 164-164
D3S1308 0.69 150.31 165.85 157.07 193-191 193-193 193-193
D3S3705 0 .67 150.32 165 .32 157 .53 227-225 227-227 227-227
D3S1299 0.62 151.46 166.93 158.56 200-198 200-188 200-200
D3S1279 0.85 152.3 169.6 160.19 265-263 265-267 265-265
D3S4531 0.69 152.53 169.6 160.46 260-256 260-260 260-260
D3S1746 0.85 153.01 169.6 / 251-247 251-251 251-251
D3S1280 0.75 153.38 170.14 161.6 216-212 216-216 216-216
D3S1237 0.79 153.44 172.27 161.34 317-317 317-315 317-317
D3S3710 0 .74 155.38 170.67 / 246-252 246-248 246-246
D3S3531 0.73 155.49 170.14 162.79 218-218 218-218 218-218
D3S1607 0.8 158.24 172.27 164.61 248-246 248-236 248-248
D3S3692 0.62 159.89 172.27 165.07 241-253 241-241 241-241
D3S3575 0.79 160.63 173.34 165.61 193-193 193-189 193-193
D3S3579 0.79 161.86 173.87 166.45 186-182 186-184 186-186
D3S1268 0.86 165.29 174.94 / 204-204 204-196 204-204
D3S3668 0.83 165.72 175.47 167.47 228-226 228-228 228-228
D3S1763 0.8 168.64 176.54 168.52 276-276 276-276 276-276
D3S1614 0.83 169.61 177.75 169.98 110-106 110-108 110-110
D3S1282 0.78 170.29 180.8 170.46 170-170 170-166 170-170mm
D3S3523 0.68 170.93 181.87 171.02 185-189 189-187 185-189
D3S3723 0.63 171.65 180.08 171.45 165-161 163-161 165-163
R3 / 171.8 / /
D3S1574 / 172 / /
Table 4.22 Haplotype analysis results of chromosome 3q24-q26 region in consanguineous 
Family 8. In patient II.l there is a region of homozygosity between markers D3S1593 and 
D3S3523. Note how some markers are semi-informative as they are homozygous in at least 
one of the two parents as well as in the affected child. Blue lines define the homozygous 
region in patient IV.3 from Family 1. The telomeric boundary is now between D3S1282 
and D3S3523 (red line) narrowing down the candidate region by about 3 cM/3 Mb.
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Fam ily 14
Markers 1.1 1.2 11.1 11.3 11.4
Chromosome 3 father mother unaff. proband proband
‘  ~ ........... ' ' 1
D3S1306 158-164 164-164 158-164 158-164 158-164
D3S1308 193-195 193-191 193-193 193-193 193-193 informative
D3S1279 265-269 267-267 265-267 265-267
D3S4531 263-259 259-251 263-259 263-259 263-259 informative
D3S1280 212-212 214-214 212-214
D3S1607 248-236 244-232 248-244 248-244 248-244 informative
D3S3575 188-192 190-196 188-190 188-190 188-190 informative
D3S3580 242-240 242-244 242-244 242-242 242-242 cross-over in
AC026118 187-181 181-187 187-187 187-181 187-181
AC024221 237-239 237-237 237-237 237-237 237-237
AC069224 221-219 223-223 221-223 221-223 221-223
D3S3579 184-186 186-184 184-184 184-186 184-186
D3S1268 206-208 196-208 206-208 206-196 206-196 informative
D3S3668 220-228 224-224 220-224 220-224 220-224
D3S1763 268-268 264-260 268-260 268-264 268-264
D3S1614 106-104 112-116 106-116 106-112 106-112 , informative
D3S1282 175-167 167-167 175-167 175-167 175-167
D3S3523 186-186 184-190 186-190 186-184 186-184
D3S3723 163-163 161-161 163-161 163-161
R1 271-265 267-271 271-271 271-267 271-267 informative
R2 203-211 201-201 203-201 203-201
R3 288-258 288-288 288-288 288-288
D3S1574 127-137 127-129 127-127 127-127 137-127 cross-over in
D3S3053 234-226 234-226 234-234 234-234 226-234 and II.4
D3S3725 199-203 209-209 199-209 199-209 203-209
D3S1565 176-180 182-178 176-182 176-182 180-182 informative
Table 4.23 Haplotype analysis results of chromosome 3q24-q26 region in non-consanguineous 
Family 14. Patients II.3 and II.4 display the same haplotypes across the region from D3S1306 to 
R3 (highlighted in blue box) where a paternal cross-over occurs in patient II.4. Unaffected sib II. 1 
shares the same haplotypes as her affected sibs up to D3S3580 (upper red line). A maternal cross­
over in II.l allows the region to be narrowed down at the centromeric end between D3S3575 and 
D3S3580. A second maternal cross-over in II.l occurs at the telomeric end between R1 and 
D3S1574. Blue lines define the homozygous interval in Family 1. The lower red line indicates the 
telomeric end of the region homozygous in patient II.l from Family 8. Fully informative markers 
are indicated. The yellow box shows the region in which unaffected individual II. 1 has a different 
haplotype from her sibs.
236
event which occurred in individual II.l (Table 4.23). Different colours for allele sizes 
represent different haplotypes to show how they segregate in the family. Some markers 
were uninformative or semi-informative. In this case, the allele sizes were left in black 
for the children. Markers D3S3580 as well as repeats identified in BAC clones 
AC026118, AC024221 and AC069224 were ascertained and typed only in this family 
in the attempt to better refine the cross-over in individual II.l.
A summary of the genotyping for affected individuals in families 1, 5, 6, 8 and for the 
unaffected sib in Family 14 is given in Table 4.24. The common region of 
homozygosity of 10.3 Mb and 5.4 cM, according to the deCode genetic map, was 
defined between markers D3S3575 and D3S3523. The recombination event which 
occurred in unaffected individual II.l in non-consanguineous Family 14 defines the 
centromeric boundary. The telomeric boundary is defined by the first heterozygous 
markers in patient II.l from Family 8.
It was noted that for three consecutive markers in the interval certain alleles appeared 
more often than others amongst the affected individuals of the same ethnic origin 
(Table 4.24). Allele 186 for marker D3S3579 appeared in Pakistani patients IV. 1 and 
IV.3 (Family 1), II.l (Family 8), II.3 and II.4 (Family 14), but not in the unaffected sib
11.1 of Family 14 (Table 5.19) or in affected Turkish child II.2 from Family 6. Allele 
204 for marker D3S1268 was present in Pakistani patients IV. 1, IV.3 (Family 1) and
11.1 (Family 8). Allele 228 for marker D3S3668 was detected in Pakistani affected 
individuals IV. 1 and IV.3 (Family 1), II.l (Family 5) and II.l (Family 8). This 
suggested the presence of a shared ancestral chromosomal segment in the Pakistani 
population inherited from a distant common ancestor and was consistent with the 
possibility of linkage to this locus.
Consanguineous Family 7 could be consistent with linkage to this locus, but no DNA 
from the affected, deceased child (II.3) was available. Haplotype analysis was 
performed in the parents (1.1 and 1.2) and unaffected sibs (II.l and II.4) and was 
consistent with linkage (Table 4.25). The two unaffected sibs were heterozygous across 
the region and the parents shared a haplotype in common, so the affected child could, in 
principle, be homozygous. DNA extraction from paraffin embedded tissues from the 
proband II.3 was performed using the QIAamp tissue kit (QIAGEN Ltd.), but with no
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Markers 
Chromosome 3
Mb 
Build 33
cM
M arshfield
cM
deCode
Fam ily 1
IV. 1 IV J
Pakistani
Fam ily 5 
II.l
Pakistani
Fam ily 6 
11.2
Turkish
Fam ily 8 
II.l
Pakistani
Fam ily 14 
II.l
Pakistani
D3S1764 140.46 152.62 145.53 241-241 241-245
D3S1309 142 153.74 146.63 167-167 171-165
D3S3694 143.47 153.74 148.82 302-302 294-300
D3S1569 144.65 158.38 150.58 152-152 152-152
D3S1593 146.6 161.04 152.31 226-226 212-226
D3S1744 148.37 161.04 153.36 150-150 150-150 150-150 161-161
D3S1306 149.08 164.25 154.18 158-158 164-158 163-163 157-157 164-164 158-164
D3S1555 150.08 165.32 156.59 211-211 203-211
D3S1308 150.31 165.85 157.07 190-190 190-190 193-193 193-193 193-193 193-193
D3S3705 150.32 165.32 157.03 227-227
D3S1299 151.46 166.93 158.56 196-196 196-196 200-200
D3S1279 152.3 169.6 160.19 266-266 266-266 264-264 269-269 265-265
D3S4531 152.53 169.6 160.46 263-263 263-263 261-261 260-260 263-259
D3SI746 153.01 169.6 / 271-271 271-271 275-275 267-267 251-251
D3S1280 153.38 170.14 161.6 210-210 210-210 212-212 216-216
D3S1237 153.44 172.27 161.34 317-317
D3S3710 155.38 170.67 / 246-246
D3S3531 155.49 170.14 162.79 218-218 218-218 254-254 218-218
D3S1607 158.24 172.27 164.61 235-235 235-235 246-246 248-248 248-244
D3S3692 159.87 172.27 165.07 241-241
D3S3575 160.^3 173.34 165.61 196-196 196-196 193-193 188-190
D3S3580 160.900 173.34 166.11 242-244
AC026118 160.994 / / 187-187
AC024221 161.424 / / 237-237
AC069224 161.800 / / 221-223
D3S3579 161.86 173.87 166.45 186-186 186-186 180-180 186-186 184-184
D3SI268 165.29 174.94 / 204-204 204-204 194-194 204-204 206-208
D3S3668 165.72 175.47 167.47 228-228 228-228 228-228 222-222 228-228 220-224
D3S1763 168.64 176.54 168.52 277-277 277-277 276-276 276-276 268-260
D3S1614 169.61 177.75 169.98 110-110 110-110 116-116 110-110 110-110 106-116
D3S1282 170.29 180.8 170.46 168-168 168-168 168-168 __ 166-166 170-170 175-167
D3S3523 170.93 181.87 171.02 188-188 188-188 188 191-191 185-189 186-190
D3S3723 171.65 180.08 171.45 161-161 161-161 163-165
R1 171.8 / / 271-271 271-271 271-271
R2 172 / / 201-201 201-201
R3 172.6 / / 160-160 160-160
D3S1574 173.08 181.87 174.03 144-144 126-144 137-137 126-126 127-127
D3S3053 173.15 181.87 / 232-232 236-232 234-234
D3S3725 173.21 181.87 174.44 200-200 198-200 197-197 199-209
D3S1565 174.88 186.04 177.94 182-182 182-182 176-182
D3S2427 177.18 188.29 / 230-230 236-230
D3S3730 179.94 191.79 184.15 274-274 274-274
D3S1262 187.62 201.14 194.33 114-114 114-114
D3S2436 188.23 203.28 / 171-171 171-171
D3S1580 189.94 207.73 202 224-218 218-218
D3S2398 190.82 209.41 203.31 274-294 294-294
D3S2418 193.72 215.84 / 106-109 106-109
Table 4.24 Summary diagram of the genotyping in affected individuals in Families 1, 
5, 6 and 8 as well as unaffected individual in Family 14. These data are consistent 
with linkage to 3q24-q26. Homozygous typings are highlighted in bright green. The 
region in which unaffected individual II.l (Family 14) does not share the same 
haplotypes as her two affected sibs is highlighted in yellow. Untyped markers are 
highlighted in white. The markers highlighted in pale blue between the two red lines 
denote the region of shared homozygosity flanked by markers D3S3575 and 
D3S3523. Note how the genetic distances of some markers (highlighted in orange) 
sometimes differ from their positions in Mb making the integration between the two 
maps often difficult. The ethnic origins of the families are also shown.
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Fam ily 7
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
unaff.
II.4
unaff.
D3S1306 0.72 149.08 164.25 154.18 157-157 157-161 157-157 157-161
D3S1308 0.69 150.31 165.85 157.07 193-193 193-191 193-193 193-191
D3S1299 0.62 151.46 166.93 158.56 202-196 202-200 196-202 202-200
D3S1279 0.85 152.3 169.6 160.19 267-267 267-275 267-267 267-275
D3S1746 0.85 153.01 169.6 / 251-263 251-255 263-251 251-255
D3S1280 0.75 153.38 170.14 161.6 215-213 215-217 213-215 215-217
D3S3531 0.73 155.49 170.14 162.79 218-220 218-216 220-216 218-216
D3S1607 0.8 158.24 172.27 164.61 234-242 234-234 242-234 234-234
D3S3575 0.79 160.63 173.34 165.61 192-190 192-190 190-190 192-190
D3S3579 0.79 161.86 173.87 166.45 188-180 188-182 180-182 188-182
D3S3668 0.83 165.72 175.47 167.47 224-224 224-224 224-224 224-224
D3S1282 0.78 170.29 180.8 170.46 168-166 168-166 166-166 168-166
D3S3523 0.68 170.93 181.87 171.02 189-193 189-197 193-197 189-197
R1 / 171.8 / / 268-262 268-268 262-268 268-268
D3S1574 0.79 173.08 181.87 174.03 121-137 121-127 137-127 121-127
Table 4.25 Haplotype analysis results of chromosome 3q24-q26 region in consanguineous 
Family 7. Parents LI and 1.2 have a haplotype in common (in red) which is not 
homozygously inherited by the two unaffected children II.l and II.4. No DNA was 
available from affected individual II.3, therefore linkage could not be supported in this 
family. Red lines define the minimal critical interval as defined in Table 4.24. Unaff. means 
individual is unaffected.
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success. These tissue samples were quite old and the DNA did not amplify, even after 
amplification with the GenomiPhi™ DNA Amplification Kit. An attempt to amplify the 
child’s DNA was then made using E.coli exonuclease III, an enzyme for amplification 
of damaged templates like tissue extracted DNA from old paraffin sections as explained 
in section 2.3.2.6, but again this was not successful. Therefore, linkage to this locus 
could not be corroborated in this family.
4.3.1.2 Genotyping not consistent with linkage to chromosome 3q24-q26
Consanguineous Family 2 was previously found not to be consistent with linkage to the 
region on chromosome 3q24-q26 (see Table 4.9). Families 3, 11, 12, 13 and 15 showed 
no evidence of linkage to this locus. Families 4 and 16 were difficult to categorise. 
Linkage to this locus was excluded in Families 9 and 10 by Dr Colin Johnson and Dr 
Valerie Cormier-Daire, respectively.
In consanguineous Family 3, linkage was excluded because the affected child II.l was 
heterozygous across the region (Table 4.27). Affected sibs II.l and II.2 in 
consanguineous Family 11 were both heterozygous across the 3q24-q26 region, 
therefore linkage could not be supported (Table 4.28). Linkage was also excluded in 
distantly consanguineous Family 12 as fetus II.2 was heterozygous across the region 
(Table 4.29). In Family 13, parents were thought to be distantly consanguineous, 
therefore genotyping was performed in the parents II.l and II.2 and affected child III. 1. 
Linkage was excluded as no region of homozygosity was detected in affected 
individual III.l (Table 4.30).
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242
»Fam ily 3
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
proband
D3S1306 0.72 149.08 164.25 154.18 163-163 163-163 163-163
D3S1308 0.69 150.31 165.85 157.07 195-191 191-191 195-191
D3S1279 0.85 152.3 169.6 160.19 266-270 268-274 266-268
D3S1607 0.80 158.24 172.27 164.61 244-246 240-242 244-240
D3S3668 0.83 165.72 175.47 167.47 226-228 224-224 226-224
D3S1282 0.78 170.29 180.8 170.46 172-168 170-166 172-170
D3S1574 0.79 173.08 181.87 174.03 129-127 131-129 129-131
Table 4.27 Haplotype analysis results of chromosome 3q24-q26 region in 
consanguineous Family 3, showing no evidence for linkage as affected individual II.l is 
heterozygous for all the markers typed (except for D3S1306, which is uninformative). 
Red lines define the minimal critical interval as defined in Table 4.24.
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Fam ily  11
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1 1.2 II.l 11.2 
father mother proband proband
D3S1306
D3S1308
D3S1746
D3S1607
0.72
0.69
0.85
0.80
149.08
150.31
153.01
158.24
164.25
165.85
169.6
172.27
154.18
157.07
/
164.61
157-163
191-195
267-267
236-244
157-157
191-195
251-283
244-234
157-157
191-195
267-283
236-234
163-157
191-191
267-251
236-244
D3S3668
D3S1282
0.83
0.78
165.72
170.29
175.47
180.8
167.47
170.46
222-226
170-168
236-218
166-166
222-218
170-166
222-236
170-166
R1 / 171.8 / / 269-265 271-269 269-269 269-271
Table 4.28 Haplotype analysis results of chromosome 3q24-q26 region in consanguineous 
Family 11, showing no evidence for linkage. Affected individuals II.l and II.2 are in fact 
both heterozygous across the region. Red lines define the minimal critical interval as 
defined in Table 4.24.
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F am ily  12
Markers 1.1 1.2 II.l II.3 II.2
Chromosome 3 father mother unaff. unaff. proband
D3S1308 193-193 195-191 193-191 193-195 193-191
D3S1746 274-259 251-263 274-263 274-251 274-263
D3S1607 243-245 239-243 239-243 239-245
D3S3668 224-228 220-220 224-220 224-220 228-220
D3S1282 166-168 168-174 166-168 166-168 168-174
R1 265-275 267-269 265-267 265-267 275-269
Table 4.29 Haplotype analysis results of chromosome 3q24-q26 region in 
consanguineous Family 12, showing no evidence for linkage. Affected 
individual II.2 is in fact heterozygous across the region. Red lines define the 
minimal critical interval as defined in table 4.24. Unaff. means individual is 
unaffected.
Fam ily 13
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
II.l
father
II.2
mother
III.l
proband
D3S1308 0.69 150.31 165.85 157.07 195-193 195-191 195-195
D3S1299 0.62 151.46 166.93 158.56 196-194 200-200 196-200
D3S1279 0.85 152.3 169.6 160.19 279-267 271-271 279-271
D3S1280 0.75 153.38 170.14 161.6 213-225 211-217 213-211
D3S3531 0.73 155.49 170.14 162.79 214-216 216-214 214-216
D3S1607 0.80 158.24 172.27 164.61 239-245 243-235 239-243
D3S3575 0.79 160.63 173.34 165.61 194-190 192-194 194-192
D3S3579 0.79 161.86 173.87 166.45 189-189 189-189 189-189
D3S1268 0.86 165.29 174.94 / 200-198 196-206 200-196
D3S3668 0.83 165.72 175.47 167.47 222-224 234-228 222-234
D3S1763 0.8 168.64 176.54 168.52 280-272 264-276 280-264
D3S1614 0.83 169.61 177.75 169.98 108-116 112-116 108-112
D3S1282 0.78 170.29 180.8 170.46 172-164 166-172 172-166
R1 / 171.8 / / 262-262 266-262 262-266
Table 4.30 Haplotype analysis results of chromosome 3q24-q26 region in 
consanguineous Family 13, showing no evidence for linkage. Affected individual III. 1 is 
heterozygous across the region, except for markers D3S3579 which is uninformative. 
Red lines define the minimal critical interval as defined in Table 4.24.
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Linkage to this locus was also excluded in non-consanguineous Family 15. Two of the 
three affected fetuses (II.3 and II.4) had the same haplotype, while fetus II.2 had a 
different haplotype, which was the same as unaffected sib II.l (Table 4.31).
In consanguineous Family 4, individual II.6 showed a no evidence for linkage (Table 
4.32). Marker D3S1614 was heterozygous in the proband II.6. In non-consanguineous 
Family 16, affected child II.3 shared the same pair of haplotypes across the region as 
her unaffected sister II.2, but results were inconclusive as almost all the markers typed 
(except D3S1282) were semi-informative with at least one of the two parents being 
homozygous or the parents having the same haplotype (Table 4.33).
4.3.2 Chromosome 8q24 locus
Consanguineous Families 3-12 and non-consanguineous Families 13-16 were 
genotyped across the 8q24 region with a selection of evenly spaced markers across the 
region homozygous in individual VI.5 from Family 2 (see Table 4.14). Not all the 
markers used for typing Family 2 were used in the other families. Details of all the 
markers are shown in Table 2.6.
4.3.2.1 Genotyping in JATD families consistent with linkage to 8q24
Consanguineous Families 9 and 10 supported the hypothesis for linkage to 8q24 as 
affected children demonstrated regions of homozygosity.
In Family 9, affected individual II.l demonstrated homozygosity between marker 
D8S274 and telomeric marker D8S1926 spanning about 16 cM/8 Mb (Table 4.34). 
DNA from the mother 1.2 was of limited quantity and of poor quality, so genotyping 
was possible only for two markers in the region. Attempts to amplify the mother’s 
DNA with GenomiPhi™ DNA Amplification Kit failed.
In Family 10, a region of homozygosity of about 20 cM/11 Mb was demonstrated in 
affected child 11.10 between markers D8S256 and D8S2334 (Table 4.35). Markers
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Fam ily 15
Markers 
Chromosome 3
1.1 1.2 II.l II.2 II.3 11.4 
father mother unaff. proband proband proband
D3S1308
D3S1746
191-193
259-267
193-193
251-255
193-191
251-259
193-191
251-259
193-193
255-267
193-193
255-267
226-230
174-166
269-271
D3S3668
D3S1282
226-226
168-174
222-230
170-166
226-222
168-170
226-222
168-170
226-230
174-166
R1 275-269 267-271 275-267 275-267 269-271
Table 4.31 Haplotype analysis results of chromosome 3q24-q26 region in non- 
consanguineous Family 15, showing no evidence for linkage. Affected fetus II.2 has a 
different haplotype (highlighted in pink) compared to the other two affected fetuses II.3 
and II.4 (highlighted in purple). Note that fetus II.2 has the same haplotype as unaffected 
sib II.l. Red lines define the minimal critical interval as defined in Table 4.24. Unaff. 
means individual is unaffected.
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Fam ily 4
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.6
proband
D3S1764 0.79 140.46 152.62 145.53 233-233
D3S1744 0.77 148.37 161.04 153.36 242-246
D3S1306 0.72 149.08 164.25 154.18 155-159 161-161 155-161
D3S1308 0.69 150.31 165.85 157.07 193-191 193-193 193-193
D3S1279 0.85 152.3 169.6 160.19 268-268 270-266 268-270
D3S4531 0.69 152.53 169.6 160.46 257-261
D3S1607 0.8 158.24 172.27 164.61 248-234 244-234 248-244
D3S3575 0.79 160.63 173.34 165.61 180-190
D3S3668 0.83 165.72 175.47 167.47 220-224 220-220 220-220
D3S1763 0.80 168.64 176.54 168.52 227-227
D3S1614 0.83 169.61 177.75 169.98 116-112 108-110 116-108
D3S1282 0.78 170.29 180.8 170.46 166-166 166-166 166-166
D3S3523 0.68 170.93 181.87 171.02 188-190
R1 / 171.8 / / 266-270
D3S1574 / 171.8 / / 139-119 133-127 139-133
D3S2427 0.85 177.18 188.29 / 230-236
D3S2398 0.77 190.82 209.41 203.31 290-290
Table 4.32 Haplotype analysis results of chromosome 3q24-q26 region in 
consanguineous Family 4, showing no evidence for linkage. Note that markers 
D3S3668 and D3S1282 are uninformative. Red lines define the minimal critical interval 
as defined in Table 4.24.
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Fam ily 16
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
LI 1.2 II.2 11.3 
father mother unaff. proband
D3S1306
D3S1308
D3S1746
D3S1607
0.72
0.69
0.85
0.80
149.08
150.31
153.01
158.24
164.25
165.85
169.6
172.27
154.18
157.07
/
164.61
163-163
192-192
240-246
157-167
190-190
262-270
236-236
163-167
192-190
284-270
240-236
163-167
192-190
284-270
240-236
D3S3668
D3S1282
0.83
0.78
165.72
170.29
175.47
180.8
167.47
170.46
225-235
168-166
221-221
172-178
225-221
168-172
225-221
168-178
D3S1574 / 171.8 / / 129-135 129-135
Table 4.33 Haplotype analysis results of chromosome 3q24-q26 region in non- 
consanguineous Family 16, showing no evidence for linkage as affected individual II.3 
has the same haplotype as her unaffected sib II.2. Red lines define the minimal critical 
interval as defined in Table 4.24. Unaff. means individual is unaffected.
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Fam ily 9
Markers 
Chromosome 8
D8S537
D8S1100
D8S1783
D8S274
D8S272
D8S1837
AFM316xbl
AC087711
AC087711-2
AC068467
AC105130-R1
AC053480-R1
D8S1743
D8S373
D8S2334
D8S1926
Het Mb 
Build 33
cM
Marshfield
cM
deCode
0.89 135.51 150.8 147.41
0.65 136.77 154.02 148.81
0.78 136.69 154.02 148.81
0.77 137.3 154.02 150.07
0.8 137.41 154.02 /
0.81 138.91 156.59 152.44
/ 138.933 / /
/ 138.939 / /
/ 138.955 / /
/ 139.150 / /
/ 139.350 / /
/ 140.000 / /
0.83 140.33 162.94 /
/ 145.74 167.9 166.08
/ 145.73 167.9 /
/ 145.74 167.9 166.08
1.1
father
1.2
mother
II.l
proband
163-177 163-179
195-183 195-192
172-172 172-176
112-114 112-110
247-261 247-247 247-247
243-231 243-243
190-190 190-190
187-203 187-207 187-187
250-230 250-250
211-207 211-211
244-244 244-244
286-286 286-286
241-247 241-241
268-260 268-268
156-160 156-156
252-254 252-250
Table 4.34 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 9. Patient II. 1 displays homozygosity across the locus. Individual 1.2 was typed 
only for two markers.
251
F am ily  10
Markers 
Chromosome 8
Het Mb 
Build 33
cM
M arshfield
cM
deCode
D8S557 0.76 132.761 145.97 142.18
D8S256 0.83 134.115 148.12 145.26
D8S1708 0.68 134.24 148.12 145.91
D8S1746 0.66 134.91 149.46 146.6
D821462 0.75 135.06 / /
D8S1710 0.78 135.32 150.8 146.68
D8S537 0.89 135.51 150.8 147.41
D8S1100 0.65 136.77 154.02 148.81
D8S1783 0.78 136.69 154.02 148.81
D8S274 0.77 137.3 154.02 150.07
D8S272 0.8 137.41 154.02 /
D8S1837 0.81 138.91 156.59 152.44
AFM316xbl / 138.933 / /
AC087711 / 138.939 / /
AC087711-2 / 138.955 / /
AC068467 / 139.150 / /
AC105130-R1 / 139.350 / /
AC053480-R1 / 140.000 / /
D8S1743 0.83 140.33 162.94 /
D8S373 / 145.74 167.9 166.08
D8S2334 / 145.73 167.9 /
D8S1926 / 145.74 167.9 166.08
1.1
father
1.2
mother
11.10
proband
204-212
214-218
157-157 157-153 157-157
210-210 210-204 210-210
160-156 160-156 160-160
257-259 257-253 257-257
163-177 163-179 163-163
183-189 183-189 183-183
172-176 172-172 172-172
118-116 118-110 118-118
239-253 239-257 239-239
247-243 247-233 247-247
190-186 190-190 190-190
207-203 207-199 207-207
252-252
213-213
244-244
292-292
239-227 239-221 239-239
272-264 272-276 272-272
157-139 155-165 157-155
246-250
Table 4.35 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 10. Patient 11.10 displays homozygosity across the locus between markers 
D8S256 and D8S2334.
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D8S1708 and D8S1746 were typed only in this family to refine the centromeric 
boundary of the region.
A summary of the genotyping for affected individuals in families 2, 9 and 10 is given in 
Table 4.36. The overlapping region of homozygosity of about 2 cM (1.65 Mb) is 
defined by marker D8S274 at the centromeric end and marker AC087711-2 at the 
telomeric end.
4.3.2.2 Genotyping not consistent with linkage to chromosome 8q24
Consanguineous Family 1 was previously found not to be consistent with linkage to 
this locus (see Table 4.15). Consanguineous Families 3, 4, 6, 7, 8, 11, 12, showed no 
evidence of linkage to 8q24. Linkage was also excluded in possibly consanguineous 
Family 13 as well as non-consanguineous Families 14, 15 and 16. Family 5 could not 
be typed at this locus because DNA from affected individual II.l was of limited 
quantity.
In consanguineous Family 3, linkage was excluded because the affected child II.l was 
heterozygous across the region (Table 4.38). Further typing in this family was carried 
out by Dr Colin Johnson and the region was definitely excluded (personal 
communication).
In consanguineous Family 4, no evidence for linkage was demonstrated as affected 
individual II.6 showed heterozygosity across the region (Table 4.39).
253
254
Markers 
Chromosome 8
Mb 
Build 33
cM
Marshfield
cM
deCode
Family 2
VI .3  V I.5  
Dutch
Family 9 
I I .l
Italian
Family 10 
11.10
Maroccan
D8S1128 128.26 139.53 135.57 238-242
D8S1720 128.62 140.61 137.06 156-158 156-158
D8S1732 130.04 143.29 139.58 212-214 212-214
D8S1701 130.56 142.22 / 275-279 275-279
AC'131568 130.65 / / 182-176 182-176
AC 103725 130.758 / / 219-223 219-223
AC009682 130.952 / / 239-239 239-239
D8S284 131.18 143.82 139.79 296-296 296-296
D8S1712 131.323 144.36 / 225-225 225-225
D8S557 132.761 145.97 142.18 202-202 202-202 204-212
D8S558 133.163 145.97 143.14 171-171 171-171
D8S529 133.770 148.12 144.75 235-235 235-235
D8S256 134.115 148.12 145.26 232-232 232-232 214-218
D8S1708 134.24 148.12 145.91 157-157
D8S1746 134.91 149.46 146.6 210-210
D8S1462 135.06 / / 160-160 160-160 160-160
D8SI710 135.32 150.8 146.68 255-255 255-255 257-257
D8S537 135.51 150.8 147.41 180-180 180-180 163-179 163-163
D8S1100 136.77 154.02 148.81 182-182 182-182 195-192 183-183
D8SI783 136.69 154.02 148.81 172-176 172-172
D8S1761 137.25 154.02 150.07 290-290 290-290 112-110
D8S274 1373 154.02 150.07 112-110 118-118
D8S272 137.41 154.02 / 253-253 253-253 247-247 239-239
D8S1837 138.91 156.59 152.44 233-233 233-233 243-243 247-247
AFM 316xbl 138.933 / / 193-193 193-193 190-190 190-190
AC087711 138.939 / / 204-204 204-204 187-187 207-207
AC087711-2 138.955 / / 248-248 248-250 250-250 252-252
AC068467 139.15 / / 209-209 209-211 211-211 213-213
AC105130-R1 139.35 / / 257-257 257-245 244-244 244-244
AC053480-RI 140.00 / / 285-285 285-287 286-286 292-292
D8S1743 140.33 162.94 / 220-220 220-246 241-241 239-239
D8S373 144.00 167.9 166.08 264-264 264-276 268-268 272-272
D8S2334 145.73 167.9 / 156-156 157-155
D8S1926 145.74 167.9 166.08 ■ hhh 246-248 246-250
Table 4.36 Summary diagram of the genotyping in affected individuals in Families 2, 9 
and 10. These data are consistent with linkage to 8q24. Homozygous typings are 
highlighted in bright green. Untyped markers are highlighted in white. The markers 
highlighted in pale blue between the two pink lines denote the overlapping region of 
homozygosity between the patients, flanked by markers D8S274 and AC087711-2. The 
ethnic origins of the families are also shown.
255
256
iF am ily  3
Markers 
Chromosome 8
Het Mb 
Build 33
cM
M arshfield
cM
deCode
1.1 1.2 II.l 
father mother proband
D8S558
D8S537
0.86
0.89
133.163
135.51
145.97
150.8
143.14
147.41
175-175
181-185
169-175
185-185
175-169
181-185
D8S1837 0.81 138.91 156.59 152.44 238-240 242-240 238-242
Table 4.38 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 3, showing no evidence for linkage. Affected individual II.l is heterozygous for 
all the three markers typed. Pink lines define the minimal critical interval as defined in 
Table 4.36.
257
Fam ily 4
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1 1.2 II.l 
father mother proband
D8S557
D8S1710
D8S1100
0.76
0.78
0.65
132.761
135.32
136.77
145.97
150.8
154.02
142.18
146.68
148.81
207-215
253-259
205-211
257-253
207-205
253-257
182-188
D3S1837
AC087711
0.81
/
138.91
138.939
156.59
/
152.44
/
235-243
193-195
237-233
187-203
235-237
193-187
Table 4.39 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 4, showing no evidence for linkage. Patient II.6 is heterozygous across the 
region. Pink lines define the minimal critical interval as defined in Table 4.36.
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In consanguineous Family 6, linkage was also excluded as no region of homozygosity 
was detected in affected individual II.2 (Table 4.40).
The parents 1.1 and 1.2 in consanguineous Family 7 did not have a haplotype in 
common except for allele 298 for marker D8S284 and allele 195 for marker 
AC087711-2, excluding the possibility of homozygosity in affected child II.3 (Table 
4.41). DNA from the latter, as previously explained, was not available, therefore 
linkage could not be completely excluded.
The affected child in consanguineous Family 8 was heterozygous across the region 
(Table 4.42). Further typing in this family was carried out by Dr Colin Johnson and 
linkage was excluded (personal communication). Affected sibs II.l and II.2 in 
consanguineous Family 11 were both heterozygous across the 8q24 region, therefore 
linkage was excluded (Table 4.43).
In distantly consanguineous Family 12, affected fetus II.2 showed no convincing 
homozygosity across the region, thus excluding linkage to this locus (Table 4.44). In 
Family 13 parents were thought to be distantly consanguineous, therefore genotyping 
was performed in the parents II.l and II.2 and affected child III. 1. Linkage was 
excluded as no region of homozygosity was detected in affected individual III. 1 (Table 
4.45). Haplotype analysis for two markers in the region was performed in non- 
consanguineous Family 14 and was not consistent with linkage (Table 4.46).
Linkage to this locus was also excluded in non-consanguineous Family 15. Two of the 
three affected fetuses (II.2 and II.4) had the same pair of haplotypes, the same as 
unaffected sib II.l (Table 4.47). Fetus II.3 on the other hand, had a different pair of 
haplotypes compared to the other two fetuses. In non-consanguineous Family 16, 
affected child II.3 shared the same pair of haplotypes across the region as her 
unaffected sister II.2 excluding linkage to this locus (Table 4.48).
259
Fam ily 6
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
unaff.
II.2
proband
D8S284 0.83 131.18 143.82 139.79 296-278 278-268 296-268 296-278
D8S557 0.76 132.761 145.97 142.18 202-208 208-214 202-214 202-208
D8S256 0.83 134.115 148.12 145.26 213-213 213-213 213-213 213-213
D8S1100 0.65 136.77 154.02 148.81 191-188 188-182 191-182 191-188
D8S1837 0.81 138.91 156.59 152.44 230-230 230-230 230-230 230-230
D8S1743 0.83 140.33 162.94 / 225-245 221-221 245-221 225-221
Table 4.40 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 6. Patient II.2 displays heterozygosity across the region except for markers D8S256 
and D8S1837, which are uninformative. Pink lines define the minimal critical interval as 
defined in Table 4.36. Unaff. means individual is unaffected.
260
Fam ily 7
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
unaff.
II.4
unaff.
D8S284 0.83 131.18 143.82 139.79 282-298 296-298 298-298 282-298
D8S557 0.76 132.761 145.97 142.18 210-216 212-212 216-212 210-212
D8S256 0.83 134.115 148.12 145.26 231-235 229-213 235-213 231-213
D8S1837 0.81 138.91 156.59 152.44 248-248 242-238 248-238 248-238
AC087711-2 / 138.955 / / 201-195 195-187 195-187 201-187
Table 4.41 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 7. Parents 1.1 and 1.2 do not have alleles in common for the markers typed, with the 
exception of D8S284 and AC087711-2 (highlighted in red). No DNA was available from 
the affected individual II.3, thus linkage could not be completely substantiated or excluded 
in this family. Pink lines define the minimal critical interval as defined in Table 4.36. 
Unaff. means individual is unaffected.
261
'Fam ily 8
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1 1.2 11.1 
father mother proband
D8S558
D8S537
0.86
0.89
133.163
135.51
145.97
150.8
143.14
147.41
167-177
181-177
175-169
183-181
167-175
181-183
D8S1837 0.81 138.91 156.59 152.44 244-240 240-234 244-240
Table 4.42 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 8. Linkage was excluded as affected child II.l is heterozygous across the region. 
Pink lines define the minimal critical interval as defined in Table 4.36.
262
'Fam ily 11
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1 1.2 11.1 II.2 
father mother proband proband
D8S284
D8S256
0.83
0.83
131.18
134.115
143.82
148.12
139.79
145.26
300-300
227-231
268-298
231-227
300-268
227-231
300-268
227-231
D8S1837 0.81 138.91 156.59 152.44 240-238 234-238 240-234 240-234
AC087711-2 / 138.955 / / 195-195 191-195 195-191 195-191
Table 4.43 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 11, showing no evidence for linkage as affected individuals II.l and II.2 are both 
heterozygous across the region. Pink lines define the minimal critical interval as defined 
in Table 4.36.
263
'Fam ily 12
Markers 
Chromosome 8
1  r
1.1
father
1.2
mother
11.1
unaff.
II.3
unaff.
II.2
proband
D8S529 236-254 246-248 236-248 236-248 236-246
D8S256 223-213 213-213 223-213 223-213 223-213
D8S1462 160-156 164-156 160-156 160-156 160-164
D8S1710 257-257 257-251 257-251 257-251 257-257
D8S537 180-184 180-178 180-178 180-178 180-180
D8S1108 260-268 260-264 260-264 260-264 260-260
D8S534 178-182 182-172 178-172 178-172 178-182
D8S1100 189-192 189-189 189-189 189-189 189-189
D8S1783 172-176 172-172 172-172 172-172 172-172
D8S274 110-116 108-116 110-116 110-116 110-108
D8S272 252-249 252-249 252-249 252-252
D8S1837 246-238 242-238 246-238 246-238 246-242
AC087711 197-203 203-197 197-197 197-197 197-203
Table 4.44 Haplotype analysis results of chromosome 8q24 region in 
consanguineous Family 12, showing no convincing homozygosity in affected 
fetus II.2 across the locus, except for a small region outside the minimal critical 
interval from markers D8S1710 to D8S1108. Pink lines define the minimal 
critical interval as defined in Table 4.36. Unaff. means individual is unaffected.
264
Fam ily 13
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
11.1
father
11.2
mother
III.l
proband
D8S284 0.83 131.18 143.82 139.79 278-280 270-296 278-270
D8S557 0.76 132.761 145.97 142.18 212-208 222-210 212-222
D8S558 0.86 133.163 145.97 143.14 177-163 165-167 177-165
D8S529 0.81 133.770 148.12 144.75 241-243 247-235 241-247
D8S256 0.83 134.115 148.12 145.26 227-213 213-225 227-213
D8S1462 0.75 135.06 / / 156-164 160-156 156-160
D8S1710 0.78 135.32 150.8 146.68 258-256 258-254 258-258
D8S537 0.89 135.51 150.8 147.41 182-158 179-184 182-179
D8S1100 0.65 136.77 154.02 148.81 183-189 192-189 183-192
D8S274 0.77 137.3 154.02 150.07 112-112 118-112 112-118
D8S1837 0.81 138.91 156.59 152.44 245-239 231-243 245-231
AC087711 / 138.939 / / 197-201 195-211 197-195
Table 4.45 Haplotype analysis results of chromosome 8q24 region in consanguineous 
Family 13, showing no evidence for linkage. Affected individual III. 1 is heterozygous 
across the region. Pink lines define the minimal critical interval as defined in Table 4.36.
265
Fam ily 14
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.3
proband
11.4
proband
D8S558 0.86 133.163 145.97 143.14 165-169 167-169 169-167 165-167
D8S1837 0.81 138.91 156.59 152.44 230-238 236-230 238-236 230-236
Table 4.46 Haplotype analysis results of chromosome 8q24 region in non-consanguineous 
Family 14, showing no evidence for linkage as affected individuals II.3 and II.4 have 
inherited different paternal haplotypes. Pink lines define the minimal critical interval as 
defined in Table 4.36.
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Fam ily 15
Markers 
Chromosome 8
1.1 1.2 II.l II.2 11.3 II.4 
father mother unaff. proband proband proband
D8S529
D8S256
D8S1710
D8S1100
240-258
213-221
261-255
192-180
242-252
233-235
257-257
189-183
240-242
213-233
/
192-189
240-242
213-233
261-257
192-189
258-252
221-235
255-257
180-183
240-242
213-233
261-257
192-189
D8S1837 
AC087711
238-230
197-187
230-230
195-201
238-230
197-195
238-230
197-195
230-230
187-201
238-230
197-195
Table 4.47 Haplotype analysis results of chromosome 8q24 region in non-consanguineous 
Family 15, showing no evidence for linkage. Affected fetus II.3 has a different haplotype 
(highlighted in purple) compared to the other two affected fetuses II.2 and II.4 (highlighted 
in pink). Note that unaffected sib II.l has the same haplotype as fetuses II.2 and II.4. Pink 
lines define the minimal critical interval as defined in Table 4.36. Unaff. means individual 
is unaffected.
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IFam ily 16
Markers 
Chromosome 8
Het Mb 
Build 33
cM
Marshfield
cM
deCode
D8S1720 0.82 128.62 140.61 137.06
D8S558 0.86 133.163 145.97 143.14
D8S256 0.83 134.115 148.12 145.26
D8S1710 0.78 135.32 150.8 146.68
D8S1837 0.81 138.91 156.59 152.44
D8S1743 0.83 140.33 162.94 /
1.1 1.2 II.2 II.3 
father mother unaff. proband
158-156
167-165
213-227
/
148-156
163-161
229-235
261-257
158-148
167-163
213-229
259-261
158-148
167-163
213-229
259-261
/
221-223
246-238
245-225
230-246
221-245
230-246
221-245
Table 4.48 Haplotype analysis results of chromosome 8q24 region in non-consanguineous 
Family 16, showing no evidence for linkage. Affected individual II.3 has the same 
haplotype as her unaffected sib II.2. Pink lines define the minimal critical interval as 
defined in Table 4.36. Unaff. means individual is unaffected.
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4.3.3 Chromosome 12q23-q24 locus
As explained in section 4.2.5, the locus on chromosome 12q23-q24 was identified by 
Dr Valerie Cormier-Daire in two JATD consanguineous families. A selection of 
polymorphic markers were obtained from Dr Cormier-Daire and were used for 
genotyping consanguineous Families 1, 2, 3, 4, 6, 7, 8, 11 and 12 and non- 
consanguineous Families 13, 14, 15 and 16. Family 5 could not be typed at this locus 
because there was little DNA from affected individual II.l. Families 9 and 10 were 
typed by Dr Johnson and Dr Cormier-Daire, respectively. None of the above families 
showed evidence for linkage to 12q23-q24. Details of markers are given in Table 2.7 
and their position in Table 4.49. The minimal critical interval of about 2 cM/ 3 Mb was 
identified between markers D12S1342 and D12S1339 (Table 4.49).
Affected individuals from consanguineous Families 1 and 2 were typed and the results 
were not consistent with linkage to 12q23-q24 (Table 4.50). Affected individual IV.3 in 
Family 1 was found to be homozygous for three consecutive markers within the 
minimal critical interval, but his affected cousin IV. 1 was heterozygous for two of them 
and homozygous for a different allele for marker D12S1339. In Family 2, proband VI.3 
was heterozygous for the three markers typed within the minimal critical interval 
(Table 4.50).
In consanguineous Family 3, affected individual II.l was not consistent with linkage to 
12q23-q24 (Table 4.51). Although she was homozygous for D12S1645, this marker 
was semi-informative. Moreover, she was heterozygous for a very close marker 
D12S1583. In consanguineous Family 4, linkage was also excluded as patient II.6 was 
heterozygous across the region (Table 4.52).
Affected child II.2 in Family 6 was homozygous for two consecutive markers D12S353 
and D12S1605 spanning less than 2 cM (Table 4.53). The same two markers were also 
homozygous in the father 1.1 and in the unaffected sib II.l. Although it is likely that the 
unaffected sib had inherited a different paternal haplotype compared to his affected 
sister, results in this family were inconclusive (Table 4.53).
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Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
D12S346 0.84 99.46 104.65 111.02
PAH 0.8 103.17 / /
D12S78 0.91 104.1 114.28 117.32
D12S317 0.71 105.52 114.28 117.32
D12S1342 0.83 106.99 116.08 121.28
D12S353 0.77 107.96 115.18 /
D12S1605 0.78 108.63 116.66 122.79
D12S84 0.84 108.95 117.81 123.34
D12S1583 0.87 109.71 119.55 124.65
D12S1645 0.77 109.93 119.55 /
D12S1339 0.71 109.96 118.68 /
D12S1646 0.72 114.59 121.84 /
D12S1341 0.79 114.87 123.00 /
D12S79 0.87 115.84 125.31 131.88
D12S2070 0.79 115.86 125.31 /
D12S395 0.85 119.97 136.82 140.07
D12S324 0.69 126.34 147.17 148.64
Table 4.49 Markers on chromosome 12q23-q24 used for 
haplotype analysis. Heterozygosity, physical and genetic 
positions for each marker are given. Blue lines define the 
minimal critical interval identified in two consanguineous 
JATD families by Dr Cormier-Daire.
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
Family 1 
IV .l IV.3
Family 2 
V I3  VI.5
D12S346
PAH
0.84
0.8
99.46
103.17
104.65
/
111.02
/
187-197
241-253
195-197
241-245
189-195
244-244
191-191
236-256
D12S353
D12S84
D12S1583
0.77
0.84
0.87
107.96
108.95
109.71
115.18
117.81
119.55
/
123.34
124.65
178-186
214-224
219-241
174-188
200-200
239-239
178-188
202-212
237-241
176-176
210-216
235-235
D12S1339
D12S79
D12S2070
D12S395
D12S324
0.71
0.87
0.79
0.85
0.69
109.96 
115.84 
115.86
119.97 
126.34
118.68
125.31
125.31 
136.82 
147.17
/
131.88
/
140.07
148.64
266-266
162-162
98-98
244-248
242-246
268-268
156-162
88-98
240-248
242-246
269-271
154-156
84-88
240-240
242-244
269-271
154-156
88-88
224-232
238-244
Table 4.50 Haplotype analysis results on chromosome 12q23-q24 in patients from 
consanguineous Families 1 and 2. In Family 1, affected child IV.3 is homozygous for two 
consecutive markers, D12S84 and D12S1583 within the minimal critical interval, although his 
affected cousin (IV. 1) is heterozygous for the same two markers. Both affected cousins, IV. 1 
and IV.3, are homozygous for D12S1339, but for different alleles. In Family 2, proband VI.5 is 
homozygous for two non-consecutive markers, D12S353 and D12S1583, and his affected sib 
VI.3 is heterozygous for both of them. Therefore linkage was excluded in both families. 
Heterozygosity, physical and genetic positions for each marker are given. Blue lines define the 
minimal critical interval.
Fam ily 3
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
proband
D12S346 0.84 99.46 104.65 111.02 202-190 200-184 202-200
D12S353 0.77 107.96 115.18 / 186-178 178-178 186-178
D12S84 0.84 108.95 117.81 123.34 216-218 198-212 216-198
D12S1583 0.87 109.71 119.55 124.65 237-243 239-239 237-239
D12S1645 0.77 109.93 119.55 / 213-213 213-217 213-213
D12S1339 0.71 109.96 118.68 / 269-273 269-271 269-269
D12S1646 0.72 114.59 121.84 / 257-257 249-251 257-249
D12S1341 0.79 114.87 123.00 / 204-208 210-216 204-210
D12S79 0.87 115.84 125.31 131.88 160-154 160-158 160-160
Table 4.51 Haplotype analysis results on chromosome 12q23-q24 in consanguineous 
Family 3. Linkage in this family could not be supported. Affected individual II.l is 
homozygous for D12S1645 although this marker is semi-informative and she is 
heterozygous for a very close marker, D12S1583. Heterozygosity, physical and 
genetic positions for each marker are given. Blue lines define the minimal critical 
interval.
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Fam ily 4
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
11.6
proband
D12S346
PAH
D12S78
D12S317
D12S1342
0.84
0.8
0.91
0.71
0.83
99.46
103.17
104.1
105.52
106.99
104.65
/
114.28
114.28 
116.08
111.02
/
117.32
117.32 
121.28
192-188
236-240
197-191
250-270
277-273
194-190
240-244
189-181
250-270
281-271
192-194
236-240
197-189
250-250
277-281
D12S353
D12S1605
D12S84
D12S1583
0.77
0.78
0.84
0.87
107.96
108.63
108.95
109.71
115.18
116.66
117.81
119.55
/
122.79
123.34
124.65
184-182
196-202
215-209
242-221
184-186
204-198
217-219
221-234
184-184
196-204
215-217
242-221
D12S1339
D12S79
0.71
0.87
109.96
115.84
118.68
125.31
/
131.88
268-270
174-156
266-266
162-168
268-266
174-162
Table 4.52 Haplotype analysis results on chromosome 12q23-q24 in consanguineous 
Family 4. Linkage in this family could not be supported. Affected individual II.6 is 
homozygous for D12S353 within the region, although he is heterozygous for the two 
flanking markers, D12S1342 and D12S1605. Heterozygosity, physical and genetic 
positions for each marker are given. Blue lines define the minimal critical interval.
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Fam ily 6
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
11.1
unaff.
11.2
proband
D12S78
D12S317
D12S1342
0.91
0.71
0.83
104.1
105.52
106.99
114.28
114.28 
116.08
117.32
117.32 
121.28
193-185
270-270
281-279
173-183
250-250
273-281
185-173
270-250
279-273
193-173
270-250
281-273
D12S353
D12S1605
D12S84
D12S1583
0.77
0.78
0.84
0.87
107.96
108.63
108.95
109.71
115.18
116.66
117.81
119.55
/
122.79
123.34
124.65
176-176
200-200
213-215
225-225
176-188
200-202
219-221
223-225
176-176
200-200
215-219
225-223
176-176
200-200
213-219
225-223
D12S1339 0.71 109.96 118.68 / 265-267 267-269 267-267 265-267
Table 4.53 Haplotype analysis results on chromosome 12q23-q24 in consanguineous 
Family 6. Patient II.2 displays a short stretch of homozygosity within the minimal critical 
interval but both markers are semi-informative and unaffected sib II. 1 is also homozygous 
for the same two markers. Therefore, linkage in this family could not be supported. 
Heterozygosity, physical and genetic positions for each marker are given. Blue lines 
define the minimal critical interval. Unaff. means individual is unaffected.
F am ily  7
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
11.1
unaff.
11.4
unaff.
D12S353
D12S84
D12S1583
0.77
0.84
0.87
107.96
108.95
109.71
115.18
117.81
119.55
/
123.34
124.65
172-178
219-213
225-225
176-178 
217-213 
235-241
172-176
219-217
225-235
178-178
213-213
225-241
D12S1339 0.71 109.96 118.68 / 265-267 275-267 265-275 267-267
Table 4.54 Haplotype analysis results on chromosome 12q23-q24 in consanguineous 
Family 7 are not consistent with linkage. Parents 1.1 and 1.2 have alleles in common for 
markers D12S353, D12S84 and D12S1339 (shown in red), although unaffected individual 
II.4 is homozygous for those markers. No DNA was available from affected individual 
II.3. Herozygosity, physical and genetic positions for each marker are given. Blue lines 
define the minimal critical interval. Unaff. means individual is unaffected.
274
In consanguineous Family 7, haplotype analysis was not consistent with linkage as 
parents 1.1 and 1.2 do not have an allele in common at D12S1583 and unaffected child 
II.4 is homozygous for D12S353, D12S84 and D12S1339 (Table 4.54). No DNA from 
the affected, deceased child (II.3) was available for typing.
Affected individual II. 1 in consanguineous Family 8 was homozygous only for D12S84 
within the minimal critical interval and heterozygous for the two flanking markers 
D12S353 and D12S1583 (Table 4.55). Linkage could not be supported in this family. 
In consanguineous Family 11, no evidence for linkage could be corroborated as the two 
affected children II. 1 and II.2 were heterozygous across the interval (Table 4.56).
In distantly consanguineous Family 12, affected fetus II.2 showed no evidence for 
linkage to the region (Table 4.57). Fetus II.2 had the same pair of haplotypes as his 
unaffected sister II. 1 across the region and was homozygous for D12S353, but so was 
her sister.
No evidence for linkage could be demonstrated in distantly consanguineous Family 13 
as no region of homozygosity was detected in affected individual III.l (Table 4.58). In 
non-consanguineous Family 14, affected children II.3 and II.4 did not have the same 
haplotypes across the region, therefore linkage could not be supported (Table 4.59). 
The three affected fetuses II.2, II.3 and II.4 in non-consanguineous Family 15 did not 
have the same haplotypes in the region, therefore linkage could not be demonstrated 
(Table 4.60). Haplotype analysis results in non-consanguineous Family 16 were 
inconclusive (Table 4.61). Although the affected child II.3 had the same haplotype as 
her unaffected sister, possibly excluding linkage, most of the markers were 
uninformative in the father.
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Fam ily 8
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
proband
D12S346 0.84 99.46 104.65 111.02 190-190 188-198 190-188
D12S353
D12S84
D12S1583
0.77
0.84
0.87
107.96
108.95
109.71
115.18
117.81
119.55
/
123.34
124.65
178-184
200-210
/
176-176
200-216
220-239
178-176
200-200
239-220
D12S1339
D12S79
0.71
0.87
109.96
115.84
118.68
125.31
/
131.88
267-269
162-172
265-273
156-156
267-265
162-156
Table 4.55 Haplotype analysis results on chromosome 12q23-q24 in consanguineous 
Family 8. Linkage in this family could not be supported, although affected individual 
II. 1 is homozygous for D12S84 within the interval, and could be homozygous for a 
small region (2 cM) between markers D12S353 and D12S1583. Heterozygosity, 
physical and genetic positions for each marker are given. Blue lines define the 
minimal critical interval.
F am ily  11
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
proband
II.2
proband
D12S353
D12S84
D12S1583
0.77
0.84
0.87
107.96
108.95
109.71
115.18
117.81
119.55
/
123.34
124.65
186-176
199-215
243-237
172-178
213-201
241-241
186-172
199-213
243-241
186-172
199-213
243-241
D12S1339 0.71 109.96 118.68 / 267-267 275-267 267-275 267-275
Table 4.56 Haplotype analysis results on chromosome 12q23-q24 in consanguineous 
Family 11 are not consistent with linkage. Both affected individuals II. 1 and II.2 are 
heterozygous across the region. Heterozygosity, physical and genetic positions for each 
marker are given. Blue lines define the minimal critical interval.
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Fam ily 12
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
unaff.
11.3
unaff.
11.2
proband
D12S353
D12S84
D12S1583
0.77
0.84
0.87
107.96
108.95
109.71
115.18
117.81
119.55
/
123.34
124.65
177-185
215-199
240-224
177-179
219-217
236-242
177-177
215-219
240-236
185-177
199-219
224-236
177-177
215-219
240-236
D12S1339 0.71 109.96 118.68 / 268-276 270-268 268-270 276-270 268-270
Table 4.57 Haplotype analysis results on chromosome 12q23-q24 in consanguineous Family 12 are not 
consistent with linkage to this locus. D12S353 is homozygous in patient II.2 as well as in unaffected sib 
II.l. Heterozygosity, physical and genetic distances of each marker are indicated. Blue lines define the 
minimal critical interval. Unaff. means individual is unaffected.
Fam ily 13
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
11.1
father
11.2
mother
III.l
proband
D12S346 0.84 99.46 104.65 111.02 188-196 198-180 188-198
D12S353
D12S84
D12S1583
0.77
0.84
0.87
107.96
108.95
109.71
115.18
117.81
119.55
/
123.34
124.65
188-176
212-216
223-235
186-178
210-212
237-235
188-186
212-210
223-237
D12S1339
D12S79
0.71
0.87
109.96
115.84
118.68
125.31
/
131.88
265-267
154-156
267-267
168-154
265-267
154-168
Table 4.58 Haplotype analysis results on chromosome 12q23-q24 in consanguineous 
Family 13 showing no evidence for linkage as affected individual III. 1 is 
heterozygous across the region. Heterozygosity, physical and genetic positions for 
each marker are given. Blue lines define the minimal critical interval.
F am ily  14
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
11.3
proband
II.4
proband
D12S353
D12S84
D12S1583
0.77
0.84
0.87
107.96
108.95
109.71
115.18
117.81
119.55
/
123.34
124.65
178-178
223-213
221-225
186-184
213-213
225-241
178-186
223-213
221-225
178-184
213-213
225-225
D12S1339 0.71 109.96 118.68 / 266-270 266-280 266-266 270-266
Table 4.59 Haplotype analysis results on chromosome 12q23-q24 in non-consanguineous 
Family 14 are not consistent with linkage. Affected individuals II.3 and II.4 have inherited 
different haplotypes from the parents. Heterozygosity, physical and genetic positions for 
each marker are given. Blue lines define the minimal critical interval.
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F am ily  15
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
unaff.
II.2
proband
113
proband
II.4 
proband
D12S353
D12S84
D12S1583
D12S1645
0.77
0.84
0.87
0.77
107.96
108.95
109.71
109.93
115.18
117.81
119.55
119.55
/
12334
124.65
/
179-177
217-215
238-240
213-213
179-177
201-213
221-238
219-213
179-177
217-213
238-238
213-213
177-177
215-213
240-238
213-213
177-177
215-213
240-221
213-219
179-179
217-201
238-221
213-219
D12S1339 0.71 109.96 118.68 / 268-268 266-266 268-266 268-266 268-266 268-266
Table 4.60 Haplotype analysis results on chromosome 12q23-q24 in non-consanguineous Family 15 are not consistent 
with linkage to this locus. The three affected fetuses H.2, II.3 and II.4 have different haplotypes in the region. 
Heterozygosity, physical and genetic distances of each marker are indicated. Blue lines define the minimal critical 
interval. Unaff. means individual is unaffected.
Fam ily 16
Markers 
Chromosome 12
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.2
unaff.
II.3
proband
D12S346 0.84 99.46 104.65 111.02 189-201 181-199 189-181 189-199
D12S353
D12S1605
D12S84
D12S1583
D12S1645
0.77
0.78
0.84
0.87
0.77
107.96
108.63
108.95
109.71
109.93
115.18
116.66
117.81
119.55
119.55
/
122.79
123.34
124.65
/
175-175
200-204
215-215
238-238
212-212
173-181
204-200
199-215
240-236
212-216
175-173
200-204
215-199
238-240
212-212
175-173
200-204
215-199
238-240
212-212
D12S1339 0.71 109.96 118.68 / 266-266 266-266 266-266 266-266
Table 4.61 Haplotype analysis results on chromosome 12q23-q24 in non-consanguineous 
Family 16. Affected individual II.3 and her unaffected sib II.2 have the same haplotypes 
except for marker D12S346 at which they have inherited different maternal alleles. Note 
how the father 1.1 is uninformative for most of the markers. Heterozygosity, physical and 
genetic distances of each marker are indicated. Blue lines define the minimal critical 
interval. Unaff. means individual is unaffected.
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4.3.4 Chromosome 15ql3 locus
As explained in section 4.2.5, the locus on chromosome 15ql3 was identified by Dr 
Colin Johnson and supported by data from five consanguineous families and three non- 
consanguineous families (Morgan et al., 2003). Families A, C and D, reported in the 
paper by Morgan and collaborators, correspond to Families 3, 8 and 9, respectively, as 
described in this study (Morgan et al., 2003).
Subsequent to the publication of the paper, more typing was carried out in Families 3 
and 8 with the aim of refining further the boundaries of the region. Consanguineous 
Families 3-12 and non-consanguineous Families 13-16 were also genotyped across the 
15ql3 locus with a selection of evenly spaced markers across the region. A few 
polymorphic markers were obtained from Dr Colin Johnson and others were designed 
as explained in section 2.3.2.2. Details of all the markers are given in Table 2.8.
4.3.4.1 Families 3 and 8
Results described by Morgan and collaborators have been summarised in Table 4.62. 
The minimal critical interval was 1.2 cM (-1.5 Mb) in size between markers D15S165 
and D15S1010 (Morgan et al., 2003). In this study, PCRs to amplify almost all markers 
typed by Morgan and collaborators on 15ql3 were repeated and run again in Families 3 
and 8. Further finely spaced markers were also typed in these two families. The results 
of haplotype analysis in Family 3 are shown in Table 4.63. A large homozygous region 
(22 cM/7 Mb) was demonstrated in affected child II.l from D15S817 to D15S165, 
although markers D15S976 and D15S1031 gave different results compared to those 
published. The child was in fact heterozygous for both markers (Table 4.63). Therefore, 
assuming linkage, the region was narrowed down in this family at the telomeric end to 
D15S165.
In Family 8, the affected child II.l showed homozygosity from D15S1019 to 
GATA50C03, spanning about 24 cM/11 Mb, although only two markers, D15S165 and 
D15S1031, were fully informative (Table 4.64). These results were then collated with
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M arkers 
C hrom osom e 15
Het Mb 
Build 33
cM
M arshfield
cM
deCode
Proband A 
Fam 3 (11.1)
Proband B Proband C 
Fam 8 (II .l)
Proband D 
Fam 9 (11.1)
Proband E
D15S128 0.78 22.54 6.11 5.82 202-202 192-192 198-198 198-206 198-198
D15S822 0.79 24.82 12.3 / 260-260 260-260 260-284 286-306 264-264
D15S1048 0.84 27.44 19.12 21.07 223-223 229-229 227-227 211-231 225-225
D15S165 0.77 28.84 20.24 22.64 199-199 199-199 193-193 197-201 197-197
D15S976 0.63 29.13 21.58 22.65 150-150 150-150 144-144 150-150 154-154
D15S1013 0.53 29.31 21.58 24.63 168-168 178-178 168-168 168-168 168-168
D15S1031 0.74 29.66 21.58 24.63 229-229 303-303 303-303 305-305 303-303
D15S1010 0.8 30.66 23.89 / 227-233 229-229 227-227 213-213 213-213
D15S231 0.5 30.82 24.06 26.48 108-112 108-108 108-108 108-108 108-108
D15S1007 0.87 31.31 25.86 28.86 174-176 176-186 184-184 182-176 174-188
GATA50C03 0.72 / 34.83 / 272-272 272-272 272-272 280-280 276-284
D15S659 0.84 43.95 43.47 44.5 197-173 197-197 177-201 186-186 178-198
D15S643 57.29 53.33 59.51 205-213 221-221 221-221 203-209 213-213
D15S1507 208-204 204-204 212-216 204-204 208-208
Table 4.62 Summary of haplotype results published by Morgan and colleagues (Morgan et a l 2003) in five consanguineous 
JATD families. Only the haplotypes of the affected children are shown. Green lines define the minimal critical interval between 
D15S165 and D15S1010.
NJ
OOto
F a m ily  3
Markers 
Chromosom e 15
Het Mb 
Build 33
cM
M arshfield
cM
deCode
D15S817 0.79 22.02 4.78 /
D15S1021 0.79 22.43 4.78 4.84
D15S128 0.78 22.54 6.11 5.82
D15S822 0.79 24.82 12.30 /
D15S1002 0.79 25.32 14.58 15.05
D15S219 / 25.37 14.58 15.05
D15S156 0.51 25.38 14.58 15.05
D15S217 / 25.54 / /
AC079090 / 25.66 / /
AC024474 / 26.68 / /
D15S1019 0.63 27.24 19.12 20.59
AC090763 / 27.28 / /
D15S1048 0.84 27.44 19.12 21.07
AC022613 / 27.50 / /
D15S1043 0.52 27.81 20.24 21.57
D15S165 0.77 28.84 20.24 22.64
D15S976 0.63 29.13 21.58 22.65
D15S1013 0.53 29.31 21.58 24.63
D15S1031 0.74 29.66 21.58 24.63
D15S1010 0.80 30.66 23.89 /
D15S231 0.50 30.82 24.06 26.48
D15S1007 0.87 31.31 25.86 28.86
ACTC 0.87 32.66 31.46 /
GATA50C03 0.72 / / /
D15S659 0.84 43.95 43.47 44.5
1.1
father
1.2
mother
11.1
proband
164-164
222-222 222-224 222-222
202-202
260-260
148-135 148-135 148-148
223-223 223-219 223-223
238-238 238-250 238-238
246-246
242-238 242-246 242-242
215-211 215-205 215-215
220-220 220-222 220-220
262-260 262-260 262-262
223-223
273-275 273-273 273-273
231-231 231-231 231-231
199-199
148-148 150-148 148-150
168-168
245-261 247-245 245-247
227-233
108-112
167-171
69-89
284-272
197-173
Table 4.63 Haplotype analysis results on chromosome 15ql3 in consanguineous 
Family 3. The region of homozygosity in patient II.l does not extend as telomeric as 
D15S1010 as originally reported by Morgan and colleagues (Morgan et a l ., 2003). 
The results which were found to differ from those published in proband II.l are 
highlighted in yellow. Not all the markers were typed in the unaffected parents. 
Heterozygosity, physical and genetic distances of each marker are indicated. Markers 
included in the paper by Morgan and colleagues are shown in bold.
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Fam ily  8
Markers Het Mb cM cM 1.1 1.2 II.l
Chromosome 15 Build 33 Marshfield deCode father mother proband
D15S817 0.79 22.02 4.78 / 158-154 158-150 158-158
D15S128 0.78 22.54 6.11 5.82 198-202 198-198 198-198
D15S822 0.79 24.82 12.30 / 260-292 284-264 260-284
D15S1002 0.79 25.32 14.58 15.05 135-148 135-148 135-135
D15S219 / 25.37 14.58 15.05 203-203 223-227 203-223
D15S156 0.51 25.38 14.58 15.05 238-259 240-256 238-240
D15S217 / 25.54 / / 237-237 245-237 237-245
AC079090 / 25.66 / / 238-240 228-238 238-228
AC024474 / 26.68 / / 209-213 211-205 209-211
D15S1019 0.63 27.24 19.12 20.59 220-220 220-230 220-220
AC090763 / 27.28 / / 262-262 262-262 262-262
D15S1048 0.84 27.44 19.12 21.07 226-220 226-226 226-226
AC022613 / 27.50 / / 273-273 273-273 273-273
D15S1043 0.52 27.81 20.24 21.57 231-231 231-231 231-231
D15S165 0.77 28.84 20.24 22.64 193-197 193-195 193-193
D15S976 0.63 29.13 21.58 22.65 142-148 142-142 142-142
D15S1031 0.74 29.66 21.58 24.63 249-253 249-245 249-249
D15S1010 0.80 30.66 23.89 / 227-227 227-227 227-227
D15S231 0.50 30.82 24.06 26.48 108-108 108-112 108-108
AC019278 / 31.00 / / 192-192 192-203 192-192
D15S995 0.67 31.24 25.86 28.86 242-242 242-244 242-242
D15S1007 0.87 31.31 25.86 28.86 177-177 177-177 177-177
AC087638 / 31.59 / / 280-280 280-316 280-280
D15S1232 / 32.56 31.46 / 319-319 319-315 319-319
ACTC 0.87 32.66 31.46 / 91-91 91-71 91-91
D15S971 0.82 32.96 31.46 32.71 306-306 306-300 306-306
D15S1042 0.82 33.84 32.58 / 286-286 286-274 286-286
GATA50C03 0.72 / / / 280-280 280-276 280-280
D15S994 0.72 38.16 40.25 / 164-171 171-166 164-171
D15S659 0.84 43.95 43.47 44.5 201-176 176-197 201-176
Table 4.64 Haplotype analysis results on chromosome 15ql3 in consanguineous 
Family 8. The region of homozygosity in proband II.l from D15S1019 to 
GATA50C03 is about 24 cM/11 Mb in size. Note how almost all the markers 
homozygous in the proband are semi-informative except for D15S165 and 
D15S1031. Heterozygosity, physical and genetic distances of each marker are 
indicated. Markers included in the paper by Morgan and colleagues are shown in bold 
(Morgan et a l ., 2003).
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the previous ones reported by Morgan and collaborators and it was noted that the 
homozygous regions in the affected children from Families 3 and 9 no longer 
overlapped (Table 4.65).
Following genotyping in Families 3 and 8 carried out in this study and assuming 
linkage, the candidate region of 2 cM/2.5 Mb was refined between markers AC024474 
at the centromeric end and D15S976 at the telomeric end (Table 4.65). However, 
patient II.l in Family 8 was also homozygous for a 19 cM/25 Mb region on 
chromosome 3q24-q26 (see Table 4.22), while data from the affected child II.l in 
Family 9 was also consistent with linkage to the 8q24 locus, showing a 16 cM/8 Mb 
region of homozygosity (see Table 4.34). The stretch of homozygosity in proband II.l 
in Family 9 on 15ql3 was about 6 cM/2.5 Mb and did not overlap with the 
homozygous region in Family 3.
4.3.4.2 Genotyping not consistent with linkage to chromosome 15ql3
Genotyping across the 15ql3 locus was performed in consanguineous Families 1, 2, 4, 
5, 6, 7, 11 and 12 and non-consanguineous Families 13, 14, 15 and 16. Family 10 was 
typed by Dr Valerie Cormier-Daire. None of the above families were consistent with 
linkage to this locus. Results of haplotype analysis obtained in patients from Families 1, 
2, 4 and 5 are shown in Table 4.66 and were not consistent with linkage. Affected 
individuals from Families 1, 2, 3, 4 and 8 all shared identical homozygous alleles at 
marker D15S1013, although the heterozygosity of this marker was 0.53. Therefore 
D15S1013 was not used for typing in further families.
In consanguineous Family 6, the proband II.2 was homozygous for four markers within 
the minimal critical interval, although only two, AC090763 and D15S165, were fully 
informative (Table 4.67). Furthermore, the small potential region of homozygosity in 
the affected child II.2 was interrupted by heterozygous marker AC022613. Therefore 
the results in II.2 were not consistent with linkage to 15ql3.
Consanguineous Family 7 could be consistent with linkage to this locus, but no DNA 
from the affected deceased child (II.3) was available to corroborate the hypothesis of
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Markers Het Mb cM cM
Chromosome 15 Build 33 Marshfield deCode
D15S817 0.79 22.02 4.78 /
D15S1021 0.79 22.43 4.78 4.84
D15S128 0.78 22.54 6.11 5.82
D15S822 0.79 24.82 12.30 /
D15S1002 0.79 25.32 14.58 15.05
D15S219 / 25.37 14.58 15.05
D15S156 0.51 25.38 14.58 15.05
D15S217 / 25.54 / /
AC079090 / 25.66 / /
AC024474 / 26.68 / /
D15S1019 0.63 27.24 19.12 20.59
AC090763 / 27.28 / /
D15S1048 0.84 27.44 19.12 21.07
AC022613 / 27.50 / /
D15S1043 0.52 27.81 20.24 21.57
D15S165 0.77 28.84 20.24 22.64
D15S976 0.63 29.13 21.58 22.65
D15S1013 0.53 29.31 21.58 24.63
D15S1031 0.74 29.66 21.58 24.63
D15S1010 0.80 30.66 23.89 /
D15S231 0.50 30.82 24.06 26.48
ACO19278 / 31.00 / /
D15S995 0.67 31.24 25.86 28.86
D15S1007 0.87 31.31 25.86 28.86
AC087638 / 31.59 / /
D15S1232 / 32.56 31.46 /
ACTC 0.87 32.66 31.46 /
D15S971 0.82 32.96 31.46 32.71
D15S1042 0.82 33.84 32.58 /
GATA50C03 0.72 / / /
D15S994 0.72 38.16 40.25 /
D15S659 0.84 43.95 43.47 44.5
Proband A 
Fam 3 (11.1)
Proband B Proband C 
Fam 8 (II .l)
Proband D 
Fam 9 (II .l)
Proband E
198-206
286-306
164-164
222-222
202-202
260-260
148-148
223-223
238-238
246-246
242-242
215-215
158-158
192-192
260-260
198-198
260-284
198-198
264-264
135-135
203-223
238-240
237-245
238-228 
209-211
220-220
262-262
223-223
273-273
231-231
199-199
220-220
262-262
226-226
273-273
231-231
193-193
211-231
197-201
229-229 225-225
199-199 197-197
148-150
168-168
245-247
227-233
108-112
167-171
69-89
284-272
197-173
150-150
178-178
303-303
229-229
108-108
142-142
168-168
249-249
227-227
108-108
192-192
242-242
177-177
280-280
319-319
91-91
306-306
286-286
280-280
150-150
168-168
305-305
213-213
108-108
154-154
168-168
303-303
213-213
108-108
176-186
272-272
182-176
280-280
174-188
276-284
178-198197-197
164-171
201-176 186-186
Table 4.65 Summary of haplotype analysis results on chromosome 15ql3 after further 
typing in consanguineous Families 3 and 8. Only the haplotypes from the affected 
children are shown. Note the heterozygous results for markers D15S976 and D15S1031 
(highlighted in yellow) in patient II.l in Family 3, differ from the previously reported 
data, thus the homozygous region in Family 3 does not overlap with the one in Family 
9. Orange lines define the minimal critical interval determined by Families 3 and 8. 
Heterozygosity, physical and genetic distances of each marker are indicated. Markers 
included in the paper by Morgan and colleagues are shown in bold (Morgan et a l , 
2003).
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Markers 
Chromosome 15
Het Mb 
Build 33
cM
Marshfield
cM
deCode
Family 1 
IV .l IV.3
Family 2 
VI.3 VI.5
Family 4 
11.6
Family 5 
II.l
D15S817 0.79 22.02 4.78 / 154-154 154-154 150-154 158-158 164-174
D15S128 0.78 22.54 6.11 5.82 200-200 202-206 198-200 200-204 202-204 202-204
D15S822 0.79 24.82 12.3 / 259-287 259-294 263-287 263-291 259-267 279-295
D15S217 / 25.54 / / 234-250 218-250 238-246 246-250 230-246 242-246
D15S1048 0.84 27.44 19.12 21.07 220-226 224-226 218-220 220-228 200-208 218-220
D15S165 0.77 28.84 20.24 22.64 183-199 183-205 183-199 183-183 197-201 183-201
D15S976 0.63 29.13 21.58 22.65 142-142 142-148 142-148 142-142 148-150 148-148
D15S1013 0.53 29.31 21.58 24.63 168-168 168-168 168-168 168-168 168-168 176-176
D15S1031 0.74 29.66 21.58 24.63 246-246 246-250 261-261 249-261 249-253 249-249
D15S1010 0.8 30.66 23.89 / 229-233 225-229 229-233 227-231 225-229 229-233
D15S231 0.5 30.82 24.06 26.48 107-107 107-107 107-111 107-111 103-107 107-111
D15S1007 0.87 31.31 25.86 28.86 169-175 169-177 163-169 169-179 163-169 169-177
ACTC 0.87 32.66 31.46 / 83-87 83-89 69-89 80-89 83-83 69-91
GATA50C03 0.72 / / / 280-280 276-280 280-284 276-284 276-292 276-284
D15S659 0.84 43.95 43.47 44.5 176-176 176-196 180-200 180-184
Table 4.66 Haplotype analysis results on chromosome 15ql 3 in affected individuals in consanguineous Families 1, 2, 4 and 5. None of the 
children show homozygosity across the region determined by the results shown in Table 4.65. Heterozygosity, physical and genetic 
distances of each marker are indicated. Orange lines define the new minimal critical interval determined by the results shown in Table 4.65.
K>oooc
Fam ily 6
Markers 
Chromosome 15
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
II.l
unaff.
II.2
proband
D15S128 0.78 22.54 6.11 5.82 198-204 204-198 204-198 198-204
D15S822 0.79 24.82 12.30 / 283-287 287-279 287-279 283-287
D15S1002 0.79 25.32 14.58 15.05 135-149 135-137 135-137 135-135
D15S156 0.51 25.38 14.58 15.05 260-256 238-238 260-238 260-238
D15S217 / 25.54 / / 217-237 241-245 217-245 217-241
AC079090 / 25.66 / / 240-234 240-228 240-228 240-240
AC024474 / 26.68 / / 217-209 211-209 217-209 217-211
D15S1019 0.63 27.24 19.12 20.59 220-220 220-220 220-220 220-220
AC090763 / 27.28 / / 263-269 263-261 263-261 263-263
AC022613 / 27.50 / / 272-272 274-274 272-274 272-274
D15S1043 0.52 27.81 20.24 21.57 231-223 231-231 231-231 231-231
D15S165 0.77 28.84 20.24 22.64 197-183 197-183 197-183 197-197
D15S1031 0.74 29.66 21.58 24.63 249-249 249-261 249-261 249-249
D15S1010 0.80 30.66 23.89 / 229-227 227-233 229-233 229-227
D15S1007 0.87 31.31 25.86 28.86 161-165 165-175 161-175 161-165
Table 4.67 Haplotype analysis results on chromosome 15ql3 in consanguineous Family 6. 
Proband II.2 was not consistent with linkage to this locus as she was heterozygous for 
marker AC022613. Heterozygosity, physical and genetic distances of each marker are 
indicated. Orange lines define the minimal critical interval determined by the results shown 
in Table 4.65. Unaff. means individual is unaffected.
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linkage. Haplotype analysis was performed in the parents (1.1 and 1.2) and unaffected 
sibs (II.l and II.4) and was consistent with linkage (Table 4.68). The parents in fact had 
a haplotype in common across the region, thus the affected child could in principle be 
homozygous. Only one marker in the minimal critical interval, AC090763, was fully 
informative and the two unaffected children were heterozygous for it.
Consanguineous Family 11 was not consistent with linkage to 15ql3 as both affected 
children II.l and II.2 were heterozygous for two markers in the region (Table 4.69). In 
Family 12, linkage could not be supported, as the affected child II.2 was homozygous 
only for D15S165 within the critical interval (Table 4.70). In Family 13, assuming the 
parents were distantly related, linkage could not be supported, as patient III.3 was 
heterozygous across the region (Table 4.71).
In non-consanguineous Family 14 linkage could not be supported, as the two affected 
sibs did not share the same pair of haplotypes across the region (Table 4.72). Linkage 
to this locus was also excluded in non-consanguineous Family 15. Two of the three 
affected fetuses (II.2 and II.4) had the same haplotypes while the third affected fetus 
II.3 had a different pair of haplotypes, the same as the unaffected sib II.l (Table 4.73). 
Non-consanguineous Family 16 was also not consistent with linkage to 15ql3, as the 
affected child II.3 had the same pair of haplotypes as her unaffected sister (Table 4.74).
4.3.5 Chromosome 14q24-q32 locus
The locus on chromosome 14q24-q32 was identified in consanguineous Family 4 
following a genome-wide screen in patient II.6. The homozygous region in probands
II.6 and II.8 was about 19 cM/14 Mb in size between markers D14S74 and D14S977 
(see Table 4.19). Haplotype analysis was performed in non-consanguineous Family 15 
across this locus. Results are shown in Table 4.75 and were not consistent with linkage.
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Fam ily 7
Markers 
Chromosome 15
Het Mb 
Build 33
cM
Marshfield
cM
deCode
LI
father
1.2
mother
11.1
unaff.
II.4
unaff.
D15S1021 0.79 22.43 4.78 4.84 221-221 221-233 221-221 221-221
D15S128 0.78 22.54 6.11 5.82 198-206 206-200 198-206 198-206
D15S1513 0.61 23.60 12.3 8.60 227-231 231-231 227-231 227-231
D15S822 0.79 24.82 12.30 / 260-286 286-260 260-286 260-286
D15S1002 0.79 25.32 14.58 15.05 147-135 135-135 147-135 135-135
D15S219 / 25.37 14.58 15.05 223-227 227-203 223-227 227-203
D15S156 0.51 25.38 14.58 15.05 238-238 238-238 238-238 238-238
D15S217 / 25.54 / / 217-237 237-245 217-237 237-245
AC079090 / 25.66 / / 238-238 238-228 238-238 238-228
AC024474 / 26.68 / / 207-207 207-209 207-207 207-209
D15S1019 0.63 27.24 19.12 20.59 222-220 220-220 220-222 220-220
AC090763 / 27.28 / / 261-257 257-259 261-257 257-259
D15S1048 0.84 27.44 19.12 21.07 222-220 220-220 222-220 220-220
AC022613 / 27.50 / / 274-274 274-274 274-274 274-274
D15S1043 0.52 27.81 20.24 21.57 231-231 231-231 231-231 231-231
D15S1031 0.74 29.66 21.58 24.63 245-253 253-245 245-253 253-245
D15S1010 0.80 30.66 23.89 / 229-233 233-227 229-233 233-227
D15S1007 0.87 31.31 25.86 28.86 169-171 171-183 169-171 171-183
Table 4.68 Haplotype analysis results on chromosome 15ql3 in consanguineous Family 7. 
The parents 1.1 and 1.2 have a haplotype in common (in red) which could have been 
homozygously inherited by the affected child II.3, but no DNA was available from him. 
Therefore linkage could not be supported in this family. Heterozygosity, physical and 
genetic distances of each marker are indicated. Orange lines define the minimal critical 
interval determined by the results shown in Table 4.65. Unaff. means individual is 
unaffected.
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Fam ily 11
Markers Het Mb cM cM u 1.2 11.1 II.2
Chromosome 15 Build 33 Marshfield deCode father mother proband proband
D15S1021 0.79 22.43 4.78 4.84 233-233 221-233 233-221 233-233
D15S128 0.78 22.54 6.11 5.82 198-198 198-200 198-200 198-200
D15S1513 0.61 23.60 12.3 8.60 231-231 231-235 231-235 231-235
D15S822 0.79 24.82 12.30 / 256-260 282-290 256-290 256-290
D15S1002 0.79 25.32 14.58 15.05 135-149 135-135 135-135 135-135
D15S219 / 25.37 14.58 15.05 223-223 223-221 223-221 223-221
D15S156 0.51 25.38 14.58 15.05 238-238 238-238 238-238 238-238
D15S217 / 25.54 / / 245-229 217-245 245-245 245-245
AC079090 / 25.66 / / 238-234 228-228 238-228 238-228
AC024474 / 26.68 / / 207-207 207-215 207-215 207-215
D15S1019 0.63 27.24 19.12 20.59 220-220 220-220 220-220 220-220
AC090763 / 27.28 / / 270-266 262-264 270-264 270-264
D15S1048 0.84 27.44 19.12 21.07 222-222 220-222 222-222 222-222
AC022613 / 27.50 / / 272-274 272-272 272-272 272-272
D15S1043 0.52 27.81 20.24 21.57 221-231 231-231 221-231 221-231
D15S1031 0.74 29.66 21.58 24.63 249-249 249-249 249-249 249-249
D15S1010 0.80 30.66 23.89 / 233-229 211-227 233-227 233-227
Table 4.69 Haplotype analysis results on chromosome 15ql3 in consanguineous Family 11. 
Patients II.l and II.2 are heterozygous for two markers within the critical region, AC090763 
and D15S1043. Therefore linkage could not be supported in this family. Note how almost 
all the markers are semi- or uninformative. Heterozygosity, physical and genetic distances of 
each marker are indicated. Orange lines define the minimal critical interval determined by 
the results shown in Table 4.65.
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Fam ily 12
Markers 
Chromosome 15
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
11.1
unaff.
11.3
unaff.
11.2
proband
D15S128 0.78 22.54 6.11 5.82 205-207 201-209 205-209 205-201 205-201
D15S822 0.79 24.82 12.30 / 290-282 282-286 290-282 290-282 290-286
D15S219 / 25.37 14.58 15.05 233-203 225-223 233-225 233-225 233-225
AC079090 / 25.66 / / 228-228 228-238 228-228 228-228 228-238
AC024474 / 26.68 / / 211-215 211-211 21 1-211 211-211 211-211
D15S1048 0.84 27.44 19.12 21.07 222-226 222-226 222-222 222-222 222-226
D15S165 0.77 28.84 20.24 22.64 183-197 193-183 183-193 183-193 183-183
D15S1031 0.74 29.66 21.58 24.63 307-303 303-299 307-303 307-303 307-299
Table 4.70 Haplotype analysis results on chromosome 15ql3 in consanguineous Family 12 are not 
consistent with linkage to this locus. Fetus II.2 is homozygous for D15S165, although heterozygous for 
marker D15S1048. Heterozygosity, physical and genetic distances of each marker are indicated. Orange 
lines define the minimal critical interval determined by the results shown in Table 4.65. Unaff. means 
individual is unaffected.
Fam ily 13
Markers 
Chromosome 15
Het Mb 
Build 33
cM
Marshfield
cM
deCode
II.l
father
II.2
mother
III.l
proband
D15S128
D15S822
D15S219
AC024474
0.78
0.79
/
/
22.54
24.82
25.37
26.68
6.11
12.30
14.58
/
5.82
/
15.05
/
199-199
286-268
227-223
205-197
203-203
252-286
223-225
211-205
199-203
286-252
227-223
205-211
D15S1048
D15S165
0.84
0.77
27.44
28.84
19.12
20.24
21.07
22.64
221-225
197-183
228-228
199-183
221-228
197-199
Table 4.71 Haplotype analysis results on chromosome 15ql3 in consanguineous 
Family 13. The affected child III. 1 was heterozygous for all the markers typed, thus 
excluding linkage to this locus. Heterozygosity, physical and genetic distances of each 
marker are indicated. Orange lines define the minimal critical interval determined by 
the results shown in Table 4.65.
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Fam ily 14
Markers 
Chromosome 15
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
11.3 
proband
II.4
proband
D15S128
D15S219
AC024474
0.78
/
/
22.54
25.37
26.68
6.11
14.58
/
5.82
15.05
/
208-212
223-203
203-211
202-206
227-227
203-213
208-206
223-227
203-213
212-202
203-227
211-203
D15S1048 0.84 27.44 19.12 21.07 220-224 222-224 220-222 224-222
D15S1031
D15S1010
0.74
0.80
29.66
30.66
21.58
23.89
24.63
/
245-249
211-227
241-249
235-227
245-241
211-235
249-241
227-235
Table 4.72 Haplotype analysis results on chromosome 15ql3 in non-consanguineous 
Family 14. Patients II.3 and II.4 have inherited different paternal haplotypes, therefore 
linkage could not be supported. Heterozygosity, physical and genetic distances of each 
marker are indicated. Orange lines define the minimal critical interval determined by the 
results shown in Table 4.65.
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F am ily  15
M arkers 
Chromosome 15
D15S128
D15S822
D15S219
AC024474
D15S1048
D15S165
Het
0.78
0.79
/
/
0.84
0.77
Mb 
Build 33
22.54
24.82
25.37
26.68
27.44
28.84
cM
M arshfield
6.11
12.30
14.58
/
19.12
20.24
cM
deCode
5.82
/
15.05
/
21.07
22.64
1.1
father
203- 203 
282-294 
223-225 
209-209
226-202
183-183
1.2
mother
203-193
282-298
223-225
211-209
202-222
187-183
II.l
unaff.
203-203 
282-282 
223-223 
209-211 
226-202 
183-187
II.2
proband
203-193
294-298
225-225
209-209
202-222
183-183
113
proband
203- 203 
282-282 
223-223 
209-211 
226-202 
183-187
II.4
proband
203-193
294-298
225-225
209-209
202-222
183-183
Table 4.73 Haplotype analysis results on chromosome 15ql3 in non-consanguineous Family 15 are not consistent with 
linkage to this locus. Note how affected fetus II.3 has different haplotypes (highlighted in pink) compared to the other two 
affected fetuses II.2 and II.4 (highlighted in purple), but the same haplotypes as unaffected sib II.l. Heterozygosity, 
physical and genetic distances of each marker are indicated. Orange lines define the minimal critical interval determined 
by the results shown in Table 4.65. Unaff. means individual is unaffected.
Fam ily 16
Markers 
Chromosome 15
Het Mb 
Build 33
cM
Marshfield
cM
deCode
1.1
father
1.2
mother
11.2
unaff.
11.3
proband
D15S128
D15S822
0.78
0.79
22.54
24.82
6.11
12.30
5.82
/
199-205
303-259
197-199
299-287
199-197
303-299
199-197
303-299
D15S1048
D15S165
0.84
0.77
27.44
28.84
19.12
20.24
21.07
22.64
219-225
199-183
211-219
183-183
219-211
199-183
219-211
199-183
Table 4.74 Haplotype analysis results on chromosome 15ql3 in non-consanguineous 
Family 16. Patient II.3 has inherited the same pair of haplotypes as her unaffected sib H.2, 
therefore, linkage could not be supported. Heterozygosity, physical and genetic distances of 
each marker are indicated. Orange lines define the minimal critical interval determined by 
the results shown in Table 4.65. Unaff. means individual is unaffected.
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Fam ily 15
Markers 
Chromosome 14
Het Mb 
Build 33
cM
Marshfield
cM
deCode
D14S739 0.83 80.26 91.62 81.73
D14S68 0.91 86.62 95.89 /
D14S1044 0.67 88.06 99.88 90.62
D14S617 0.78 90.19 105.53 94.47
1.1
father
1.2
mother
11.1
unaff.
11.2
proband
11.3
proband
11.4
proband
180-192
138-138
205-201
158-146
180-188
129-138
199-201
142-146
180-180
138-129
205-199
158-142
180-180
138-129
205-199
158-146
192-180
138-129
201-199
146-142
192-188
138-138
/
146-146
Table 4.75 Haplotype analysis results on chromosome 14q24-q32 in non-consanguineous Family 15 are not consistent 
with linkage to this locus. The three affected fetuses have in fact different haplotypes across the region determined by the 
results shown in Table 4.19. Heterozygosity, physical and genetic distances of each marker are indicated. Unaff. means 
individual is unaffected.
4.3.6 Summary
In conclusion, genotyping and haplotype analysis was performed in a total of twelve 
consanguineous and four non-consanguineous JATD families across the four main 
putative JATD loci identified on chromosomes 3, 8,12 and 15.
Five families were consistent with linkage to 3q24-q26. The results in three other 
families supported linkage to 8q24. Three families were consistent with linkage to 
15ql3, while none of the families typed were consistent with linkage to the 12q23-q24 
locus. Homozygous regions were detected on both chromosomes 3 and 15 in Family 8 
and on both chromosomes 8 and 15 in Family 9. The region on 14q24-q32 was 
investigated only in two families due to time constraints. Each region was refined as 
tightly as possible by typing a large number of closely spaced microsatellite markers, 
thus allowing the search for suitable candidate genes to begin.
4.4 Screening of candidate genes
The three putative JATD loci identified in this study (3q24-q26, 8q24 and 14q24-q32) 
were analysed for candidate genes using three main tools to interrogate human genome 
data, namely, the Ensembl genome browser, the Golden Path at the UCSC human 
genome browser and the NCBI Map View (Build 33, April 2003 freeze). These three 
tools were used to generate an integrated view of genetic and physical maps across the 
defined loci and to locate genes on the chromosomal assemblies. Candidate genes were 
then selected in each interval and screened for causative mutations. The nomenclature 
for describing sequence variants is according to den Dunnen and Antonarakis (2000) 
and the new recommendations at http://www.hgvs.org/mutnomen/recs.html (den 
Dunnen and Antonarakis, 2000).
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4.4.1 Chromosome 3q24-q26
4.4.1.1 SHOX2 as a candidate gene
The common homozygous region originally identified in affected cousins IV. 1 and
IV.3 in Family 1 was about 17 cM/23 Mb in size between markers D3S1555 and 
D3S1574 and contained 145 known or predicted genes. A good candidate gene in this 
region was thought to be the short stature homeobox 2 gene SHOX2 (NM_006884.1), 
located at 3q25-q26.1, between markers D3S1607 and D3S3692 (see Table 4.24). This 
gene lies in the common homozygous interval in Family 1, 5, 6 and 8.
SHOX2 is closely related to the pseudoautosomal homeobox gene SHOX, defects in 
which are known to lead to idiopathic short stature (Rao et al., 2001), Leri-Weill 
syndrome (Shears et al., 1998) and short stature associated with Turner syndrome 
(Clement-Jones et al., 2000). Homozygous SHOX mutations have been shown to cause 
Langer-type mesomelic dwarfism (Shears et al., 2002). SHOX2 is the othologue of the 
mouse gene Ogl2x. SHOX2 is expressed in a variety of human embryonic tissues 
including limbs, metanephric mesoderm, heart and pharyngeal arches (Clement-Jones 
et al., 2000). During mouse embryonic development, expression of Ogl2x could be 
detected in mesoderm derivatives that contribute to bone and cartilage formation in the 
limb, ribs and spinal cord (Blaschke et al., 1998).
4.4.1.2 Structure ofSHOX2
SHOX2 was cloned and mapped to chromosome 3q25-q26 by Blaschke and colleagues 
(Blaschke et al., 1998). Two different isoforms were identified, SHOX2a and SHOX2b 
and their mRNA transcripts were available in the database (NM_006884.1 and 
NM_003030.2 respectively) providing the full coding sequence. The intron/exon 
structure was determined by BLAST interrogation of the transcript sequences against 
the genomic sequence using the BLAST program available at NCBI 
(http://www.ncbi.nlm.nih.gov/BLAST/). The coding sequence was then translated
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using Biology Workbench (http://workbench.sdsc.edu) to identify the start codon. The 
larger transcript SHOX2a (NM 006884.1) is comprised of five exons and encodes a 
protein of 331 amino acids.
Primers to amplify the five exons were designed and synthesised as described in section
2.3.2.3. Primer details and PCR conditions are shown in Table 2.11. The primers were 
spaced so that splice sites as well as exons could be screened.
4.4.1.3 Mutation screening
PCR amplification of SHOX2 was carried out as described in section 2.3.2.5. Each exon 
was successfully amplified by PCR in both the carrier father (III. 1) and affected child 
(IV. 1) from Family 1; the carrier mother (1.2) and affected child (II.2) from Family 6; 
the carrier mother (1.2) and affected child (II. 1) from Family 8 as well as in the father 
(1.1) from Family 5. The patient II. 1 in Family 5 could not be screened as there was 
little DNA and this was difficult to amplify. A single product of the expected size was 
obtained for each individual exon. Therefore, no evidence of a small homozygous 
insertion or deletion within any of the exons was detected on PCR in any of the 
patients, except for the affected child in Family 5 who was not screened.
All five exons were screened for mutations by direct sequencing using protocols 
detailed in section 2.3.8. Data were analysed using Sequencher 4.1 (see section 2.3.8.3) 
in both the carrier father (III. 1) and affected child (IV. 1) from Family 1, the carrier 
mothers 1.2 and 1.2 from Family 6 and Family 8 respectively as well as the father (1.1) 
from Family 5. No pathogenic mutations were identified. Two known intronic variants 
were found in all the individuals screened: c.557+42G>A (dbSNP4462902) in intron 2 
and c.703+131T>C (dbSNP9833383) in intron 4. The affected child IV. 1 was 
homozygous for both changed alleles as were his unaffected father and unaffected 
individuals 1.2 (Family 6) and 1.1 (Family 5). The unaffected mother 1.2 from Family 8 
was heterozygous for both variants.
SH0X2 lies in the homozygous region common to consanguineous Families 1, 5, 6 and 
8. However, assuming linkage to 3q24-q26 in non-consanguineous Family 14, SH0X2
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lies outside the interval identified by the recombination event in unaffected child II. 1 
from this family (see Table 4.24). Twenty-eight known or predicted genes map to the 8 
cM/12 Mb homozygous region common to Family 1, 5, 6, 8 and 14 between markers 
D3S3575 and D3S3523, although only eighteen were thought to represent likely 
candidate genes (Table 4.76).
4.4.2 Chromosome 8q24
4.4.2.1 WISP1 as a candidate gene
The common homozygous region originally identified in affected sibs VI.3 and VI.5 in 
Family 2 was about 13 cM/ 8 Mb in size between markers AC103725 and AC087711-2 
(Table 4.14). A schematic representation of the genes in the region is given in Figure 
4.15 and their details in Table 4.77. A good candidate gene in the region was thought to 
be WISP1 (NM_003882.2) located at 133.9 Mb on 8q24.1-q24.3, between markers 
D8S529 and D8S256. WISP1 encodes the Wntl-inducible signalling pathway protein 1
(WISP1/CCN4) which belongs to the CCN family of secreted proteins (connective 
tissue growth factors) including cystein-rich 61 (CYR61/CCN1), connective tissue 
growth factor (CTGF/CCN2), nephroblastoma overexpressed (NOV/CCN3), Wntl- 
inducible signalling pathway proteins-2 (WISP2/CCN5) and -3 (WISP3/CCN6). 
Collectively, these proteins regulate fundamental biological processes, including cell 
adhesion, growth, differentiation, apoptosis, embryogenesis, vascular diseases 
tumorigenesis and skeletogenesis.
WISP1 was thought to be a good functional candidate for JATD. Recently, the role of 
WISP1 during skeletogenesis has been elucidated and expression during embryonic 
development was shown in osteoblast and osteoblastic progenitor cells of the 
perichondral mesenchyme (French et al., 2004). In human tissues, WISP1 expression 
was seen in a variety of adult organs including kidney, pancreas, lung, heart, ovary and 
spleen (Pennica et al., 1998). Furthermore, mutations in the WISP3/CCN6 gene are 
associated with progressive pseudorheumatoid dysplasia (PPAC; MIM 208230), an
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Gene OMIM Description of protein
D3S3575
SCHIP1 Schwannomin-interacting protein 1; interacts with NF2 (neurofibromatosis protein type 2); widely expressed
IL12A 161560 Interleukin 12A precursor; subunit of cytokine that acts on T 8c natural killer cells; important in resistance to TB and leishmania
AB037795 Not RefSeq gene; hypothetical protein, unknown function; WD40 repeats; Aceview says widely expressed
SMC4L1 605575
Structural maintenance of chromosome 4; important role in DNA repair/condensation & segregation of mitotic chromosomes; 
housekeeping gene; widely expressed
TSBF1 Tumour suppressor TSFBl-like; hypothetical protein, unknown function; zinc-binding motifs; not widely expressed
KPN A 4 602970 Karyopherin alpha 4 (importin alpha 3); mediates nuclear import; housekeeping gene; expressed in testis, ovary, intestine & pancreas
FU22595 Hypothetical protein, unknown function; ADP ribosylation factor; not widely expressed, but not expressed in the right tissues
PPM1L Hypothetical protein; probable protein phosphatase type 2C; not widely expressed - brain, muscle
B3GALT3 603094
Beta-l,3-galactosyltransferase subunit 3; housekeeping gene; membrane-bound glycoprotein - role in protein glycosylation; mutations 
cause globoside-deficient blood group phenotype
CGI-07 CGI-07 protein, possibly related to ribosomal function or nonsense-mediated mRNA decay; very widely expressed
ADMP
Anti-dorsalising morphogenetic protein; TGF-beta homolog related to BMP-3 with important role in dorsal-ventral patterning v. early in 
development; not widely expressed
BC027488 Not a Refseq gene - hypothetical protein
AF109183 Endogenous retrovirus mRNA
SI 222900 Sucrase isomaltase; congenital deficiency causes sucrose intolerance
SLITRK3 SLIT and NTRK-like family, member 3
BCHE 177400 Butyrylcholinesterase precursor; mutated in suxamethonium sensitivity (apnea)
FU 23049 Hypothetical protein, unknown function; not widely expressed - testis, brain, lung
SERPINI2 605587 Serine protease inhibitor 14; expressed mainly/exclusively in pancreas - role in growth-suppressing pathway
WD40A66 Not a Refseq gene - hypothetical protein
PDCD10 Programmed cell death 10; resembles proteins that participate in apoptosis; very widely expressed
SERPINI1 602445 Protease inhibitor 12 (neuroserpin); expressed mainly in brain; mutated in familial encephalopathy
GOLPH4 606805 Golgi phosphoprotein 4; may assist in protein processing & transport in the Golgi; widely expressed
BC011266 Not a Refseq gene - hypothetical protein
EVI1
Ecotropic virus integration 1 site & Myelodysplasia syndrome protein 1; different transcripts - EVI1 & MDS1/EVI1; role as 
transcriptional activator; involved in fusions in AML; not very widely expressed
MDS1 600049 Myelodysplasia syndrome 1
ARP M l Actin-related protein M l; probable role in cytoskeletal organisation; widely expressed
MYNN 606042 Myoneurin; zinc finger transcription factor; mainly in skeletal muscle, also testis, ovary, placenta; clones include cartilage, kidney
MGC27085 Hypothetical protein, unknown function; leucine-rich repeat; quite widely expressed induing kidney & eye
D3S3523
Table 4.76 List of genes on chromosome 3q24-q26 between markers D3S3575 and D3S3523. While several of these genes can be ruled 
out on the grounds of inappropriate expression patterns and/or known roles in other human disorders (highlighted in grey), only 
eighteen of them were thought to represent possible candidate genes requiring further investigation. Many are genes encoding 
hypothetical proteins of unknown function.
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Figure 4.15 Schematic representation of candidate genes lying in the homozygous 
interval identified in Family 2 on chromosome 8q24 (left). Overlapping regions of 
homozygosity between Families 2, 9 and 10 are shown on the right. Microstallite 
markers that define each intervals are also listed. In red are highlighted the genes 
screened for mutations. For a brief description of each gene see Table 4.77.
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Gene OMIM Description of protein
ACl 03725
HSPC054 Hypothetical protein, unknown function; may be a pseudogene
ADCY8 103070 Adenylate cyclase type 8; predominantly expressed in brain
D63477 Hypothetical protein, unknown function; quite widely expressed
OC90 601658 Otoconin 90-glycoprotein found in otoconia of the inner ear, expressed only in developing otocyst
HHLA1 604109 HERV-H LTR- associated 1; novel gene, unknown function; endogenous retrovirus in an intron
KCNQ3 602232 Subunit of voltage gated K+ channel; mutated in a rare form of AD epilepsy (benign neonatal familial convulsions)
TSLRP Testis- specific leucine-repeat rich protein; hypothetical protein, unknown function; not expressed only in testis
FU33069 Hypothetical protein, unknown function; quite widely expressed
CGI-72 Hypothetical protein, unknown function; probably nuclear; widely expressed
TG 188480 Thyroglobulin; precursor of thyroid hormones
SLA 601099 Src-like adaptor; negative regulator of antigen receptor; mediated signal transduction in B and T lymphocytes
WISP1 603398 WNT1-inducible signalling pathway protein 1; connective tissue growth factor
NDRG1 605262
N-myc downstream regulated gene 1; mutated in rare recessive HSMN (Lorn type); expressed especially in Schwann cells of PNS; role 
in growth arrest/cell differentiation
SIAT4A 607187 Syalyltransferase 4A; widely expressed
ZNF406 Zinc finger protein 406; putative zinc finger transcription factor; widely expressed
KHDRBS3 Testis signal transduction and activation of RNA (T-STAR); expressed mainly in testis, skeletal muscle, brain and heart
GLYLU Hypothetical protein, unknown function; expressed especially in brain and testis
AC087711-2
Table 4.77 List of genes on chromosome 8q24 between markers AC 103725 and AC087711-2. A few of these genes can be ruled out on 
the grounds of inappropriate expression patterns and/or known roles in other human disorders (highlighted in grey), whereas others 
represent possible candidate genes requiring further investigation. Many are genes encoding hypothetical proteins of unknown function. 
WISP1 ,GLYLU and ZNF406 were screened for mutations in this study.
autosomal recessive skeletal disorder characterized by continued cartilage loss and 
bone destruction (Hurvitz et al., 1999).
4.4.2.2 Structure o f WISP 1
WISP1 was cloned and mapped to chromosome 8q24.1-q24.3 by Pennica and 
colleagues (Pennica et al., 1998). Alternative splicing of the gene generates two 
transcripts (NM_003882.2 and NM_080838). The larger transcript (NM_003882.2) 
comprises five exons and encodes the full length protein of 367 amino acids. The 
transcript sequence, the intron/exon boundaries, as well as the full protein sequence 
were available in the database at the Ensembl Human Genome Browser.
Primers for the five exons were designed and synthesised as described in section
2.3.2.3. Primer details and PCR conditions are shown in Table 2.12. The primers were 
spaced so that splice sites as well as exons could be screened.
4.4.2.3 Mutation screening o f WISP1
All five exons were mutation screened by direct sequencing using protocols detailed in 
section 2.3.8 and analysed using Sequencher 4.1 (see section 2.3.8.3) in the mother 
(V.6) from consanguineous Family 2 as well as in thirteen sporadic affected 
individuals: probands III.l from Family 13, II.3 from Family 18, II. 1 from Family 19, 
II. 1 from Family 20, II.2 from Family 21, II. 1 from Family 24, II. 1 from Family 25, II. 1 
from Family 26, II. 1 from Family 27, II.4 from Family 28, II. 1 from Family 29, II.3 
from Family 30, II. 1 from Family 31. DNA samples from the three probands in 
Families 17, 22 and 23 were not available for screening, therefore the six unaffected 
parents were screened instead. A control DNA was also included in the analysis.
No pathogenic mutations were identified, although a number of variants, mainly 
intronic, were found during sequence analysis. A nucleotide substitution was identified
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in exon 3 in affected individual II. 1 from Family 31 (c.550G>A) resulting in a 
p.Vall84Ile alteration.
In exon 5, a silent substitution c.921T>C, which did not change Asn at position 307, 
was identified. Six probands were heterozygous for the change, as was the control. This 
synonymous variant was listed in the NCBI SNP database (dbSNP3739261).
In the proband from Family 24, a heterozygous G>A variant at -115 from the ATG was 
found in the 5’UTR. It was not listed in the NCBI SNP database as a known SNP.
A heterozygous c.70-39T>C intronic variant (dbSNP 10089461) was identified in intron 
1 in five affected individuals (Families 13, 19, 24, 25 and 28) and in the unaffected 
parents from Families 2, 17, 22 and 23. Probands in Families 18, 21, 26 and 27 were 
homozygous for the C allele.
A heterozygous c.611-55G>C intronic variant (dbSNP2280834) was found in intron 3 
in almost all the individuals screened, including the control. Exceptions were 
individuals from Families 17, 18 and 27 who were homozygous for the C allele and 
probands from Families 29 and 31 who were homozygous for the G allele.
4.4.2.4 GLYLU as a candidate gene
Following genotyping analysis of other JATD families, Families 9 and 10 were 
consistent with linkage to 8q24. Assuming linkage in these families, the common 
homozygous interval in Families 2, 9 and 10 was narrowed down to a 2 cM (1.65 Mb) 
region defined by marker D8S274 at the centromeric end and marker AC087711-2 at 
the telomeric end (Fig. 4.15). WISP1 lies outside this interval. Analysis of the region 
using the UCSC Genome Browser showed no gaps in the sequence and led to the 
identification of only one gene predicted by Ensembl and Acembly between markers 
AFM316xbl and AC087711-2. The gene encoding hypothetical protein LOC51059 
(NM_015912.2) was called GLYLU by Acembly and was predicted to have four 
different spliced forms. Supporting evidence for this gene came from Twinscan and 
SGP gene prediction programs using mouse/human homology, the presence of human
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mRNA transcripts (the longest being AK091433) and spliced ESTs. Furthermore, the 
gene appeared to be conserved in mouse and fugu.
GLYLU was considered an excellent positional candidate, although information about 
the protein’s (hypothetical protein LOC51059) expression and function were poor. It 
does not belong to any known protein family. Supporting clones came from brain, testis 
and pooled germ cell tumours. PSORT predicts that it localizes to the nucleus; 
PROSITE predicts a thiol protease site in exon 12.
4.4.2.5 Structure o f GLYLU
Ensembl, Acembly and Twinscan made slightly different predictions of the gene. All 
exons identified by these programs were analysed and the complete cDNA was 
assembled and translated using Biology Workbench, the start codon in exon 2 and the 
longest open reading frame determined. Primers were designed for each exon and 
synthesised as described in section 2.3.2.3. Primer details and PCR conditions are 
shown in Table 2.13. The primers were spaced so that splice sites as well as exons 
could be screened. This novel gene was determined to comprise twenty-two exons.
4.4.2.6 Mutation screening o f GLYLU
Mutation screening was carried out in a single parent from each of the three families 
(Families 2, 9 and 10) consistent with linkage to 8q24. All twenty-two exons were 
mutation screened by direct sequencing using protocols detailed in section 2.3.8 and 
analysed using Sequencher 4.1 (see section 2.3.8.3). Each exon was successfully 
amplified by PCR in the three parents and also in affected individual (VI.3) from 
Family 2, thus excluding a microdeletion in any of the exons in this family.
No pathogenic mutations were identified, although a number of heterozygous 
synonymous alterations (that did not alter amino acids, due to third base wobble) were 
found throughout the gene. Only one nucleotide substitution identified in all three
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individuals screened altered an amino acid in exon 8 (p.Arg362Ser). Exon 8 was then 
sequenced in proband VI.3 from Family 2 and she was homozygous for the serine 
residue, but so was her unaffected mother. Moreover, exon 8 was thought not to 
represent a true exon as it was predicted only by Ensembl (transcript 
ENST00000303060) and was not supported by evidence from any other source.
4.4.2.7 Further genes on 8q24
No further genes were identified in the common region of homozygosity in Families 2,
9 and 10 therefore the attention shifted to the region of overlap between Families 2 and
10 defined by markers D8S256 and D8S274 (Fig. 4.36). A reason for that was the 
uncertainty about the diagnosis in the affected child from Family 9. He had in fact 
extremely mild radiological findings and was described as not a classic JATD case. It 
was thought that the homozygosity across this region might have been a chance finding 
considering the fact that he also showed homozygosity across the 15ql3 locus.
Three genes lie in this 3 Mb interval with no gaps in the sequence, SIAT4A, ZNF406 
and KHDRBS3 (Fig. 4.15). SIAT4A (sialyltransferase 4A) is a glycosyltransferase 
widely expressed in adult tissues, cancer and fetal tissues. ZNF406 contains multiple 
zinc finger motifs and an AT-hook and appears to encode a zinc finger transcription 
factor. It is expressed in a wide variety of adult tissues and tumours and was predicted 
by PSORT to localise to the nucleus. KHDRBS3 alternatively named T-STAR (testis- 
signal transduction and activation of RNA) is a Sam68-like phosphotyrosine nuclear 
protein involved in RNA processing and signal transduction, specifically in regulating 
alternative splicing in response to extra-cellular signals. It is expressed in testis, skeletal 
muscle, brain and heart. ZNF406 was thought to be the best candidate gene of the three, 
and was therefore sequenced first.
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4.4.2.8 Structure o f  ZNF406
ZNF406 (NM_020863.2) was predicted by Acembly, Ensembl, Twinscan and SGP 
gene prediction programs. Ensembl predicts three slightly different transcripts. Exon 1 
(transcript ENST318135) seems to contain the true start codon of the gene encoding a 
methionine, preceded by a convincing Kozak sequence and a CpG island. The complete 
cDNA was assembled and translated using Biology Workbench. The larger transcript 
comprises seventeen exons and encodes a protein of 1284 amino acids. The protein 
appears to be conserved not only in mouse, but also partially in fugu. Primers were 
designed for each exon and synthesised as described in section 2.3.2.3. Five primer 
pairs were designed to screen exon 7. Primer details and PCR conditions are shown in 
Table 2.14. The primers were spaced so that splice sites as well as exons could be 
screened.
4.4.2.9 Mutation screening o f ZNF406
All seventeen exons were screened for mutations by direct sequencing using protocols 
detailed in section 2.3.8 and analysed using Sequencher 4.1 (see section 2.3.8.3) in the 
unaffected father (V.5) from Family 2 and the unaffected mother (1.2) from Family 10.
In the mother from Family 10, two intronic variants and four heterozygous synonymous 
polymorphisms were found throughout the gene. A heterozygous c.20-41A>G variant 
was identified in intron 1. A heterozygous c.637+74A>G intronic known variant 
(dbSNP2277138) was found in intron 5. A heterozygous synonymous c.990T>C known 
alteration (dbSNP3739422) that did not change the Tyr residue at position 371 was 
identified in exon 7. In exon 8 a c.2409A>G reported alteration (dbSNP894344) which 
did not change the Asp residue 844 was found. In exon 17 a non-reported heterozygous 
synonymous variant (c.3621G>A) resulted in the same amino acid residue (Thr 1248).
A poor quality sequence was obtained for exon 9. Primers ZNF4069F and ZNF4069R 
(listed in Table 2.14) were therefore used to amplify a 426 bp PCR fragment containing 
exon 9 of the gene and PCR products from both parents (Family 2 and 10) were
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subcloned using the PCR-Script™ Amp Cloning kit as described in section 2.3.9. 
Colony PCR was then performed as explained in section 2.3.10 and the products were 
sequenced as described in section 2.3.8. In individual 1.2 from Family 10 a 
heterozygous synonymous known variant c.2493T>C (dbSNP3739425) that did not 
change the Ser residue 872 was identified in exon 9.
In the father (V.5) of Family 2, a heterozygous synonymous known alteration 
c.1257T>C (dbSNP3739423) that did not change the Arg residue 460 was identified in 
exon 7. In exon 16 a synonymous reported variant c.3384C>T (dbSNP 11778717) 
resulted in the same amino acid residue (Ala 1169). In this family, two non- 
synonymous alterations were identified in exons 3 and 4.
In exon 3, a heterozygous c.190G>A transition resulting in an amino acid change 
(p.Glyl05Arg) was identified in the father (V.5). This is not a conservative change and 
the mouse protein has Gly at the same position. To analyse the segregation of the 
alteration with the disease within the family, a Hpall restriction digest was performed 
(see section 2.2.4). Primers ZNF4063F and ZNF4063R (listed in Table 2.14) were used 
to amplify a 387 bp PCR fragment containing exon 3 of the gene. A Hpall restriction 
site occurs after base 292 of this fragment if the nucleotide G is present. After 
digestion, normal 387 bp, 292 bp and 95 bp bands were detected on a 4% agarose gel in 
the unaffected father (V.5), mother (V.6) and unaffected sib (VI.2) indicating that they 
were heterozygous for the alteration (Fig. 4.16). In unaffected child VI.4 only the 292 
bp and 95 bp bands were detected on agarose gel, indicating that she was homozygous 
for the G allele. In the affected children VI.3 and VI.5 only the uncut 387 bp PCR 
product was detected, indicating that they were both homozygous for the variant allele 
A and therefore homozygous for the Arg residue at position 105. This amino acid 
substitution does not occur in a region of the gene of obvious functional significance 
and Blast interrogation revealed the presence of one human mRNA IMAGE clone 
(3840083) which has the same base alteration.
In exon 4, a heterozygous c.304C>T substitution results in a p.Prol43Ser change. This 
is not a conservative change and the mouse protein also has a Pro at the same position, 
although this was a reported variant (dbSNP 12541381). To analyse the segregation of 
the alteration with the disease within the family, an Acil restriction digest was
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Figure 4.16 Segregation of the c.190G>A transition in Family 2. The alteration 
destroys a Hpall site that occurs after base 292 of the 387 bp PCR product 
ZNF4063F/R containing exon 3. In affected individuals VI.3 and VI.5, PCR 
amplification of genomic DNA using primers pair ZNF4063F and ZNF4063R, 
followed by digestion with Hpall and analysis on a 4% agarose gel, gave the 387 
bp fragment representing the uncut PCR product indicating that they were 
homozygous for the variant allele A. In unaffected individuals V.5, V.6 and VI.2 
all three bands were seen, indicating that they were heterozygous for the change. 
In unaffected individual VIA only the 292 bp and the 95 bp fragments were 
detected, indicating that she was homozygous for allele G. Solid symbols 
represent affected individuals. Lane 2, V.5. Lane 3, V.6. Lane 4, VI.2, Lane 5, 
VIA. Lane 6, VIA. Lane 7, VIA. The size marker in Lanes 1 and 8 is a 50 bp 
DNA ladder.
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Figure 4.17 Segregation of the c.304C>T transition in Family 2. Acil cuts the 
459 bp PCR product ZNF4064F/R (containing exon 4) in two positions, at 184 
and 91. The alteration destroys the Acil site that occurs after base 91 of the PCR 
product. In affected individuals VI.3 and VI.5, PCR amplification of genomic 
DNA using primers pair ZNF4064F and ZNF4064R, followed by digestion with 
Acil and analysis on a 4% agarose gel, gave 184 bp and 91 bp fragments, 
indicating that they were homozygous for allele C. In unaffected individuals V.5,
V.6 and VI.2 all three bands were seen, indicating that they were heterozygous 
for the change. In unaffected individual VI.4 only the 274 bp and the 184 bp 
fragments were detected, indicating that she was homozygous for allele T. Solid 
symbols represent affected individuals. Lane 2, V.5. Lane 3, V.6. Lane 4, VI.2, 
Lane 5, VIA. Lane 6, VI.3. Lane 7, VI.5. The size marker in Lanes 1 and 8 is a 
50 bp DNA ladder.
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performed (see section 2.3.4). Primers ZNF4064F and ZNF4064R (listed in Table 2.14) 
were used to amplify a 459 bp PCR fragment containing exon 4 of the gene. Two Acil 
restriction sites occur after base 184 and base 91 of this fragment if the nucleotide C is 
present. However, if nucleotide T is present, the site after base 91 is destroyed resulting 
in a 274 bp fragment and a 184 bp fragment. After digestion, 274 bp, 184 bp and 91 bp 
bands were detected on a 4% agarose gel in the unaffected father (V.5), mother (V.6) 
and unaffected sib (VI.2) indicating that they were heterozygous for the alteration (Fig. 
4.17). In the affected children VI.3 and VI.5 a 184 bp band and a 91 bp band were 
detected, indicating that they were both homozygous for allele C and therefore 
homozygous for the Pro at residue 143. In unaffected child VI.4 only the 274 bp and 91 
bp bands were detected on an agarose gel, indicating that she was homozygous for the 
T allele. Therefore, it is very unlikely that the change is pathogenic.
4.4.3 Chromosome 14q24-q32
The region on chromosome 14q24-q32 was homozygous in probands II.6 and II.8 from 
Family 4. The region was about 19 cM/14 Mb in size between markers D14S74 and 
D14S977 (see Table 4.19) and contained sixty-nine known and predicted genes.
Interestingly, BBS8 (TTC8), mutations in which are responsible for Bardet-Biedl 
syndrome (BBS; MIM 209900), lies in this interval (Ansley et a l, 2003). BBS is a 
genetically heterogeneous disease with linkage to eight loci characterized by multiple 
clinical features and a complex model of inheritance (Ansley et a l, 2003; Katsanis et 
al, 2001). Six BBS genes have been identified and recent studies have suggested that 
ciliary defects compromising intraflagellar transport (IFT) are responsible, at least in 
part, for the BBS phenotype (Kim et al, 2004; Kulaga et a l, 2004; Blacque et al, 
2004). Three proteins, BBS4, BBS5 and BBS8 localized to ciliated borders in tissues, 
and to the basal body in cultured cells. The latter have a role in microtubule 
organization of ciliated cells (Kim et al, 2004; Ansley et a l, 2003; Badano et al, 
2003). BBS4 and BBS8 contain several tetratricopeptide repeats (TPRs) that are
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involved in protein-protein interactions (Ansley et al., 2003). BBS8 is a centrosomal 
protein and localizes specifically to ciliated structures, such as the connecting cilium of 
the retina and columnar epithelial cells in the lung (Ansley et al., 2003). BBS4 is a 
pericentriolar protein necessary for recruiting cargo to centriolar satellites by acting as a 
dynein-associated adaptor protein (Kim et al., 2004).
As described in more detail in section 5.4.3, it has been suggested that genes encoding 
intraflagellar transport (IFT) proteins might be promising candidate disease genes for 
JATD (Pazour and Rosenbaum, 2002; Rosenbaum and Witman, 2002). Typical features 
of JATD such as cystic kidneys and retinal degeneration in combination with skeletal 
defects and other abnormalities might be caused by defects in cilia, as has been 
demonstrated for BBS and Senior-Loken syndrome (MIM 266900) (Pazour and 
Rosenbaum, 2002; Rosenbaum and Witman, 2002; Schuermann et al., 2002).
4.4.3.1 TTC7B as a candidate gene
A gene encoding a tetratricopeptide repeat domain 7B protein TTC7B (XM 085175.4) 
was identified on 14q24-q32 at 89 Mb between markers D14S1044 and D14S995 (see 
Table 4.19) and represented an excellent candidate gene for JATD. TTC7B contains 
five TPR domains, one coatomer WD associated region and a domain similar to the 
prokaryotic pilF  domain involved in pilus assembly and intracellular trafficking. It is 
conserved in mouse and fugu and the homologous mouse protein is expressed in bone, 
kidney, pancreas, retina and lung.
4.4.3.2 Structure o f TTC7B
The structure of TTC7B (XM_085175.4) was retrieved from the NCBI database and 
intron-exon boundaries determined from AL832848 (except for exon 1 which was 
identified in genomic contig NT_026437.1447). Ensembl also predicted exon 3-21 
(ENS267557). The complete cDNA was assembled and translated using Biology 
Workbench. The larger transcript comprises twenty-one exons and encodes a protein of
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860 amino acid. Primers were designed for each exon and synthesised as described in 
section 2.3.2.3. Primer details and PCR conditions are shown in Table 2.15. The 
primers were spaced so that splice sites as well as exons could be screened.
4.4.3.3 Mutation screening o f TTC7B
Seventeen exons were successfully amplified and screened for mutations by direct 
sequencing using protocols detailed in section 2.3.8 and analysed using Sequencher 4.1 
(see section 2.3.8.3) in the affected child II.6 from Family 4. Exons IB, 2, 8 and 21 
could not be amplified and therefore were not screened.
No pathogenic mutations were identified in the coding sequence of the gene. Only a 
known synonymous variant c.1292A>G (dbSNP342660), which did not change the Pro 
residue 428 was identified in exon 11.
4.4.4 Further investigations of candidate loci
A yeast two hybrid (Y2H) screen for proteins that might interact with EVC was carried 
out by Prof. Goodship’s group. EVC Y2H positives were checked to see if any of them 
mapped to the five JATD loci, but none did (personal communication).
Nucleotide and protein homology searches for genes and proteins similar to EVC and 
EVC2 within the putative JATD loci have been performed in this study with no success.
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Chapter 5 JATD Discussion
This study aimed to map the gene or genes for JATD by linkage analysis using the 
technique of homozygosity mapping. At the beginning of the project, two candidate 
regions, the EVC/EVC2 region and the 12pl l-pl2 region had been proposed for JATD. 
A mouse model (srt) for JATD had also been suggested. Srt maps to mouse 
chromosome 17 and in humans the three regions which are likely to contain the human 
homologue of the gene at the srt locus are on 6p21, 6q25-q27 and 16pl3.3. Linkage to 
all loci was excluded in a number of JATD families.
Following a genome-wide screen in three consanguineous JATD families, three regions 
were identified, one in each of the families studied. In each case the potential JATD 
locus was refined by typing other consanguineous and non-consanguineous families. 
Candidate genes were then chosen in these loci and screened for causative mutations by 
direct sequencing of coding regions. No mutations have been identified in the genes 
screened.
The project started when two large consanguineous JATD families (Families 1 and 2) 
were recruited. In Family 1, where the two affected children are double first cousins, it 
was calculated that, if DNA could be obtained from the 2 unaffected children in 
generation IV as well (giving a total of 12 informative meioses), a lod score of 3.6 
could be obtained with a highly-polymorphic marker tightly linked to the disease locus. 
In Family 2, where the two affected sisters are the children of a third-cousin marriage, 
it was calculated that, if DNA could be obtained from all 3 unaffected siblings (giving a 
total of 16 informative meioses), a lod score of 4.8 could be obtained. Subsequently, 
DNA was obtained from a further 10 consanguineous families and 19 non- 
consanguineous families. A second genome-wide screen was performed in the affected 
individual in consanguineous Family 4.
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5.1 Exclusion of candidate genes/loci
Linkage to the E VC/E VC2 region, previously thought to be a candidate locus for JATD, 
was excluded in this study in seven JATD families. These results support those of 
Krakow et al., who excluded linkage to EVC in one JATD family (Krakow et al., 
2000). Family 12 was not consistent with linkage to any of the identified JATD loci 
and a region of homozygosity was identified in the affected fetus across the EVC/EVC2 
locus. The affected fetus was said to have a phenotype compatible both with JATD and 
with EVC.
Linkage to the candidate JATD locus on 12pl 1.21-pi2.2 in Families 1 and 2 was also 
excluded. Finally, linkage in Families 1 and 2 to 6p21, 6q25-q27 and 16pl3, which are 
homologous to part of the critical region on mouse chromosome 17 where the srt 
mouse maps (Herron et al., 2002), was also excluded.
5.2 Homozygosity mapping
The homozygosity mapping approach was then adopted. Initially a genome-wide screen 
in the four affected children from Families 1 and 2 was performed. Calculations suggest 
that, if the parents are first cousins, the region of homozygosity around the disease 
locus in the affected child is likely to be about 28 cM; if the parents are second cousins, 
about 22 cM; if third cousins, smaller still (Genin et al., 1998). It has also been 
calculated that highly-polymorphic markers spaced on average every 5 cM should be 
sufficient to demonstrate linkage in four affected individuals who are the offspring of 
different first or second cousin marriages (Lander and Botstein, 1987). Therefore, it 
was estimated that the new Single Chromosome Scan linkage marker set from Research 
Genetics, which has an average marker spacing of 7 cM, would be sufficient; but as 
explained in section 4.2.1.2, the first-pass screen with this marker set did not give 
adequate coverage of the genome. Furthermore, only four markers were found at which 
all four affected children were homozygous: D4S3249 and D4S2394 on different parts
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of 4q, D8S1119 on 8q and D17S1298 on 17p. All four regions were excluded when 
adjacent markers were typed. Therefore a second-pass screen was carried out, using 
additional polymorphic markers, aiming to fill in any gaps greater than 7-10 cM 
between the markers tested.
After the second-pass screen, more regions in which all four affected children were 
homozygous were identified, but subsequently excluded when adjacent markers were 
found to be heterozygous in the patients. A region that was IBD in all four children was 
not identified. Inividual regions of homozygosity within each family were then sought, 
and each investigated further. Two distinct loci were identified in Families 1 and 2 as a 
result of the second-pass complete genome-wide. In this study, a third candidate locus 
was identified following another genome-wide screen in Family 4. Two different loci 
were independently identified by our collaborators in Paris and Birmingham following 
genome-wide screens. Locus heterogeneity for JATD was therefore demonstrated, with 
at least five loci identified so far. This had been considered, but not assumed, during the 
first stages of the project. Therefore, the initial interpretation of the results from the 
genome-wide screen was misleading as only common regions of homozygosity in both 
families were investigated.
5.3 Candidate regions
The five JATD loci are on chromosomes 3q24-q26, 8q24 and 14q24-q32, identified in 
this project and 12q23-q24 and 15ql3 as identified by the Paris and Birmingham 
groups respectively.
5.3.1 Chromosome 3q24-q26
The first locus on 3q24-q26 was identified in Family 1 following a genome-wide screen 
and was the only large region in the whole genome in which the two affected children 
were both homozygous for the same alleles. Evidence for linkage to this locus was
321
supported by genotyping results in three other consanguineous families (Families 5, 6 
and 8) and one non-consanguineous family (Family 14). Furthermore, Pakistani 
Families 1, 5, 8 and 14 shared identical alleles at markers D3S3579, D3S1268 and 
D3S3668 within the minimal critical interval suggesting the presence of a shared 
ancestral chromosomal segment inherited from a distant common ancestor and 
supporting evidence for linkage to this locus.
However, Family 8 was also consistent with linkage to the region on chromosome 
15ql3, whereas Family 5 was not screened across the 8q24 and 12q23-q24 loci as there 
was insufficient DNA from the proband. Moreover, a genome-wide screen was not 
performed in Families 5 and 14 and none of the families were typed across the 14q24- 
q32 locus as this region was identified in the last stages of the project.
5.3.2 Chromosome 8q24
The second locus was identified on 8q24 in Family 2 following a genome-wide screen. 
Two more consanguineous families (Families 9 and 10) were found to be consistent 
with linkage to this locus and a common 2 cM/1.65 Mb region of homozygosity was 
detected between marker D8S274 at the centromeric end and marker AC087711-2 at 
the telomeric end. Little DNA was obtained from the mother of affected child II. 1 in 
Family 9 and therefore she could not be typed for all the markers. Furthermore, not all 
markers typed in this region were fully informative and the homozygosity in the child 
could be IBS. Doubts were cast about whether the diagnosis of JATD in Family 10 was 
correct. The affected child 11.10 in this family, in fact, also had severe mental 
retardation, never previously associated with JATD as well as Dandy-Walker
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malformations, not a common feature of JATD. The affected child in Family 9 was also 
described as not being a classical JATD case. Furthermore, he was homozygous for a 
small region of about 6 cM/2.5 Mb on 15ql3 as described by Morgan and colleagues 
(proband D) as well as the region on chromosome 8 (Morgan et a l , 2003).
A genome-wide screen was performed in families 2 and 9 and although 8q24 was the 
most promising region throughout the genome, other regions might need to be 
investigated further. In Family 2, for example, a number of quite large gaps from the 
genome-wide screen are still present and there might well be another homozygous 
region in the two affected sibs that has not yet been identified.
5.3.3 Chromosome 12q23-q24
The locus on chromosome 12q23-q24 was mapped by collaborator Dr Valerie Cormier- 
Daire and was supported by data from two JATD consanguineous families. The 
minimal critical interval of 2 cM/ 3 Mb in size was identified between markers 
D12S1342 and D12S1339. None of the families analysed in this study were found to be 
consistent with linkage to this locus.
5.3.4 Chromosome 15ql3
The locus on chromosome 15ql3 was identified by collaborator Dr Colin Johnson and 
is supported by data from five consanguineous families and three non-consanguineous 
families with a maximum two-point Lod score of 3.77 at 0=0 obtained at D15D1031 
(Morgan et a l, 2003). The minimal critical interval was 1.2 cM/ 1.5 Mb in size and 
contained 16 known and predicted genes (Morgan et a l, 2003). Two of these, FMN-1 
and GREMLIN, initially appeared to be good candidates, but none of the linked families 
were found to harbour mutations in the coding sequence of either gene.
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In this study, evidence for linkage to this locus was confirmed in consanguineous 
Families 3 and 8 ((Morgan et al., 2003), probands A and C respectively). Further 
typing in these two families refined the boundaries of the region between AC024474 
and D15S976. In light of these results, both FMN-1 and GREMLIN lie outside the 
minimal critical interval and the homozygous region in patient II. 1 from Family 3 
(proband A) do not overlap with the homozygous region in patient II. 1 from Family 9 
(proband D). It is still possible that there is a small overlapping homozygous interval of 
about 300 Kb in the two probands between markers D15S165 and D15S976, although 
this family might not be linked to this locus. The homozygous region in proband II. 1 
from Family 9 (about 6 cM/2.5 Mb) was in fact thought to be small considering that the 
parents were first cousins. Moreover, as the heterozygosity of the markers typed by 
Morgan and collaborators was low, the father was also homozygous for D15S1013, 
while marker D15S231 was uninformative as both parents were homozygous (Morgan 
et al, 2003). Furthermore, as explained in section 5.3.2, Family 9 was also consistent 
with linkage to the locus on 8q24. The affected child II. 1 showed homozygosity 
through a larger region (16 cM/8 Mb) on chromosome 8q24 than on 15ql3, as expected 
from a first cousin mating.
As explained in section 5.3.1, Family 8 also demonstrated homozygosity across two 
JATD loci, 3q24-q26 as well as 15ql3. It is possible that one of the two regions is IBS 
and not IBD in the affected child, but thus far this cannot be corroborated because a 
number of markers on 15ql3 were uninformative. Therefore, this family needs to be 
screened for mutations in candidate genes from both regions. It is possible that once the 
JATD genes are identified, this family may harbour mutations in two different genes, 
thus suggesting a more complex mode of inheritance (see section 5.5).
In conclusion, the results described in this project supersede the ones previously 
reported by Morgan and collaborators (Morgan et a l, 2003). The minimal critical 
interval is located more centromeric than previously thought and does not include 
FMN-1 or GREMLIN. Families 8 and 9 seem to map also to two loci identified in this 
study, 3q24-q26 and 8q24 respectively.
324
5.3.5 Chromosome 14q24-q32
The locus on 14q24-q32 was identified in Family 4 following a genome-wide screen in 
one of the two affected children. Although most of the markers were uninformative 
across the locus and therefore more genotyping needs to be carried out, this was the 
most promising region found in this particular family. Due to time constraints, only one 
other family (non-consanguineous Family 15) was genotyped across 14q24-q32, and 
linkage was excluded.
The phenotype in the probands from Family 4 was thought to be atypical for JATD and 
could be the reason why this family was not consistent with linkage to any other 
putative JATD loci. The child had postaxial polydactyly in one foot, with dysplastic 
toenails bilaterally and short third toes bilaterally. He had normal fingernails. 
Hypoplastic/dysplastic nails are a common feature in EVC and do not occur at all in 
JATD. According to Dr Brueton's review, postaxial polydactyly is always present in 
EVC, but only occasionally present in JATD (Brueton et al., 1990). Moreover, the 
pattern of polydactyly is different. In EVC it is always present in the hands and only 
rarely in the feet, whereas in JATD when it is present, it usually affects both the hands 
and feet. Therefore the phenotype in this patient does not fit with either JATD or EVC. 
Linkage to the EVC/EVC2 locus was excluded in this family.
5.3.6 Summary of genotyping results
A summary of the genotyping screen carried out in this project is shown in Figure 5.1.
Families 3, 5, 6, 8 and 14 were consistent with linkage to 3q24-q26; families 2, 9 and 
10 were consistent with linkage to 8q24; families 3, 8 and 9 were consistent with 
linkage to 15ql3. Homozygous regions were detected on both chromosomes 3 and 15 
in Family 8 and on both chromosomes 8 and 15 in Family 9. None of the families were 
screened across the 14q24-q32 locus identified in Family 4 except for non-
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Family Ethnic
origin chr 3
Consistent with linkage to: 
chr 8 chr 12 chrl5 chr 14 EVC
1 Pakistani Y N N N / N
2 Dutch N Y N N / N
3 Pakistani N N N Y / N
4 Arab possible N N N Y N
5 Pakistani Y / / N / N
6 Turkish Y N N N / /
7 Turkish possible N N possible / /
8 Pakistani Y N N Y / N
9 Italian N Y N Y / N
10 Maroccan N Y N N / ?
11 Turkish N N N N / N
12 English N N N N / EVC
13 Italian N N N N / N
14 Pakistani Y N N N / /
15 English N N N N N N
16 Lithuanian possible N possible N / N
Figure 5.1 Summary of genotyping results in JATD families. A genomewide screen 
was carried out in Families 1, 2, 3 and 4 in this study and in Families 8, 9 and 16 by our 
collaborators. Y highlighted in orange indicates that the family is consistent with 
linkage to that locus. N indicates that the family is not consistent with linkage to that 
locus. / indicates that the region has not been tested. Family 8 was consistent with 
linkage to both chromosomes 3 and 15, while Family 9 to both chromosomes 8 and 15. 
Family 12 was found to be consistent with linkage to the EVC/EVC2 locus, while 
Family 11 was found to have a different condition.
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consanguineous Family 15 for which linkage to this locus could not be demonstrated. 
Linkage to the EVC/EVC2 locus was not excluded in all the families. Family 5 could 
not be typed across the chromosome 8 or 12 regions as little DNA from the proband 
was available. In Family 7, as DNA from the patient was not available, haplotype 
analysis was carried out only in the parents and the two unaffected sibs and could be 
consistent with linkage to both regions on chromosome 3 and 15. Non-consanguineous 
Family 16 could also be consistent with linkage to both 3q24-q26 and 12q23-q24.
The parents of patient III. 1 in Family 13 were thought to be distantly related. Assuming 
this, the affected child was not consistent with linkage to any of the JATD candidate 
loci, even though this family was not typed across the 14q24-q32 region. In non- 
consanguineous Family 15 linkage could not be demonstrated to any of the five loci or 
the EVC/EVC2 locus, suggesting that there is at least one additional locus to be 
identified.
Following screening of the candidate regions, Family 11 and 12 were diagnosed with 
different conditions. Family 11 was not consistent with linkage to any of the JATD 
putative loci or the EVC/EVC2 locus. An exact diagnosis could not be determined in 
the affected child. However, Prof. Christine Hall suggested acromesomelic dysplasia, 
Maroteaux type after reviewing X-rays from the patient. Dr Valerie Cormier-Daire 
suggested an atypical form of EVC. Family 12 on the other hand was consistent with 
linkage to the E VC/E VC2 locus, therefore DNA samples were sent to Prof. Judith 
Goodship to investigate further the presence of a mutation in EVC or EVC2 as the
1possible cause of the phenotype in this family. This investigation is ongoing. This 
highlights the necessity of formulating a correct diagnosis in each family before the 
commencement of any linkage study to avoid confusion in the interpretation of the 
results. J
A formal genotype phenotype study is not possible with a small number of families 
such as these, however it is interesting to note that both severely and mildly affected 
families map to the same regions and may suggest that phenotypic variation in JATD 
reflects allelic heterogeneity and not locus heterogeneity. A consistent relationship 
between families linked to a particular locus and their countries of origin could not be 
shown, although on 3q24-q26 four families out of five were Pakistani.
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The region on chromosome 3q24-q26 was the first one to be identified and was 
supported by data from five families. Linkage to the 8q24 region was supported by data 
from three families, although in Families 9 and 10 doubts arose about the diagnosis. 
The region on 14q24-q32 was the last one to be identified and requires further 
investigation. Nevertheless, the search for candidate genes in these three regions has 
begun.
5.4 Candidate genes
5.4.1 Chromosome 3q24-q26: SHOX2
The short stature homeobox 2 gene SHOX2 was originally thought to be a good 
candidate gene for JATD. SHOX2 maps to 3q25-q26.1 and lies within the common 
homozygous interval in patients from consanguineous Families 1, 5, 6 and 8 between 
markers D3S1607 and D13S3692 (see Table 4.24). The two affected sibs from non- 
consanguineous Family 14 also have the same haplotypes in the interval (see Table 
4.23).
SHOX2 belongs to the homeobox family of genes, which encode proteins characterized 
by a 60 amino acid DNA binding domain, and are known to be involved in pattern 
formation during embryonic development. Mutations in homeobox genes have been 
described in a number of human disorders: HOXD13 in synpolydactyly (SPD; MIM 
186000); HOXA13 in hand-foot-genital syndrome (HFG; MIM 140000); PAX3 in 
Waardenburg syndrome (WS1; MIM 193500); PAX6 in aniridia (AN2; MIM 106210); 
HLXB9 in Currino-Triad syndrome (MIM 146450). The closely related 
pseudoautosomal homeobox gene SHOX is known to be mutated in Leri-Weill 
syndrome, a mesomelic short stature syndrome and homozygous SHOX mutations have 
been shown to cause Langer type mesomelic dwarfism (Shears et a l , 2002; Shears et 
a l , 1998). In addition, defects in SHOX are known to lead to idiopathic short stature 
and short stature associated with Turner syndrome (Clement-Jones et a l , 2000).
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Two isoforms, SHOX2a and SHOX2b, have been identified. The SHOX2b transcript 
differs from the SH0X2a transcript in that the translation start site lies 131 codons 
downstream from that of SHOX2a. SHOX2b is also lacking an exon in the C-terminal 
region. Expression studies in human embryos have shown that SHOX2 is expressed in a 
variety of organ systems, including limbs, pharyngeal arches and genital tubercles 
(Clement-Jones et al., 2000). SHOX2 is also expressed in heart, liver, lung, and 
pancreas (Blaschke et a l, 1998). The murine orthologue Ogl2x shows a high degree of 
conservation with SHOX2 and is expressed in the fore- and hind-limb buds, the ribs, the 
metanephric mesoderm as well as the central nervous system, the heart and the 
craniofacial tissues during mouse embryonic development (Blaschke et al, 1998; 
Clement-Jones et a l, 2000).
SHOX2 represented a plausible candidate gene for JATD because of its expression 
pattern in tissues which are likely to be affected in JATD patients and because of its 
homology with SHOX, which is known to be mutated in a number of short stature 
syndromes characterized by skeletal abnormalities. However, no pathogenic mutations 
in the coding sequence of the gene were identified in the four JATD families screened. 
In the last stages of the project, DNA was obtained from an unaffected member of non- 
consanguineous Family 14 and, assuming linkage to 3q24-q26 in this family, SHOX2 
lies outside the interval identified by the recombination event which occurred in the 
unaffected child (see Table 4.23), thus excluding SHOX2 as a candidate gene.
Twenty-eight known or predicted genes map to the 8 cM/12 Mb homozygous region 
common to Families 1, 5, 6, 8 and 14. While several of these genes can be ruled out on 
the grounds of inappropriate expression patterns and/or known roles in other human 
disorders, only eighteen of them were thought to represent possible candidate genes 
requiring further investigation. Many are genes encoding hypothetical proteins of 
unknown function and there are no obvious reasons for prioritising the screening of any 
of them.
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5.4.2 Chromosome 8q24
5.4.2.1 WISP1
The WISP1 gene, encoding the Wntl-inducible signalling pathway protein 1 
(WISP1/CCN4), belongs to the CCN family of secreted proteins and was thought to be 
a good candidate gene for JATD. WISP1 maps to 8q24.1-q24.3 and lies within the 
overlapping homozygous interval in the two affected sibs from consanguineous Family 
2, between markers D8S529 and D8S256 (see Figure 4.15).
The CCN family of secreted proteins (connective tissue growth factors) includes 
cysteine-rich 61 (CYR61/CCN1), connective tissue growth factor (CTGF/CCN2), 
nephroblastoma overexpressed (NOV/CCN3), Wntl-inducible signalling pathway 
proteins-2 (WISP2/CCN5) and -3 (WISP3/CCN6). The CCN members are 
characterized by four conserved cysteine-rich domains: an insulin-like growth factor 
(IGF)-binding domain, a von Willebrand type C module, a thrombospondin-1 domain 
and a C-terminal domain containing a putative cysteine knot. Collectively, these 
proteins regulate fundamental biological processes, including cell adhesion, growth, 
differentiation, apoptosis, embryogenesis, vascular diseases and tumorigenesis and can 
interact with multiple signal transduction pathways as well as regulate other signalling 
molecules, including transforming growth factor p (TGF-p) and bone morphogenetic 
proteins (BMPs) during development. CCN members are known to be involved in 
skeletogenesis.
CYR61/CCN1 promotes collagen and cartilage production in limb buds and stimulates 
chondrogenesis, mitogenesis and adhesion in limb mesenchymal cells (Wong et a l ,
1997). CTGF/CCN2 is expressed in zones containing hypertrophic chondrocytes or 
calcifying cartilage of long bones, ribs, the vertebral column and phalanges (Takigawa 
et a l , 2003). Increased levels of CTGF/CCN2 in skeletal cells are stimulated by TGF-P 
and BMP-2. CTGF/CCN2 is required for cell proliferation and matrix remodelling 
during chondrogenesis (Ivkovic et a l , 2003). Ctgf homozygous null mice die 
perinatally from respiratory failure as a consequence of impaired skeletal development.
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Ctgf null mice suffer multiple skeletal dysmorphisms as a result of defective 
chondrocyte proliferation and decreased extracellular matrix components. Skeletal 
defects include sternum, rib cage and limb abnormalities (Ivkovic et al., 2003).
WISP2/CCN5 is expressed at high levels in human bone tissue and plays an important 
role in regulating bone turnover (Kumar et al., 1999). Mutations in the WISP3/CCN6 
gene are associated with progressive pseudorheumatoid dysplasia (PPAC; MIM 
208230), an autosomal recessive skeletal disorder characterized by continued cartilage 
loss and bone destruction (Hurvitz et al., 1999). Radiographic findings include osseous 
distension of the proximal and middle phalanges, enlargement of the femoral and tibial 
epiphyses and flattening of the vertebral bodies. Wisp3 null mice have more mature 
vertebral endplates, a phenomenon that may be due to accelerated endochondral 
maturation (Perbal et al., 2003).
WISP1/CCN4 was originally identified as a probable downstream effector of the Wnt 
signalling pathway in mouse mammary ephithelial cell lines transformed by Wnt-1 
(Pennica et a l, 1998). In human tissues, WISP1 expression was seen in a variety of 
adult organs including kidney, pancreas, lung, heart, ovary and spleen (Pennica et al,
1998). High levels of expression have been demonstrated in fibroblast cells and colon 
tumors (Pennica et a l, 1998). Recently, the role of WISP 1 during skeletal development 
has been elucidated and its expression during embryogenesis was shown in osteoblast 
and osteoblastic progenitor cells of the perichondral mesenchyme, making this gene an 
excellent functional candidate gene for JATD (French et a l, 2004).
WISP1 was screened for causative mutations in seventeen JATD families and although 
a number of SNPs were identified, no obvious mutations could be detected. The only 
changes found in the mother of the two affected sibs in Family 2 were two known 
SNPs. In one sporadic case (Family 31), a nucleotide substitution in exon 3 results in an 
amino acid change (Vall84Ile). This is not likely to be significant, as it is a 
conservative change. Although mouse wispl has a valine at the same position, the same 
amino acid residue was not conserved in rat or chimp. In the proband from Family 24, a 
non-reported variant was found in the 5’UTR, 115 bp upstream of the start codon. This 
substitution is not listed in the NCBI SNP database. However, the surrounding region is 
not strongly conserved between human and mouse.
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Following genotyping analysis of JATD families across the 8q24 interval, two more 
families were found to be consistent with linkage to this locus, Families 9 and 10. 
WISP1 lies just outside the overlapping interval between the three families.
5A.2.2 GLYLU
The novel gene GLYLU was the only gene in the interval of common homozygosity 
between Families 2, 9 and 10 and therefore, it was screened for mutations in one parent 
from each family. Although annotations about the protein (hypothetical protein 
LOC51059) expression and function were poor, GLYLU was considered an excellent 
positional candidate. It did not belong to any known protein family and had a predicted 
localization to the nucleus and a thiol protease site.
A number of polymorphisms were detected in the three individuals screened, but no 
convincing mutations such as a premature stop or a frameshifting insertion or deletion 
were identified in the coding region of GLYLU. The only change in the coding 
sequence of all three individuals was found in exon 8 and altered an amino acid 
(p.Arg362Ser). However, exon 8 was thought not to represent a true exon as it was 
predicted only by Ensembl and was not supported by evidence from any other source.
5.4.2.2 Further candidate genes on 8q24
As discussed in section 5.3.2, the diagnosis in the affected child from Family 9 was 
uncertain. Therefore, the attention in the search for candidate genes on 8q24 shifted to 
the region of common homozygosity in Families 2 and 10. Only three genes lay in this 
3 Mb region between markers D8S256 and D8S274, SIAT4A, ZNF406 and KHDRBS3.
ZNF406 was thought to represent the best candidate gene of the three and therefore it 
was the first one to be screened in Families 2 and 10. It contains multiple zinc finger 
motifs and appeared to encode a zinc finger transcription factor. It is expressed in a 
wide variety of adult tissues and tumours but no information was available about
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whether it was expressed in cartilage/bone and during development. A number of 
human syndromes have been associated with defects in zinc finger proteins. Three 
related autosomal dominant disorders are caused by mutations in human GLI3, a zinc 
finger gene related to Drosophila cubitus interruptus. These are Greig 
cephalopolysyndactyly (GCPS; MIM 175700), Pallister-Hall syndrome (PHS; MIM 
146510) and postaxial polysyndactyly type Al (PAPA1; MIM 174200). GCPS is 
characterised by syndactyly, polydactyly, broad or bifid thumbs, hip dislocation, 
unusual skull shape, craniofacial dysmorphisms and developmental delay. PHS has a 
wide variety of features including virtually all of the findings in GCPS plus 
hypothalamic hamartoblastomas, hypopituarism, abnormalities of the palate, tongue, 
and jaw, limb shortening, postaxial polydactyly with nail dysplasia, syndactyly, fused 
ribs, imperforate anus, renal dysplasia and congenital heart defects. PAPA1 is 
characterised by an extra digit in the ulnar and/or fibular side of the upper and/or lower 
extremities. Hirschsprung disease (HSCR; MIM 235730) and Mowat-Wilson syndrome 
(MIM 235730) characterised by microcephaly, mental retardation, hypertelorism, cleft 
palate, heart defects and short stature are both caused by mutations in the zinc finger 
homeobox IB gene {ZFHX1B). Mutations in SALL4 and SALL1, two genes encoding 
zinc finger transcription factors, cause Okihiro syndrome (MIM 607323) and Townes- 
Brocks syndrome (TBS; MIM 107480), respectively. Patients affected with Okihiro 
syndrome have Duane retraction anomaly associated with radial ray abnormalities, 
whereas TBS is characterised by renal, anal, limb and ear anomalies.
ZNF406 was therefore sequenced in unaffected parents from Families 2 and 10 but no 
pathogenic mutations were identified. The only significant change in Family 2 was a 
p.Glyl05Arg identified in exon 3. This alteration is not listed in the NCBI SNP 
database and it is not a conservative change. Moreover, the Gly residue is conserved in 
the mouse protein. The variant segregates in the family consistently with a possible 
pathogenic role, although the sequence of one human mRNA IMAGE clone has the 
same nucleotide alteration. Furthermore, the substitution does not occur in a region of 
the gene of obvious functional significance and is not conserved in fugu, therefore it is 
likely to represent a rare polymorphism.
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Due to time constraints, the two other genes in the region, SIAT4A and KHDRBS3, 
were not screened. Both represent good candidate genes and need to be screened in the 
future.
SIAT4A (sialyltransferase 4A) is a glycosyltransferase which catalyses the transfer of 
sialic acid to terminal carbohydrate groups of cell-surface glycolipids and glycoproteins 
and is therefore important for cell-cell interactions. It is widely expressed in adult 
tissues, cancer and fetal tissues. It is expressed most strongly in skeletal muscle, but 
also in tissues relevant to JATD, such as liver, kidney, pancreas, retina and cartilage. 
There are two known transcripts produced by alternative splicing containing either nine 
or ten exons.
KHDRBS3, alternatively named T-STAR (testis-signal transduction and activation of 
RNA), is a Sam68-like phosphotyrosine nuclear protein involved in RNA processing 
and signal transduction specifically involved in regulating alternative splicing in 
response to extra-cellular signals. It contains an RNA binding domain, six SH3-binding 
sites, and a tyrosine-rich C-terminus. It is expressed in testis, skeletal muscle, brain and 
heart and it is represented in databases by cDNAs from a wide variety of adult tissues 
and tumours including liver, kidney and retina.
5.4.3 Chromosome 14q24-q32: TTC7B
It has been suggested that genes encoding intraflagellar transport (IFT) proteins might 
be promising candidate disease genes for human disorders such as JATD (Pazour and 
Rosenbaum, 2002; Rosenbaum and Witman, 2002). IFT is a microtubule-dependent 
motility process necessary for cilia biogenesis and maintenance (Rosenbaum and 
Witman, 2002; Scholey, 2003; Qin et a l , 2004). Defects in IFT affect the cilia in 
several organs leading to a pleiotrophic phenotype affecting several organs systems like 
the kidney and the eye in humans (Rosenbaum and Witman, 2002). In recent years, it 
has been demonstrated that defects in cilia are associated with several human disorders, 
including nephronophthisis (NPHP; MIM 608002), hydrocephalus, polycystic kidney 
disease (PKD; MIM 173900), Senior-Loken syndrome (MIM 266900) and Bardet-
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Biedl syndrome (BBS; MIM 209900) (Watnick and Germino, 2003). Some of the 
phenotypic features exhibited by JATD patients, including skeletal defects associated 
with renal cysts/malformations and retinal degeneration, resemble human diseases 
which have been associated with abnormal cilia function such as NPHP, PKD and 
BBS. These features are similar to the phenotype of the KO mouse Tg737 (Pazour and 
Rosenbaum, 2002; Watnick and Germino, 2003). In the mutant mouse Tg737 the 
primary defect is the inability to assemble cilia. The Tg737 gene encodes a protein 
(Polaris) homologous to the IFT88 subunit of the Chlamydomonas IFT particle, 
required for flagellar assembly in Chlamydomonas (Pazour et al., 2000). The Tg737 
mouse mutant develops PKD, retinal degeneration and laterality defects (situs inversus) 
as well as hepatic fibrosis, liver cysts, polydactyly and hydrocephaly (Pazour et a l , 
2000).
In JATD patients, Ozcay and colleagues described two different patterns of renal 
disease. Patients who died in the neonatal period or during infancy exhibit various 
types of renal dysplasia with cortical or diffuse cystic changes, while those who survive 
beyond childhood develop progressive renal disease with diffuse tubulointerstitial 
fibrous changes and infiltration, tubular atrophy and periglomerular fibrosis or 
glomerular sclerosis (Ozcay et al., 2001). Several reports have claimed that these 
findings are indistinguishable from those associated with juvenile NPHP (Kozlowski 
andMasel, 1976; Shah, 1980; Donaldson et al., 1985).
A feature of JATD is retinal degeneration resembling Leber congenital amaurosis and 
tapeto retinal degeneration like those described in Senior-Loken syndrome, BBS and 
NPHP. Hypertrophic retinopathy has also been described (Brueton et a l , 1990; Ozcay 
et a l , 2001).
Laterality defects caused by a defective cilia assembly in the embryonic node cells are 
also often associated with cilia dysfunction diseases such as Kartagener’s syndrome 
(MIM 244400; characterized by situs inversus and respiratory disease) and BBS 
(Ansley et a l , 2003). Situs inversus has been described in two JATD cases (Brueton et 
a l , 1990; Majewski et a l , 1996). Hepatic fibrosis, liver cysts and polydactyly are often 
associated with JATD, whereas mild congenital hydrocephalus has been described in 
two sibs with JATD (Singh et a l, 1988).
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TTC7B encoding the tetratricopeptide repeats domain 7B protein lies on 14q24-q32 and 
was thought to be a good candidate gene for JATD. Although at present there is no 
evidence to support a possible role of TTC7B in IFT, the structure of the predicted 
protein suggested a possible function of TTC7B in ciliary function, IFT, ciliogenesis or 
in the cell cycle, similar to that of BBS8 and BBS4. TTC7B contains five TPRs and a 
domain similar to the prokaryotic pilF  domain involved in pilus assembly and 
intracellular trafficking. BBS8 also contains eight TPRs towards the C-terminus and 
has a pilF  domain. It localizes to the centrosomes and basal bodies in cells interacting 
with PCM-1, a protein probably involved in ciliogenesis (Ansley et al, 2003). BBS8 
localizes specifically to ciliated structures, such as the connecting cilium of the retina 
and columnar epithelial cells in the lung. In one family, null BBS8 mutation leads to 
BBS with situs inversus (Ansley et al., 2003). BBS4 contains ten TPRs and is a 
pericentriolar protein necessary in recruiting cargo to centriolar satellites by acting as a 
dynein-associated adaptor protein (Kim et a l, 2004).
No mutations were identified in the coding sequence of TTC7B, although four exons 
have not been yet screened for mutations.
5.5 Conclusions
In conclusion, the investigation into the molecular basis of JATD carried out in this 
study led to the identification of three putative JATD loci on chromosome 3q24-q26, 
8q24 and 14q24-q32 through analysis of a number of consanguineous and non- 
consanguineous JATD families. Locus heterogeneity has therefore been demonstrated. 
Two families described in this project and several families ascertained by our 
collaborators do not appear to be consistent with linkage to any of the known loci, 
suggesting that there might be at least one additional and as yet unidentified locus.
Some families exhibited homozygosity across two JATD putative loci. The most likely 
explanation is that these families display spurious linkage across one of the two 
regions, thus the homozygosity in that region is IBS and not IBD. Alternatively, it 
might suggest a more complex pattern of inheritance such as multilocus inheritance. It
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is in fact possible that mutations at two or more loci are necessary for pathogenesis of 
JATD. The multiallelic model of inheritance is a widespread phenomenon and 
examples have been reported in a number of species including humans (Badano and 
Katsanis, 2002; Ming and Muenke, 2002). In the case of Bardet-Biedl syndrome, for 
example, the model of disease transmission postulated has been called triallelic 
inheritance, as three mutated alleles from two loci are required for penetrance of the 
BBS phenotype in some families (Katsanis et al., 2001; Katsanis et al., 2002; Beales et 
a l , 2003). As demonstrated in this study, as in BBS, JATD is a rare genetically 
heterogeneous disorder characterized by multiple clinical features with variable 
expressivity. At present, it is difficult to explain how the disruption of a single protein 
would lead to such a complex phenotype as in JATD that includes both skeletal 
dysplasias (e.g. small rib cage, short stature, rhizomelic limb shortening and 
polydactyly) and progressive renal, pancreatic, hepatic and retinal defects. At present 
the hypothesis of a complex transmission model for JATD cannot be substantiated and 
only the identification of the underlying genes and the pathogenic mutations in them 
will help to elucidate this.
Mutation screening of the most promising candidate genes lying in the three putative 
loci has been carried out in this study. Although all the genes screened appeared to 
represent excellent candidates, no pathogenic mutation such as a premature stop, an 
insertion, a deletion, or a splice-site mutation, could be identified in any of them. In 
general, it is possible that mutations in the coding sequence of the genes screened have 
been missed, although this is very unlikely as the analysis has been thoroughly carried 
out. It is known that DNA variants could lie in regulatory regions altering the 
consensus of transcription factor binding sites or promoter elements. As previously 
described (section 3.3.4) an example is given by point mutations identified in a Shh 
regulatory element located within intron 5 of the Lmbrl gene, 1 Mb upstream of Shh 
itself, in human preaxial polydactyly (Lettice et al., 2003). Alternatively, variants in the 
untranslated regions of mRNA may alter mRNA stability. Mutations within introns, 
regulatory elements, 5’ and 3’UTRs, or that create or disrupt cryptic splice sites would 
have been missed by the methodology used in this study.
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Another possibility, especially in novel genes, is that there are other spliced variants 
that have been missed and not analysed. Moreover, not all the families were screened 
for mutations in all the genes and therefore it is possible that mutations have been 
missed. For example, no mutations in the coding sequence of SHOX2 were identified in 
the four families consistent with linkage to 3q24-q26, although the gene was not 
screened in the sporadic cases. On 8q24, GLYLU and ZNF406 were sequenced only in 
the families consistent with linkage to this locus and not in the sporadic cases.
Alternatively, some of the polymorphisms identified in coding and non-coding regions 
of the genes analysed could be significant. A number of functional polymorphisms in 
gene regulatory sequences have in fact been described. For example, polymorphisms 
that appear to be innocuous on cursory examination can have functional consequences, 
such as synonymous coding changes that occur in exon splicing enhancer (ESE) 
regions, as described for the breast cancer coding gene BRCA1 (Liu et al., 2001).
Finally, it is possible that the genes underlying JATD are between the ones that have 
not yet been screened.
5.6 Future work
A number of JATD families described in this study need to be investigated further 
across the five JATD putative loci. More informative markers should be genotyped in 
Families 4 and 16 on chromosome 3q24-q26. Family 4 in particular might be useful to 
narrow down the region if linkage can be supported. More typing is necessary in 
Families 6 and 16 on chromosome 12 as the results obtained so far have been 
inconclusive. Family 5 needs to be analysed across the chromosome 8 and 12 regions. 
To support the hypothesis of linkage to either the 3q24-q26 or the 15ql3 locus in 
Family 7, it would be necessary to extract DNA from the paraffin embedded tissues 
from the affected child. Genotyping of the child might support or exclude linkage to 
one or both loci. The region identified on 14q24-q32 in Family 4 requires further study 
and, if it is proven to be a real region homozygous by descent, has to be investigated in 
all the other families. Furthermore, linkage to the previously reported candidate loci
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such as the EVC/EVC2 locus, 12pl 1.21-pi2.2 and the regions syntenic to the srt locus 
was not excluded in all families.
More JATD families should be ascertained and genotyped across the five putative 
JATD loci to validate and refine the candidate regions as tightly as possible, thus 
providing the basis for further candidate gene analysis.
An approach that could be adopted is the search for allelic homozygosity in non- 
consanguineous families within the candidate regions as described by Morgan and 
colleagues (Morgan et al., 2003). Some of the non-consanguineous families might in 
fact show homozygosity within the critical interval due to distant consanguinity. This 
approach could be useful to narrow down the putative loci as the homozygous interval 
in such families is expected to be small, although it could be time consuming if large 
numbers of families are to be analysed. A large number of closely spaced polymorphic 
markers or SNPs would be required for this kind of study.
A possible approach to validate candidate linked regions or to identify new loci in 
consanguineous families would be to perform homozygosity mapping using new 
technologies such as the Affimetrix GeneChip (Kennedy et al., 2003). This high 
throughput technique allows genotyping of 10,000 or 100,000 SNPs simultaneously per 
single target DNA using allele specific hybridisation. The advantage of using SNPs for 
genome screening instead of traditional microsatellite markers is that SNPs are 
abundant, widespread throughout the genome and represent the most frequent form of 
DNA sequence variation found in the human genome with an average spacing of one 
SNP every 210 Kb according to the November 2002 NCBI genome assembly (Build 
33). The average spacing of microsatellite markers is about one every 5.6 Mb.
Mutation screening of further candidate genes on chromosomes 3, 8 and 14 has to be 
performed. Recent scrutiny of the genomic sequence on 8q24 in the region of triple 
overlap between Families 2, 9 and 10 using Ensembl, UCSC genome browser and 
NCBI Map View (Build 35, May 2004 freeze) led to the identification of two novel 
genes (FLJ45872 and LOC442397). These genes were not annotated at the time of this 
study and need to be sequenced in the affected families. SIAT4A and KHDRBS3 lying 
in the region of common homozygosity in Families 2 and 10 on 8q24 need to be
339
screened. The region on 3q24-q26 is still quite large with a possible eighteen candidate 
genes. Therefore genes for mutation screening need to be prioritised based on their 
biological rationale in the target phenotype.
Genes can be prioritised based on expression in the disease tissues, a known or putative 
role in the disease pathway and gene knock-out models. The candidate genes should be 
expressed in the right place at the right time for the disease phenotype. Information on 
gene expression can be obtained by searching databases such as dbEST. RT-PCR, 
Northern blotting, Serial Analysis of Gene Expression (SAGE) and DNA microarrays 
are all techniques available to assess expression of candidate genes. The genes 
underlying JATD are most likely to be expressed in cartilage, therefore a possible 
approach to selecting plausible candidate genes in each region would be to investigate 
their expression in human primary chondrocytes by using an Affymetrix microarray 
system. Using a Human Genome U133 GeneChip set, a comprehensive profile of gene 
expression in this cell type could be obtained. This chip allows over 33,000 proven and 
potential transcripts to be quantitated relative to a set of 100 housekeeping genes with 
the lower limit of detection roughly corresponding to three transcripts per cell. For this 
purpose, RNA from human fetal primary chondrocytes has to be obtained.
The candidate genes and/or their proteins should have an appropriate function for the 
disease. Sometimes function of novel genes is difficult to establish as there are very 
few annotations in the databases. Clues to prioritise candidate genes may surface by 
examining the functional relationship to genes known to be involved in similar 
diseases. In the case of JATD for example, studies on the function of EVC and EVC2 
might give useful hints about the possible function of the JATD underlying genes. 
Genes encoding IFT proteins and proteins involved in ciliogenesis are also promising 
candidate disease genes for JATD. It is therefore necessary to search the putative JATD 
loci for genes encoding proteins containing domains known to be involved in these 
processes such as TPRs and pilF domains. Moreover, the identification of the genes 
underlying one or more short rib-polydactyly syndromes (SRPS) could also be valuable 
to suggest other candidate genes to investigate. Similarities in the phenotype of SRPS 
and JATD are in fact striking.
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A mouse mutant phenotypically similar to JATD could also be valuable in suggesting 
candidate genes to screen. Finally, it is possible that proteins encoded by the JATD 
genes either belong to the same family of proteins or are part of a common 
developmental pathway or interact with one another in multi-aggregates. In these cases, 
the identification of at least one gene in one of the JATD loci may direct the search for 
genes in the other putative loci.
The identification of the JATD genes will provide an important new insight into retinal, 
limb and kidney development.
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Markers
Black (e.g. D8S1119) = 7 cM Single Chromosome Scan linkage marker set (Research 
Genetics, Inc.) -  tri- and tetra-nucleotide repeats
Bold red (e.g. D2S206) = 10 cM ABI PRISM™ Linkage Mapping Set (Perkin Elmer 
Applied Biosystems Division) -  di-nucleotide repeats
Italic blue (e.g. D9S158) = 10 cM Genome-wide Human Screening Set Version 8a 
(Research Genetics, Inc.) -  tri- and tetra-nucleotide repeats
Bold purple (e.g. D15S822)= new markers chosen to fill in gaps -  di-nucleotide 
repeats
Heterozygosity and distances
Het column gives heterozygosity of the marker available on the NCBI database 
uniSTS, Marshfield genetic map
Mb column gives distances in Mb from the top (tip of short arm) of the chromosome 
according to the UCSC Human Genome Assembly (April 2003 freeze) NCBI build 33
cM (Marshfield) column gives distances in cM from the top of the chromosome 
according to the Marshfield genetic map
cM (deCode) column gives distances in cM from the top of the chromosome according 
to the deCode genetic map
light blue fillj indicates low heterozygosity
/ indicates heterozygosity or position unknown
Results
light green fill indicates individual is homozygous for that marker
Igreen fill: ndicates two individuals from the same family are homozygous for 2
different alleles 
bright g ree n llj indicates candidate regions
light orange fill indicates result not clear 
/ indicates no result could be obtained for that marker 
Empty box indicates marker not tested
Key to genome-wide screen results tables.
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Markers 
Chromosome 1
D1S243
D1S2845
D1S1612
ATA9B08
D1S1597
GATA29A05
D1S552
D1S1676
D1S1622
D1S2830
GATA137F01
D1S255
GATA129H04
D1S2874
D1S2134
D1S197
D1S1150
GATA165C03
D1S209
D1S1613
D1S2806
D1S410
D1S1630
D1S219
D1S1665
D1S1728
D1S551
D1S2766
D1S2129
Het Mb 
Build 33
CM
Marshfield
cM
deCode
0.86 0.06 0.00 /
0.84 3.91 8.85 6.43
0.83 7.71 16.22 13.82
0.76 10.59 23.35 /
0.66 13.05 29.93 23.27
0.71 16.73 37.05 /
0.71 18.41 45.33 37.30
0.77 24.38 55.10 /
0.71 29.73 56.74 48.69
0.91 33.60 62.74 /
0.56 34.86 64.38 56.08
0.74 37.07 65.47 58.66
0.88 41.19 72.59 65.87
0.73 47.26 75.66 70.35
0.83 47.63 75.66 71.29
0.82 50.10 76.27 72.05
/ 57.52 85.68 81.30
0.74 60.03 89.49 /
0.80 61.33 93.86 87.51
/ 63.59 / /
0.78 67.22 100.39 /
0.79 67.50 100.39 94.99
/ 68.80 / /
0.82 69.22 101.48 97.02
0.74 73.61 102.02 99.62
0.67 12.26 109.04 /
0.67 82.18 113.69 107.40
0.75 85.36 118.14 110.00
/ 89.44 / /
Family 1 Family 2
IV.1 IV.3 VI.3 VI.5
F a m ily  4
II.6
243-255 243-255 240-262 240-262
230-236 224-230 224-230 224-228
113-125 113-113 109-113 113-121
152-161 155-161 161-167 152-160
170-174 / / 170-174
182-182 182-202 186-198 186-202
243-251 243-247 243-247 /
148-148 148-164 152-156 152-156
259-259 259-262 / /
262-262 262-262 260-260 266-266
139-139 139-139 135-135 135-135
78-78 72-78 72-72 72-78
217-245 217-217 221-233 229-233
231-231 235-235 232-238 230-234
266-266 266-266 266-266 266-266
123-127 123-127 118-118 118-118
333-361 333-357 349-353 353-353
266-266 266-270 258-270 258-262
164-164 164-164
302-314 298-314 314-322 314-322
185-187 185-185
315-315 315-315 315-343 301-327
244-244 244-244 244-244 244-244
154-160 154-154
226-226 226-230 226-234 226-230
157-165 157-165 157-157 157-165
169-181 169-177 165-177 173-177
205-209 207-209 205-215 211-217
137-153 137-141 137-153 141-153
252-254
240-242
118-126
160-160
170-170
186-202
247-252
145-149
256-261
135-135
213-225
232-236
257-291
342-342
268-272
315-319
310-334
244-244
160-168
226-226
158-162
178-186
207-211
141-141
D1S1588 0.65 91.55 125.51 116.15
GATA45B07 0.67 99.13 131.34 /
D1S206 0.82 100.98 134.20 122.64
D1S1631 0.77 104.81 136.88 125.75
GATA176G01 0.84 106.81 140.39 /
D1S502 0.89 111.61 146.53 /
D1S1191 / 113.86 147.60 135.51
D1S252 0.82 116.70 150.27 139.16
D1S534 0.83 118.82 151.88 140.68
D1S498 0.82 148.07 155.89 144.94
D1S1653 0.63 154.71 164.09 151.68
D1S1679 0.84 159.54 170.84 /
D1S1677 0.68 160.25 175.62 161.50
D1S1625 / 162.54 / /
D1S196 0.73 164.30 181.49 169.40
D1S2851 0.83 167.01 188.32 172.90
D1S1589 0.77 170.84 192.05 176.25
D1S466 0.77 178.82 198.30 183.53
D1S518 0.84 184.07 202.19 188.02
D1S1660 0.79 195.07 212.44 194.98
D1S1678 0.67 200.26 218.46 203.75
D1S249 0.87 202.07 220.65 207.07
GATA124F08 0.66 / / /
D1S2141 0.82 211.81 233.38 219.23
D1S2871 0.84 218.68 241.26 /
D1S3462 0.77 228.42 247.23 235.37
D1S235 0.71 232.19 254.64 244.40
D1S2670 0.83 235.84 262.96 253.50
D1S547 0.77 238.05 267.51 259.16
D1S2811 0.89 239.89 274.53 /
D1S2836 0.78 242.96 285.75 271.84
U->o\
o
129-129 129-132 117-132 129-129 129-129
263-263 263-263 263-267 271-271 272-272
207-215 207-215 207-215
148-148 148-148 / 148-151 /
198-202 198-202 194-198 190-194 179-191
263-271 263-271
123-123 123-123 119-127 123-127 123-123
109-111 109-111 107-111 97-101 97-101
201-213
190-200 190-200 192-196 194-194 190-192
99-99 99-103 99-103 99-103 103-107
149-177 149-165 157-169 149-157 152-160
197-201 201-209 197-209 197-201 197-201
202-202 189-202 202-208 202-208 203-209
308-308 308-308 308-308 308-324 308-318
273-277 / 270-274
200-212 200-200 203-203 203-203 205-205
233-235 231-231 230-230
197-205 193-205 197-201 201-213 206-206
230-242 230-230 242-250 234-242 239-243
/ / 303-315 299-303 299-303
161-161 161-173 171-177 169-171 161-169
237-237 237-237 237-237 237-241 235-239
244-248 240-244 248-260 232-260 248-256
229-241 230-230 232-234 232-232 234-236
259-259 259-259 253-259 259-259 263-266
175-187 175-187 187-187 191-191 177-179
152-164 146-164 139-147 139-147 141-155
290-290 290-306 286-290 286-290 294-294
159-159 149-159 142-144 / 146-148
267-267 267-267 271-271
Markers 
Chromosome 2
Het Mb
Build 33
CM
Marshfield
CM
deCode
Family 1 Family 2 
IV.1 IV.3 VI.3 VI.5
Family 4 
11.6
D2S2393 0.88 1.94 7.05 / 204-254 252-264
D2S1780 / 3.30 / / / 1 1  ' / 315-315
D2S281 0.81 6.68 14.10 15.19 246-246 246-248? 247-251 247-251
GATA116B01 0.77 8.10 17.88 19.64 203-203 181-203 185-185 185-185 186-198
D2S162 0.75 8.88 20.03 22.73 118-118 118-132 136-138 117-134
D2S168 0.83 11.46 27.06 / 156-156 156-170
D2S1400 0.66 11.62 27.60 29.24 118-118 118-118 114-118 114-114 114-114
D2S272 0.84 16.83 37.38 38.99 294-306 294-306
D2S1360 0.86 17.47 38.33 39.96 174-178 178-178 178-178 178-178? 174-178
D2S305 0.72 19.39 38.87 / 316-328 328-328 324-324 324-324
D2S2150 0.78 20.50 40.47 43.77 280-280 280-288
D2S405 0.66 29.45 47.97 51.48 205-205 201-205 201-205 201-205 193-193
D2S1788 0.89 36.23 55.51 / 199-231 239-251 198-235 198-223 232-236
D2S1346 0.79 38.24 59.36 63.10 / / I  ' / 246-252
D2S2259 0.79 42.97 64.29 67.06 249-251 247-251 247-251 247-247
D2S2739 0.90 49.59 73.61 / 317-321 321-321 297-325 / 308-324
D2S1337 / 59.34 / / 174-178 178-178
D2S441 0.76 68.21 86.82 91.23 134-142 134-134 138-150 138-150 138-150
D2S1774 / 77.18 / / 152-152 152-152 148-152 144-152 152-172
D2S2733 0.71 78.49 99.41 / / / / 173-176
D2S1777 0.65 78.50 99.41 102.50 195-199 /
D2S139 0.82 79.73 101.56 103.88 107-127 107-127
D2S1790 / 85.04 / / 314-318 314-318 286-294 286-298 294-298
D2S113 0.79 96.76 111.21 / 206-206 206-206 222-222 206-222
GATA176C01 0.77 102.19 114.42 116.13 / / / / 227-227
D2S436 0.83 106.86 118.16 120.01 186-190 186-194 186-190 / 182-198
D2S160 0.78 113.09 122.96 124.94 210-210 206-210
D2S410 0.83 116.33 125.18 127.38 163-167 169-173? 163-167 159-163 166-170
D2S1328 0.75 126.28 132.58 137.62 154-154 146-158 150-162 162-162 142-158
D2S1334 0.81 136.66 145.08 / 274-300 274-294 290-290 278-304 306-314
D2S442 0.66 137.47 147.40 149.66 202-202 198-202 198-206 202-206
D2S1399 0.80 148.42 152.04 / 138-138 163-163 134-146 138-146
D2S142 0.76 156.48 161.26 165.19 239-239 235-235
D2S1353 0.80 159.76 164.51 167.91 147-147 153-153 150-156 /
D2S1776 0.72 169.84 173.00 / 302-302 298-302 298-298 /
D2S326 0.86 173.06 177.53 / 97-99 97-99
GATA194A05 0.56 176.13 180.79 182.23 239-239 235-239 235-235 235-235
D2S364 0.80 182.99 186.21 187.67 248-248 248-248
D2S1391 0.79 184.95 186.21 189.15 127-135 119-127 127-127 127-127
D2S117 0.82 195.58 194.45 194.63 201-205 191-205 200-204 200-204
D2S1384 0.79 205.42 200.43 201.34 144-148 144-148 144-156 144-156
D2S155 0.77 207.15 202.92 / 204-204 204-204 204-206 204-206
D2S2208 0.88 208.92 205.06 1 159-175 159-177
D2S1649 / / 208.00 1 111-131 119-131 111-127 111-127
D2S434 0.74 218.77 215.78 216.01 267-271 267-275 259-275 259-275
D2S339 0.77 222.90 221.13 224.87 150-152 150-154
D2S2228 0.78 224.66 224.33 227.17 209-223 209-209
D2S1363 0.79 227.23 227.00 229.15 178-186 / 170-170 170-170
D2S1370 0.78 229.73 231.00 / 245-249 249-249 249-257 249-257
D2S427 0.76 232.40 236.70 238.22 242-246 246-250 / /
D2S206 0.79 233.91 240.79 240.03 142-142 142-150 146-146 148-148
D2S1397 0.65 237.08 249.22 247.77 / / / /
D2S338 0.79 237.52 250.54 248.37 283-289 283-285
GATA178G09 0.72 238.36 251.94 249.60 181-181 181-181 / 181-185
D2S125 0.83 241.48 260.63 258.19 88-90 86-88
Markers 
Chromosome 3
Het Mb 
Build 33
cM
Marshfield
cM
deCode
Family 1 
IV.1 IV.3
Family 2 
VI.3 VI.5
D3S2387 0.85 1.02 5.54 2.29 193-197 197-197 / 189-209
D3S1297 0.83 2.03 8.31 / 352-354 354-356
D3S3050 0.76 3.28 14.46 10.31 205-213 205-205 205-205 205-205
D3S3030 / 6.25 / / 111-131 111-131 127-127 127-127
198-198
138-138
144-153
298-298
236-244
107-127
148-160
111-115
271-275
170-186
243-251
246-246
226-232
169-189
Family 4 
11.6
/
208-212
123-127
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